cancer.type	eQTL.type	tagSNP	LD	SNP.ID	SNP.position.hg19	Gene.symbol	Gene.position.hg19	Beta	t-stat	P-value	GWAS-Traits	
BLCA	cis	1	rs1000113	chr5:150240076	LOC134466	chr5:150310000-150326146:-	0.53	6.99	1.26E-11	Crohn's disease	
BLCA	cis	1	rs10002332	chr4:129875301	C4orf33	chr4:130014829-130033842:+	0.28	4.37	1.61E-5	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs10003641	chr4:71340427	AMTN	chr4:71384298-71398459:+	0.25	4.13	4.46E-5	Alcoholism (heaviness of drinking)	
BLCA	cis	1	rs10008757	chr4:76903036	NAAA	chr4:76831809-76862166:-	-0.39	-6.41	4.28E-10	Longevity	
BLCA	cis	1	rs10011835	chr4:71340722	AMTN	chr4:71384298-71398459:+	0.25	4.13	4.46E-5	Alcoholism (heaviness of drinking)	
BLCA	cis	1	rs10021364	chr4:310691	ZNF718	chr4:53272-156488:+	-0.33	-4.4	1.4E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs1003719	chr21:38491095	PIGP	chr21:38437664-38445458:-	-0.31	-5.45	8.92E-8	Eye color traits	
BLCA	cis	1	rs1003719	chr21:38491095	TTC3	chr21:38445571-38575406:+	0.25	5.11	5.06E-7	Eye color traits	
BLCA	cis	1	rs10041072	chr5:150259642	LOC134466	chr5:150310000-150326146:-	0.45	6.15	1.93E-9	Crohn's disease	
BLCA	cis	1	rs10051747	chr5:56083289	C5orf35	chr5:56205103-56213010:+	0.72	10.92	2.45E-24	Type 2 diabetes	
BLCA	cis	1	rs10051804	chr5:150226424	LOC134466	chr5:150310000-150326146:-	0.4	4.98	9.62E-7	Crohn's disease	
BLCA	cis	1	rs10051924	chr5:150226639	LOC134466	chr5:150310000-150326146:-	0.4	4.98	9.62E-7	Crohn's disease	
BLCA	cis	1	rs10052606	chr5:150272217	LOC134466	chr5:150310000-150326146:-	0.46	5.97	5.47E-9	Crohn's disease	
BLCA	cis	1	rs10053750	chr5:150270051	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs10057988	chr5:150272062	LOC134466	chr5:150310000-150326146:-	0.46	5.97	5.47E-9	Crohn's disease	
BLCA	cis	1	rs10058821	chr5:150226385	LOC134466	chr5:150310000-150326146:-	0.4	4.98	9.62E-7	Crohn's disease	
BLCA	cis	1	rs10058943	chr5:150226586	LOC134466	chr5:150310000-150326146:-	0.4	4.98	9.62E-7	Crohn's disease	
BLCA	cis	1	rs10061105	chr5:150255185	LOC134466	chr5:150310000-150326146:-	0.48	6.27	9.54E-10	Crohn's disease	
BLCA	cis	1	rs10065172	chr5:150227998	LOC134466	chr5:150310000-150326146:-	0.43	5.35	1.52E-7	Crohn's disease	
BLCA	cis	1	rs1006581	chr7:150511923	TMEM176A	chr7:150497854-150502208:+	-0.17	-4.54	7.38E-6	Forced expiratory volume in 1 second (environmental interaction)	
BLCA	cis	1	rs10069077	chr5:110170026	TMEM232	chr5:109624934-110062381:-	-0.36	-4.03	6.69E-5	Mortality in heart failure	
BLCA	cis	1	rs10078968	chr5:150244273	LOC134466	chr5:150310000-150326146:-	0.43	5.77	1.66E-8	Crohn's disease	
BLCA	cis	1	rs10078	chr5:438102	C5orf55	chr5:441645-443258:-	0.3	4.35	1.71E-5	Fat distribution (HIV)	
BLCA	cis	1	rs10097215	chr8:2506899	CLN8	chr8:1711870-1734735:+	0.33	3.93	0.000101	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid)	
BLCA	cis	1	rs10103769	chr8:8573036	CLDN23	chr8:8559666-8561616:+	-0.23	-3.99	7.89E-5	Obesity-related traits	
BLCA	cis	1	rs10110591	chr8:8576608	CLDN23	chr8:8559666-8561616:+	0.27	5.01	8.27E-7	Obesity-related traits	
BLCA	cis	1	rs10117059	chr9:123653477	LOC253039	chr9:123605320-123616644:+	-0.36	-6.08	2.96E-9	Rheumatoid arthritis	
BLCA	cis	1	rs10119803	chr9:21666066	KLHL9	chr9:21324054-21335429:-	-0.31	-4.81	2.13E-6	Gut microbiome composition (winter)	
BLCA	cis	1	rs10136440	chr14:104397367	TDRD9	chr14:104394817-104519002:+	-0.35	-5.51	6.46E-8	Bipolar disorder	
BLCA	cis	1	rs10140433	chr14:74659989	LIN52	chr14:74551656-74667117:+	-0.36	-8.09	7.85E-15	Common traits (Other)	
BLCA	cis	1	rs10144220	chr14:74647904	LIN52	chr14:74551656-74667117:+	-0.36	-8.28	2.14E-15	Common traits (Other)	
BLCA	cis	1	rs10149651	chr14:104394440	TDRD9	chr14:104394817-104519002:+	-0.34	-5.49	7.41E-8	Bipolar disorder	
BLCA	cis	1	rs10150201	chr14:74649157	LIN52	chr14:74551656-74667117:+	-0.36	-8.28	2.07E-15	Common traits (Other)	
BLCA	cis	1	rs10157597	chr1:45990278	CCDC163P	chr1:45960581-45965646:-	-0.79	-16.19	2.68E-45	Homocysteine levels	
BLCA	cis	1	rs1016669	chr3:41894440	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs10169714	chr2:73808773	ALMS1P	chr2:73872046-73912692:+	0.36	5.35	1.55E-7	Metabolite levels	
BLCA	cis	1	rs10175180	chr2:73673123	ALMS1P	chr2:73872046-73912692:+	0.39	5.82	1.23E-8	Metabolite levels	
BLCA	cis	1	rs10178409	chr2:73855507	ALMS1P	chr2:73872046-73912692:+	0.35	5.06	6.59E-7	Urinary metabolites	
BLCA	cis	1	rs10179134	chr2:73637519	ALMS1P	chr2:73872046-73912692:+	0.33	4.84	1.89E-6	Metabolite levels	
BLCA	cis	1	rs1018184	chr6:86648475	SNHG5	chr6:86386726-86388451:-	0.49	8.81	4.4E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs10184268	chr2:73627044	ALMS1P	chr2:73872046-73912692:+	0.35	5.19	3.51E-7	Metabolite levels	
BLCA	cis	1	rs10186501	chr2:73697844	ALMS1P	chr2:73872046-73912692:+	0.4	5.97	5.57E-9	Metabolite levels	
BLCA	cis	1	rs10187192	chr2:73713500	ALMS1P	chr2:73872046-73912692:+	0.33	4.75	2.87E-6	Metabolite levels	
BLCA	cis	1	rs10187416	chr2:73713741	ALMS1P	chr2:73872046-73912692:+	0.4	5.97	5.39E-9	Metabolite levels	
BLCA	cis	1	rs10189574	chr2:73698518	ALMS1P	chr2:73872046-73912692:+	0.39	5.84	1.1E-8	Metabolite levels	
BLCA	cis	1	rs10190219	chr2:73658331	ALMS1P	chr2:73872046-73912692:+	0.34	5.04	7.19E-7	Metabolite levels	
BLCA	cis	1	rs10193373	chr2:281886	SH3YL1	chr2:218138-264810:-	-0.46	-12.19	4.13E-29	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs10193972	chr2:73717656	ALMS1P	chr2:73872046-73912692:+	0.4	5.97	5.32E-9	Metabolite levels	
BLCA	cis	1	rs10195155	chr2:70354475	FAM136A	chr2:70523109-70529220:-	-0.24	-4.3	2.13E-5	Obesity-related traits	
BLCA	cis	1	rs10205364	chr2:27794233	C2orf16	chr2:27799389-27805588:+	0.23	3.91	0.00011	Oral cavity cancer	
BLCA	cis	1	rs10207220	chr2:73785046	ALMS1P	chr2:73872046-73912692:+	0.34	5.08	5.97E-7	Metabolite levels	
BLCA	cis	1	rs10212536	chr3:41827026	ULK4	chr3:41288091-42003660:-	0.63	9.72	4.22E-20	Diastolic blood pressure	
BLCA	cis	1	rs10216533	chr8:143763690	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs10216533	chr8:143763690	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs10217692	chr9:102710431	STX17	chr9:102668915-102736817:+	-0.19	-3.92	0.000107	Alopecia areata	
BLCA	cis	1	rs10218795	chr1:145416056	NOTCH2NL	chr1:145209111-145295525:+	0.64	5.99	4.82E-9	Coronary heart disease	
BLCA	cis	1	rs10228845	chr7:21583617	DNAH11	chr7:21582833-21941455:+	-0.29	-4.83	2.0E-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs10229224	chr7:21583921	DNAH11	chr7:21582833-21941455:+	-0.3	-4.98	9.83E-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs10234309	chr7:135311167	PL-5283	chr7:135347221-135378160:+	0.65	9.15	3.51E-18	Paget's disease	
BLCA	cis	1	rs10247526	chr7:65780696	CCT6P1	chr7:65216092-65228661:+	-0.37	-4.92	1.28E-6	Diabetic kidney disease	
BLCA	cis	1	rs1025646	chr3:41754422	ULK4	chr3:41288091-42003660:-	0.67	10.14	1.45E-21	Diastolic blood pressure	
BLCA	cis	1	rs10256972	chr7:1039003	ZFAND2A	chr7:1192544-1199855:-	0.35	5.83	1.2E-8	Longevity;Endometriosis	
BLCA	cis	1	rs1028449	chr14:35512995	PPP2R3C	chr14:35554679-35591679:-	0.25	3.86	0.000131	Atopic dermatitis	
BLCA	cis	1	rs1030831	chr4:130025037	C4orf33	chr4:130014829-130033842:+	-0.33	-5.35	1.49E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1037147	chr4:130025873	C4orf33	chr4:130014829-130033842:+	-0.33	-5.38	1.33E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1039664	chr7:65449716	CCT6P1	chr7:65216092-65228661:+	0.3	4.29	2.25E-5	Diabetic kidney disease	
BLCA	cis	1	rs10404486	chr19:53284135	ZNF600	chr19:53268750-53290034:-	0.28	4.81	2.14E-6	Phospholipid levels (plasma)	
BLCA	cis	1	rs10408916	chr19:10447770	YIPF2	chr19:11033446-11039357:-	0.25	3.99	7.79E-5	Systemic lupus erythematosus or rheumatoid arthritis	
BLCA	cis	1	rs10409485	chr19:41920765	B3GNT8	chr19:41931265-41934635:-	0.21	3.94	9.68E-5	Height	
BLCA	cis	1	rs10413735	chr19:41921071	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.09	5.33E-5	Height	
BLCA	cis	1	rs10417311	chr19:41902038	B3GNT8	chr19:41931265-41934635:-	-0.21	-4.04	6.41E-5	Height	
BLCA	cis	1	rs10422783	chr19:41906436	B3GNT8	chr19:41931265-41934635:-	-0.21	-4.03	6.6E-5	Height	
BLCA	cis	1	rs10422956	chr19:41901261	B3GNT8	chr19:41931265-41934635:-	-0.21	-4.03	6.6E-5	Height	
BLCA	cis	1	rs1042658	chr17:38173902	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.89	0.000117	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs10431505	chr12:58178589	FAM119B	chr12:58166383-58176323:+	0.28	4.45	1.13E-5	Multiple sclerosis	
BLCA	cis	1	rs10431505	chr12:58178589	TSFM	chr12:58176536-58191367:+	-0.37	-6.54	2.02E-10	Multiple sclerosis	
BLCA	cis	1	rs10431505	chr12:58178589	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.17	3.8E-5	Multiple sclerosis	
BLCA	cis	1	rs10439607	chr20:30258541	COX4I2	chr20:30225691-30232800:+	0.23	4.99	9.15E-7	Subcortical brain region volumes	
BLCA	cis	1	rs10439608	chr20:30258814	COX4I2	chr20:30225691-30232800:+	0.22	4.58	6.2E-6	Subcortical brain region volumes	
BLCA	cis	1	rs1044717	chr1:45976587	CCDC163P	chr1:45960581-45965646:-	-0.82	-16.69	2.12E-47	Homocysteine levels	
BLCA	cis	1	rs10455158	chr6:86672825	SNHG5	chr6:86386726-86388451:-	-0.5	-8.75	6.72E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs1045531	chr8:143763547	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs1045531	chr8:143763547	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs10455449	chr6:86592226	SNHG5	chr6:86386726-86388451:-	-0.56	-9.83	1.78E-20	Response to antipsychotic treatment	
BLCA	cis	1	rs10455455	chr6:86670214	SNHG5	chr6:86386726-86388451:-	-0.53	-9.26	1.51E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs10455456	chr6:86670322	SNHG5	chr6:86386726-86388451:-	-0.5	-8.72	8.82E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs1045547	chr8:143763757	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs1045547	chr8:143763757	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs1045574	chr8:143763958	LY6D	chr8:143866298-143868008:-	0.23	5.01	8.22E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs1045574	chr8:143763958	PSCA	chr8:143761875-143764142:+	0.5	15.29	1.58E-41	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs1045605	chr8:143764101	LY6D	chr8:143866298-143868008:-	0.22	4.81	2.19E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs1045605	chr8:143764101	PSCA	chr8:143761875-143764142:+	0.52	16.1	6.31E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs10456622	chr6:49396453	CENPQ	chr6:49431096-49460820:+	-0.27	-5.48	7.91E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs10456622	chr6:49396453	MUT	chr6:49398994-49431031:-	0.29	5.73	2.05E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs10461617	chr5:56104308	C5orf35	chr5:56205103-56213010:+	0.71	10.51	7.18E-23	Type 2 diabetes	
BLCA	cis	1	rs10463240	chr5:150256853	LOC134466	chr5:150310000-150326146:-	0.48	6.27	9.54E-10	Crohn's disease	
BLCA	cis	1	rs10463307	chr5:150254620	LOC134466	chr5:150310000-150326146:-	0.53	6.71	6.95E-11	Crohn's disease	
BLCA	cis	1	rs10463310	chr5:150260905	LOC134466	chr5:150310000-150326146:-	0.47	6.2	1.42E-9	Crohn's disease	
BLCA	cis	1	rs10470686	chr3:48449956	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000132	Longevity	
BLCA	cis	1	rs1048687	chr16:9212987	C16orf72	chr16:9185537-9213545:+	-0.23	-3.91	0.000107	Behavioural disinhibition (generation interaction);Non-substance related behavioral disinhibition	
BLCA	cis	1	rs10494304	chr1:156285764	BGLAP	chr1:156182784-156213112:+	-0.22	-3.86	0.000135	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs10496191	chr2:73673798	ALMS1P	chr2:73872046-73912692:+	0.39	5.82	1.23E-8	Metabolite levels	
BLCA	cis	1	rs10496193	chr2:73773503	ALMS1P	chr2:73872046-73912692:+	0.39	5.79	1.49E-8	Metabolite levels	
BLCA	cis	1	rs10498958	chr6:86649705	SNHG5	chr6:86386726-86388451:-	0.54	9.49	2.44E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs10500303	chr19:50512033	SIGLEC16	chr19:50472912-50479075:+	0.59	5.55	5.41E-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs10508921	chr10:52010708	FAM21A	chr10:51827684-51893268:+	-0.36	-4.38	1.55E-5	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs10514847	chr13:44626749	KIAA1704	chr13:45563687-45607742:+	-0.66	-4.97	1.03E-6	Uric acid levels	
BLCA	cis	1	rs10514847	chr13:44626749	NUFIP1	chr13:45513384-45563613:-	-0.67	-4.52	8.14E-6	Uric acid levels	
BLCA	cis	1	rs1052501	chr3:41925398	ULK4	chr3:41288091-42003660:-	-0.64	-9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1062794	chr20:30381758	COX4I2	chr20:30225691-30232800:+	0.2	4.23	2.93E-5	Subcortical brain region volumes	
BLCA	cis	1	rs10732856	chr11:116907113	PCSK7	chr11:117075789-117102811:-	-0.39	-4.89	1.51E-6	Protein quantitative trait loci	
BLCA	cis	1	rs10736426	chr1:45984353	CCDC163P	chr1:45960581-45965646:-	0.73	15.02	1.96E-40	Homocysteine levels	
BLCA	cis	1	rs10741741	chr11:18342081	GTF2H1	chr11:18343816-18388590:+	-0.29	-5.86	9.8E-9	Pancreatic cancer	
BLCA	cis	1	rs10741742	chr11:18342160	GTF2H1	chr11:18343816-18388590:+	0.32	6.17	1.75E-9	Pancreatic cancer	
BLCA	cis	1	rs10747783	chr12:58176614	FAM119B	chr12:58166383-58176323:+	0.28	4.37	1.62E-5	Multiple sclerosis	
BLCA	cis	1	rs10747783	chr12:58176614	TSFM	chr12:58176536-58191367:+	-0.38	-6.71	7.19E-11	Multiple sclerosis	
BLCA	cis	1	rs10747783	chr12:58176614	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-3.99	7.9E-5	Multiple sclerosis	
BLCA	cis	1	rs10749860	chr1:46328210	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs10750100	chr11:116917244	PCSK7	chr11:117075789-117102811:-	-0.39	-5.09	5.59E-7	Protein quantitative trait loci	
BLCA	cis	1	rs10750101	chr11:116979689	PCSK7	chr11:117075789-117102811:-	-0.44	-5.48	7.6E-8	Protein quantitative trait loci	
BLCA	cis	1	rs10758892	chr9:7734250	C9orf123	chr9:7796493-7799799:-	-0.4	-4.28	2.39E-5	Myopia (pathological)	
BLCA	cis	1	rs10760118	chr9:123641616	LOC253039	chr9:123605320-123616644:+	-0.34	-5.89	8.63E-9	Rheumatoid arthritis	
BLCA	cis	1	rs10760121	chr9:123647915	LOC253039	chr9:123605320-123616644:+	-0.35	-5.82	1.23E-8	Rheumatoid arthritis	
BLCA	cis	1	rs10762582	chr10:75968316	ADK	chr10:75910965-76469059:+	0.31	4.71	3.41E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs1076392	chr17:59493008	C17orf82	chr17:59489112-59490641:+	-0.19	-4.31	2.09E-5	Sitting height ratio	
BLCA	cis	1	rs1077514	chr1:23766233	TCEA3	chr1:23707555-23751261:-	-0.3	-4.23	2.88E-5	Cholesterol, total	
BLCA	cis	1	rs10783847	chr12:58196447	FAM119B	chr12:58166383-58176323:+	0.29	4.54	7.64E-6	Multiple sclerosis	
BLCA	cis	1	rs10783847	chr12:58196447	TSFM	chr12:58176536-58191367:+	-0.36	-6.42	3.97E-10	Multiple sclerosis	
BLCA	cis	1	rs10783847	chr12:58196447	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.14	4.3E-5	Multiple sclerosis	
BLCA	cis	1	rs10783848	chr12:58196528	FAM119B	chr12:58166383-58176323:+	0.29	4.54	7.64E-6	Multiple sclerosis	
BLCA	cis	1	rs10783848	chr12:58196528	TSFM	chr12:58176536-58191367:+	-0.36	-6.42	3.97E-10	Multiple sclerosis	
BLCA	cis	1	rs10783848	chr12:58196528	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.14	4.3E-5	Multiple sclerosis	
BLCA	cis	1	rs10788795	chr1:150758047	HORMAD1	chr1:150670542-150693352:-	0.4	4.07	5.67E-5	Congenital left-sided heart lesions	
BLCA	cis	1	rs10789475	chr1:46304177	CCDC163P	chr1:45960581-45965646:-	-0.36	-6.71	6.92E-11	Body mass index	
BLCA	cis	1	rs10789481	chr1:46383583	CCDC163P	chr1:45960581-45965646:-	-0.36	-6.64	1.1E-10	Body mass index	
BLCA	cis	1	rs10789487	chr1:46420221	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs10790172	chr11:116927740	PCSK7	chr11:117075789-117102811:-	-0.39	-5.02	7.78E-7	Protein quantitative trait loci	
BLCA	cis	1	rs1080060	chr2:27768808	C2orf16	chr2:27799389-27805588:+	0.22	3.83	0.000152	Oral cavity cancer	
BLCA	cis	1	rs10804632	chr3:134294501	ANAPC13	chr3:134196547-134204865:-	0.47	7.52	3.83E-13	Height	
BLCA	cis	1	rs10807701	chr7:65724686	CCT6P1	chr7:65216092-65228661:+	-0.33	-4.52	8.25E-6	Diabetic kidney disease	
BLCA	cis	1	rs10807702	chr7:65767843	CCT6P1	chr7:65216092-65228661:+	0.32	4.4	1.42E-5	Diabetic kidney disease	
BLCA	cis	1	rs10818480	chr9:123643170	LOC253039	chr9:123605320-123616644:+	-0.33	-5.77	1.67E-8	Rheumatoid arthritis	
BLCA	cis	1	rs10819471	chr9:131896325	CRAT	chr9:131857075-131873070:-	0.25	4.53	7.83E-6	Blood metabolite ratios	
BLCA	cis	1	rs10819471	chr9:131896325	SH3GLB2	chr9:131770314-131790579:-	-0.16	-4.74	3.06E-6	Blood metabolite ratios	
BLCA	cis	1	rs10819861	chr9:98867813	C9orf130	chr9:98568372-98638259:-	-0.27	-4.62	5.16E-6	Electrocardiographic traits	
BLCA	cis	1	rs10819861	chr9:98867813	ZNF367	chr9:99148227-99180669:-	-0.16	-4.39	1.45E-5	Electrocardiographic traits	
BLCA	cis	1	rs10824075	chr10:75880254	ADK	chr10:75910965-76469059:+	0.3	4.62	5.36E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824076	chr10:75886956	ADK	chr10:75910965-76469059:+	0.28	4.46	1.09E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824078	chr10:75892120	ADK	chr10:75910965-76469059:+	0.31	4.61	5.4E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824083	chr10:75911342	ADK	chr10:75910965-76469059:+	0.28	4.37	1.58E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824084	chr10:75911415	ADK	chr10:75910965-76469059:+	0.28	4.37	1.58E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824085	chr10:75911984	ADK	chr10:75910965-76469059:+	0.29	4.5	9.08E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824088	chr10:75921490	ADK	chr10:75910965-76469059:+	0.3	4.55	7.32E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824088	chr10:75921490	AP3M1	chr10:75880016-75910826:-	0.3	3.86	0.000132	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824090	chr10:75923446	ADK	chr10:75910965-76469059:+	0.28	4.34	1.82E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824096	chr10:75937554	ADK	chr10:75910965-76469059:+	0.32	4.75	2.93E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824096	chr10:75937554	AP3M1	chr10:75880016-75910826:-	0.31	3.98	8.08E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824098	chr10:75943579	ADK	chr10:75910965-76469059:+	0.28	4.32	2.01E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824099	chr10:75943625	ADK	chr10:75910965-76469059:+	0.31	4.57	6.71E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824099	chr10:75943625	AP3M1	chr10:75880016-75910826:-	0.31	4.02	7.01E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824101	chr10:75947438	ADK	chr10:75910965-76469059:+	0.33	4.75	2.9E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824101	chr10:75947438	AP3M1	chr10:75880016-75910826:-	0.33	4.21	3.22E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824101	chr10:75947438	MYST4	chr10:76586379-76792639:+	0.24	3.86	0.000131	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824102	chr10:75948915	ADK	chr10:75910965-76469059:+	0.31	4.65	4.62E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824102	chr10:75948915	AP3M1	chr10:75880016-75910826:-	0.3	3.91	0.000107	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824103	chr10:75949415	ADK	chr10:75910965-76469059:+	0.31	4.65	4.62E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824103	chr10:75949415	AP3M1	chr10:75880016-75910826:-	0.3	3.91	0.000107	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824105	chr10:75952881	ADK	chr10:75910965-76469059:+	0.33	4.81	2.13E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824105	chr10:75952881	AP3M1	chr10:75880016-75910826:-	0.31	3.99	7.82E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824105	chr10:75952881	MYST4	chr10:76586379-76792639:+	0.23	3.83	0.000149	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824106	chr10:75958408	ADK	chr10:75910965-76469059:+	-0.31	-4.41	1.33E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824110	chr10:75968098	ADK	chr10:75910965-76469059:+	0.31	4.71	3.41E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824112	chr10:75969003	ADK	chr10:75910965-76469059:+	0.3	4.62	5.23E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824113	chr10:75969018	ADK	chr10:75910965-76469059:+	0.31	4.71	3.41E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824114	chr10:75970503	ADK	chr10:75910965-76469059:+	0.3	4.62	5.23E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824125	chr10:75997498	ADK	chr10:75910965-76469059:+	0.29	4.39	1.47E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824128	chr10:76007903	ADK	chr10:75910965-76469059:+	0.28	4.28	2.36E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824129	chr10:76008855	ADK	chr10:75910965-76469059:+	0.27	4.19	3.5E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824130	chr10:76008931	ADK	chr10:75910965-76469059:+	0.27	4.21	3.23E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10824151	chr10:76092179	ADK	chr10:75910965-76469059:+	0.3	4.49	9.5E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs10825492	chr10:52008730	FAM21A	chr10:51827684-51893268:+	-0.36	-4.37	1.58E-5	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs10832921	chr11:18380835	GTF2H1	chr11:18343816-18388590:+	0.29	5.51	6.75E-8	Pancreatic cancer	
BLCA	cis	1	rs10838738	chr11:47663049	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.73	2.07E-8	Subjective well-being	
BLCA	cis	1	rs10838747	chr11:47716324	C1QTNF4	chr11:47611216-47615961:-	-0.29	-5.61	3.99E-8	Subjective well-being	
BLCA	cis	1	rs10838748	chr11:47716381	C1QTNF4	chr11:47611216-47615961:-	-0.29	-5.65	3.1E-8	Subjective well-being	
BLCA	cis	1	rs10838757	chr11:47763016	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.66	2.93E-8	Subjective well-being	
BLCA	cis	1	rs10849605	chr12:1064438	RAD52	chr12:1021255-1099219:-	-0.19	-3.88	0.000125	Lung cancer	
BLCA	cis	1	rs1085243	chr1:46544768	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.22	1.28E-9	Body mass index	
BLCA	cis	1	rs1085243	chr1:46544768	MUTYH	chr1:45794915-45806142:-	0.2	3.9	0.000115	Body mass index	
BLCA	cis	1	rs1085244	chr1:46563680	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.21	1.42E-9	Body mass index	
BLCA	cis	1	rs10853057	chr17:62998023	AMZ2P1	chr17:62962668-62971703:-	0.54	6.57	1.63E-10	White matter microstructure (global fractional anisotropy)	
BLCA	cis	1	rs10853751	chr19:41903220	B3GNT8	chr19:41931265-41934635:-	-0.21	-4.04	6.41E-5	Height	
BLCA	cis	1	rs10865914	chr3:41919499	ULK4	chr3:41288091-42003660:-	-0.64	-9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs10874122	chr1:75235866	CRYZ	chr1:75171175-75199092:-	-0.29	-4.56	6.83E-6	Resistin levels	
BLCA	cis	1	rs10876480	chr12:54066271	ATP5G2	chr12:54058945-54070512:-	0.22	4.81	2.18E-6	Height	
BLCA	cis	1	rs10876481	chr12:54066743	ATP5G2	chr12:54058945-54070512:-	0.22	4.81	2.18E-6	Height	
BLCA	cis	1	rs10877012	chr12:58162085	FAM119B	chr12:58166383-58176323:+	0.29	4.44	1.17E-5	Multiple sclerosis	
BLCA	cis	1	rs10877012	chr12:58162085	TSFM	chr12:58176536-58191367:+	-0.39	-6.87	2.67E-11	Multiple sclerosis	
BLCA	cis	1	rs10877012	chr12:58162085	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.09	5.29E-5	Multiple sclerosis	
BLCA	cis	1	rs10877013	chr12:58165085	FAM119B	chr12:58166383-58176323:+	0.29	4.56	6.8E-6	Multiple sclerosis	
BLCA	cis	1	rs10877013	chr12:58165085	TSFM	chr12:58176536-58191367:+	-0.36	-6.51	2.33E-10	Multiple sclerosis	
BLCA	cis	1	rs10877013	chr12:58165085	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-4.1	5.07E-5	Multiple sclerosis	
BLCA	cis	1	rs10877014	chr12:58167661	FAM119B	chr12:58166383-58176323:+	0.28	4.54	7.68E-6	Multiple sclerosis	
BLCA	cis	1	rs10877014	chr12:58167661	TSFM	chr12:58176536-58191367:+	-0.37	-6.73	6.35E-11	Multiple sclerosis	
BLCA	cis	1	rs10877014	chr12:58167661	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.3	2.21E-5	Multiple sclerosis	
BLCA	cis	1	rs10877015	chr12:58167788	FAM119B	chr12:58166383-58176323:+	0.28	4.32	2.0E-5	Multiple sclerosis	
BLCA	cis	1	rs10877015	chr12:58167788	TSFM	chr12:58176536-58191367:+	-0.4	-7.12	5.51E-12	Multiple sclerosis	
BLCA	cis	1	rs10877015	chr12:58167788	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.2	3.38E-5	Multiple sclerosis	
BLCA	cis	1	rs10877019	chr12:58172929	FAM119B	chr12:58166383-58176323:+	-0.27	-4.19	3.47E-5	Multiple sclerosis	
BLCA	cis	1	rs10877019	chr12:58172929	TSFM	chr12:58176536-58191367:+	0.37	6.62	1.21E-10	Multiple sclerosis	
BLCA	cis	1	rs10882644	chr10:97388579	ENTPD1	chr10:97471536-97637022:+	0.19	4.92	1.32E-6	Blood metabolite levels	
BLCA	cis	1	rs10888396	chr1:150777514	HORMAD1	chr1:150670542-150693352:-	0.4	4.17	3.72E-5	Congenital left-sided heart lesions	
BLCA	cis	1	rs10890352	chr1:46283628	CCDC163P	chr1:45960581-45965646:-	-0.37	-6.99	1.19E-11	Body mass index	
BLCA	cis	1	rs10890354	chr1:46305347	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs10890361	chr1:46346234	CCDC163P	chr1:45960581-45965646:-	-0.35	-6.6	1.37E-10	Body mass index	
BLCA	cis	1	rs10890363	chr1:46356148	CCDC163P	chr1:45960581-45965646:-	0.37	7.01	1.09E-11	Body mass index	
BLCA	cis	1	rs10890383	chr1:46588503	CCDC163P	chr1:45960581-45965646:-	-0.32	-5.88	8.8E-9	Body mass index	
BLCA	cis	1	rs10898211	chr11:71210677	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.87	0.000128	Vitamin D levels	
BLCA	cis	1	rs10898234	chr11:71236684	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.83	0.000151	Vitamin D levels	
BLCA	cis	1	rs10902728	chr1:26598281	ZNF593	chr1:26496388-26497362:+	0.21	4.35	1.77E-5	Obesity-related traits	
BLCA	cis	1	rs10908498	chr1:156278175	BGLAP	chr1:156182784-156213112:+	0.23	3.92	0.000107	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs10908499	chr1:156279176	BGLAP	chr1:156182784-156213112:+	0.23	3.92	0.000107	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs10908500	chr1:156280671	BGLAP	chr1:156182784-156213112:+	0.23	4.05	6.15E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs10908502	chr1:156300082	BGLAP	chr1:156182784-156213112:+	0.22	3.84	0.000145	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs10913582	chr1:171715585	VAMP4	chr1:171669298-171711214:-	0.3	4.28	2.35E-5	Hippocampal atrophy	
BLCA	cis	1	rs10917151	chr1:22422721	HSPC157	chr1:22351707-22357713:+	-0.29	-3.9	0.000114	Endometriosis	
BLCA	cis	1	rs10935120	chr3:134233092	ANAPC13	chr3:134196547-134204865:-	-0.45	-7.12	5.51E-12	Height	
BLCA	cis	1	rs10944161	chr6:86630376	SNHG5	chr6:86386726-86388451:-	-0.51	-9.01	9.54E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs10944163	chr6:86658693	SNHG5	chr6:86386726-86388451:-	-0.54	-9.35	7.6E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs10944169	chr6:86683036	SNHG5	chr6:86386726-86388451:-	-0.5	-8.88	2.56E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs10944170	chr6:86685469	SNHG5	chr6:86386726-86388451:-	-0.49	-8.64	1.49E-16	Response to antipsychotic treatment	
BLCA	cis	1	rs10946198	chr6:167404432	RNASET2	chr6:167343008-167412795:-	-0.25	-5.15	4.08E-7	Crohn's disease	
BLCA	cis	1	rs10946199	chr6:167404492	RNASET2	chr6:167343008-167412795:-	-0.25	-5.19	3.37E-7	Crohn's disease	
BLCA	cis	1	rs1094677	chr3:195129744	C3orf21	chr3:194789015-194991895:-	-0.28	-5.38	1.28E-7	Body mass index	
BLCA	cis	1	rs10950032	chr7:65738591	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.72	3.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs10951593	chr7:39121390	RALA	chr7:39663162-39747715:+	0.27	4.6	5.64E-6	IgG glycosylation	
BLCA	cis	1	rs10955943	chr8:120944143	DEPDC6	chr8:120885900-121063156:+	-0.25	-3.97	8.61E-5	Interstitial lung disease	
BLCA	cis	1	rs11000887	chr10:75897542	ADK	chr10:75910965-76469059:+	0.3	4.47	1.02E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000888	chr10:75901929	ADK	chr10:75910965-76469059:+	0.3	4.72	3.36E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000890	chr10:75904073	ADK	chr10:75910965-76469059:+	0.3	4.64	4.77E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000894	chr10:75906598	ADK	chr10:75910965-76469059:+	0.3	4.53	7.84E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000897	chr10:75911276	ADK	chr10:75910965-76469059:+	0.29	4.39	1.46E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000900	chr10:75918440	ADK	chr10:75910965-76469059:+	0.28	4.25	2.74E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000901	chr10:75919971	ADK	chr10:75910965-76469059:+	0.3	4.54	7.44E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000901	chr10:75919971	AP3M1	chr10:75880016-75910826:-	0.3	3.86	0.000131	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000902	chr10:75920483	ADK	chr10:75910965-76469059:+	0.33	4.8	2.33E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000902	chr10:75920483	AP3M1	chr10:75880016-75910826:-	0.33	4.14	4.34E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000902	chr10:75920483	SAMD8	chr10:76871393-76936607:+	0.26	3.86	0.000133	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000905	chr10:75925532	ADK	chr10:75910965-76469059:+	0.3	4.47	1.02E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000909	chr10:75944828	ADK	chr10:75910965-76469059:+	0.3	4.5	9.11E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000912	chr10:75948477	ADK	chr10:75910965-76469059:+	0.31	4.63	5.07E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000912	chr10:75948477	AP3M1	chr10:75880016-75910826:-	0.3	3.91	0.00011	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000916	chr10:75953909	ADK	chr10:75910965-76469059:+	0.31	4.71	3.41E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000922	chr10:75969305	ADK	chr10:75910965-76469059:+	0.33	4.81	2.14E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000922	chr10:75969305	AP3M1	chr10:75880016-75910826:-	0.33	4.18	3.68E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000922	chr10:75969305	MYST4	chr10:76586379-76792639:+	0.25	3.99	7.97E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000924	chr10:75972311	ADK	chr10:75910965-76469059:+	0.3	4.62	5.23E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000925	chr10:75972601	ADK	chr10:75910965-76469059:+	0.3	4.62	5.23E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000930	chr10:75982982	ADK	chr10:75910965-76469059:+	-0.35	-4.99	9.05E-7	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000930	chr10:75982982	AP3M1	chr10:75880016-75910826:-	-0.38	-4.72	3.26E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000930	chr10:75982982	MYST4	chr10:76586379-76792639:+	-0.26	-4.11	4.92E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000930	chr10:75982982	VDAC2	chr10:76970563-76991204:+	-0.31	-4.32	2.0E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000931	chr10:75984800	ADK	chr10:75910965-76469059:+	-0.25	-3.9	0.000115	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000936	chr10:75992383	ADK	chr10:75910965-76469059:+	0.28	4.24	2.81E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000941	chr10:76018301	ADK	chr10:75910965-76469059:+	0.31	4.56	7.04E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11000941	chr10:76018301	AP3M1	chr10:75880016-75910826:-	0.3	3.85	0.000138	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11039255	chr11:47495746	C1QTNF4	chr11:47611216-47615961:-	-0.29	-5.52	6.24E-8	Subjective well-being	
BLCA	cis	1	rs11039390	chr11:47796295	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.65	3.22E-8	Subjective well-being	
BLCA	cis	1	rs11039412	chr11:47841581	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.58	4.54E-8	Subjective well-being	
BLCA	cis	1	rs11039426	chr11:47863119	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.6	4.09E-8	Subjective well-being	
BLCA	cis	1	rs11051970	chr12:32537488	FGD4	chr12:32638906-32798982:+	-0.34	-5.39	1.27E-7	Response to tocilizumab in rheumatoid arthritis	
BLCA	cis	1	rs1105881	chr15:42072530	SPTBN5	chr15:42140345-42186275:-	0.25	4.21	3.2E-5	Educational attainment	
BLCA	cis	1	rs1106287	chr1:113242122	ST7L	chr1:113066142-113162405:-	0.44	6.47	3.03E-10	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs11064881	chr12:120146925	PRKAB1	chr12:120105757-120119428:+	-0.67	-6.59	1.48E-10	Ulcerative colitis;Inflammatory bowel disease	
BLCA	cis	1	rs11072603	chr15:76881138	SCAPER	chr15:76640529-77197744:-	-0.21	-4.64	4.69E-6	Blood metabolite levels	
BLCA	cis	1	rs11074454	chr16:20390151	C16orf88	chr16:19717676-19729492:-	-0.37	-4.05	6.11E-5	Urinary uromodulin levels	
BLCA	cis	1	rs11079034	chr17:40288890	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.85E-6	Fibrinogen levels	
BLCA	cis	1	rs11084785	chr19:35282054	ZNF181	chr19:35225151-35233774:+	-0.27	-5.4	1.17E-7	Urate levels (BMI interaction)	
BLCA	cis	1	rs11084786	chr19:35282181	ZNF181	chr19:35225151-35233774:+	-0.26	-5.34	1.6E-7	Urate levels (BMI interaction)	
BLCA	cis	1	rs11086102	chr19:18398628	KIAA1683	chr19:18367906-18385319:-	-0.23	-4.23	2.91E-5	Waist-to-hip ratio adjusted for body mass index	
BLCA	cis	1	rs11088226	chr21:33925531	TCP10L	chr21:33947152-33957845:-	-0.34	-4.54	7.57E-6	Gastritis	
BLCA	cis	1	rs1109114	chr5:148615946	AFAP1L1	chr5:148651401-148721365:+	0.26	4.7	3.65E-6	Body mass index	
BLCA	cis	1	rs1109227	chr3:48479207	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000134	Longevity	
BLCA	cis	1	rs1109501	chr4:71329490	AMTN	chr4:71384298-71398459:+	0.26	4.22	3.01E-5	Alcoholism (heaviness of drinking)	
BLCA	cis	1	rs1109619	chr8:8571616	CLDN23	chr8:8559666-8561616:+	-0.23	-3.87	0.000127	Obesity-related traits	
BLCA	cis	1	rs1110042	chr1:113236534	ST7L	chr1:113066142-113162405:-	0.44	6.49	2.68E-10	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs1110183	chr9:38456365	MCART1	chr9:37877572-37904350:-	0.23	4.13	4.48E-5	Hypertension	
BLCA	cis	1	rs11123170	chr2:113978940	LOC654433	chr2:113993107-114024579:+	-0.36	-5.64	3.35E-8	Renal function-related traits (BUN)	
BLCA	cis	1	rs11123170	chr2:113978940	PAX8	chr2:113973575-114036498:-	-0.3	-4.85	1.83E-6	Renal function-related traits (BUN)	
BLCA	cis	1	rs11127188	chr2:28972852	TRMT61B	chr2:29072690-29093175:-	-0.31	-5.41	1.12E-7	Body mass index	
BLCA	cis	1	rs111295372	chr2:86283357	LOC90784	chr2:86247339-86250991:-	-0.41	-4.21	3.18E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
BLCA	cis	1	rs11130170	chr3:48449897	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000134	Longevity	
BLCA	cis	1	rs111315781	chr2:201738724	PPIL3	chr2:201735680-201753999:-	-0.71	-8.23	3.02E-15	Triptolide cytotoxicity	
BLCA	cis	1	rs11132254	chr4:185611592	MLF1IP	chr4:185615220-185655286:-	-0.47	-10.86	3.96E-24	Kawasaki disease	
BLCA	cis	1	rs1114380	chr2:73804708	ALMS1P	chr2:73872046-73912692:+	0.36	5.33	1.7E-7	Metabolite levels	
BLCA	cis	1	rs11156875	chr14:35619816	PPP2R3C	chr14:35554679-35591679:-	0.24	4.03	6.59E-5	Atopic dermatitis	
BLCA	cis	1	rs11158609	chr14:24688814	TGM1	chr14:24718322-24732416:-	0.28	3.9	0.000111	Systolic blood pressure (cigarette smoking interaction)	
BLCA	cis	1	rs11159067	chr14:74637444	LIN52	chr14:74551656-74667117:+	0.33	7.81	5.66E-14	Common traits (Other)	
BLCA	cis	1	rs11167515	chr5:150239471	LOC134466	chr5:150310000-150326146:-	0.5	6.3	8.38E-10	Crohn's disease	
BLCA	cis	1	rs11167518	chr5:150258920	LOC134466	chr5:150310000-150326146:-	0.47	6.22	1.33E-9	Crohn's disease	
BLCA	cis	1	rs11167519	chr5:150265407	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs11167520	chr5:150265639	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs11167521	chr5:150271785	LOC134466	chr5:150310000-150326146:-	0.45	5.81	1.33E-8	Crohn's disease	
BLCA	cis	1	rs11167526	chr5:150332481	LOC134466	chr5:150310000-150326146:-	0.65	7	1.15E-11	Crohn's disease	
BLCA	cis	1	rs111704178	chr10:75957251	ADK	chr10:75910965-76469059:+	0.3	4.62	5.23E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11172333	chr12:58170335	FAM119B	chr12:58166383-58176323:+	0.28	4.39	1.48E-5	Multiple sclerosis	
BLCA	cis	1	rs11172333	chr12:58170335	TSFM	chr12:58176536-58191367:+	-0.4	-7.05	8.18E-12	Multiple sclerosis	
BLCA	cis	1	rs11172333	chr12:58170335	XRCC6BP1	chr12:58335445-58351051:+	-0.25	-4.26	2.6E-5	Multiple sclerosis	
BLCA	cis	1	rs11172335	chr12:58175201	FAM119B	chr12:58166383-58176323:+	0.28	4.29	2.3E-5	Multiple sclerosis	
BLCA	cis	1	rs11172335	chr12:58175201	TSFM	chr12:58176536-58191367:+	-0.39	-6.81	3.7E-11	Multiple sclerosis	
BLCA	cis	1	rs11172335	chr12:58175201	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-3.98	8.12E-5	Multiple sclerosis	
BLCA	cis	1	rs11172342	chr12:58187758	FAM119B	chr12:58166383-58176323:+	0.28	4.37	1.6E-5	Multiple sclerosis	
BLCA	cis	1	rs11172342	chr12:58187758	TSFM	chr12:58176536-58191367:+	-0.38	-6.72	6.57E-11	Multiple sclerosis	
BLCA	cis	1	rs11172342	chr12:58187758	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-3.95	9.44E-5	Multiple sclerosis	
BLCA	cis	1	rs11172343	chr12:58188157	FAM119B	chr12:58166383-58176323:+	0.28	4.37	1.6E-5	Multiple sclerosis	
BLCA	cis	1	rs11172343	chr12:58188157	TSFM	chr12:58176536-58191367:+	-0.38	-6.72	6.57E-11	Multiple sclerosis	
BLCA	cis	1	rs11172343	chr12:58188157	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-3.95	9.44E-5	Multiple sclerosis	
BLCA	cis	1	rs11172344	chr12:58193448	FAM119B	chr12:58166383-58176323:+	0.29	4.54	7.64E-6	Multiple sclerosis	
BLCA	cis	1	rs11172344	chr12:58193448	TSFM	chr12:58176536-58191367:+	-0.36	-6.42	3.97E-10	Multiple sclerosis	
BLCA	cis	1	rs11172344	chr12:58193448	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.14	4.3E-5	Multiple sclerosis	
BLCA	cis	1	rs11172349	chr12:58212528	FAM119B	chr12:58166383-58176323:+	0.29	4.49	9.52E-6	Multiple sclerosis	
BLCA	cis	1	rs11172349	chr12:58212528	TSFM	chr12:58176536-58191367:+	-0.39	-6.95	1.6E-11	Multiple sclerosis	
BLCA	cis	1	rs11172349	chr12:58212528	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.17	3.76E-5	Multiple sclerosis	
BLCA	cis	1	rs11172351	chr12:58213485	FAM119B	chr12:58166383-58176323:+	0.3	4.62	5.23E-6	Multiple sclerosis	
BLCA	cis	1	rs11172351	chr12:58213485	TSFM	chr12:58176536-58191367:+	-0.39	-6.84	3.13E-11	Multiple sclerosis	
BLCA	cis	1	rs11172351	chr12:58213485	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.12	4.69E-5	Multiple sclerosis	
BLCA	cis	1	rs1117367	chr15:76872330	SCAPER	chr15:76640529-77197744:-	-0.2	-4.47	1.03E-5	Blood metabolite levels	
BLCA	cis	1	rs11188394	chr10:97365458	ENTPD1	chr10:97471536-97637022:+	0.19	4.89	1.51E-6	Blood metabolite levels	
BLCA	cis	1	rs11188396	chr10:97367510	ENTPD1	chr10:97471536-97637022:+	0.19	4.99	9.3E-7	Blood metabolite levels	
BLCA	cis	1	rs11188398	chr10:97369093	ENTPD1	chr10:97471536-97637022:+	0.19	4.99	9.3E-7	Blood metabolite levels	
BLCA	cis	1	rs11188400	chr10:97371327	ENTPD1	chr10:97471536-97637022:+	0.19	4.99	9.3E-7	Blood metabolite levels	
BLCA	cis	1	rs11188406	chr10:97390195	ENTPD1	chr10:97471536-97637022:+	0.19	4.92	1.32E-6	Blood metabolite levels	
BLCA	cis	1	rs11188407	chr10:97390533	ENTPD1	chr10:97471536-97637022:+	0.19	4.92	1.32E-6	Blood metabolite levels	
BLCA	cis	1	rs11188411	chr10:97397344	ENTPD1	chr10:97471536-97637022:+	0.2	5.13	4.67E-7	Blood metabolite levels	
BLCA	cis	1	rs11188417	chr10:97411680	ENTPD1	chr10:97471536-97637022:+	-0.2	-5.14	4.35E-7	Blood metabolite levels	
BLCA	cis	1	rs111899361	chr7:1112348	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.47	1.05E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11190172	chr10:101358381	CNNM1	chr10:101088856-101154085:+	0.34	3.87	0.000128	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels	
BLCA	cis	1	rs11190178	chr10:101363457	CNNM1	chr10:101088856-101154085:+	0.34	3.86	0.000135	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels	
BLCA	cis	1	rs111902838	chr19:50496614	SIGLEC16	chr19:50472912-50479075:+	0.59	5.59	4.36E-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs11190569	chr10:102227409	SEC31B	chr10:102246403-102289636:-	-0.21	-3.84	0.000145	Palmitoleic acid (16:1n-7) plasma levels	
BLCA	cis	1	rs11191419	chr10:104612335	AS3MT	chr10:104613967-104661653:+	-0.31	-5.72	2.14E-8	Schizophrenia	
BLCA	cis	1	rs11191419	chr10:104612335	C10orf32	chr10:104613967-104624718:+	-0.31	-5.53	6.08E-8	Schizophrenia	
BLCA	cis	1	rs11191425	chr10:104625970	AS3MT	chr10:104613967-104661653:+	-0.33	-3.85	0.000138	Hypertension;Systolic blood pressure;Diastolic blood pressure	
BLCA	cis	1	rs11191425	chr10:104625970	SFXN2	chr10:104474298-104498946:+	-0.35	-4.03	6.62E-5	Hypertension;Systolic blood pressure;Diastolic blood pressure	
BLCA	cis	1	rs11201312	chr10:81795778	LOC219347	chr10:81805991-81838949:-	0.39	4.87	1.63E-6	Chronic obstructive pulmonary disease-related biomarkers	
BLCA	cis	1	rs11201660	chr10:81854531	LOC219347	chr10:81805991-81838949:-	-0.33	-4.68	4.06E-6	Chronic obstructive pulmonary disease-related biomarkers	
BLCA	cis	1	rs11201799	chr10:81881954	LOC219347	chr10:81805991-81838949:-	-0.35	-4.35	1.75E-5	Chronic obstructive pulmonary disease-related biomarkers	
BLCA	cis	1	rs11204700	chr1:150660702	HORMAD1	chr1:150670542-150693352:-	0.38	3.98	8.24E-5	Congenital left-sided heart lesions	
BLCA	cis	1	rs11210359	chr1:74339167	LRRIQ3	chr1:74491704-74663871:-	0.26	4.04	6.37E-5	Bipolar disorder and schizophrenia	
BLCA	cis	1	rs11211132	chr1:45990516	CCDC163P	chr1:45960581-45965646:-	-0.79	-16.21	2.35E-45	Homocysteine levels	
BLCA	cis	1	rs11211199	chr1:46287869	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs11211208	chr1:46334256	CCDC163P	chr1:45960581-45965646:-	-0.37	-7.02	9.9E-12	Body mass index	
BLCA	cis	1	rs11211230	chr1:46406767	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs11211234	chr1:46438787	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs11211241	chr1:46452683	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs11211309	chr1:47045213	CYP4A11	chr1:47394848-47407156:-	0.32	3.83	0.000151	Schizophrenia	
BLCA	cis	1	rs11216316	chr11:117081500	PCSK7	chr11:117075789-117102811:-	0.37	4.65	4.59E-6	Protein quantitative trait loci	
BLCA	cis	1	rs11233933	chr11:71210070	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.84	0.000145	Vitamin D levels	
BLCA	cis	1	rs11233977	chr11:71221605	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.85	0.000136	Vitamin D levels	
BLCA	cis	1	rs11234027	chr11:71234107	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.92	0.000105	Vitamin D levels	
BLCA	cis	1	rs11248009	chr4:220149	ZNF718	chr4:53272-156488:+	0.36	4.68	3.93E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11248013	chr4:311425	ZNF718	chr4:53272-156488:+	0.35	4.65	4.58E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11249502	chr4:71341161	AMTN	chr4:71384298-71398459:+	0.24	3.97	8.76E-5	Alcoholism (heaviness of drinking)	
BLCA	cis	1	rs1125203	chr3:41760895	ULK4	chr3:41288091-42003660:-	0.64	9.9	9.78E-21	Diastolic blood pressure	
BLCA	cis	1	rs113066613	chr7:1094128	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.41	1.32E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs113146460	chr7:1105164	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.48	1.0E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs113231679	chr11:10351345	IPO7	chr11:9406169-9469673:+	0.27	3.99	7.85E-5	Systolic blood pressure;Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs113575110	chr7:1084394	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.53	7.81E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs113638727	chr15:40706101	C15orf23	chr15:40674922-40686488:+	0.34	5.7	2.37E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs1138273	chr3:134261437	ANAPC13	chr3:134196547-134204865:-	0.5	7.97	1.89E-14	Height	
BLCA	cis	1	rs1138273	chr3:134261437	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.33E-5	Height	
BLCA	cis	1	rs113858334	chr7:1073476	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs1140047	chr11:18327684	GTF2H1	chr11:18343816-18388590:+	0.31	5.96	5.66E-9	Pancreatic cancer	
BLCA	cis	1	rs1141321	chr6:49412433	CENPQ	chr6:49431096-49460820:+	-0.28	-5.6	4.04E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs1141321	chr6:49412433	MUT	chr6:49398994-49431031:-	0.29	5.59	4.37E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs114244137	chr5:150264753	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs114960066	chr3:41882323	ULK4	chr3:41288091-42003660:-	0.64	9.93	8.2E-21	Diastolic blood pressure	
BLCA	cis	1	rs114976176	chr2:264621	SH3YL1	chr2:218138-264810:-	-0.43	-11.24	1.53E-25	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs11532322	chr12:123731423	ABCB9	chr12:123413540-123459752:-	-0.3	-4.26	2.62E-5	Schizophrenia	
BLCA	cis	1	rs11532322	chr12:123731423	OGFOD2	chr12:123459354-123464588:+	-0.26	-4.48	9.73E-6	Schizophrenia	
BLCA	cis	1	rs11538349	chr7:65421871	CCT6P1	chr7:65216092-65228661:+	0.31	4.42	1.29E-5	Diabetic kidney disease	
BLCA	cis	1	rs115418388	chr10:75976296	ADK	chr10:75910965-76469059:+	0.31	4.7	3.66E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs11553746	chr2:272203	SH3YL1	chr2:218138-264810:-	-0.45	-11.82	1.03E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs11555809	chr1:27216669	GPN2	chr1:27205873-27216869:-	0.46	3.91	0.000108	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs11557072	chr15:40713374	C15orf23	chr15:40674922-40686488:+	0.34	5.51	6.52E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs11577745	chr1:171720909	VAMP4	chr1:171669298-171711214:-	0.3	4.05	6.16E-5	Hippocampal atrophy	
BLCA	cis	1	rs11579634	chr1:46466391	CCDC163P	chr1:45960581-45965646:-	0.35	6.63	1.16E-10	Body mass index	
BLCA	cis	1	rs11589562	chr1:46466721	CCDC163P	chr1:45960581-45965646:-	0.29	5.4	1.19E-7	Body mass index	
BLCA	cis	1	rs11592213	chr10:97396103	ENTPD1	chr10:97471536-97637022:+	0.19	4.94	1.15E-6	Blood metabolite levels	
BLCA	cis	1	rs11604149	chr11:6519642	RRP8	chr11:6621154-6624811:-	-0.21	-3.87	0.000127	DNA methylation (variation)	
BLCA	cis	1	rs11605774	chr11:47832793	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.58	4.54E-8	Subjective well-being	
BLCA	cis	1	rs116139393	chr7:6771660	PMS2CL	chr7:6749757-6793492:+	-0.45	-6.41	4.4E-10	Alzheimer's disease (APOE e4 interaction)	
BLCA	cis	1	rs11622475	chr14:104509076	TDRD9	chr14:104394817-104519002:+	0.29	4.47	1.05E-5	Bipolar disorder	
BLCA	cis	1	rs11625697	chr14:104464800	TDRD9	chr14:104394817-104519002:+	0.33	5.37	1.37E-7	Bipolar disorder	
BLCA	cis	1	rs11628710	chr14:74649280	LIN52	chr14:74551656-74667117:+	0.37	8.44	6.55E-16	Common traits (Other)	
BLCA	cis	1	rs11632465	chr15:85282045	LOC388152	chr15:84867600-84898920:-	-0.24	-4.17	3.84E-5	Schizophrenia	
BLCA	cis	1	rs11637142	chr15:85295927	LOC388152	chr15:84867600-84898920:-	-0.24	-4.12	4.63E-5	Schizophrenia	
BLCA	cis	1	rs11638290	chr15:85227636	LOC388152	chr15:84867600-84898920:-	-0.25	-4.27	2.47E-5	Schizophrenia	
BLCA	cis	1	rs11638297	chr15:84782417	LOC388152	chr15:84867600-84898920:-	-0.27	-4.73	3.09E-6	Schizophrenia	
BLCA	cis	1	rs11638394	chr15:84778928	LOC388152	chr15:84867600-84898920:-	-0.27	-4.67	4.27E-6	Schizophrenia	
BLCA	cis	1	rs11644601	chr16:15172118	RRN3	chr16:15153881-15188158:-	-0.25	-3.91	0.000109	Metabolite levels (lipid measures)	
BLCA	cis	1	rs11645002	chr16:20617841	ACSM1	chr16:20634559-20709066:-	0.38	5.45	9.01E-8	Urinary metabolites	
BLCA	cis	1	rs11646919	chr16:20400969	C16orf88	chr16:19717676-19729492:-	-0.35	-3.85	0.000137	Urinary uromodulin levels	
BLCA	cis	1	rs11650372	chr17:45721795	C17orf57	chr17:45401142-45518675:+	0.25	5.57	4.86E-8	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs11651264	chr17:79576394	TSPAN10	chr17:79609349-79615778:+	-0.49	-8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs11652797	chr17:79574124	TSPAN10	chr17:79609349-79615778:+	0.48	8.69	1.08E-16	Eye color traits	
BLCA	cis	1	rs11670668	chr19:41920454	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.06	5.97E-5	Height	
BLCA	cis	1	rs11674602	chr2:73723185	ALMS1P	chr2:73872046-73912692:+	0.35	5.07	6.22E-7	Metabolite levels	
BLCA	cis	1	rs1167613	chr7:65487439	CCT6P1	chr7:65216092-65228661:+	0.3	4.33	1.9E-5	Diabetic kidney disease	
BLCA	cis	1	rs1167827	chr7:75163169	PMS2L3	chr7:75137070-75157418:-	-0.42	-8.57	2.58E-16	Body mass index	
BLCA	cis	1	rs11681777	chr2:192121467	STAT4	chr2:191894306-192038902:-	0.14	3.84	0.000147	Obesity-related traits	
BLCA	cis	1	rs11688129	chr2:28952581	TRMT61B	chr2:29072690-29093175:-	0.29	5.1	5.37E-7	Body mass index	
BLCA	cis	1	rs11689392	chr2:73622026	ALMS1P	chr2:73872046-73912692:+	0.36	5.27	2.26E-7	Metabolite levels	
BLCA	cis	1	rs11690423	chr2:28951537	TRMT61B	chr2:29072690-29093175:-	0.29	5.09	5.59E-7	Body mass index	
BLCA	cis	1	rs11701091	chr21:33920244	TCP10L	chr21:33947152-33957845:-	-0.36	-4.71	3.55E-6	Gastritis	
BLCA	cis	1	rs11701627	chr21:33927794	TCP10L	chr21:33947152-33957845:-	-0.37	-4.85	1.8E-6	Gastritis	
BLCA	cis	1	rs11705483	chr22:46630544	PKDREJ	chr22:46651561-46659219:-	-0.45	-4.2	3.35E-5	Cholesterol, total;LDL cholesterol	
BLCA	cis	1	rs11706117	chr3:134212526	ANAPC13	chr3:134196547-134204865:-	0.51	8.12	6.27E-15	Height	
BLCA	cis	1	rs11706117	chr3:134212526	CEP63	chr3:134204575-134293852:+	0.25	4.38	1.54E-5	Height	
BLCA	cis	1	rs11708531	chr3:134224902	ANAPC13	chr3:134196547-134204865:-	0.5	7.95	2.1E-14	Height	
BLCA	cis	1	rs11708531	chr3:134224902	CEP63	chr3:134204575-134293852:+	0.23	4.07	5.68E-5	Height	
BLCA	cis	1	rs11712111	chr3:156608940	LEKR1	chr3:156544076-156763918:+	0.24	4.61	5.48E-6	Multiple sclerosis (severity)	
BLCA	cis	1	rs11718834	chr3:52963668	TMEM110	chr3:52867139-52931547:-	0.38	3.89	0.000117	Immune reponse to smallpox (secreted IL-2)	
BLCA	cis	1	rs11722197	chr4:281707	ZNF718	chr4:53272-156488:+	0.36	4.79	2.36E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11722521	chr4:276765	ZNF718	chr4:53272-156488:+	0.34	4.66	4.33E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11723261	chr4:282499	ZNF718	chr4:53272-156488:+	0.36	4.79	2.36E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11723615	chr4:276983	ZNF718	chr4:53272-156488:+	0.35	4.77	2.6E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11723803	chr4:292369	ZNF718	chr4:53272-156488:+	0.26	4.02	6.87E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11724176	chr4:224901	ZNF718	chr4:53272-156488:+	0.34	4.49	9.44E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11724417	chr4:223352	ZNF718	chr4:53272-156488:+	0.34	4.49	9.44E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11729365	chr4:272524	ZNF718	chr4:53272-156488:+	0.35	4.73	3.22E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11729657	chr4:1737585	FAM53A	chr4:1641609-1685854:-	-0.31	-4.5	9.09E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs11730202	chr4:210096	ZNF718	chr4:53272-156488:+	0.32	4.33	1.95E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs11732213	chr4:1704244	FAM53A	chr4:1641609-1685854:-	0.29	4.12	4.66E-5	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs11734039	chr4:54264428	SCFD2	chr4:53739152-54232242:-	0.25	3.86	0.000134	DNA methylation (variation)	
BLCA	cis	1	rs11739344	chr5:56111087	C5orf35	chr5:56205103-56213010:+	0.72	10.68	1.81E-23	Type 2 diabetes	
BLCA	cis	1	rs11739619	chr5:150264662	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs11739677	chr5:150294883	LOC134466	chr5:150310000-150326146:-	0.55	6.83	3.35E-11	Crohn's disease	
BLCA	cis	1	rs11740172	chr5:150300278	LOC134466	chr5:150310000-150326146:-	0.55	6.86	2.73E-11	Crohn's disease	
BLCA	cis	1	rs11741861	chr5:150277909	LOC134466	chr5:150310000-150326146:-	-0.53	-6.64	1.07E-10	Crohn's disease	
BLCA	cis	1	rs11743488	chr5:150279218	LOC134466	chr5:150310000-150326146:-	0.57	6.9	2.1E-11	Crohn's disease	
BLCA	cis	1	rs11746108	chr5:150264622	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs11746807	chr5:150300419	LOC134466	chr5:150310000-150326146:-	0.55	6.85	2.96E-11	Crohn's disease	
BLCA	cis	1	rs11747065	chr5:150295486	LOC134466	chr5:150310000-150326146:-	0.55	6.86	2.73E-11	Crohn's disease	
BLCA	cis	1	rs11747270	chr5:150258867	LOC134466	chr5:150310000-150326146:-	-0.45	-5.91	7.53E-9	Crohn's disease	
BLCA	cis	1	rs11748151	chr5:150226292	LOC134466	chr5:150310000-150326146:-	0.43	5.33	1.71E-7	Crohn's disease	
BLCA	cis	1	rs11748158	chr5:150226345	LOC134466	chr5:150310000-150326146:-	0.43	5.33	1.71E-7	Crohn's disease	
BLCA	cis	1	rs11749391	chr5:150229066	LOC134466	chr5:150310000-150326146:-	0.43	5.35	1.52E-7	Crohn's disease	
BLCA	cis	1	rs11758849	chr6:86708262	SNHG5	chr6:86386726-86388451:-	-0.52	-8.95	1.6E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs11759855	chr6:86610841	SNHG5	chr6:86386726-86388451:-	-0.53	-9.45	3.38E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs11761941	chr7:1097183	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11763793	chr7:1094342	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.4	1.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11763835	chr7:1094513	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.4	1.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11764748	chr7:1094508	ZFAND2A	chr7:1192544-1199855:-	-0.32	-3.84	0.000141	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11765693	chr7:75985373	UPK3B	chr7:76139745-76157197:+	-0.3	-6.33	6.76E-10	Multiple sclerosis	
BLCA	cis	1	rs11766526	chr7:1101433	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.45	1.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11767527	chr7:1097394	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11768761	chr7:1069807	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11770909	chr7:1086716	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.53	7.81E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11782652	chr8:82653644	CHMP4C	chr8:82644688-82671746:+	-0.71	-7.2	3.23E-12	Epithelial ovarian cancer;Ovarian cancer	
BLCA	cis	1	rs117907570	chr6:86601283	SNHG5	chr6:86386726-86388451:-	-0.57	-10.48	9.03E-23	Response to antipsychotic treatment	
BLCA	cis	1	rs118059236	chr7:1073202	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs11807824	chr1:27270338	GPN2	chr1:27205873-27216869:-	0.48	4.1	5.14E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs11810993	chr1:46478793	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs118110670	chr10:81792242	LOC219347	chr10:81805991-81838949:-	0.37	4.5	9.02E-6	Chronic obstructive pulmonary disease-related biomarkers	
BLCA	cis	1	rs11856184	chr15:43919162	ADAL	chr15:43622872-43646094:+	-0.39	-4.43	1.23E-5	Tumor biomarkers	
BLCA	cis	1	rs11856184	chr15:43919162	CATSPER2	chr15:43922774-43959900:-	-0.36	-5.27	2.33E-7	Tumor biomarkers	
BLCA	cis	1	rs11858714	chr15:40717447	C15orf23	chr15:40674922-40686488:+	0.35	5.67	2.83E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs11869069	chr17:40287101	DHX58	chr17:40253422-40264751:-	-0.25	-4.59	6.08E-6	Fibrinogen levels	
BLCA	cis	1	rs11870935	chr17:45732605	C17orf57	chr17:45401142-45518675:+	-0.26	-5.79	1.47E-8	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs1187446	chr14:104409896	TDRD9	chr14:104394817-104519002:+	0.34	5.39	1.26E-7	Bipolar disorder	
BLCA	cis	1	rs1187448	chr14:104406627	TDRD9	chr14:104394817-104519002:+	0.35	5.54	5.49E-8	Bipolar disorder	
BLCA	cis	1	rs11879853	chr19:23029434	ZNF492	chr19:22817126-22850472:+	0.28	3.96	8.8E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs11882144	chr19:42072602	CEACAM21	chr19:42055886-42093196:+	0.37	8.45	5.94E-16	Schizophrenia	
BLCA	cis	1	rs11883104	chr19:41923799	B3GNT8	chr19:41931265-41934635:-	-0.21	-3.98	8.37E-5	Height	
BLCA	cis	1	rs11893832	chr2:88507537	THNSL2	chr2:88469835-88486145:+	-0.55	-5.5	7.08E-8	Plasma clusterin levels	
BLCA	cis	1	rs11893881	chr2:73824373	ALMS1P	chr2:73872046-73912692:+	0.37	5.5	7.03E-8	Metabolite levels	
BLCA	cis	1	rs11899740	chr2:73631212	ALMS1P	chr2:73872046-73912692:+	0.31	4.46	1.06E-5	Metabolite levels	
BLCA	cis	1	rs11899902	chr2:73631564	ALMS1P	chr2:73872046-73912692:+	0.33	4.87	1.65E-6	Metabolite levels	
BLCA	cis	1	rs11901272	chr2:73720444	ALMS1P	chr2:73872046-73912692:+	0.4	5.94	6.54E-9	Metabolite levels	
BLCA	cis	1	rs11903916	chr2:73815328	ALMS1P	chr2:73872046-73912692:+	0.38	5.65	3.06E-8	Metabolite levels	
BLCA	cis	1	rs11919350	chr3:134235970	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.88	3.42E-14	Height	
BLCA	cis	1	rs11919350	chr3:134235970	CEP63	chr3:134204575-134293852:+	-0.24	-4.04	6.44E-5	Height	
BLCA	cis	1	rs11923562	chr3:41760331	ULK4	chr3:41288091-42003660:-	0.66	9.67	6.31E-20	Diastolic blood pressure	
BLCA	cis	1	rs11927068	chr3:134266321	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs11927068	chr3:134266321	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs11928499	chr3:134232350	ANAPC13	chr3:134196547-134204865:-	-0.5	-8	1.47E-14	Height	
BLCA	cis	1	rs11928499	chr3:134232350	CEP63	chr3:134204575-134293852:+	-0.26	-4.45	1.12E-5	Height	
BLCA	cis	1	rs11928580	chr3:41885722	ULK4	chr3:41288091-42003660:-	0.64	9.83	1.74E-20	Diastolic blood pressure	
BLCA	cis	1	rs11932207	chr4:71330534	AMTN	chr4:71384298-71398459:+	0.25	4.2	3.33E-5	Alcoholism (heaviness of drinking)	
BLCA	cis	1	rs11938970	chr4:119660152	METTL14	chr4:119606574-119632075:+	-0.37	-4.84	1.89E-6	Cannabis dependence	
BLCA	cis	1	rs11950957	chr5:150253914	LOC134466	chr5:150310000-150326146:-	0.47	6.11	2.43E-9	Crohn's disease	
BLCA	cis	1	rs11951694	chr5:150254338	LOC134466	chr5:150310000-150326146:-	0.48	6.23	1.22E-9	Crohn's disease	
BLCA	cis	1	rs11955172	chr5:150254378	LOC134466	chr5:150310000-150326146:-	0.48	6.23	1.22E-9	Crohn's disease	
BLCA	cis	1	rs11957134	chr5:150230950	LOC134466	chr5:150310000-150326146:-	-0.51	-6.73	6.15E-11	Crohn's disease	
BLCA	cis	1	rs11965538	chr6:28239915	ZNF389	chr6:28129551-28137375:+	-0.34	-4.32	1.98E-5	Depression	
BLCA	cis	1	rs11975942	chr7:143740580	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.99	4.75E-9	Obesity-related traits	
BLCA	cis	1	rs11976020	chr7:72247800	TYW1B	chr7:72023729-72298813:-	0.99	15.64	5.37E-43	Educational attainment (years of education)	
BLCA	cis	1	rs11976037	chr7:143741024	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.04	3.73E-9	Obesity-related traits	
BLCA	cis	1	rs11976180	chr7:143741580	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.04	3.63E-9	Obesity-related traits	
BLCA	cis	1	rs1198433	chr1:23756695	ASAP3	chr1:23755056-23811057:-	0.28	3.86	0.000131	Cholesterol, total	
BLCA	cis	1	rs1198433	chr1:23756695	TCEA3	chr1:23707555-23751261:-	0.29	4.01	7.33E-5	Cholesterol, total	
BLCA	cis	1	rs1198440	chr1:23780861	ASAP3	chr1:23755056-23811057:-	0.3	4.17	3.83E-5	Cholesterol, total	
BLCA	cis	1	rs1198440	chr1:23780861	TCEA3	chr1:23707555-23751261:-	0.33	4.58	6.39E-6	Cholesterol, total	
BLCA	cis	1	rs12021587	chr1:46472759	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs12022194	chr1:156312331	BGLAP	chr1:156182784-156213112:+	0.23	3.88	0.000122	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12030612	chr1:113215637	ST7L	chr1:113066142-113162405:-	0.41	5.91	7.39E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs12030641	chr1:113215717	ST7L	chr1:113066142-113162405:-	0.41	5.91	7.39E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs12038481	chr1:156284815	BGLAP	chr1:156182784-156213112:+	0.23	3.91	0.000109	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12040988	chr1:113173804	ST7L	chr1:113066142-113162405:-	0.41	5.91	7.39E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs12041164	chr1:156279811	BGLAP	chr1:156182784-156213112:+	0.23	3.92	0.000107	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12045807	chr1:150584834	HORMAD1	chr1:150670542-150693352:-	0.43	4.53	8.0E-6	Congenital left-sided heart lesions	
BLCA	cis	1	rs12049588	chr1:46472422	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs12054923	chr5:150249059	LOC134466	chr5:150310000-150326146:-	0.44	5.86	1.0E-8	Crohn's disease	
BLCA	cis	1	rs12091564	chr1:145395604	NOTCH2NL	chr1:145209111-145295525:+	-0.65	-5.96	5.84E-9	Coronary heart disease	
BLCA	cis	1	rs12117903	chr1:156311165	BGLAP	chr1:156182784-156213112:+	0.22	3.84	0.000145	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12117951	chr1:156305286	BGLAP	chr1:156182784-156213112:+	0.23	3.88	0.000122	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12120956	chr1:113202571	ST7L	chr1:113066142-113162405:-	0.42	6.17	1.76E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs12126971	chr1:113231286	ST7L	chr1:113066142-113162405:-	0.41	6.03	3.93E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs12130243	chr1:113169667	ST7L	chr1:113066142-113162405:-	0.41	5.91	7.39E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs12132919	chr1:156318141	BGLAP	chr1:156182784-156213112:+	0.23	3.88	0.000122	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12133583	chr1:113240790	ST7L	chr1:113066142-113162405:-	0.43	6.24	1.13E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs12134983	chr1:156290409	BGLAP	chr1:156182784-156213112:+	0.23	3.86	0.000132	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12139630	chr1:46350935	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.16E-11	Body mass index	
BLCA	cis	1	rs12141236	chr1:156302575	BGLAP	chr1:156182784-156213112:+	0.22	3.84	0.000145	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs12144263	chr1:46352446	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.16E-11	Body mass index	
BLCA	cis	1	rs12148786	chr15:76800362	SCAPER	chr15:76640529-77197744:-	-0.21	-4.67	4.17E-6	Blood metabolite levels	
BLCA	cis	1	rs12154056	chr6:86634094	SNHG5	chr6:86386726-86388451:-	-0.51	-9.01	9.54E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12171333	chr4:129879711	C4orf33	chr4:130014829-130033842:+	0.31	4.68	4.04E-6	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs12185102	chr15:75352201	SCAMP5	chr15:75287901-75313836:+	0.29	4.83	1.97E-6	Blood trace element (Zn levels)	
BLCA	cis	1	rs12190598	chr6:86686074	SNHG5	chr6:86386726-86388451:-	-0.49	-7.97	1.88E-14	Response to antipsychotic treatment	
BLCA	cis	1	rs12190604	chr6:86716215	SNHG5	chr6:86386726-86388451:-	-0.51	-8.98	1.2E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs12192208	chr6:124693764	NKAIN2	chr6:124125069-125146784:+	0.28	4.76	2.8E-6	Neuroticism	
BLCA	cis	1	rs12192992	chr6:86609915	SNHG5	chr6:86386726-86388451:-	-0.53	-9.42	4.49E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12196037	chr6:86694631	SNHG5	chr6:86386726-86388451:-	-0.53	-9.35	7.19E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12196411	chr6:86779762	SNHG5	chr6:86386726-86388451:-	-0.54	-9.34	7.81E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12196937	chr6:49382808	CENPQ	chr6:49431096-49460820:+	-0.28	-5.66	2.91E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs12196937	chr6:49382808	MUT	chr6:49398994-49431031:-	0.28	5.53	5.94E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs12197114	chr6:109735498	SMPD2	chr6:109761931-109765121:+	0.22	4.06	5.93E-5	Height	
BLCA	cis	1	rs12199516	chr6:86726221	SNHG5	chr6:86386726-86388451:-	-0.53	-9.37	6.58E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12199784	chr6:86726808	SNHG5	chr6:86386726-86388451:-	-0.54	-9.4	5.22E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12200330	chr6:86656653	SNHG5	chr6:86386726-86388451:-	-0.53	-9.46	3.14E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12201571	chr6:86609750	SNHG5	chr6:86386726-86388451:-	-0.53	-9.45	3.38E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12201735	chr6:86656939	SNHG5	chr6:86386726-86388451:-	-0.51	-8.95	1.55E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs12201741	chr6:86602619	SNHG5	chr6:86386726-86388451:-	-0.51	-9.02	9.09E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12201880	chr6:86627007	SNHG5	chr6:86386726-86388451:-	-0.51	-9.01	9.54E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12202075	chr6:49427655	CENPQ	chr6:49431096-49460820:+	-0.28	-5.65	3.17E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs12202075	chr6:49427655	MUT	chr6:49398994-49431031:-	0.28	5.51	6.48E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs12203493	chr6:86758642	SNHG5	chr6:86386726-86388451:-	-0.53	-9.25	1.64E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12203924	chr6:86776412	SNHG5	chr6:86386726-86388451:-	-0.53	-9.25	1.64E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12204015	chr6:86598334	SNHG5	chr6:86386726-86388451:-	-0.59	-10.66	2.13E-23	Response to antipsychotic treatment	
BLCA	cis	1	rs12204365	chr6:86700532	SNHG5	chr6:86386726-86388451:-	-0.49	-8.73	7.95E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs12204812	chr6:124681503	NKAIN2	chr6:124125069-125146784:+	0.26	4.51	8.61E-6	Neuroticism	
BLCA	cis	1	rs12205336	chr6:86722367	SNHG5	chr6:86386726-86388451:-	-0.53	-9.35	7.51E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12205548	chr6:86759770	SNHG5	chr6:86386726-86388451:-	-0.53	-9.25	1.56E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12207305	chr6:86723502	SNHG5	chr6:86386726-86388451:-	-0.54	-9.4	5.22E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12207610	chr6:86688016	SNHG5	chr6:86386726-86388451:-	-0.5	-8.87	2.81E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs12208493	chr6:86662267	SNHG5	chr6:86386726-86388451:-	-0.53	-9.22	1.97E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12209127	chr6:86724427	SNHG5	chr6:86386726-86388451:-	-0.53	-9.35	7.51E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12212733	chr6:86726013	SNHG5	chr6:86386726-86388451:-	-0.53	-9.38	5.71E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12213149	chr6:86668644	SNHG5	chr6:86386726-86388451:-	-0.53	-9.22	1.97E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12213740	chr6:86656733	SNHG5	chr6:86386726-86388451:-	-0.51	-9.05	7.12E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12215037	chr6:86727631	SNHG5	chr6:86386726-86388451:-	-0.54	-9.39	5.34E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12215903	chr6:86675028	SNHG5	chr6:86386726-86388451:-	-0.5	-8.81	4.46E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs12216203	chr6:86675301	SNHG5	chr6:86386726-86388451:-	-0.53	-9.3	1.08E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12216328	chr6:86703418	SNHG5	chr6:86386726-86388451:-	-0.52	-9.26	1.43E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs12220238	chr10:75952670	ADK	chr10:75910965-76469059:+	0.31	4.65	4.62E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12220238	chr10:75952670	AP3M1	chr10:75880016-75910826:-	0.3	3.91	0.000107	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12220777	chr10:81788104	LOC219347	chr10:81805991-81838949:-	-0.36	-4.42	1.29E-5	Chronic obstructive pulmonary disease-related biomarkers	
BLCA	cis	1	rs12252705	chr10:75984863	ADK	chr10:75910965-76469059:+	0.28	4.36	1.66E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12256105	chr10:75909634	ADK	chr10:75910965-76469059:+	0.28	4.37	1.58E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12286683	chr11:18348662	GTF2H1	chr11:18343816-18388590:+	0.31	6	4.7E-9	Pancreatic cancer	
BLCA	cis	1	rs12299125	chr12:123862447	CDK2AP1	chr12:123745542-123756687:-	-0.37	-5.17	3.82E-7	Educational attainment;Height;Head circumference (infant)	
BLCA	cis	1	rs12329875	chr21:30137796	N6AMT1	chr21:30244513-30257693:-	-0.29	-4.78	2.53E-6	Cognitive test performance	
BLCA	cis	1	rs12355771	chr10:75894404	ADK	chr10:75910965-76469059:+	0.27	4.02	6.95E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12355784	chr10:65121565	NRBF2	chr10:64893007-64914785:+	-0.23	-4.35	1.72E-5	Educational attainment;Liver enzyme levels (alkaline phosphatase)	
BLCA	cis	1	rs12357530	chr10:75928654	ADK	chr10:75910965-76469059:+	0.3	4.47	1.02E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12358614	chr10:75906173	ADK	chr10:75910965-76469059:+	0.3	4.53	7.84E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12359272	chr10:97365163	ENTPD1	chr10:97471536-97637022:+	0.19	4.92	1.28E-6	Blood metabolite levels	
BLCA	cis	1	rs12359456	chr10:75937994	ADK	chr10:75910965-76469059:+	0.32	4.75	2.93E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12359456	chr10:75937994	AP3M1	chr10:75880016-75910826:-	0.31	3.98	8.08E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs12361031	chr11:47783076	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.58	4.59E-8	Subjective well-being	
BLCA	cis	1	rs12363232	chr11:47623890	C1QTNF4	chr11:47611216-47615961:-	-0.28	-5.5	6.96E-8	Subjective well-being	
BLCA	cis	1	rs12405451	chr1:46384326	CCDC163P	chr1:45960581-45965646:-	-0.35	-6.56	1.75E-10	Body mass index	
BLCA	cis	1	rs12409773	chr1:46358831	CCDC163P	chr1:45960581-45965646:-	-0.38	-7.18	3.73E-12	Body mass index	
BLCA	cis	1	rs12410060	chr1:75245848	CRYZ	chr1:75171175-75199092:-	-0.27	-4.14	4.28E-5	Resistin levels	
BLCA	cis	1	rs12410071	chr1:46358886	CCDC163P	chr1:45960581-45965646:-	-0.38	-7.15	4.53E-12	Body mass index	
BLCA	cis	1	rs12411269	chr1:46271052	CCDC163P	chr1:45960581-45965646:-	-0.37	-6.99	1.19E-11	Body mass index	
BLCA	cis	1	rs12416687	chr10:104629011	C10orf32	chr10:104613967-104624718:+	-0.37	-5.7	2.39E-8	Arsenic metabolism	
BLCA	cis	1	rs12418852	chr11:47868853	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.55	5.34E-8	Subjective well-being	
BLCA	cis	1	rs12419692	chr11:47624714	C1QTNF4	chr11:47611216-47615961:-	0.29	5.73	2.0E-8	Subjective well-being	
BLCA	cis	1	rs12421210	chr11:47779586	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.57	4.7E-8	Subjective well-being	
BLCA	cis	1	rs12422267	chr12:132601596	DDX51	chr12:132621142-132628880:-	0.49	4.4	1.38E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
BLCA	cis	1	rs12422267	chr12:132601596	EP400NL	chr12:132568828-132600084:+;chr12	-0.61	-5.21	3.05E-7	Plasma amyloid beta peptide concentrations (ABx-40)	
BLCA	cis	1	rs1242229	chr11:117062370	PCSK7	chr11:117075789-117102811:-	-0.37	-4.7	3.57E-6	Protein quantitative trait loci	
BLCA	cis	1	rs12441433	chr15:76816015	SCAPER	chr15:76640529-77197744:-	-0.22	-4.75	2.86E-6	Blood metabolite levels	
BLCA	cis	1	rs12443102	chr15:43932103	ADAL	chr15:43622872-43646094:+	-0.39	-4.42	1.26E-5	Tumor biomarkers	
BLCA	cis	1	rs12443102	chr15:43932103	CATSPER2	chr15:43922774-43959900:-	-0.33	-4.78	2.56E-6	Tumor biomarkers	
BLCA	cis	1	rs12443137	chr15:76840832	SCAPER	chr15:76640529-77197744:-	-0.2	-4.46	1.08E-5	Blood metabolite levels	
BLCA	cis	1	rs12459123	chr19:12689741	C19orf56	chr19:12778881-12780465:-	0.2	3.86	0.000134	Bipolar disorder	
BLCA	cis	1	rs12473740	chr2:88527647	THNSL2	chr2:88469835-88486145:+	-0.57	-5.69	2.53E-8	Plasma clusterin levels	
BLCA	cis	1	rs12479491	chr20:30265450	COX4I2	chr20:30225691-30232800:+	0.21	4.43	1.22E-5	Subcortical brain region volumes	
BLCA	cis	1	rs12484859	chr22:29844884	NIPSNAP1	chr22:29950800-29977144:-	0.29	4.01	7.44E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs12490835	chr3:134223730	ANAPC13	chr3:134196547-134204865:-	0.51	8.16	5.01E-15	Height	
BLCA	cis	1	rs12490835	chr3:134223730	CEP63	chr3:134204575-134293852:+	0.25	4.42	1.28E-5	Height	
BLCA	cis	1	rs12505835	chr4:297525	ZNF718	chr4:53272-156488:+	0.36	4.72	3.33E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs12547721	chr8:8570671	CLDN23	chr8:8559666-8561616:+	-0.23	-3.97	8.41E-5	Obesity-related traits	
BLCA	cis	1	rs12550762	chr8:8576535	CLDN23	chr8:8559666-8561616:+	-0.23	-4.07	5.62E-5	Obesity-related traits	
BLCA	cis	1	rs12561806	chr1:46396776	CCDC163P	chr1:45960581-45965646:-	-0.35	-6.56	1.75E-10	Body mass index	
BLCA	cis	1	rs12564541	chr1:46380237	CCDC163P	chr1:45960581-45965646:-	-0.36	-6.79	4.29E-11	Body mass index	
BLCA	cis	1	rs1257200	chr2:135036696	RAB3GAP1	chr2:135809853-135933964:+	0.19	3.85	0.000138	Multiple sclerosis (severity)	
BLCA	cis	1	rs12577464	chr11:43662440	HSD17B12	chr11:43702143-43878160:+	-0.42	-6.86	2.82E-11	Forced vital capacity	
BLCA	cis	1	rs12594212	chr15:76802014	SCAPER	chr15:76640529-77197744:-	-0.21	-4.52	8.36E-6	Blood metabolite levels	
BLCA	cis	1	rs12594541	chr15:76834368	SCAPER	chr15:76640529-77197744:-	-0.2	-4.41	1.35E-5	Blood metabolite levels	
BLCA	cis	1	rs12600993	chr17:28291222	EFCAB5	chr17:28256874-28435469:+	0.22	3.89	0.000117	Coffee consumption (cups per day)	
BLCA	cis	1	rs12608504	chr19:18389135	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.3	2.15E-5	Waist-to-hip ratio adjusted for body mass index	
BLCA	cis	1	rs12610373	chr19:18398284	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.38	1.56E-5	Waist-to-hip ratio adjusted for body mass index	
BLCA	cis	1	rs12621280	chr2:232132984	ARMC9	chr2:232063342-232238606:+	0.18	3.91	0.00011	Food antigen IgG levels	
BLCA	cis	1	rs12637751	chr3:134266124	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs12637751	chr3:134266124	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs12638253	chr3:156626091	LEKR1	chr3:156544076-156763918:+	-0.23	-4.42	1.31E-5	Multiple sclerosis (severity)	
BLCA	cis	1	rs12639255	chr3:41861738	ULK4	chr3:41288091-42003660:-	0.62	9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs12652003	chr5:150231945	LOC134466	chr5:150310000-150326146:-	0.52	6.35	6.03E-10	Crohn's disease	
BLCA	cis	1	rs12656538	chr5:150251380	LOC134466	chr5:150310000-150326146:-	0.54	6.52	2.24E-10	Crohn's disease	
BLCA	cis	1	rs12656600	chr5:150311872	LOC134466	chr5:150310000-150326146:-	0.55	6.82	3.57E-11	Crohn's disease	
BLCA	cis	1	rs12659118	chr5:150324622	LOC134466	chr5:150310000-150326146:-	0.55	6.63	1.18E-10	Crohn's disease	
BLCA	cis	1	rs12661204	chr6:86678586	SNHG5	chr6:86386726-86388451:-	-0.54	-9.39	5.42E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12663651	chr6:86701655	SNHG5	chr6:86386726-86388451:-	-0.49	-8.73	7.95E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs12663690	chr6:86640162	SNHG5	chr6:86386726-86388451:-	0.51	8.94	1.7E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs12664335	chr6:86597774	SNHG5	chr6:86386726-86388451:-	0.52	9.38	5.71E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs12665321	chr6:86769289	SNHG5	chr6:86386726-86388451:-	-0.53	-9.25	1.56E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs1267817	chr7:66110040	CCT6P1	chr7:65216092-65228661:+	0.34	4.6	5.78E-6	Gout	
BLCA	cis	1	rs1267818	chr7:66107024	CCT6P1	chr7:65216092-65228661:+	0.35	4.78	2.49E-6	Gout	
BLCA	cis	1	rs1267820	chr7:66050295	CCT6P1	chr7:65216092-65228661:+	0.37	4.89	1.48E-6	Diabetic kidney disease	
BLCA	cis	1	rs12698509	chr7:65418876	CCT6P1	chr7:65216092-65228661:+	0.32	4.5	9.19E-6	Diabetic kidney disease	
BLCA	cis	1	rs12741472	chr1:27221609	GPN2	chr1:27205873-27216869:-	0.47	3.96	8.9E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs12752711	chr1:27250258	GPN2	chr1:27205873-27216869:-	0.47	3.96	8.9E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs12760175	chr1:46447840	CCDC163P	chr1:45960581-45965646:-	-0.32	-5.83	1.19E-8	Body mass index	
BLCA	cis	1	rs12787330	chr11:47812311	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.53	5.92E-8	Subjective well-being	
BLCA	cis	1	rs12787909	chr11:117546482	ARCN1	chr11:118443102-118473745:+	0.62	5.24	2.61E-7	Lipoprotein (a) - cholesterol levels	
BLCA	cis	1	rs12787909	chr11:117546482	ATP5L	chr11:118272104-118280561:+	0.42	3.88	0.000123	Lipoprotein (a) - cholesterol levels	
BLCA	cis	1	rs12787909	chr11:117546482	UBE4A	chr11:118230302-118269924:+	0.56	4.65	4.51E-6	Lipoprotein (a) - cholesterol levels	
BLCA	cis	1	rs12800378	chr11:87865942	RAB38	chr11:87846431-87908599:-	0.25	4.12	4.72E-5	Frontotemporal dementia	
BLCA	cis	1	rs12828421	chr12:7335217	PEX5	chr12:7341759-7371167:+	-0.25	-4.21	3.23E-5	IgG glycosylation	
BLCA	cis	1	rs12886745	chr14:104523839	TDRD9	chr14:104394817-104519002:+	0.32	4.82	2.1E-6	Bipolar disorder	
BLCA	cis	1	rs12889168	chr14:104481957	TDRD9	chr14:104394817-104519002:+	0.32	5.3	1.96E-7	Bipolar disorder	
BLCA	cis	1	rs12898430	chr15:76874923	SCAPER	chr15:76640529-77197744:-	-0.21	-4.57	6.55E-6	Blood metabolite levels	
BLCA	cis	1	rs12899981	chr15:85302373	LOC388152	chr15:84867600-84898920:-	-0.24	-4.16	3.87E-5	Schizophrenia	
BLCA	cis	1	rs12902672	chr15:84716986	LOC388152	chr15:84867600-84898920:-	-0.26	-4.55	7.19E-6	Schizophrenia	
BLCA	cis	1	rs12903134	chr15:85337699	LOC388152	chr15:84867600-84898920:-	-0.23	-4.16	4.0E-5	Schizophrenia	
BLCA	cis	1	rs12903820	chr15:84723820	LOC388152	chr15:84867600-84898920:-	-0.26	-4.55	7.19E-6	Schizophrenia	
BLCA	cis	1	rs12905057	chr15:85210765	LOC388152	chr15:84867600-84898920:-	-0.25	-4.25	2.73E-5	Schizophrenia	
BLCA	cis	1	rs12908161	chr15:85207825	LOC388152	chr15:84867600-84898920:-	-0.24	-4.07	5.81E-5	Schizophrenia	
BLCA	cis	1	rs12908549	chr15:85322351	LOC388152	chr15:84867600-84898920:-	-0.23	-4.18	3.68E-5	Schizophrenia	
BLCA	cis	1	rs12910012	chr15:85298662	LOC388152	chr15:84867600-84898920:-	-0.24	-4.15	4.1E-5	Schizophrenia	
BLCA	cis	1	rs12911736	chr15:85240008	LOC388152	chr15:84867600-84898920:-	-0.25	-4.27	2.47E-5	Schizophrenia	
BLCA	cis	1	rs12912388	chr15:85344550	LOC388152	chr15:84867600-84898920:-	-0.23	-4.16	4.0E-5	Schizophrenia	
BLCA	cis	1	rs12914047	chr15:52970993	ARPP19	chr15:52839432-52861364:-	0.22	4	7.63E-5	Schizophrenia	
BLCA	cis	1	rs12915234	chr15:84758301	LOC388152	chr15:84867600-84898920:-	-0.27	-4.66	4.31E-6	Schizophrenia	
BLCA	cis	1	rs12916348	chr15:84765527	LOC388152	chr15:84867600-84898920:-	-0.27	-4.65	4.65E-6	Schizophrenia	
BLCA	cis	1	rs12948099	chr17:79600799	TSPAN10	chr17:79609349-79615778:+	0.48	8.34	1.34E-15	Eye color traits	
BLCA	cis	1	rs12975854	chr19:45120592	ZNF235	chr19:44732357-44809178:-	-0.22	-3.85	0.00014	Late-onset Alzheimer's disease	
BLCA	cis	1	rs12980225	chr19:23026745	ZNF492	chr19:22817126-22850472:+	-0.29	-3.97	8.62E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs12980403	chr19:18398139	KIAA1683	chr19:18367906-18385319:-	-0.24	-4.38	1.56E-5	Waist-to-hip ratio adjusted for body mass index	
BLCA	cis	1	rs12983770	chr19:23023614	ZNF492	chr19:22817126-22850472:+	-0.29	-3.97	8.62E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs12999430	chr2:70306785	FAM136A	chr2:70523109-70529220:-	-0.26	-4.22	3.01E-5	Obesity-related traits	
BLCA	cis	1	rs13000817	chr2:70273707	FAM136A	chr2:70523109-70529220:-	-0.27	-4.28	2.4E-5	Obesity-related traits	
BLCA	cis	1	rs13004237	chr2:172833139	MAP1D	chr2:172864804-172945586:+	-0.28	-4.95	1.1E-6	Schizophrenia	
BLCA	cis	1	rs13026475	chr2:239178455	LOC151174	chr2:239133754-239140318:-	0.46	4.51	8.67E-6	Irritable bowel syndrome	
BLCA	cis	1	rs13026621	chr2:27807624	C2orf16	chr2:27799389-27805588:+	0.22	3.86	0.000135	Oral cavity cancer	
BLCA	cis	1	rs13033501	chr2:239181860	LOC151174	chr2:239133754-239140318:-	0.45	4.55	7.1E-6	Irritable bowel syndrome	
BLCA	cis	1	rs13053758	chr22:29855489	MTMR3	chr22:30279158-30426855:+	0.25	3.94	9.79E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13053758	chr22:29855489	NIPSNAP1	chr22:29950800-29977144:-	0.28	3.88	0.000125	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13054220	chr22:31704492	C22orf30	chr22:32072242-32146120:-	0.21	3.9	0.000114	Paclitaxel-induced neuropathy	
BLCA	cis	1	rs13055259	chr22:29856892	MTMR3	chr22:30279158-30426855:+	0.25	3.94	9.79E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13055259	chr22:29856892	NIPSNAP1	chr22:29950800-29977144:-	0.28	3.88	0.000125	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13055707	chr22:29851172	MTMR3	chr22:30279158-30426855:+	0.25	3.99	7.85E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13055707	chr22:29851172	NIPSNAP1	chr22:29950800-29977144:-	0.28	3.92	0.000105	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13057382	chr22:29850334	MTMR3	chr22:30279158-30426855:+	0.25	4.01	7.37E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13057382	chr22:29850334	NIPSNAP1	chr22:29950800-29977144:-	0.3	4.2	3.32E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13057815	chr22:29853526	MTMR3	chr22:30279158-30426855:+	0.25	3.94	9.79E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13057815	chr22:29853526	NIPSNAP1	chr22:29950800-29977144:-	0.28	3.88	0.000125	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs13059720	chr3:134242021	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.96	2.01E-14	Height	
BLCA	cis	1	rs13059720	chr3:134242021	CEP63	chr3:134204575-134293852:+	-0.24	-4.2	3.39E-5	Height	
BLCA	cis	1	rs13059843	chr3:195028183	C3orf21	chr3:194789015-194991895:-	0.29	5.58	4.62E-8	Body mass index	
BLCA	cis	1	rs13062518	chr3:195038287	C3orf21	chr3:194789015-194991895:-	0.28	5.37	1.34E-7	Body mass index	
BLCA	cis	1	rs13071551	chr3:134310867	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.94	2.24E-14	Height	
BLCA	cis	1	rs13071551	chr3:134310867	CEP63	chr3:134204575-134293852:+	-0.24	-4.14	4.32E-5	Height	
BLCA	cis	1	rs13072826	chr3:195064755	C3orf21	chr3:194789015-194991895:-	0.28	5.33	1.66E-7	Body mass index	
BLCA	cis	1	rs13076033	chr3:52898427	TMEM110	chr3:52867139-52931547:-	0.41	3.85	0.000138	Immune reponse to smallpox (secreted IL-2)	
BLCA	cis	1	rs13081177	chr3:134289860	ANAPC13	chr3:134196547-134204865:-	-0.51	-8	1.53E-14	Height	
BLCA	cis	1	rs13081177	chr3:134289860	CEP63	chr3:134204575-134293852:+	-0.25	-4.25	2.73E-5	Height	
BLCA	cis	1	rs13081688	chr3:134259954	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.96	2.01E-14	Height	
BLCA	cis	1	rs13081688	chr3:134259954	CEP63	chr3:134204575-134293852:+	-0.24	-4.2	3.39E-5	Height	
BLCA	cis	1	rs13087719	chr3:41951576	ULK4	chr3:41288091-42003660:-	-0.63	-9.74	3.43E-20	Diastolic blood pressure	
BLCA	cis	1	rs13087875	chr3:134261123	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs13087875	chr3:134261123	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs13089966	chr3:134279197	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs13089966	chr3:134279197	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs13090969	chr3:134307257	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.94	2.24E-14	Height	
BLCA	cis	1	rs13090969	chr3:134307257	CEP63	chr3:134204575-134293852:+	-0.24	-4.14	4.32E-5	Height	
BLCA	cis	1	rs13091785	chr3:48494098	TREX1	chr3:48501186-48509043:+	-0.19	-3.92	0.000105	Longevity	
BLCA	cis	1	rs13091924	chr3:195051136	C3orf21	chr3:194789015-194991895:-	0.29	5.61	3.97E-8	Body mass index	
BLCA	cis	1	rs13096604	chr3:134250099	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.96	2.01E-14	Height	
BLCA	cis	1	rs13096604	chr3:134250099	CEP63	chr3:134204575-134293852:+	-0.24	-4.2	3.39E-5	Height	
BLCA	cis	1	rs13096715	chr3:195074488	C3orf21	chr3:194789015-194991895:-	0.28	5.47	8.34E-8	Body mass index	
BLCA	cis	1	rs13109003	chr4:129975969	C4orf33	chr4:130014829-130033842:+	-0.32	-5.26	2.42E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs13130762	chr4:130022875	C4orf33	chr4:130014829-130033842:+	-0.33	-5.42	1.04E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs13148900	chr4:71361114	AMTN	chr4:71384298-71398459:+	-0.25	-3.95	9.39E-5	Alcoholism (heaviness of drinking)	
BLCA	cis	1	rs13161048	chr5:148615269	AFAP1L1	chr5:148651401-148721365:+	-0.25	-4.63	4.99E-6	Body mass index	
BLCA	cis	1	rs1317149	chr11:47486885	C1QTNF4	chr11:47611216-47615961:-	-0.28	-5.36	1.42E-7	Subjective well-being	
BLCA	cis	1	rs13194429	chr6:86646705	SNHG5	chr6:86386726-86388451:-	-0.54	-9.5	2.25E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs13195401	chr6:26463574	BTN3A2	chr6:26365398-26378546:+	-0.73	-7.89	3.1E-14	Schizophrenia	
BLCA	cis	1	rs13195402	chr6:26463575	BTN3A2	chr6:26365398-26378546:+	-0.73	-7.89	3.1E-14	Schizophrenia	
BLCA	cis	1	rs13196930	chr6:86652245	SNHG5	chr6:86386726-86388451:-	-0.54	-9.53	1.9E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs13199006	chr6:86608708	SNHG5	chr6:86386726-86388451:-	-0.55	-10.04	3.34E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs13200462	chr6:28218199	ZNF389	chr6:28129551-28137375:+	-0.33	-4.07	5.63E-5	Depression	
BLCA	cis	1	rs1320893	chr7:143752112	ARHGEF35	chr7:143883677-143892736:-	-0.33	-5.82	1.26E-8	Obesity-related traits	
BLCA	cis	1	rs1320894	chr7:143751802	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.98	5.07E-9	Obesity-related traits	
BLCA	cis	1	rs1320996	chr6:56100431	COL21A1	chr6:55921389-56258892:-	0.36	6.56	1.79E-10	Pulse pressure	
BLCA	cis	1	rs13217384	chr6:86720000	SNHG5	chr6:86386726-86388451:-	-0.53	-9.17	3.03E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs13220510	chr6:56779141	BEND6	chr6:56819773-56892138:+	-0.31	-4.31	2.05E-5	Menarche (age at onset)	
BLCA	cis	1	rs13220979	chr7:65363204	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs13226728	chr7:143746578	ARHGEF35	chr7:143883677-143892736:-	-0.33	-5.84	1.11E-8	Obesity-related traits	
BLCA	cis	1	rs13235972	chr7:65883605	CCT6P1	chr7:65216092-65228661:+	0.37	4.98	9.6E-7	Diabetic kidney disease	
BLCA	cis	1	rs13237037	chr7:65997882	CCT6P1	chr7:65216092-65228661:+	0.37	4.89	1.48E-6	Diabetic kidney disease	
BLCA	cis	1	rs13243677	chr7:143746572	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.92	7.23E-9	Obesity-related traits	
BLCA	cis	1	rs13247184	chr7:65358928	CCT6P1	chr7:65216092-65228661:+	0.33	4.45	1.11E-5	Diabetic kidney disease	
BLCA	cis	1	rs13252719	chr8:71734569	XKR9	chr8:71581600-71648176:+	0.82	17.79	5.09E-52	Bone mineral density	
BLCA	cis	1	rs13253842	chr8:71625503	XKR9	chr8:71581600-71648176:+	0.82	17.69	1.34E-51	Bone mineral density	
BLCA	cis	1	rs13282915	chr8:8570891	CLDN23	chr8:8559666-8561616:+	-0.23	-4.01	7.24E-5	Obesity-related traits	
BLCA	cis	1	rs13310597	chr7:65598540	CCT6P1	chr7:65216092-65228661:+	0.34	4.59	5.95E-6	Diabetic kidney disease	
BLCA	cis	1	rs13322305	chr3:134310791	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs13324903	chr3:195086647	C3orf21	chr3:194789015-194991895:-	-0.27	-5.27	2.29E-7	Body mass index	
BLCA	cis	1	rs13325965	chr3:41914942	ULK4	chr3:41288091-42003660:-	0.62	9.23	1.83E-18	Diastolic blood pressure	
BLCA	cis	1	rs13361189	chr5:150223387	LOC134466	chr5:150310000-150326146:-	0.48	5.93	6.69E-9	Crohn's disease	
BLCA	cis	1	rs1337844	chr6:86677273	SNHG5	chr6:86386726-86388451:-	-0.5	-8.81	4.42E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs1337850	chr6:86729103	SNHG5	chr6:86386726-86388451:-	-0.53	-9.35	7.51E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs13383871	chr2:73631779	ALMS1P	chr2:73872046-73912692:+	0.32	4.65	4.51E-6	Metabolite levels	
BLCA	cis	1	rs13385191	chr2:20888265	C2orf43	chr2:20883803-21022827:-	-0.4	-5.92	7.11E-9	Prostate cancer	
BLCA	cis	1	rs13398075	chr2:202376269	PPIL3	chr2:201735680-201753999:-	0.44	4.1	5.14E-5	Rheumatoid arthritis	
BLCA	cis	1	rs13398956	chr2:73720258	ALMS1P	chr2:73872046-73912692:+	0.34	5.03	7.46E-7	Metabolite levels	
BLCA	cis	1	rs13408294	chr2:202171573	PPIL3	chr2:201735680-201753999:-	-0.44	-4.92	1.3E-6	Rheumatoid arthritis	
BLCA	cis	1	rs13421462	chr2:73719875	ALMS1P	chr2:73872046-73912692:+	0.33	4.77	2.63E-6	Metabolite levels	
BLCA	cis	1	rs13428235	chr2:73633430	ALMS1P	chr2:73872046-73912692:+	0.33	4.87	1.65E-6	Metabolite levels	
BLCA	cis	1	rs13431267	chr2:73782200	ALMS1P	chr2:73872046-73912692:+	0.35	5.1	5.44E-7	Metabolite levels	
BLCA	cis	1	rs13432605	chr2:73810981	ALMS1P	chr2:73872046-73912692:+	0.36	5.2	3.22E-7	Metabolite levels	
BLCA	cis	1	rs134869	chr22:42652074	C22orf32	chr22:42475699-42480287:+	0.2	5.34	1.63E-7	Cognitive function	
BLCA	cis	1	rs134869	chr22:42652074	CCDC134	chr22:42196678-42222303:+	0.26	4.26	2.58E-5	Cognitive function	
BLCA	cis	1	rs134869	chr22:42652074	CYP2D6	chr22:42522502-42526883:-	-0.38	-8.08	8.39E-15	Cognitive function	
BLCA	cis	1	rs134869	chr22:42652074	NAGA	chr22:42454339-42466846:-	0.3	5.46	8.68E-8	Cognitive function	
BLCA	cis	1	rs134873	chr22:42657566	C22orf32	chr22:42475699-42480287:+	0.21	5.52	6.11E-8	Cognitive function	
BLCA	cis	1	rs134873	chr22:42657566	CCDC134	chr22:42196678-42222303:+	0.25	4.07	5.8E-5	Cognitive function	
BLCA	cis	1	rs134873	chr22:42657566	CYP2D6	chr22:42522502-42526883:-	-0.36	-7.65	1.65E-13	Cognitive function	
BLCA	cis	1	rs134873	chr22:42657566	NAGA	chr22:42454339-42466846:-	0.3	5.31	1.88E-7	Cognitive function	
BLCA	cis	1	rs134882	chr22:42670965	C22orf32	chr22:42475699-42480287:+	0.2	5.25	2.52E-7	Cognitive function	
BLCA	cis	1	rs134882	chr22:42670965	CCDC134	chr22:42196678-42222303:+	0.24	4.01	7.3E-5	Cognitive function	
BLCA	cis	1	rs134882	chr22:42670965	CYP2D6	chr22:42522502-42526883:-	-0.36	-7.78	6.79E-14	Cognitive function	
BLCA	cis	1	rs134882	chr22:42670965	NAGA	chr22:42454339-42466846:-	0.27	4.82	2.11E-6	Cognitive function	
BLCA	cis	1	rs134900	chr22:42683343	C22orf32	chr22:42475699-42480287:+	0.17	4.68	4.07E-6	Cognitive function	
BLCA	cis	1	rs134900	chr22:42683343	CYP2D6	chr22:42522502-42526883:-	-0.35	-7.56	3.06E-13	Cognitive function	
BLCA	cis	1	rs134900	chr22:42683343	NAGA	chr22:42454339-42466846:-	0.26	4.59	5.95E-6	Cognitive function	
BLCA	cis	1	rs134902	chr22:42683997	C22orf32	chr22:42475699-42480287:+	0.17	4.57	6.47E-6	Cognitive function	
BLCA	cis	1	rs134902	chr22:42683997	CYP2D6	chr22:42522502-42526883:-	-0.35	-7.53	3.57E-13	Cognitive function	
BLCA	cis	1	rs134902	chr22:42683997	NAGA	chr22:42454339-42466846:-	0.24	4.38	1.51E-5	Cognitive function	
BLCA	cis	1	rs1351452	chr11:116943354	PCSK7	chr11:117075789-117102811:-	0.38	4.93	1.25E-6	Protein quantitative trait loci	
BLCA	cis	1	rs1357762	chr3:134264859	ANAPC13	chr3:134196547-134204865:-	0.47	7.54	3.54E-13	Height	
BLCA	cis	1	rs1371135	chr15:90391270	AP3S2	chr15:90373832-90456222:-	-0.7	-10.55	5.08E-23	Type 2 diabetes	
BLCA	cis	1	rs137115	chr22:43011403	SERHL	chr22:42896585-42968535:+	0.38	5.01	8.22E-7	Parental extreme longevity (95 years and older)	
BLCA	cis	1	rs1374469	chr4:1724799	FAM53A	chr4:1641609-1685854:-	-0.33	-4.9	1.44E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs1374531	chr4:106523932	INTS12	chr4:106603787-106629881:-	-0.46	-3.91	0.000108	Post bronchodilator FEV1	
BLCA	cis	1	rs1390006	chr17:56890663	RAD51C	chr17:56769963-56811690:+	-0.28	-5.03	7.47E-7	Cognitive test performance	
BLCA	cis	1	rs1392104	chr7:65759107	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.72	3.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs1392635	chr15:69398026	CALML4	chr15:68483044-68498448:-	0.24	3.88	0.000122	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	
BLCA	cis	1	rs1401999	chr3:183678342	VWA5B2	chr3:183948317-183960116:+	-0.24	-3.91	0.00011	Anterior chamber depth	
BLCA	cis	1	rs1402002	chr3:183642794	VWA5B2	chr3:183948317-183960116:+	-0.23	-3.86	0.000131	Anterior chamber depth	
BLCA	cis	1	rs1402003	chr3:183642879	ABCC5	chr3:183637726-183735727:-	-0.2	-3.92	0.000104	Anterior chamber depth	
BLCA	cis	1	rs1402003	chr3:183642879	VWA5B2	chr3:183948317-183960116:+	-0.25	-4.03	6.6E-5	Anterior chamber depth	
BLCA	cis	1	rs1403284	chr2:73726662	ALMS1P	chr2:73872046-73912692:+	-0.31	-4.49	9.38E-6	Metabolite levels	
BLCA	cis	1	rs1404147	chr7:65264524	CCT6P1	chr7:65216092-65228661:+	0.32	5.04	7.11E-7	Diabetic kidney disease	
BLCA	cis	1	rs1415753	chr6:86753074	SNHG5	chr6:86386726-86388451:-	-0.53	-9.25	1.64E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs1419183	chr6:28242794	ZNF389	chr6:28129551-28137375:+	-0.34	-4.32	1.98E-5	Depression	
BLCA	cis	1	rs1423620	chr5:56100996	C5orf35	chr5:56205103-56213010:+	0.66	10.21	8.29E-22	Type 2 diabetes	
BLCA	cis	1	rs1423621	chr5:56101035	C5orf35	chr5:56205103-56213010:+	0.64	10.2	8.83E-22	Type 2 diabetes	
BLCA	cis	1	rs1428551	chr5:150259832	LOC134466	chr5:150310000-150326146:-	0.44	5.81	1.31E-8	Crohn's disease	
BLCA	cis	1	rs1428552	chr5:150259831	LOC134466	chr5:150310000-150326146:-	0.46	6.09	2.68E-9	Crohn's disease	
BLCA	cis	1	rs1428554	chr5:150257616	LOC134466	chr5:150310000-150326146:-	0.48	6.25	1.09E-9	Crohn's disease	
BLCA	cis	1	rs1428555	chr5:150257391	LOC134466	chr5:150310000-150326146:-	-0.46	-5.8	1.41E-8	Crohn's disease	
BLCA	cis	1	rs1451707	chr6:56801877	BEND6	chr6:56819773-56892138:+	-0.3	-4.11	4.92E-5	Menarche (age at onset)	
BLCA	cis	1	rs1451708	chr6:56802201	BEND6	chr6:56819773-56892138:+	-0.3	-4.11	4.92E-5	Menarche (age at onset)	
BLCA	cis	1	rs1469712	chr19:19528821	YJEFN3	chr19:19639720-19648393:+	-0.23	-4.44	1.16E-5	Schizophrenia	
BLCA	cis	1	rs1473248	chr19:41923314	B3GNT8	chr19:41931265-41934635:-	0.21	4.03	6.61E-5	Height	
BLCA	cis	1	rs1474698	chr6:56064197	COL21A1	chr6:55921389-56258892:-	-0.33	-6.12	2.34E-9	Pulse pressure	
BLCA	cis	1	rs1484994	chr20:30305975	COX4I2	chr20:30225691-30232800:+	0.22	4.59	6.11E-6	Subcortical brain region volumes	
BLCA	cis	1	rs1488193	chr3:112681585	C3orf17	chr3:112721294-112738555:-	-0.45	-4.65	4.56E-6	Economic and political preferences	
BLCA	cis	1	rs1498718	chr3:134205920	ANAPC13	chr3:134196547-134204865:-	0.47	7.39	9.45E-13	Height	
BLCA	cis	1	rs1499613	chr7:65730860	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.72	3.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs1499614	chr7:65730798	CCT6P1	chr7:65216092-65228661:+	0.35	4.76	2.78E-6	Diabetic kidney disease	
BLCA	cis	1	rs1519466	chr9:111860797	C9orf5	chr9:111777416-111882225:-	-0.29	-3.93	0.0001	Information processing speed	
BLCA	cis	1	rs151964	chr5:96123666	ERAP1	chr5:96096515-96149837:-	-0.51	-10.92	2.47E-24	Ankylosing spondylitis	
BLCA	cis	1	rs151964	chr5:96123666	ERAP2	chr5:96211644-96255398:+	0.32	5.44	9.74E-8	Ankylosing spondylitis	
BLCA	cis	1	rs1520884	chr11:18309700	GTF2H1	chr11:18343816-18388590:+	-0.29	-5.43	9.82E-8	Pancreatic cancer	
BLCA	cis	1	rs1533266	chr7:143766714	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.02	3.98E-9	Obesity-related traits	
BLCA	cis	1	rs1533267	chr7:143766440	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.08	2.92E-9	Obesity-related traits	
BLCA	cis	1	rs1533268	chr7:143766358	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.3E-9	Obesity-related traits	
BLCA	cis	1	rs1534025	chr3:134313304	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.84	4.46E-14	Height	
BLCA	cis	1	rs1534025	chr3:134313304	CEP63	chr3:134204575-134293852:+	-0.24	-4.1	5.07E-5	Height	
BLCA	cis	1	rs1534026	chr3:134284767	ANAPC13	chr3:134196547-134204865:-	0.49	7.74	8.99E-14	Height	
BLCA	cis	1	rs1534026	chr3:134284767	CEP63	chr3:134204575-134293852:+	0.23	3.97	8.43E-5	Height	
BLCA	cis	1	rs1534471	chr2:73647508	ALMS1P	chr2:73872046-73912692:+	0.37	5.47	8.03E-8	Metabolite levels	
BLCA	cis	1	rs1538767	chr3:195007852	C3orf21	chr3:194789015-194991895:-	0.3	5.91	7.67E-9	Body mass index	
BLCA	cis	1	rs1540894	chr7:143767676	ARHGEF35	chr7:143883677-143892736:-	-0.31	-5.44	9.44E-8	Obesity-related traits	
BLCA	cis	1	rs1546059	chr7:65654709	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.75	2.86E-6	Diabetic kidney disease	
BLCA	cis	1	rs1546753	chr3:119557075	KTELC1	chr3:119187785-119213552:+	0.23	3.98	8.29E-5	HDL cholesterol	
BLCA	cis	1	rs1553174	chr7:65731194	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.72	3.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs1559282	chr5:56099375	C5orf35	chr5:56205103-56213010:+	0.65	9.62	8.98E-20	Type 2 diabetes	
BLCA	cis	1	rs156425	chr7:23309119	GPNMB	chr7:23286316-23314728:+	0.24	4.07	5.6E-5	Parkinson's disease	
BLCA	cis	1	rs1564472	chr15:84569793	C15orf40	chr15:83657724-83680393:-	0.24	4.1	5.01E-5	Waist circumference adjusted for body mass index;Waist circumference	
BLCA	cis	1	rs1564716	chr3:41862613	ULK4	chr3:41288091-42003660:-	0.62	9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs15676	chr9:131572027	ENDOG	chr9:131580779-131584954:+	-0.18	-4	7.75E-5	Blood metabolite levels	
BLCA	cis	1	rs1577917	chr6:86691940	SNHG5	chr6:86386726-86388451:-	-0.54	-9.69	5.26E-20	Response to antipsychotic treatment	
BLCA	cis	1	rs1577919	chr6:86757296	SNHG5	chr6:86386726-86388451:-	-0.53	-9.25	1.64E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs1599280	chr6:56792576	BEND6	chr6:56819773-56892138:+	-0.29	-3.97	8.44E-5	Menarche (age at onset)	
BLCA	cis	1	rs1599932	chr12:58177943	FAM119B	chr12:58166383-58176323:+	0.28	4.28	2.32E-5	Multiple sclerosis	
BLCA	cis	1	rs1599932	chr12:58177943	TSFM	chr12:58176536-58191367:+	-0.39	-6.83	3.34E-11	Multiple sclerosis	
BLCA	cis	1	rs1599932	chr12:58177943	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-3.97	8.45E-5	Multiple sclerosis	
BLCA	cis	1	rs160633	chr7:65528228	CCT6P1	chr7:65216092-65228661:+	0.34	4.68	3.93E-6	Diabetic kidney disease	
BLCA	cis	1	rs160637	chr7:65584318	CCT6P1	chr7:65216092-65228661:+	0.35	4.95	1.13E-6	Diabetic kidney disease	
BLCA	cis	1	rs160639	chr7:65579987	CCT6P1	chr7:65216092-65228661:+	0.33	4.84	1.85E-6	Diabetic kidney disease	
BLCA	cis	1	rs160642	chr7:65558373	CCT6P1	chr7:65216092-65228661:+	0.34	4.8	2.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs160644	chr7:65558186	CCT6P1	chr7:65216092-65228661:+	0.34	4.8	2.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs160646	chr7:65556280	CCT6P1	chr7:65216092-65228661:+	0.34	4.8	2.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs160648	chr7:65543384	CCT6P1	chr7:65216092-65228661:+	0.34	4.53	8.07E-6	Diabetic kidney disease	
BLCA	cis	1	rs160652	chr7:65538431	CCT6P1	chr7:65216092-65228661:+	0.37	4.93	1.22E-6	Diabetic kidney disease	
BLCA	cis	1	rs160655	chr7:65533214	CCT6P1	chr7:65216092-65228661:+	0.34	4.51	8.48E-6	Diabetic kidney disease	
BLCA	cis	1	rs1607908	chr3:41905196	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1609810	chr9:123642351	LOC253039	chr9:123605320-123616644:+	-0.34	-5.84	1.1E-8	Rheumatoid arthritis	
BLCA	cis	1	rs1612124	chr3:41967893	ULK4	chr3:41288091-42003660:-	-0.62	-9.64	8.11E-20	Diastolic blood pressure	
BLCA	cis	1	rs1613759	chr3:41906183	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1615243	chr3:41965234	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1615543	chr3:41906404	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1628874	chr3:41955714	ULK4	chr3:41288091-42003660:-	-0.63	-9.74	3.43E-20	Diastolic blood pressure	
BLCA	cis	1	rs1629460	chr3:41927449	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs1633360	chr12:58108052	TSFM	chr12:58176536-58191367:+	0.26	4.61	5.6E-6	Rheumatoid arthritis	
BLCA	cis	1	rs1638731	chr7:66144679	CCT6P1	chr7:65216092-65228661:+	0.38	4.99	9.26E-7	Gout	
BLCA	cis	1	rs1638734	chr7:66097539	CCT6P1	chr7:65216092-65228661:+	0.35	4.78	2.49E-6	Diabetic kidney disease	
BLCA	cis	1	rs1665362	chr4:1726367	FAM53A	chr4:1641609-1685854:-	-0.34	-4.97	1.0E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs1665364	chr4:1727206	FAM53A	chr4:1641609-1685854:-	0.33	5.13	4.6E-7	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs1665366	chr4:1728381	FAM53A	chr4:1641609-1685854:-	0.36	5.19	3.43E-7	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs166868	chr15:80014686	MTHFS	chr15:80137320-80189370:-	-0.24	-4.46	1.08E-5	IgG glycosylation	
BLCA	cis	1	rs1679709	chr6:28228342	ZNF389	chr6:28129551-28137375:+	0.34	4.3	2.13E-5	Depression	
BLCA	cis	1	rs1679732	chr6:28221264	ZNF389	chr6:28129551-28137375:+	0.33	4.24	2.83E-5	Depression	
BLCA	cis	1	rs16826864	chr3:156580033	LEKR1	chr3:156544076-156763918:+	-0.47	-6.39	4.95E-10	Bone mineral density	
BLCA	cis	1	rs16837131	chr2:202173812	PPIL3	chr2:201735680-201753999:-	0.42	4.62	5.25E-6	Rheumatoid arthritis	
BLCA	cis	1	rs16870629	chr5:1015063	CLPTM1L	chr5:1318007-1345002:-	-0.23	-4.19	3.47E-5	QT interval	
BLCA	cis	1	rs16876529	chr6:86591202	SNHG5	chr6:86386726-86388451:-	-0.6	-10.81	5.77E-24	Response to antipsychotic treatment	
BLCA	cis	1	rs16942155	chr15:60418758	GTF2A2	chr15:59930263-59949737:-	0.41	3.88	0.000122	Type 2 diabetes	
BLCA	cis	1	rs16952611	chr18:48382668	MRO	chr18:48321491-48351754:-	-0.23	-4.24	2.77E-5	Entorhinal cortical thickness	
BLCA	cis	1	rs16974263	chr19:40913539	ZNF546	chr19:40502943-40523514:+	0.25	4.16	4.01E-5	Otitis media (recurrent);Otitis media (chronic);Otitis media	
BLCA	cis	1	rs1699379	chr4:129992337	C4orf33	chr4:130014829-130033842:+	-0.33	-5.43	1.02E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1699389	chr4:130004079	C4orf33	chr4:130014829-130033842:+	-0.34	-5.6	4.12E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1699391	chr4:130005096	C4orf33	chr4:130014829-130033842:+	-0.34	-5.6	4.12E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1699392	chr4:130022347	C4orf33	chr4:130014829-130033842:+	-0.33	-5.42	1.04E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1699393	chr4:130019352	C4orf33	chr4:130014829-130033842:+	-0.33	-5.44	9.44E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1699394	chr4:130019312	C4orf33	chr4:130014829-130033842:+	-0.34	-5.66	3.01E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1701750	chr7:65467145	CCT6P1	chr7:65216092-65228661:+	0.3	4.29	2.25E-5	Diabetic kidney disease	
BLCA	cis	1	rs1701758	chr7:65470201	CCT6P1	chr7:65216092-65228661:+	0.3	4.28	2.37E-5	Diabetic kidney disease	
BLCA	cis	1	rs17030613	chr1:113190807	ST7L	chr1:113066142-113162405:-	0.41	6.02	4.16E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs17030651	chr1:113239382	ST7L	chr1:113066142-113162405:-	0.4	5.9	8.12E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs17036023	chr1:117129711	VANGL1	chr1:116184574-116240845:+	0.5	4.08	5.41E-5	Asthma (childhood onset)	
BLCA	cis	1	rs17061431	chr3:41792655	ULK4	chr3:41288091-42003660:-	0.61	9.43	4.0E-19	Diastolic blood pressure	
BLCA	cis	1	rs17062109	chr3:41810364	ULK4	chr3:41288091-42003660:-	0.61	9.5	2.39E-19	Diastolic blood pressure	
BLCA	cis	1	rs17063584	chr3:41861463	ULK4	chr3:41288091-42003660:-	0.63	9.78	2.63E-20	Diastolic blood pressure	
BLCA	cis	1	rs17063599	chr3:41861676	ULK4	chr3:41288091-42003660:-	0.62	9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs17063649	chr3:41863406	ULK4	chr3:41288091-42003660:-	0.62	9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs17064124	chr3:41890803	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1707304	chr1:46598269	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.37	5.54E-10	Body mass index	
BLCA	cis	1	rs1707321	chr1:46505309	CCDC163P	chr1:45960581-45965646:-	-0.36	-6.84	3.15E-11	Body mass index	
BLCA	cis	1	rs1707335	chr1:46571921	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.21	1.42E-9	Body mass index	
BLCA	cis	1	rs1707336	chr1:46493460	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.9E-10	Body mass index	
BLCA	cis	1	rs1707340	chr1:46514942	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.25	1.11E-9	Body mass index	
BLCA	cis	1	rs17096228	chr14:74558669	LIN52	chr14:74551656-74667117:+	0.35	7.97	1.8E-14	Common traits (Other)	
BLCA	cis	1	rs17102580	chr12:66902873	CAND1	chr12:67663061-67708388:+	0.23	4.42	1.27E-5	Age of smoking initiation	
BLCA	cis	1	rs17106890	chr12:70052448	CPSF6	chr12:69633317-69668137:+	0.29	4.2	3.31E-5	Orofacial clefts	
BLCA	cis	1	rs17106890	chr12:70052448	LRRC10	chr12:70002347-70004942:-	0.21	4.07	5.82E-5	Orofacial clefts	
BLCA	cis	1	rs17108533	chr14:71249802	MAP3K9	chr14:71194856-71275888:-	-0.36	-4.11	4.89E-5	Response to antipsychotic treatment in schizophrenia (reasoning)	
BLCA	cis	1	rs17111376	chr5:150226899	LOC134466	chr5:150310000-150326146:-	0.4	4.98	9.62E-7	Crohn's disease	
BLCA	cis	1	rs17120139	chr11:116774201	PCSK7	chr11:117075789-117102811:-	0.43	5.24	2.64E-7	Protein quantitative trait loci	
BLCA	cis	1	rs17149161	chr7:75978229	UPK3B	chr7:76139745-76157197:+	-0.3	-6.33	6.76E-10	Multiple sclerosis	
BLCA	cis	1	rs1715235	chr7:65488394	CCT6P1	chr7:65216092-65228661:+	0.31	4.42	1.31E-5	Diabetic kidney disease	
BLCA	cis	1	rs17156099	chr7:28006442	HIBADH	chr7:27565063-27702602:-	-0.37	-3.84	0.000144	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs17162339	chr1:27252823	GPN2	chr1:27205873-27216869:-	-0.48	-4.18	3.58E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs17164747	chr4:260587	ZNF718	chr4:53272-156488:+	0.34	4.66	4.33E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs1716642	chr3:41965865	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716644	chr3:41968028	ULK4	chr3:41288091-42003660:-	-0.62	-9.64	8.11E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716651	chr3:41975099	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716657	chr3:41918456	ULK4	chr3:41288091-42003660:-	-0.64	-9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1716660	chr3:41929960	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716661	chr3:41962818	ULK4	chr3:41288091-42003660:-	-0.62	-9.53	1.8E-19	Diastolic blood pressure	
BLCA	cis	1	rs1716664	chr3:41948378	ULK4	chr3:41288091-42003660:-	-0.63	-9.74	3.43E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716668	chr3:41907850	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1716669	chr3:41908681	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1716676	chr3:41903208	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1716683	chr3:41923074	ULK4	chr3:41288091-42003660:-	-0.64	-9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1716685	chr3:41925301	ULK4	chr3:41288091-42003660:-	0.62	9.75	3.22E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716688	chr3:41926546	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716690	chr3:41922102	ULK4	chr3:41288091-42003660:-	-0.64	-9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1716692	chr3:41983786	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716693	chr3:41985600	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716696	chr3:41935811	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716984	chr3:41965532	ULK4	chr3:41288091-42003660:-	-0.64	-9.81	2.05E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716987	chr3:41970516	ULK4	chr3:41288091-42003660:-	-0.61	-9.43	3.93E-19	Diastolic blood pressure	
BLCA	cis	1	rs1716993	chr3:41974556	ULK4	chr3:41288091-42003660:-	-0.62	-9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs1716997	chr3:41924333	ULK4	chr3:41288091-42003660:-	-0.64	-9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1716999	chr3:41930041	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs1717000	chr3:41930219	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs1717001	chr3:41934949	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs1717006	chr3:41940448	ULK4	chr3:41288091-42003660:-	0.6	9.44	3.81E-19	Diastolic blood pressure	
BLCA	cis	1	rs1717009	chr3:41946308	ULK4	chr3:41288091-42003660:-	-0.63	-9.74	3.43E-20	Diastolic blood pressure	
BLCA	cis	1	rs1717011	chr3:41980199	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1717014	chr3:41917395	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1717017	chr3:41915616	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1717020	chr3:41981490	ULK4	chr3:41288091-42003660:-	0.62	9.53	1.8E-19	Diastolic blood pressure	
BLCA	cis	1	rs1717021	chr3:41983860	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1717024	chr3:41984888	ULK4	chr3:41288091-42003660:-	-0.59	-9.21	2.1E-18	Diastolic blood pressure	
BLCA	cis	1	rs1717027	chr3:41987920	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs1717031	chr3:41905791	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1717033	chr3:41910216	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs1723267	chr7:65473314	CCT6P1	chr7:65216092-65228661:+	0.31	4.37	1.63E-5	Diabetic kidney disease	
BLCA	cis	1	rs1723269	chr7:65472786	CCT6P1	chr7:65216092-65228661:+	0.32	4.35	1.79E-5	Diabetic kidney disease	
BLCA	cis	1	rs1723270	chr7:65469830	CCT6P1	chr7:65216092-65228661:+	0.32	4.36	1.7E-5	Diabetic kidney disease	
BLCA	cis	1	rs17290219	chr3:150881774	P2RY12	chr3:151055238-151102544:-	0.28	3.95	9.22E-5	Heschl's gyrus morphology	
BLCA	cis	1	rs17311679	chr19:50521331	SIGLEC16	chr19:50472912-50479075:+	-0.6	-5.72	2.13E-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs17433780	chr1:89474818	GBP3	chr1:89472367-89488549:-	0.84	18.51	4.2E-55	Carotid intima media thickness	
BLCA	cis	1	rs17433780	chr1:89474818	GBP7	chr1:89597434-89641723:-	0.26	4.38	1.53E-5	Carotid intima media thickness	
BLCA	cis	1	rs17450853	chr6:56788004	BEND6	chr6:56819773-56892138:+	-0.28	-4.11	4.75E-5	Menarche (age at onset)	
BLCA	cis	1	rs17496332	chr1:107546375	PRMT6	chr1:107599267-107601907:+	0.37	5.89	8.27E-9	Sex hormone-binding globulin levels	
BLCA	cis	1	rs1757924	chr4:130019599	C4orf33	chr4:130014829-130033842:+	-0.34	-5.65	3.13E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1757925	chr4:130020791	C4orf33	chr4:130014829-130033842:+	0.33	5.43	1.03E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1757927	chr4:130022069	C4orf33	chr4:130014829-130033842:+	-0.33	-5.42	1.04E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1757928	chr4:130022161	C4orf33	chr4:130014829-130033842:+	-0.33	-5.42	1.04E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1757930	chr4:130022356	C4orf33	chr4:130014829-130033842:+	-0.34	-5.5	6.99E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1757935	chr4:130023759	C4orf33	chr4:130014829-130033842:+	-0.33	-5.42	1.04E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs17596617	chr11:43690717	HSD17B12	chr11:43702143-43878160:+	-0.45	-7.73	9.63E-14	Forced vital capacity	
BLCA	cis	1	rs17600551	chr15:85319258	LOC388152	chr15:84867600-84898920:-	-0.24	-4.17	3.85E-5	Schizophrenia	
BLCA	cis	1	rs17601029	chr15:85347709	LOC388152	chr15:84867600-84898920:-	-0.24	-4.15	4.08E-5	Schizophrenia	
BLCA	cis	1	rs17608059	chr17:13910549	CDRT15P	chr17:13927815-13928915:+	-0.44	-8.53	3.45E-16	Temperament	
BLCA	cis	1	rs176084	chr15:80014968	MTHFS	chr15:80137320-80189370:-	-0.24	-4.36	1.66E-5	IgG glycosylation	
BLCA	cis	1	rs17608677	chr2:219936871	FAM134A	chr2:220042939-220050190:+	0.3	3.9	0.000112	Height	
BLCA	cis	1	rs17608677	chr2:219936871	RNF25	chr2:219528588-219536781:-	0.25	3.99	7.9E-5	Height	
BLCA	cis	1	rs17608677	chr2:219936871	ZNF142	chr2:219502644-219524261:-	0.29	4.02	7.13E-5	Height	
BLCA	cis	1	rs17614559	chr15:52878719	ARPP19	chr15:52839432-52861364:-	0.23	4.24	2.78E-5	Schizophrenia	
BLCA	cis	1	rs17649250	chr1:171720586	VAMP4	chr1:171669298-171711214:-	0.29	3.92	0.000106	Hippocampal atrophy	
BLCA	cis	1	rs17661933	chr19:50534520	SIGLEC16	chr19:50472912-50479075:+	-0.53	-5.27	2.3E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs17671194	chr15:40667539	C15orf23	chr15:40674922-40686488:+	0.36	6.11	2.41E-9	Heschl's gyrus morphology	
BLCA	cis	1	rs17671250	chr15:40673124	C15orf23	chr15:40674922-40686488:+	-0.25	-4.44	1.18E-5	Heschl's gyrus morphology	
BLCA	cis	1	rs17671250	chr15:40673124	IVD	chr15:40697686-40713512:+	0.33	4.55	7.34E-6	Heschl's gyrus morphology	
BLCA	cis	1	rs17685143	chr6:56774788	BEND6	chr6:56819773-56892138:+	-0.31	-4.28	2.36E-5	Menarche (age at onset)	
BLCA	cis	1	rs1768803	chr1:46546208	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.22	1.28E-9	Body mass index	
BLCA	cis	1	rs1768803	chr1:46546208	MUTYH	chr1:45794915-45806142:-	0.2	3.9	0.000115	Body mass index	
BLCA	cis	1	rs1768816	chr1:46528599	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.74E-10	Body mass index	
BLCA	cis	1	rs1768816	chr1:46528599	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000117	Body mass index	
BLCA	cis	1	rs17694011	chr3:134213981	ANAPC13	chr3:134196547-134204865:-	0.49	7.74	8.8E-14	Height	
BLCA	cis	1	rs17694011	chr3:134213981	CEP63	chr3:134204575-134293852:+	0.23	4.02	7.02E-5	Height	
BLCA	cis	1	rs17694493	chr9:22041998	CDKN2A	chr9:21967752-21994490:-	0.31	4.62	5.37E-6	Prostate cancer	
BLCA	cis	1	rs17694493	chr9:22041998	CDKN2B	chr9:22002906-22009312:-	0.32	4.77	2.67E-6	Prostate cancer	
BLCA	cis	1	rs17694493	chr9:22041998	KLHL9	chr9:21324054-21335429:-	0.3	4.28	2.41E-5	Prostate cancer	
BLCA	cis	1	rs17713396	chr2:227201	SH3YL1	chr2:218138-264810:-	-0.43	-11.03	9.8E-25	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs17713729	chr2:249092	SH3YL1	chr2:218138-264810:-	-0.45	-11.8	1.3E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs17714252	chr2:285471	SH3YL1	chr2:218138-264810:-	-0.45	-11.64	5.13E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs17727568	chr5:150244688	LOC134466	chr5:150310000-150326146:-	0.54	6.45	3.38E-10	Crohn's disease	
BLCA	cis	1	rs1775148	chr1:205757824	PM20D1	chr1:205797154-205819245:-	-0.26	-4.85	1.79E-6	Prostate cancer	
BLCA	cis	1	rs1775148	chr1:205757824	RAB7L1	chr1:205737115-205744610:-	0.36	5.82	1.22E-8	Prostate cancer	
BLCA	cis	1	rs1775151	chr1:205745684	RAB7L1	chr1:205737115-205744610:-	0.27	4	7.56E-5	Parkinson's disease	
BLCA	cis	1	rs17752459	chr6:56798755	BEND6	chr6:56819773-56892138:+	-0.29	-4.02	7.02E-5	Menarche (age at onset)	
BLCA	cis	1	rs17761723	chr17:2107090	SRR	chr17:2207248-2228553:+	0.37	6.36	5.75E-10	Esophageal cancer (squamous cell)	
BLCA	cis	1	rs17761864	chr17:2171637	SRR	chr17:2207248-2228553:+	-0.39	-6.81	3.86E-11	Esophageal cancer (squamous cell)	
BLCA	cis	1	rs1778508	chr6:28229881	ZNF389	chr6:28129551-28137375:+	0.35	4.5	9.14E-6	Depression	
BLCA	cis	1	rs1778511	chr6:28229411	ZNF389	chr6:28129551-28137375:+	0.34	4.3	2.13E-5	Depression	
BLCA	cis	1	rs17800886	chr5:150309539	LOC134466	chr5:150310000-150326146:-	0.53	6.69	8.09E-11	Crohn's disease	
BLCA	cis	1	rs17800987	chr5:150323428	LOC134466	chr5:150310000-150326146:-	0.54	6.8	4.03E-11	Crohn's disease	
BLCA	cis	1	rs17818399	chr2:46826026	ATP6V1E2	chr2:46738988-46769696:-	-0.26	-4.27	2.42E-5	Height	
BLCA	cis	1	rs17878846	chr10:104630412	AS3MT	chr10:104613967-104661653:+	-0.34	-3.95	9.24E-5	Hypertension;Systolic blood pressure;Diastolic blood pressure	
BLCA	cis	1	rs17878846	chr10:104630412	SFXN2	chr10:104474298-104498946:+	-0.35	-3.94	9.88E-5	Hypertension;Systolic blood pressure;Diastolic blood pressure	
BLCA	cis	1	rs1794693	chr6:167405670	RNASET2	chr6:167343008-167412795:-	-0.25	-5.15	4.08E-7	Crohn's disease	
BLCA	cis	1	rs1796220	chr7:66062100	CCT6P1	chr7:65216092-65228661:+	0.35	4.82	2.04E-6	Diabetic kidney disease	
BLCA	cis	1	rs1796228	chr7:66033084	CCT6P1	chr7:65216092-65228661:+	0.37	4.89	1.48E-6	Diabetic kidney disease	
BLCA	cis	1	rs1800615	chr1:15832281	CASP9	chr1:15817324-15851384:-	0.24	4.55	7.28E-6	Glomerular filtration rate (creatinine)	
BLCA	cis	1	rs1807019	chr18:48378106	MRO	chr18:48321491-48351754:-	-0.24	-4.34	1.79E-5	Entorhinal cortical thickness	
BLCA	cis	1	rs1814336	chr3:134200823	ANAPC13	chr3:134196547-134204865:-	0.51	8.15	5.2E-15	Height	
BLCA	cis	1	rs1814336	chr3:134200823	CEP63	chr3:134204575-134293852:+	0.26	4.46	1.06E-5	Height	
BLCA	cis	1	rs1814337	chr3:134200682	ANAPC13	chr3:134196547-134204865:-	0.49	7.78	6.88E-14	Height	
BLCA	cis	1	rs1814337	chr3:134200682	CEP63	chr3:134204575-134293852:+	0.24	4.14	4.28E-5	Height	
BLCA	cis	1	rs1815787	chr11:116921397	PCSK7	chr11:117075789-117102811:-	-0.4	-5.13	4.67E-7	Subjective well-being	
BLCA	cis	1	rs1816256	chr5:150272853	LOC134466	chr5:150310000-150326146:-	0.46	5.89	8.37E-9	Crohn's disease	
BLCA	cis	1	rs1818950	chr15:84722521	LOC388152	chr15:84867600-84898920:-	-0.27	-4.67	4.2E-6	Schizophrenia	
BLCA	cis	1	rs1819333	chr6:167373547	RNASET2	chr6:167343008-167412795:-	-0.22	-4.75	2.95E-6	Crohn's disease	
BLCA	cis	1	rs1820682	chr5:150262142	LOC134466	chr5:150310000-150326146:-	0.47	6.2	1.42E-9	Crohn's disease	
BLCA	cis	1	rs1830074	chr7:6718674	C7orf28B	chr7:6838572-6865861:-	-0.26	-3.95	9.31E-5	Body mass index	
BLCA	cis	1	rs1830074	chr7:6718674	PMS2CL	chr7:6749757-6793492:+	-0.32	-5.09	5.65E-7	Body mass index	
BLCA	cis	1	rs1833896	chr5:56097669	C5orf35	chr5:56205103-56213010:+	0.65	9.62	8.98E-20	Type 2 diabetes	
BLCA	cis	1	rs1848093	chr15:84755527	LOC388152	chr15:84867600-84898920:-	-0.26	-4.61	5.56E-6	Schizophrenia	
BLCA	cis	1	rs1854774	chr4:129988405	C4orf33	chr4:130014829-130033842:+	-0.32	-5.36	1.41E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs1857964	chr6:86635994	SNHG5	chr6:86386726-86388451:-	-0.54	-9.48	2.8E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs1857965	chr6:86630776	SNHG5	chr6:86386726-86388451:-	-0.51	-9.01	9.54E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs1862619	chr5:56098256	C5orf35	chr5:56205103-56213010:+	0.65	9.62	8.98E-20	Type 2 diabetes	
BLCA	cis	1	rs186378	chr7:65582058	CCT6P1	chr7:65216092-65228661:+	0.35	4.95	1.13E-6	Diabetic kidney disease	
BLCA	cis	1	rs1863913	chr3:134200205	ANAPC13	chr3:134196547-134204865:-	0.47	7.47	5.37E-13	Height	
BLCA	cis	1	rs1863998	chr5:150271753	LOC134466	chr5:150310000-150326146:-	0.44	5.72	2.14E-8	Crohn's disease	
BLCA	cis	1	rs1872829	chr12:32535100	FGD4	chr12:32638906-32798982:+	-0.33	-5.34	1.6E-7	Response to tocilizumab in rheumatoid arthritis	
BLCA	cis	1	rs1873494	chr7:65649899	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs1874883	chr3:134205071	ANAPC13	chr3:134196547-134204865:-	0.5	8.05	1.03E-14	Height	
BLCA	cis	1	rs1874883	chr3:134205071	CEP63	chr3:134204575-134293852:+	0.25	4.42	1.28E-5	Height	
BLCA	cis	1	rs1875124	chr12:58196802	FAM119B	chr12:58166383-58176323:+	0.28	4.37	1.6E-5	Multiple sclerosis	
BLCA	cis	1	rs1875124	chr12:58196802	TSFM	chr12:58176536-58191367:+	-0.38	-6.72	6.57E-11	Multiple sclerosis	
BLCA	cis	1	rs1875124	chr12:58196802	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-3.95	9.44E-5	Multiple sclerosis	
BLCA	cis	1	rs1880376	chr3:134270347	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs1880376	chr3:134270347	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs1880377	chr3:134270468	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs1880377	chr3:134270468	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs1881123	chr7:1084706	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.53	7.81E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs1881245	chr2:73649928	ALMS1P	chr2:73872046-73912692:+	0.37	5.48	7.92E-8	Metabolite levels	
BLCA	cis	1	rs1882655	chr7:66147057	CCT6P1	chr7:65216092-65228661:+	-0.38	-4.99	9.26E-7	Gout	
BLCA	cis	1	rs1884537	chr14:101251989	DLK1	chr14:101193253-101201474:+	-0.18	-3.95	9.46E-5	Optic nerve measurement (disc area)	
BLCA	cis	1	rs1896707	chr5:150245129	LOC134466	chr5:150310000-150326146:-	0.43	5.76	1.69E-8	Crohn's disease	
BLCA	cis	1	rs1896708	chr5:150245076	LOC134466	chr5:150310000-150326146:-	0.44	5.84	1.12E-8	Crohn's disease	
BLCA	cis	1	rs1896709	chr5:150245032	LOC134466	chr5:150310000-150326146:-	0.43	5.77	1.66E-8	Crohn's disease	
BLCA	cis	1	rs1899669	chr18:48371698	MRO	chr18:48321491-48351754:-	-0.22	-4.09	5.36E-5	Entorhinal cortical thickness	
BLCA	cis	1	rs1903330	chr6:56776985	BEND6	chr6:56819773-56892138:+	0.3	4.17	3.82E-5	Menarche (age at onset)	
BLCA	cis	1	rs190414	chr5:56116772	C5orf35	chr5:56205103-56213010:+	0.74	11.19	2.38E-25	Type 2 diabetes	
BLCA	cis	1	rs1908331	chr10:75885817	ADK	chr10:75910965-76469059:+	0.31	4.77	2.57E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs1911155	chr15:84787635	LOC388152	chr15:84867600-84898920:-	-0.28	-4.87	1.63E-6	Schizophrenia	
BLCA	cis	1	rs1911552	chr6:86638024	SNHG5	chr6:86386726-86388451:-	-0.55	-10.02	3.91E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs1911553	chr6:86630892	SNHG5	chr6:86386726-86388451:-	-0.51	-9.04	7.68E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs1917130	chr3:134313773	ANAPC13	chr3:134196547-134204865:-	-0.48	-7.64	1.79E-13	Height	
BLCA	cis	1	rs1919125	chr2:27801403	C2orf16	chr2:27799389-27805588:+	0.23	3.94	9.54E-5	Oral cavity cancer	
BLCA	cis	1	rs1919126	chr2:27801418	C2orf16	chr2:27799389-27805588:+	0.23	3.94	9.54E-5	Oral cavity cancer	
BLCA	cis	1	rs1919948	chr7:143762843	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.3E-9	Obesity-related traits	
BLCA	cis	1	rs1919949	chr7:143767723	ARHGEF35	chr7:143883677-143892736:-	-0.31	-5.46	8.47E-8	Obesity-related traits	
BLCA	cis	1	rs1919950	chr7:143767898	ARHGEF35	chr7:143883677-143892736:-	-0.32	-5.55	5.33E-8	Obesity-related traits	
BLCA	cis	1	rs1919951	chr7:143768891	ARHGEF35	chr7:143883677-143892736:-	-0.33	-5.88	8.91E-9	Obesity-related traits	
BLCA	cis	1	rs1925148	chr6:56095672	COL21A1	chr6:55921389-56258892:-	0.36	6.61	1.32E-10	Pulse pressure	
BLCA	cis	1	rs1925152	chr6:56102709	COL21A1	chr6:55921389-56258892:-	0.33	5.86	1.01E-8	Pulse pressure	
BLCA	cis	1	rs1930961	chr22:25875265	CRYBB2	chr22:25615612-25627836:+	0.95	10.44	1.24E-22	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs1933182	chr1:109999838	AMIGO1	chr1:110049447-110052336:-	-0.24	-3.97	8.58E-5	Chronic kidney disease	
BLCA	cis	1	rs1935496	chr6:144068066	PEX3	chr6:143771918-143811749:+	0.21	3.95	9.14E-5	Erectile dysfunction in type 1 diabetes	
BLCA	cis	1	rs1936365	chr6:28268452	ZNF389	chr6:28129551-28137375:+	0.31	4.04	6.45E-5	Depression	
BLCA	cis	1	rs1953126	chr9:123640500	LOC253039	chr9:123605320-123616644:+	-0.38	-6.59	1.43E-10	Rheumatoid arthritis	
BLCA	cis	1	rs1957977	chr14:50090603	RPL36AL	chr14:50085407-50087349:-	0.24	4.44	1.16E-5	Carotid intima media thickness	
BLCA	cis	1	rs1962716	chr6:86648436	SNHG5	chr6:86386726-86388451:-	-0.54	-9.5	2.33E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs1964692	chr7:65454183	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.54E-5	Diabetic kidney disease	
BLCA	cis	1	rs1971762	chr12:54058238	ATP5G2	chr12:54058945-54070512:-	0.22	4.86	1.71E-6	Height	
BLCA	cis	1	rs1972669	chr2:27767107	C2orf16	chr2:27799389-27805588:+	0.23	3.97	8.5E-5	Oral cavity cancer	
BLCA	cis	1	rs1979823	chr7:65704613	CCT6P1	chr7:65216092-65228661:+	-0.33	-4.52	8.25E-6	Diabetic kidney disease	
BLCA	cis	1	rs1979	chr6:26377591	BTN3A2	chr6:26365398-26378546:+	-0.74	-12.03	1.76E-28	Schizophrenia	
BLCA	cis	1	rs198806	chr6:26133616	BTN3A2	chr6:26365398-26378546:+	0.2	4.12	4.66E-5	Schizophrenia	
BLCA	cis	1	rs198811	chr6:26128446	BTN3A2	chr6:26365398-26378546:+	-0.19	-4.03	6.7E-5	Schizophrenia	
BLCA	cis	1	rs199347	chr7:23293746	GPNMB	chr7:23286316-23314728:+	-0.25	-4.26	2.6E-5	Parkinson's disease	
BLCA	cis	1	rs199348	chr7:23293098	GPNMB	chr7:23286316-23314728:+	-0.23	-3.83	0.000148	Parkinson's disease	
BLCA	cis	1	rs199351	chr7:23300049	GPNMB	chr7:23286316-23314728:+	-0.25	-4.1	4.99E-5	Parkinson's disease	
BLCA	cis	1	rs199357	chr7:23288309	GPNMB	chr7:23286316-23314728:+	0.24	4.02	6.96E-5	Parkinson's disease	
BLCA	cis	1	rs1994157	chr3:41897482	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs1995688	chr6:86632319	SNHG5	chr6:86386726-86388451:-	-0.51	-9.03	8.38E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs1997243	chr7:1083777	ZFAND2A	chr7:1192544-1199855:-	-0.39	-4.55	7.23E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs1999852	chr6:86705738	SNHG5	chr6:86386726-86388451:-	-0.52	-9.19	2.57E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs2000614	chr11:116915742	PCSK7	chr11:117075789-117102811:-	-0.39	-5.09	5.59E-7	Protein quantitative trait loci	
BLCA	cis	1	rs2000615	chr11:116915819	PCSK7	chr11:117075789-117102811:-	-0.39	-5.05	7.01E-7	Protein quantitative trait loci	
BLCA	cis	1	rs2000616	chr11:116916529	PCSK7	chr11:117075789-117102811:-	-0.39	-5.09	5.59E-7	Protein quantitative trait loci	
BLCA	cis	1	rs2004711	chr5:150225068	LOC134466	chr5:150310000-150326146:-	0.43	5.26	2.42E-7	Crohn's disease	
BLCA	cis	1	rs2006751	chr11:43670501	HSD17B12	chr11:43702143-43878160:+	-0.42	-6.9	2.22E-11	Forced vital capacity	
BLCA	cis	1	rs2010648	chr14:35604892	PPP2R3C	chr14:35554679-35591679:-	0.25	4.13	4.45E-5	Atopic dermatitis	
BLCA	cis	1	rs2013815	chr6:167373812	RNASET2	chr6:167343008-167412795:-	0.22	4.7	3.57E-6	Crohn's disease	
BLCA	cis	1	rs2014521	chr17:40283413	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs2019097	chr2:202193463	PPIL3	chr2:201735680-201753999:-	-0.42	-4.58	6.39E-6	Rheumatoid arthritis	
BLCA	cis	1	rs2028299	chr15:90374257	AP3S2	chr15:90373832-90456222:-	-0.7	-10.63	2.6E-23	Type 2 diabetes	
BLCA	cis	1	rs2045554	chr3:48494542	TREX1	chr3:48501186-48509043:+	0.2	4.04	6.42E-5	Longevity	
BLCA	cis	1	rs2056486	chr2:73717567	ALMS1P	chr2:73872046-73912692:+	0.4	5.97	5.32E-9	Metabolite levels	
BLCA	cis	1	rs2056544	chr15:76826003	SCAPER	chr15:76640529-77197744:-	-0.2	-4.4	1.43E-5	Blood metabolite levels	
BLCA	cis	1	rs2056603	chr3:134312749	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs2056604	chr3:134312648	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs2057671	chr7:27999195	HIBADH	chr7:27565063-27702602:-	-0.37	-3.83	0.000152	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs2058059	chr7:72311817	TYW1B	chr7:72023729-72298813:-	-0.43	-5.3	1.98E-7	Subcutaneous adipose tissue	
BLCA	cis	1	rs2061164	chr11:18329006	GTF2H1	chr11:18343816-18388590:+	0.32	6.11	2.46E-9	Pancreatic cancer	
BLCA	cis	1	rs2066656	chr13:50804716	CAB39L	chr13:49882787-50018221:-	0.24	4.59	5.93E-6	Celiac disease	
BLCA	cis	1	rs2069502	chr12:58144665	FAM119B	chr12:58166383-58176323:+	-0.26	-4.07	5.71E-5	Multiple sclerosis	
BLCA	cis	1	rs2069502	chr12:58144665	TSFM	chr12:58176536-58191367:+	0.38	6.74	5.79E-11	Multiple sclerosis	
BLCA	cis	1	rs2069502	chr12:58144665	XRCC6BP1	chr12:58335445-58351051:+	0.23	3.95	9.32E-5	Multiple sclerosis	
BLCA	cis	1	rs2072052	chr12:58146719	FAM119B	chr12:58166383-58176323:+	0.25	3.84	0.000145	Multiple sclerosis	
BLCA	cis	1	rs2072052	chr12:58146719	TSFM	chr12:58176536-58191367:+	-0.4	-7.03	9.42E-12	Multiple sclerosis	
BLCA	cis	1	rs2072052	chr12:58146719	XRCC6BP1	chr12:58335445-58351051:+	-0.25	-4.24	2.82E-5	Multiple sclerosis	
BLCA	cis	1	rs2072293	chr14:74537885	LIN52	chr14:74551656-74667117:+	0.34	7.86	4.03E-14	Common traits (Other)	
BLCA	cis	1	rs2072435	chr7:75959188	UPK3B	chr7:76139745-76157197:+	-0.3	-6.18	1.67E-9	Multiple sclerosis	
BLCA	cis	1	rs2075292	chr11:116732512	PCSK7	chr11:117075789-117102811:-	-0.42	-5.45	8.84E-8	Protein quantitative trait loci	
BLCA	cis	1	rs2077808	chr1:45988115	CCDC163P	chr1:45960581-45965646:-	-0.79	-16.21	2.35E-45	Homocysteine levels	
BLCA	cis	1	rs2079795	chr17:59496649	C17orf82	chr17:59489112-59490641:+	-0.21	-4.62	5.24E-6	Sitting height ratio	
BLCA	cis	1	rs2083634	chr4:129976478	C4orf33	chr4:130014829-130033842:+	-0.32	-5.36	1.41E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs2093395	chr6:41155026	LOC221442	chr6:41068773-41108567:+	-0.24	-4.19	3.47E-5	Alzheimer's disease (late onset)	
BLCA	cis	1	rs2093396	chr6:41155000	LOC221442	chr6:41068773-41108567:+	0.24	4.27	2.49E-5	Alzheimer's disease (late onset)	
BLCA	cis	1	rs2113078	chr5:56087190	C5orf35	chr5:56205103-56213010:+	0.68	9.88	1.22E-20	Type 2 diabetes	
BLCA	cis	1	rs2113079	chr5:56157951	C5orf35	chr5:56205103-56213010:+	0.77	11.84	8.81E-28	Type 2 diabetes	
BLCA	cis	1	rs2115069	chr5:150252365	LOC134466	chr5:150310000-150326146:-	0.49	6.25	1.07E-9	Crohn's disease	
BLCA	cis	1	rs2126129	chr2:212548	SH3YL1	chr2:218138-264810:-	-0.42	-10.75	1.02E-23	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs2127905	chr11:117026374	PCSK7	chr11:117075789-117102811:-	-0.41	-5.13	4.7E-7	Protein quantitative trait loci	
BLCA	cis	1	rs2128834	chr3:41862645	ULK4	chr3:41288091-42003660:-	0.6	9.42	4.5E-19	Diastolic blood pressure	
BLCA	cis	1	rs2128835	chr3:41862873	ULK4	chr3:41288091-42003660:-	0.62	9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs2130392	chr4:185639169	MLF1IP	chr4:185615220-185655286:-	-0.45	-11.33	7.65E-26	Kawasaki disease	
BLCA	cis	1	rs2134688	chr1:150816886	HORMAD1	chr1:150670542-150693352:-	0.38	3.95	9.36E-5	Congenital left-sided heart lesions	
BLCA	cis	1	rs2140195	chr2:73702344	ALMS1P	chr2:73872046-73912692:+	0.39	5.94	6.4E-9	Metabolite levels	
BLCA	cis	1	rs2141924	chr7:66186246	CCT6P1	chr7:65216092-65228661:+	0.36	4.78	2.52E-6	Gout	
BLCA	cis	1	rs2143950	chr14:35572357	PPP2R3C	chr14:35554679-35591679:-	0.29	4.56	6.9E-6	Atopic dermatitis	
BLCA	cis	1	rs2147712	chr14:50091684	RPL36AL	chr14:50085407-50087349:-	0.24	4.36	1.67E-5	Carotid intima media thickness	
BLCA	cis	1	rs2149085	chr6:167371110	RNASET2	chr6:167343008-167412795:-	0.23	4.72	3.36E-6	Crohn's disease	
BLCA	cis	1	rs2149090	chr6:167372764	RNASET2	chr6:167343008-167412795:-	0.22	4.71	3.4E-6	Crohn's disease	
BLCA	cis	1	rs2149091	chr6:167372786	RNASET2	chr6:167343008-167412795:-	0.22	4.71	3.4E-6	Crohn's disease	
BLCA	cis	1	rs2149423	chr13:36772381	SOHLH2	chr13:36742347-36871992:-	0.27	4.53	7.72E-6	Glucose homeostasis traits	
BLCA	cis	1	rs2152916	chr10:97392265	ENTPD1	chr10:97471536-97637022:+	0.19	4.86	1.73E-6	Blood metabolite levels	
BLCA	cis	1	rs2154536	chr21:38492147	PIGP	chr21:38437664-38445458:-	-0.3	-5.3	1.95E-7	Eye color traits	
BLCA	cis	1	rs2154536	chr21:38492147	TTC3	chr21:38445571-38575406:+	0.25	5.14	4.38E-7	Eye color traits	
BLCA	cis	1	rs2155583	chr11:116915217	PCSK7	chr11:117075789-117102811:-	-0.39	-5.05	6.74E-7	Protein quantitative trait loci	
BLCA	cis	1	rs216345	chr9:33799370	NUDT2	chr9:34329504-34343695:+	-0.24	-4.9	1.4E-6	Bipolar disorder	
BLCA	cis	1	rs2166580	chr4:1743169	FAM53A	chr4:1641609-1685854:-	-0.31	-4.45	1.11E-5	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs2166663	chr6:86593896	SNHG5	chr6:86386726-86388451:-	-0.56	-10.22	7.62E-22	Response to antipsychotic treatment	
BLCA	cis	1	rs2169748	chr2:28957753	TRMT61B	chr2:29072690-29093175:-	0.3	5.26	2.46E-7	Body mass index	
BLCA	cis	1	rs2169751	chr2:28966758	TRMT61B	chr2:29072690-29093175:-	-0.29	-5.03	7.45E-7	Body mass index	
BLCA	cis	1	rs2177601	chr3:134245434	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs2177601	chr3:134245434	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs2177703	chr7:65391717	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs2187143	chr18:48371565	MRO	chr18:48321491-48351754:-	0.25	4.58	6.33E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs2198042	chr4:129885499	C4orf33	chr4:130014829-130033842:+	0.31	4.91	1.35E-6	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs2210913	chr1:157668993	FCRL3	chr1:157646278-157670775:-	0.29	9.3	1.06E-18	Type 1 diabetes autoantibodies	
BLCA	cis	1	rs2217266	chr5:150272621	LOC134466	chr5:150310000-150326146:-	0.46	5.97	5.47E-9	Crohn's disease	
BLCA	cis	1	rs2227564	chr10:75673101	BMS1P4	chr10:75458909-75490272:-	-0.33	-5.36	1.42E-7	Inflammatory bowel disease	
BLCA	cis	1	rs2229384	chr6:49425521	CENPQ	chr6:49431096-49460820:+	0.39	8.38	1.03E-15	Homocysteine levels	
BLCA	cis	1	rs2236246	chr14:104379206	TDRD9	chr14:104394817-104519002:+	-0.34	-5.64	3.36E-8	Bipolar disorder	
BLCA	cis	1	rs2236247	chr14:104378087	TDRD9	chr14:104394817-104519002:+	0.31	5.29	2.09E-7	Bipolar disorder	
BLCA	cis	1	rs2236786	chr4:1719294	FAM53A	chr4:1641609-1685854:-	0.31	4.35	1.73E-5	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs2239557	chr14:74551970	LIN52	chr14:74551656-74667117:+	0.35	7.97	1.8E-14	Common traits (Other)	
BLCA	cis	1	rs2240009	chr17:40283142	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs2240010	chr17:40278081	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs2241706	chr19:41912807	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.1	5.13E-5	Height	
BLCA	cis	1	rs2241709	chr19:41912250	B3GNT8	chr19:41931265-41934635:-	-0.2	-3.84	0.000143	Height	
BLCA	cis	1	rs2241710	chr19:41912092	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.1	5.15E-5	Height	
BLCA	cis	1	rs2241711	chr19:41911980	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.1	4.98E-5	Height	
BLCA	cis	1	rs2242471	chr4:76878716	NAAA	chr4:76831809-76862166:-	0.38	6.23	1.23E-9	Longevity	
BLCA	cis	1	rs2242473	chr4:76878956	NAAA	chr4:76831809-76862166:-	0.38	6.23	1.23E-9	Longevity	
BLCA	cis	1	rs2242474	chr4:76878982	NAAA	chr4:76831809-76862166:-	0.38	6.23	1.23E-9	Longevity	
BLCA	cis	1	rs2243480	chr7:65599196	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.03E-5	Diabetic kidney disease	
BLCA	cis	1	rs2245715	chr15:43818052	ADAL	chr15:43622872-43646094:+	-0.42	-5.15	4.21E-7	Tumor biomarkers	
BLCA	cis	1	rs2245715	chr15:43818052	CATSPER2	chr15:43922774-43959900:-	-0.31	-4.74	3.09E-6	Tumor biomarkers	
BLCA	cis	1	rs2251115	chr6:49446509	CENPQ	chr6:49431096-49460820:+	-0.38	-8.23	3.02E-15	Homocysteine levels	
BLCA	cis	1	rs2251844	chr15:43836478	ADAL	chr15:43622872-43646094:+	-0.43	-5.36	1.46E-7	Tumor biomarkers	
BLCA	cis	1	rs2251844	chr15:43836478	CATSPER2	chr15:43922774-43959900:-	-0.31	-4.84	1.86E-6	Tumor biomarkers	
BLCA	cis	1	rs2255042	chr15:43834318	ADAL	chr15:43622872-43646094:+	0.45	5.55	5.22E-8	Tumor biomarkers	
BLCA	cis	1	rs2255042	chr15:43834318	CATSPER2	chr15:43922774-43959900:-	0.33	5.09	5.63E-7	Tumor biomarkers	
BLCA	cis	1	rs2255051	chr15:43846161	ADAL	chr15:43622872-43646094:+	-0.43	-5.28	2.12E-7	Tumor biomarkers	
BLCA	cis	1	rs2255051	chr15:43846161	CATSPER2	chr15:43922774-43959900:-	-0.33	-5.21	3.04E-7	Tumor biomarkers	
BLCA	cis	1	rs2255440	chr15:43830467	ADAL	chr15:43622872-43646094:+	-0.42	-5.21	3.03E-7	Tumor biomarkers	
BLCA	cis	1	rs2255440	chr15:43830467	CATSPER2	chr15:43922774-43959900:-	-0.31	-4.87	1.63E-6	Tumor biomarkers	
BLCA	cis	1	rs2256920	chr11:6508124	RRP8	chr11:6621154-6624811:-	-0.21	-3.93	9.92E-5	DNA methylation (variation)	
BLCA	cis	1	rs2257790	chr7:65600450	CCT6P1	chr7:65216092-65228661:+	0.32	4.46	1.07E-5	Diabetic kidney disease	
BLCA	cis	1	rs2260160	chr15:43895643	ADAL	chr15:43622872-43646094:+	-0.36	-4.21	3.21E-5	Tumor biomarkers	
BLCA	cis	1	rs2260160	chr15:43895643	CATSPER2	chr15:43922774-43959900:-	-0.32	-4.86	1.74E-6	Tumor biomarkers	
BLCA	cis	1	rs2269186	chr14:104379912	TDRD9	chr14:104394817-104519002:+	0.34	5.55	5.28E-8	Bipolar disorder	
BLCA	cis	1	rs2269381	chr22:51020069	CPT1B	chr22:51007291-51017096:-	-0.38	-3.9	0.000112	Narcolepsy	
BLCA	cis	1	rs2269558	chr16:682250	WFIKKN1	chr16:679239-684116:+	0.29	5.46	8.46E-8	Height	
BLCA	cis	1	rs2272006	chr3:41997059	ULK4	chr3:41288091-42003660:-	-0.63	-9.76	2.93E-20	Diastolic blood pressure	
BLCA	cis	1	rs2272007	chr3:41996136	ULK4	chr3:41288091-42003660:-	-0.65	-10.12	1.79E-21	Diastolic blood pressure	
BLCA	cis	1	rs2272390	chr2:202195311	PPIL3	chr2:201735680-201753999:-	-0.44	-3.91	0.000109	Rheumatoid arthritis	
BLCA	cis	1	rs2273610	chr14:104387642	TDRD9	chr14:104394817-104519002:+	0.35	5.6	4.0E-8	Bipolar disorder	
BLCA	cis	1	rs2273	chr4:76889388	NAAA	chr4:76831809-76862166:-	0.37	6.07	3.05E-9	Longevity	
BLCA	cis	1	rs2275426	chr1:46487552	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.89E-10	Body mass index	
BLCA	cis	1	rs2276547	chr2:28975107	TRMT61B	chr2:29072690-29093175:-	-0.3	-5.31	1.89E-7	Body mass index	
BLCA	cis	1	rs2277862	chr20:34152782	CPNE1	chr20:34213968-34262539:-	-0.54	-6.68	8.34E-11	Cholesterol, total	
BLCA	cis	1	rs2278086	chr2:86281905	LOC90784	chr2:86247339-86250991:-	-0.46	-4.77	2.59E-6	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
BLCA	cis	1	rs2279077	chr3:48474249	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000134	Longevity	
BLCA	cis	1	rs2279648	chr10:75867193	ADK	chr10:75910965-76469059:+	0.28	4.03	6.64E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs2280017	chr16:15151361	RRN3	chr16:15153881-15188158:-	0.22	3.94	9.78E-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
BLCA	cis	1	rs2280018	chr16:15150833	RRN3	chr16:15153881-15188158:-	-0.24	-4.26	2.6E-5	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
BLCA	cis	1	rs2281006	chr1:171110869	FMO2	chr1:171154388-171181822:+	-0.24	-4.38	1.53E-5	Blood metabolite levels	
BLCA	cis	1	rs2285657	chr17:40272594	DHX58	chr17:40253422-40264751:-	-0.25	-4.59	5.98E-6	Fibrinogen levels	
BLCA	cis	1	rs2285946	chr7:21583329	DNAH11	chr7:21582833-21941455:+	-0.3	-4.97	9.88E-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs2285947	chr7:21584088	DNAH11	chr7:21582833-21941455:+	0.28	4.76	2.79E-6	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs2285949	chr7:21584243	DNAH11	chr7:21582833-21941455:+	-0.3	-4.98	9.83E-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs2285950	chr7:21584432	DNAH11	chr7:21582833-21941455:+	0.3	5.03	7.44E-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs2288073	chr2:24413298	LOC375190	chr2:24299728-24397519:+	0.22	3.88	0.000124	Venous thromboembolism (SNP x SNP interaction)	
BLCA	cis	1	rs2288271	chr15:52886466	ARPP19	chr15:52839432-52861364:-	0.22	3.97	8.59E-5	Schizophrenia	
BLCA	cis	1	rs2289681	chr17:42989088	CCDC103	chr17:42977154-42982758:+	0.34	3.89	0.00012	Cognitive function	
BLCA	cis	1	rs2290850	chr11:47807774	C1QTNF4	chr11:47611216-47615961:-	-0.29	-5.41	1.11E-7	Subjective well-being	
BLCA	cis	1	rs2290911	chr2:224919	SH3YL1	chr2:218138-264810:-	-0.45	-11.69	3.26E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs2292239	chr12:56482180	RPS26	chr12:56435686-56438005:+	0.43	7.5	4.52E-13	Cognitive function	
BLCA	cis	1	rs2294008	chr8:143761931	LY6D	chr8:143866298-143868008:-	0.23	4.83	2.02E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2294008	chr8:143761931	PSCA	chr8:143761875-143764142:+	0.52	15.91	4.17E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2294010	chr8:143762430	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2294010	chr8:143762430	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2296691	chr10:97370989	ENTPD1	chr10:97471536-97637022:+	0.19	4.99	9.3E-7	Blood metabolite levels	
BLCA	cis	1	rs2305188	chr4:1739592	FAM53A	chr4:1641609-1685854:-	-0.31	-4.47	1.05E-5	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs2306937	chr1:113246506	ST7L	chr1:113066142-113162405:-	0.4	5.71	2.22E-8	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs2306940	chr1:113241052	ST7L	chr1:113066142-113162405:-	0.43	6.21	1.4E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs2315281	chr19:19480099	YJEFN3	chr19:19639720-19648393:+	0.23	4.58	6.27E-6	Schizophrenia	
BLCA	cis	1	rs2318131	chr2:237933966	IQCA1	chr2:237232794-237416092:-	-0.23	-3.86	0.000131	Motion sickness	
BLCA	cis	1	rs2319399	chr3:119636207	KTELC1	chr3:119187785-119213552:+	-0.22	-3.83	0.000151	HDL cholesterol	
BLCA	cis	1	rs2324843	chr6:86617501	SNHG5	chr6:86386726-86388451:-	-0.54	-9.46	3.23E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs2326680	chr20:5942955	MCM8	chr20:5931298-5975829:+	-0.21	-4.43	1.26E-5	HIV-1 viral setpoint	
BLCA	cis	1	rs2340727	chr1:161946727	RPL31P11	chr1:161653497-161655042:-	0.3	3.89	0.000116	Hematology traits	
BLCA	cis	1	rs2344180	chr5:150267357	LOC134466	chr5:150310000-150326146:-	0.47	6.15	1.94E-9	Crohn's disease	
BLCA	cis	1	rs2344181	chr5:150262574	LOC134466	chr5:150310000-150326146:-	0.46	6.12	2.36E-9	Crohn's disease	
BLCA	cis	1	rs2345001	chr5:150266518	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs2351706	chr15:90384115	AP3S2	chr15:90373832-90456222:-	-0.7	-10.62	2.88E-23	Type 2 diabetes	
BLCA	cis	1	rs2351707	chr15:90384045	AP3S2	chr15:90373832-90456222:-	-0.7	-10.67	1.87E-23	Type 2 diabetes	
BLCA	cis	1	rs2353605	chr4:219538	ZNF718	chr4:53272-156488:+	0.29	4.06	6.07E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs2356559	chr1:45981512	CCDC163P	chr1:45960581-45965646:-	-0.76	-15.61	7.05E-43	Homocysteine levels	
BLCA	cis	1	rs2356561	chr1:45980862	CCDC163P	chr1:45960581-45965646:-	-0.73	-14.77	2.1E-39	Homocysteine levels	
BLCA	cis	1	rs2358628	chr14:74631757	LIN52	chr14:74551656-74667117:+	-0.36	-8.05	1.06E-14	Common traits (Other)	
BLCA	cis	1	rs2358633	chr14:74647418	LIN52	chr14:74551656-74667117:+	-0.35	-8.2	3.8E-15	Common traits (Other)	
BLCA	cis	1	rs236104	chr20:5958960	MCM8	chr20:5931298-5975829:+	-0.21	-4.54	7.7E-6	HIV-1 viral setpoint	
BLCA	cis	1	rs236121	chr20:5972594	MCM8	chr20:5931298-5975829:+	-0.21	-4.36	1.67E-5	HIV-1 viral setpoint	
BLCA	cis	1	rs2362450	chr3:48461313	TREX1	chr3:48501186-48509043:+	-0.19	-3.92	0.000105	Longevity	
BLCA	cis	1	rs2363286	chr7:1091625	ZFAND2A	chr7:1192544-1199855:-	-0.34	-4.09	5.18E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs2363731	chr2:88521793	THNSL2	chr2:88469835-88486145:+	-0.58	-5.91	7.68E-9	Plasma clusterin levels	
BLCA	cis	1	rs2368984	chr14:104372055	TDRD9	chr14:104394817-104519002:+	0.34	5.59	4.26E-8	Bipolar disorder	
BLCA	cis	1	rs236918	chr11:117091609	PCSK7	chr11:117075789-117102811:-	0.37	4.63	4.91E-6	Protein quantitative trait loci	
BLCA	cis	1	rs2370578	chr3:134199612	ANAPC13	chr3:134196547-134204865:-	0.51	8.23	2.91E-15	Height	
BLCA	cis	1	rs2370578	chr3:134199612	CEP63	chr3:134204575-134293852:+	0.26	4.44	1.16E-5	Height	
BLCA	cis	1	rs2370641	chr3:134222161	ANAPC13	chr3:134196547-134204865:-	0.49	7.8	6.04E-14	Height	
BLCA	cis	1	rs2370641	chr3:134222161	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.17E-5	Height	
BLCA	cis	1	rs2370642	chr3:134222136	ANAPC13	chr3:134196547-134204865:-	0.51	8.18	4.34E-15	Height	
BLCA	cis	1	rs2370642	chr3:134222136	CEP63	chr3:134204575-134293852:+	0.26	4.46	1.07E-5	Height	
BLCA	cis	1	rs2371244	chr7:143757611	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.97	5.56E-9	Obesity-related traits	
BLCA	cis	1	rs2371247	chr7:143764179	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.97	5.43E-9	Obesity-related traits	
BLCA	cis	1	rs2371248	chr7:143764189	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.3E-9	Obesity-related traits	
BLCA	cis	1	rs2371623	chr3:41761083	ULK4	chr3:41288091-42003660:-	0.64	9.9	9.78E-21	Diastolic blood pressure	
BLCA	cis	1	rs2371627	chr3:41839219	ULK4	chr3:41288091-42003660:-	0.64	9.96	6.32E-21	Diastolic blood pressure	
BLCA	cis	1	rs2373865	chr3:134291556	ANAPC13	chr3:134196547-134204865:-	-0.51	-8	1.45E-14	Height	
BLCA	cis	1	rs2373865	chr3:134291556	CEP63	chr3:134204575-134293852:+	-0.24	-4.14	4.32E-5	Height	
BLCA	cis	1	rs2395077	chr10:75932001	ADK	chr10:75910965-76469059:+	0.3	4.53	7.84E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs239935	chr6:167411788	RNASET2	chr6:167343008-167412795:-	-0.24	-4.94	1.19E-6	Crohn's disease	
BLCA	cis	1	rs2404602	chr15:77030792	SCAPER	chr15:76640529-77197744:-	-0.18	-3.86	0.000134	Blood metabolite levels	
BLCA	cis	1	rs2404740	chr15:76852143	SCAPER	chr15:76640529-77197744:-	-0.22	-4.75	2.88E-6	Blood metabolite levels	
BLCA	cis	1	rs2404741	chr15:76851735	SCAPER	chr15:76640529-77197744:-	-0.22	-4.75	2.88E-6	Blood metabolite levels	
BLCA	cis	1	rs2413049	chr22:31686144	C22orf30	chr22:32072242-32146120:-	-0.21	-3.89	0.000117	Paclitaxel-induced neuropathy	
BLCA	cis	1	rs2420170	chr7:65656053	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.75	2.86E-6	Diabetic kidney disease	
BLCA	cis	1	rs2420171	chr7:65637760	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs2421555	chr2:73816955	ALMS1P	chr2:73872046-73912692:+	0.39	5.73	2.03E-8	Metabolite levels	
BLCA	cis	1	rs2432195	chr5:56120413	C5orf35	chr5:56205103-56213010:+	0.73	11.13	4.15E-25	Type 2 diabetes	
BLCA	cis	1	rs2447196	chr15:43893818	ADAL	chr15:43622872-43646094:+	0.35	4.15	4.18E-5	Tumor biomarkers	
BLCA	cis	1	rs2447196	chr15:43893818	CATSPER2	chr15:43922774-43959900:-	0.33	4.98	9.51E-7	Tumor biomarkers	
BLCA	cis	1	rs2447208	chr15:43933895	ADAL	chr15:43622872-43646094:+	-0.38	-4.4	1.42E-5	Tumor biomarkers	
BLCA	cis	1	rs2447208	chr15:43933895	CATSPER2	chr15:43922774-43959900:-	-0.37	-5.58	4.47E-8	Tumor biomarkers	
BLCA	cis	1	rs2447208	chr15:43933895	CKMT1A	chr15:43985084-43991419:+	-0.34	-3.95	9.25E-5	Tumor biomarkers	
BLCA	cis	1	rs2447211	chr15:43936351	ADAL	chr15:43622872-43646094:+	-0.39	-4.43	1.23E-5	Tumor biomarkers	
BLCA	cis	1	rs2447211	chr15:43936351	CATSPER2	chr15:43922774-43959900:-	-0.36	-5.27	2.33E-7	Tumor biomarkers	
BLCA	cis	1	rs2448704	chr6:49453672	CENPQ	chr6:49431096-49460820:+	0.41	8.85	3.37E-17	Homocysteine levels	
BLCA	cis	1	rs2448707	chr6:49446951	CENPQ	chr6:49431096-49460820:+	0.28	5.56	4.93E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs2448707	chr6:49446951	MUT	chr6:49398994-49431031:-	-0.28	-5.5	6.93E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs2460422	chr7:65601505	CCT6P1	chr7:65216092-65228661:+	0.33	4.56	6.79E-6	Diabetic kidney disease	
BLCA	cis	1	rs2462569	chr7:65474846	CCT6P1	chr7:65216092-65228661:+	-0.3	-4.28	2.37E-5	Diabetic kidney disease	
BLCA	cis	1	rs246454	chr5:96123264	ERAP1	chr5:96096515-96149837:-	-0.51	-10.9	2.87E-24	Ankylosing spondylitis	
BLCA	cis	1	rs246454	chr5:96123264	ERAP2	chr5:96211644-96255398:+	0.33	5.45	9.03E-8	Ankylosing spondylitis	
BLCA	cis	1	rs2465120	chr7:65620974	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs2470134	chr15:43849886	ADAL	chr15:43622872-43646094:+	0.39	4.33	1.91E-5	Tumor biomarkers	
BLCA	cis	1	rs2470134	chr15:43849886	CATSPER2	chr15:43922774-43959900:-	0.3	4.26	2.56E-5	Tumor biomarkers	
BLCA	cis	1	rs2471884	chr11:117010320	PCSK7	chr11:117075789-117102811:-	-0.43	-5.26	2.41E-7	Protein quantitative trait loci	
BLCA	cis	1	rs2486447	chr1:46545724	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.12	2.3E-9	Body mass index	
BLCA	cis	1	rs2501962	chr6:49453636	CENPQ	chr6:49431096-49460820:+	0.28	5.57	4.7E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs2501962	chr6:49453636	MUT	chr6:49398994-49431031:-	-0.28	-5.52	6.18E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs2501963	chr6:49454281	CENPQ	chr6:49431096-49460820:+	0.28	5.57	4.7E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs2501963	chr6:49454281	MUT	chr6:49398994-49431031:-	-0.28	-5.52	6.18E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs2513093	chr11:116806687	PCSK7	chr11:117075789-117102811:-	-0.4	-4.86	1.71E-6	Protein quantitative trait loci	
BLCA	cis	1	rs2513095	chr11:116806269	PCSK7	chr11:117075789-117102811:-	-0.4	-4.86	1.75E-6	Protein quantitative trait loci	
BLCA	cis	1	rs2524005	chr6:29899677	HCG4	chr6:29758809-29760850:-	-0.27	-3.83	0.000147	Bipolar disorder and schizophrenia	
BLCA	cis	1	rs2524005	chr6:29899677	ZFP57	chr6:29640171-29648887:-	0.45	6.41	4.16E-10	Bipolar disorder and schizophrenia	
BLCA	cis	1	rs2524306	chr17:39035811	KRT12	chr17:39017430-39023462:-	0.2	3.94	9.76E-5	Height	
BLCA	cis	1	rs252887	chr5:56166188	C5orf35	chr5:56205103-56213010:+	0.75	11.61	6.9E-27	Type 2 diabetes	
BLCA	cis	1	rs252898	chr5:56188931	C5orf35	chr5:56205103-56213010:+	0.75	11.57	9.06E-27	Type 2 diabetes	
BLCA	cis	1	rs252902	chr5:56116085	C5orf35	chr5:56205103-56213010:+	0.74	11.35	6.18E-26	Type 2 diabetes	
BLCA	cis	1	rs252904	chr5:56118733	C5orf35	chr5:56205103-56213010:+	0.72	11.24	1.58E-25	Type 2 diabetes	
BLCA	cis	1	rs252909	chr5:56121131	C5orf35	chr5:56205103-56213010:+	0.73	10.99	1.34E-24	Type 2 diabetes	
BLCA	cis	1	rs252910	chr5:56192983	C5orf35	chr5:56205103-56213010:+	0.78	11.43	3.13E-26	Type 2 diabetes	
BLCA	cis	1	rs252915	chr5:56121754	C5orf35	chr5:56205103-56213010:+	-0.75	-11.37	5.13E-26	Type 2 diabetes	
BLCA	cis	1	rs252916	chr5:56121788	C5orf35	chr5:56205103-56213010:+	0.74	11.59	7.71E-27	Type 2 diabetes	
BLCA	cis	1	rs252919	chr5:56124111	C5orf35	chr5:56205103-56213010:+	0.74	11.46	2.48E-26	Type 2 diabetes	
BLCA	cis	1	rs252921	chr5:56137787	C5orf35	chr5:56205103-56213010:+	0.74	11.74	2.13E-27	Type 2 diabetes	
BLCA	cis	1	rs252922	chr5:56136343	C5orf35	chr5:56205103-56213010:+	0.74	11.56	9.96E-27	Type 2 diabetes	
BLCA	cis	1	rs2533288	chr7:66056711	CCT6P1	chr7:65216092-65228661:+	0.35	4.68	4.02E-6	Diabetic kidney disease	
BLCA	cis	1	rs2541164	chr9:131876908	CRAT	chr9:131857075-131873070:-	0.3	5.24	2.61E-7	Blood metabolite ratios	
BLCA	cis	1	rs2548664	chr5:56133555	C5orf35	chr5:56205103-56213010:+	0.74	11.34	6.98E-26	Type 2 diabetes	
BLCA	cis	1	rs2548665	chr5:56131805	C5orf35	chr5:56205103-56213010:+	0.74	11.34	6.98E-26	Type 2 diabetes	
BLCA	cis	1	rs2564978	chr1:207494416	CD55	chr1:207494817-207534309:+	0.23	3.94	9.81E-5	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs2572910	chr8:143770135	LY6D	chr8:143866298-143868008:-	0.23	4.83	1.95E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2572910	chr8:143770135	PSCA	chr8:143761875-143764142:+	0.52	16.12	5.65E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2580191	chr13:50809938	CAB39L	chr13:49882787-50018221:-	0.23	4.36	1.64E-5	Celiac disease	
BLCA	cis	1	rs2581794	chr3:53036206	SFMBT1	chr3:52938628-53080070:-	0.23	3.85	0.000136	Schizophrenia	
BLCA	cis	1	rs2585179	chr8:143774193	LY6D	chr8:143866298-143868008:-	0.23	4.84	1.86E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2585179	chr8:143774193	PSCA	chr8:143761875-143764142:+	0.52	16.21	2.37E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2586759	chr18:48379064	MRO	chr18:48321491-48351754:-	-0.25	-4.48	9.97E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs2586761	chr18:48366458	MRO	chr18:48321491-48351754:-	-0.25	-4.58	6.16E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs2586762	chr18:48367625	MRO	chr18:48321491-48351754:-	-0.26	-4.75	2.93E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs2586765	chr18:48369584	MRO	chr18:48321491-48351754:-	-0.26	-4.74	3.0E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs261360	chr20:5037774	C20orf30	chr20:5049130-5093733:-	-0.25	-4.16	3.88E-5	Hair morphology	
BLCA	cis	1	rs2614811	chr15:43913487	ADAL	chr15:43622872-43646094:+	-0.4	-4.47	1.04E-5	Tumor biomarkers	
BLCA	cis	1	rs2614811	chr15:43913487	CATSPER2	chr15:43922774-43959900:-	-0.36	-5.16	3.94E-7	Tumor biomarkers	
BLCA	cis	1	rs2625667	chr3:41900951	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs2625668	chr3:41905930	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs2629540	chr10:126426148	METTL10	chr10:126447406-126480439:-	0.45	6	4.61E-9	Cocaine dependence	
BLCA	cis	1	rs2637678	chr6:116787378	FAM26F	chr6:116782556-116784933:+	0.18	4.88	1.57E-6	Ulcerative colitis	
BLCA	cis	1	rs26510	chr5:96125910	ERAP1	chr5:96096515-96149837:-	-0.51	-10.9	2.72E-24	Ankylosing spondylitis	
BLCA	cis	1	rs26510	chr5:96125910	ERAP2	chr5:96211644-96255398:+	0.32	5.44	9.49E-8	Ankylosing spondylitis	
BLCA	cis	1	rs2655310	chr4:130017919	C4orf33	chr4:130014829-130033842:+	-0.34	-5.57	4.86E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs2659903	chr7:66180931	CCT6P1	chr7:65216092-65228661:+	0.35	4.69	3.85E-6	Gout	
BLCA	cis	1	rs2659911	chr7:66158420	CCT6P1	chr7:65216092-65228661:+	0.35	4.69	3.85E-6	Gout	
BLCA	cis	1	rs2659913	chr7:66157336	CCT6P1	chr7:65216092-65228661:+	0.35	4.69	3.85E-6	Gout	
BLCA	cis	1	rs2683695	chr3:41914928	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs2683696	chr3:41914898	ULK4	chr3:41288091-42003660:-	0.65	10.01	4.27E-21	Diastolic blood pressure	
BLCA	cis	1	rs2688608	chr10:75658349	BMS1P4	chr10:75458909-75490272:-	0.25	4.7	3.56E-6	Inflammatory bowel disease	
BLCA	cis	1	rs2688608	chr10:75658349	SYNPO2L	chr10:75404645-75415832:-	0.25	3.97	8.53E-5	Inflammatory bowel disease	
BLCA	cis	1	rs2703080	chr13:50801844	CAB39L	chr13:49882787-50018221:-	0.25	4.61	5.37E-6	Celiac disease	
BLCA	cis	1	rs2707828	chr7:66171377	CCT6P1	chr7:65216092-65228661:+	0.35	4.69	3.85E-6	Gout	
BLCA	cis	1	rs2707830	chr7:66167645	CCT6P1	chr7:65216092-65228661:+	0.35	4.69	3.85E-6	Gout	
BLCA	cis	1	rs2707831	chr7:66062511	CCT6P1	chr7:65216092-65228661:+	0.35	4.82	2.04E-6	Diabetic kidney disease	
BLCA	cis	1	rs2707832	chr7:66136549	CCT6P1	chr7:65216092-65228661:+	0.38	5.22	2.94E-7	Gout	
BLCA	cis	1	rs2707838	chr7:66159201	CCT6P1	chr7:65216092-65228661:+	0.35	4.69	3.85E-6	Gout	
BLCA	cis	1	rs2707840	chr7:66158015	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.42E-6	Gout	
BLCA	cis	1	rs2707844	chr7:66059509	CCT6P1	chr7:65216092-65228661:+	0.35	4.82	2.04E-6	Diabetic kidney disease	
BLCA	cis	1	rs2717562	chr8:143776668	LY6D	chr8:143866298-143868008:-	0.22	4.67	4.19E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2717562	chr8:143776668	PSCA	chr8:143761875-143764142:+	0.52	16.19	2.64E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs27529	chr5:96126308	ERAP1	chr5:96096515-96149837:-	-0.49	-10.44	1.26E-22	Ankylosing spondylitis	
BLCA	cis	1	rs27529	chr5:96126308	ERAP2	chr5:96211644-96255398:+	0.33	5.64	3.39E-8	Ankylosing spondylitis	
BLCA	cis	1	rs2757042	chr6:167371234	RNASET2	chr6:167343008-167412795:-	0.22	4.57	6.71E-6	Crohn's disease	
BLCA	cis	1	rs2757047	chr6:167374489	RNASET2	chr6:167343008-167412795:-	0.22	4.7	3.57E-6	Crohn's disease	
BLCA	cis	1	rs2764743	chr16:20031205	LOC81691	chr16:20817767-20860989:+	0.4	3.86	0.000136	IgG glycosylation	
BLCA	cis	1	rs2765766	chr13:50805755	CAB39L	chr13:49882787-50018221:-	0.24	4.59	5.93E-6	Celiac disease	
BLCA	cis	1	rs2769347	chr6:167371737	RNASET2	chr6:167343008-167412795:-	0.22	4.67	4.22E-6	Crohn's disease	
BLCA	cis	1	rs2769352	chr6:167378619	RNASET2	chr6:167343008-167412795:-	0.22	4.49	9.34E-6	Crohn's disease	
BLCA	cis	1	rs2769354	chr6:167379771	RNASET2	chr6:167343008-167412795:-	0.22	4.62	5.18E-6	Crohn's disease	
BLCA	cis	1	rs27710	chr5:96126197	ERAP1	chr5:96096515-96149837:-	0.47	10.15	1.39E-21	Ankylosing spondylitis	
BLCA	cis	1	rs27710	chr5:96126197	ERAP2	chr5:96211644-96255398:+	-0.31	-5.15	4.13E-7	Ankylosing spondylitis	
BLCA	cis	1	rs2791603	chr3:195142939	C3orf21	chr3:194789015-194991895:-	-0.28	-5.36	1.47E-7	Body mass index	
BLCA	cis	1	rs280603	chr4:129915063	C4orf33	chr4:130014829-130033842:+	-0.31	-5.12	4.83E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs280604	chr4:129921170	C4orf33	chr4:130014829-130033842:+	-0.32	-5.31	1.83E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs2811381	chr3:127997912	EEFSEC	chr3:127872313-128127488:+	0.37	3.93	9.91E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs2811526	chr3:127995718	EEFSEC	chr3:127872313-128127488:+	0.34	3.86	0.000132	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs2811527	chr3:127994604	EEFSEC	chr3:127872313-128127488:+	0.34	3.86	0.000132	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs2811528	chr3:127994436	EEFSEC	chr3:127872313-128127488:+	0.37	3.93	9.91E-5	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs2811530	chr3:127993166	EEFSEC	chr3:127872313-128127488:+	0.36	3.88	0.000122	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs2812972	chr6:86669880	SNHG5	chr6:86386726-86388451:-	-0.54	-9.82	1.86E-20	Response to antipsychotic treatment	
BLCA	cis	1	rs2816815	chr6:86691656	SNHG5	chr6:86386726-86388451:-	-0.55	-9.95	6.51E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs2816821	chr6:86657084	SNHG5	chr6:86386726-86388451:-	-0.55	-10.04	3.3E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs2832065	chr21:30135362	N6AMT1	chr21:30244513-30257693:-	-0.29	-4.78	2.5E-6	Cognitive test performance	
BLCA	cis	1	rs2832077	chr21:30141021	N6AMT1	chr21:30244513-30257693:-	-0.29	-4.76	2.75E-6	Cognitive test performance	
BLCA	cis	1	rs2833888	chr21:33927560	TCP10L	chr21:33947152-33957845:-	-0.36	-4.78	2.52E-6	Gastritis	
BLCA	cis	1	rs2833889	chr21:33927768	TCP10L	chr21:33947152-33957845:-	0.38	5.05	6.95E-7	Gastritis	
BLCA	cis	1	rs2833890	chr21:33927886	TCP10L	chr21:33947152-33957845:-	0.35	4.72	3.35E-6	Gastritis	
BLCA	cis	1	rs2835607	chr21:38491973	PIGP	chr21:38437664-38445458:-	-0.31	-5.42	1.07E-7	Eye color traits	
BLCA	cis	1	rs2835607	chr21:38491973	TTC3	chr21:38445571-38575406:+	0.25	5.15	4.28E-7	Eye color traits	
BLCA	cis	1	rs2835608	chr21:38493455	PIGP	chr21:38437664-38445458:-	-0.3	-5.3	1.95E-7	Eye color traits	
BLCA	cis	1	rs2835608	chr21:38493455	TTC3	chr21:38445571-38575406:+	0.25	5.14	4.38E-7	Eye color traits	
BLCA	cis	1	rs28379681	chr7:1070539	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs2839181	chr21:47685939	C21orf57	chr21:47706267-47717664:+	-0.27	-5.02	8.03E-7	Testicular germ cell tumor	
BLCA	cis	1	rs2839186	chr21:47690068	C21orf57	chr21:47706267-47717664:+	-0.3	-5.52	6.2E-8	Testicular germ cell tumor	
BLCA	cis	1	rs2839434	chr21:43418905	C21orf121	chr21:43442113-43445060:+	0.32	4.5	8.85E-6	Hand grip strength	
BLCA	cis	1	rs28399702	chr14:35625217	PPP2R3C	chr14:35554679-35591679:-	0.24	4	7.55E-5	Atopic dermatitis	
BLCA	cis	1	rs28399710	chr7:1070631	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs28409322	chr3:134252385	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs28409322	chr3:134252385	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs2847577	chr18:48364819	MRO	chr18:48321491-48351754:-	-0.24	-4.52	8.15E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs2849246	chr18:48371896	MRO	chr18:48321491-48351754:-	-0.25	-4.59	6.06E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs28517362	chr6:151876387	C6orf97	chr6:151815175-151942327:+	0.28	4.1	5.13E-5	Bone mineral density (spine)	
BLCA	cis	1	rs28528096	chr7:1070912	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs28546632	chr15:69399728	CALML4	chr15:68483044-68498448:-	0.24	3.87	0.00013	Lipoprotein-associated phospholipase A2 activity change in response to statin therapy	
BLCA	cis	1	rs2862961	chr11:43656535	HSD17B12	chr11:43702143-43878160:+	0.43	7.22	2.91E-12	Forced vital capacity	
BLCA	cis	1	rs2862963	chr11:43640115	HSD17B12	chr11:43702143-43878160:+	0.43	7.19	3.49E-12	Forced vital capacity	
BLCA	cis	1	rs2862996	chr11:43653833	HSD17B12	chr11:43702143-43878160:+	-0.43	-7.17	3.77E-12	Forced vital capacity	
BLCA	cis	1	rs28661978	chr3:156579739	LEKR1	chr3:156544076-156763918:+	-0.47	-6.39	4.95E-10	Bone mineral density	
BLCA	cis	1	rs28664971	chr17:28437410	EFCAB5	chr17:28256874-28435469:+	0.23	3.93	0.000102	Coffee consumption (cups per day)	
BLCA	cis	1	rs28683528	chr12:123845351	CDK2AP1	chr12:123745542-123756687:-	-0.35	-4.93	1.24E-6	Educational attainment;Height;Head circumference (infant)	
BLCA	cis	1	rs28702390	chr3:41889920	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs28733681	chr3:41863444	ULK4	chr3:41288091-42003660:-	0.62	9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs2874490	chr3:156635513	LEKR1	chr3:156544076-156763918:+	-0.46	-6.45	3.41E-10	Bone mineral density	
BLCA	cis	1	rs2874491	chr3:156649111	LEKR1	chr3:156544076-156763918:+	-0.45	-6.22	1.29E-9	Bone mineral density	
BLCA	cis	1	rs28755797	chr3:41774446	ULK4	chr3:41288091-42003660:-	0.64	9.46	3.23E-19	Diastolic blood pressure	
BLCA	cis	1	rs2880791	chr5:150267376	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs2881020	chr2:18233271	KCNS3	chr2:18059114-18114224:+	0.25	4.08	5.42E-5	Temperament (bipolar disorder)	
BLCA	cis	1	rs2887797	chr3:134202506	ANAPC13	chr3:134196547-134204865:-	0.51	8.15	5.2E-15	Height	
BLCA	cis	1	rs2887797	chr3:134202506	CEP63	chr3:134204575-134293852:+	0.26	4.46	1.06E-5	Height	
BLCA	cis	1	rs2888674	chr7:150510915	TMEM176A	chr7:150497854-150502208:+	0.17	4.48	1.01E-5	Forced expiratory volume in 1 second (environmental interaction)	
BLCA	cis	1	rs2896954	chr15:76851692	SCAPER	chr15:76640529-77197744:-	-0.22	-4.72	3.34E-6	Blood metabolite levels	
BLCA	cis	1	rs2901438	chr2:73665656	ALMS1P	chr2:73872046-73912692:+	0.4	5.95	6.22E-9	Metabolite levels	
BLCA	cis	1	rs2905425	chr19:19475717	YJEFN3	chr19:19639720-19648393:+	0.22	4.42	1.29E-5	Schizophrenia	
BLCA	cis	1	rs2916068	chr19:19516433	YJEFN3	chr19:19639720-19648393:+	-0.22	-4.43	1.22E-5	Schizophrenia	
BLCA	cis	1	rs2920292	chr8:143765699	LY6D	chr8:143866298-143868008:-	0.22	4.81	2.21E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920292	chr8:143765699	PSCA	chr8:143761875-143764142:+	0.52	16.1	6.5E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920293	chr8:143765414	LY6D	chr8:143866298-143868008:-	0.23	4.84	1.85E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920293	chr8:143765414	PSCA	chr8:143761875-143764142:+	0.52	16.16	3.53E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920294	chr8:143765326	LY6D	chr8:143866298-143868008:-	0.22	4.81	2.21E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920294	chr8:143765326	PSCA	chr8:143761875-143764142:+	0.52	16.1	6.5E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920295	chr8:143764937	LY6D	chr8:143866298-143868008:-	0.23	4.83	1.94E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920295	chr8:143764937	PSCA	chr8:143761875-143764142:+	0.51	15.85	7.23E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920296	chr8:143763109	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920296	chr8:143763109	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920297	chr8:143763083	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920297	chr8:143763083	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920298	chr8:143763043	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920298	chr8:143763043	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2920781	chr15:43924682	ADAL	chr15:43622872-43646094:+	-0.39	-4.43	1.23E-5	Tumor biomarkers	
BLCA	cis	1	rs2920781	chr15:43924682	CATSPER2	chr15:43922774-43959900:-	-0.36	-5.27	2.33E-7	Tumor biomarkers	
BLCA	cis	1	rs2922809	chr8:6350464	AGPAT5	chr8:6565878-6619019:+	0.52	4.92	1.3E-6	Cytomegalovirus antibody response	
BLCA	cis	1	rs2927072	chr15:43922398	ADAL	chr15:43622872-43646094:+	-0.39	-4.43	1.23E-5	Tumor biomarkers	
BLCA	cis	1	rs2927072	chr15:43922398	CATSPER2	chr15:43922774-43959900:-	-0.36	-5.27	2.33E-7	Tumor biomarkers	
BLCA	cis	1	rs2932538	chr1:113216543	ST7L	chr1:113066142-113162405:-	-0.37	-5.58	4.6E-8	Systolic blood pressure;Hypertension;Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs2935183	chr17:45607572	C17orf57	chr17:45401142-45518675:+	-0.27	-6	4.65E-9	Multiple sclerosis or amyotrophic lateral sclerosis	
BLCA	cis	1	rs2951308	chr7:143767149	ARHGEF35	chr7:143883677-143892736:-	0.33	5.88	8.88E-9	Obesity-related traits	
BLCA	cis	1	rs2951353	chr7:143761116	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.97	5.43E-9	Obesity-related traits	
BLCA	cis	1	rs2951354	chr7:143761001	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.3E-9	Obesity-related traits	
BLCA	cis	1	rs2951360	chr7:143757349	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.26E-9	Obesity-related traits	
BLCA	cis	1	rs2951363	chr7:143754724	ARHGEF35	chr7:143883677-143892736:-	-0.33	-5.9	7.79E-9	Obesity-related traits	
BLCA	cis	1	rs2951364	chr7:143754483	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.98	5.07E-9	Obesity-related traits	
BLCA	cis	1	rs2951368	chr7:143752821	ARHGEF35	chr7:143883677-143892736:-	-0.33	-5.9	7.79E-9	Obesity-related traits	
BLCA	cis	1	rs2951369	chr7:143752638	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.98	5.07E-9	Obesity-related traits	
BLCA	cis	1	rs2951371	chr7:143750328	ARHGEF35	chr7:143883677-143892736:-	-0.31	-5.32	1.77E-7	Obesity-related traits	
BLCA	cis	1	rs2951372	chr7:143749503	ARHGEF35	chr7:143883677-143892736:-	-0.33	-5.87	9.2E-9	Obesity-related traits	
BLCA	cis	1	rs2955126	chr3:127926254	EEFSEC	chr3:127872313-128127488:+	0.36	3.91	0.00011	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs2961102	chr7:65424658	CCT6P1	chr7:65216092-65228661:+	0.33	4.49	9.42E-6	Diabetic kidney disease	
BLCA	cis	1	rs2961115	chr7:143753371	ARHGEF35	chr7:143883677-143892736:-	-0.33	-5.9	7.79E-9	Obesity-related traits	
BLCA	cis	1	rs2961117	chr7:143755253	ARHGEF35	chr7:143883677-143892736:-	-0.32	-5.45	9.0E-8	Obesity-related traits	
BLCA	cis	1	rs2961118	chr7:143755443	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.97	5.56E-9	Obesity-related traits	
BLCA	cis	1	rs2961119	chr7:143755852	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.05	3.43E-9	Obesity-related traits	
BLCA	cis	1	rs2961120	chr7:143756585	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.26E-9	Obesity-related traits	
BLCA	cis	1	rs2961125	chr7:143761770	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.3E-9	Obesity-related traits	
BLCA	cis	1	rs2961126	chr7:143762736	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.3E-9	Obesity-related traits	
BLCA	cis	1	rs2961128	chr7:143763483	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.06	3.3E-9	Obesity-related traits	
BLCA	cis	1	rs2961132	chr7:143768128	ARHGEF35	chr7:143883677-143892736:-	-0.32	-5.55	5.33E-8	Obesity-related traits	
BLCA	cis	1	rs2961134	chr7:143771062	ARHGEF35	chr7:143883677-143892736:-	-0.34	-6.04	3.67E-9	Obesity-related traits	
BLCA	cis	1	rs2961144	chr7:143747870	ARHGEF35	chr7:143883677-143892736:-	0.33	5.85	1.07E-8	Obesity-related traits	
BLCA	cis	1	rs2965188	chr19:19522557	YJEFN3	chr19:19639720-19648393:+	-0.23	-4.44	1.16E-5	Schizophrenia	
BLCA	cis	1	rs2965198	chr19:19473030	YJEFN3	chr19:19639720-19648393:+	0.21	4.11	4.84E-5	Schizophrenia	
BLCA	cis	1	rs2976388	chr8:143760256	LY6D	chr8:143866298-143868008:-	0.25	5.07	6.08E-7	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976388	chr8:143760256	PSCA	chr8:143761875-143764142:+	0.5	14.21	4.29E-37	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976392	chr8:143762932	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976392	chr8:143762932	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976394	chr8:143763622	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976394	chr8:143763622	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976396	chr8:143764001	LY6D	chr8:143866298-143868008:-	-0.21	-4.46	1.09E-5	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976396	chr8:143764001	PSCA	chr8:143761875-143764142:+	-0.52	-16.3	9.91E-46	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976398	chr8:143764879	LY6D	chr8:143866298-143868008:-	0.22	4.81	2.21E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2976398	chr8:143764879	PSCA	chr8:143761875-143764142:+	0.52	16.1	6.5E-45	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2978982	chr8:143763490	LY6D	chr8:143866298-143868008:-	0.22	4.79	2.43E-6	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2978982	chr8:143763490	PSCA	chr8:143761875-143764142:+	0.51	15.95	2.78E-44	Gastric adenocarcinoma (histologically verified);Non-cardia gastric cancer;Gastric cancer;Duodenal ulcer;Bladder cancer	
BLCA	cis	1	rs2985696	chr14:50094913	RPL36AL	chr14:50085407-50087349:-	0.23	4.13	4.51E-5	Carotid intima media thickness	
BLCA	cis	1	rs2985697	chr14:50092902	RPL36AL	chr14:50085407-50087349:-	0.23	4.28	2.4E-5	Carotid intima media thickness	
BLCA	cis	1	rs2993259	chr1:46001550	CCDC163P	chr1:45960581-45965646:-	-0.78	-15.66	4.56E-43	Homocysteine levels	
BLCA	cis	1	rs3007030	chr14:50086563	RPL36AL	chr14:50085407-50087349:-	0.23	4.23	2.99E-5	Carotid intima media thickness	
BLCA	cis	1	rs30187	chr5:96124330	ERAP1	chr5:96096515-96149837:-	-0.51	-10.89	3.07E-24	Ankylosing spondylitis	
BLCA	cis	1	rs30187	chr5:96124330	ERAP2	chr5:96211644-96255398:+	0.32	5.31	1.89E-7	Ankylosing spondylitis	
BLCA	cis	1	rs302668	chr11:87876911	RAB38	chr11:87846431-87908599:-	0.25	4.19	3.54E-5	Frontotemporal dementia	
BLCA	cis	1	rs30378	chr5:96121994	ERAP1	chr5:96096515-96149837:-	-0.51	-10.95	1.77E-24	Ankylosing spondylitis	
BLCA	cis	1	rs30378	chr5:96121994	ERAP2	chr5:96211644-96255398:+	0.33	5.45	9.1E-8	Ankylosing spondylitis	
BLCA	cis	1	rs30379	chr5:96122260	ERAP1	chr5:96096515-96149837:-	-0.51	-10.95	1.77E-24	Ankylosing spondylitis	
BLCA	cis	1	rs30379	chr5:96122260	ERAP2	chr5:96211644-96255398:+	0.33	5.45	9.1E-8	Ankylosing spondylitis	
BLCA	cis	1	rs30380	chr5:96122281	ERAP1	chr5:96096515-96149837:-	-0.51	-10.95	1.77E-24	Ankylosing spondylitis	
BLCA	cis	1	rs30380	chr5:96122281	ERAP2	chr5:96211644-96255398:+	0.33	5.45	9.1E-8	Ankylosing spondylitis	
BLCA	cis	1	rs3091242	chr1:25674785	RHD	chr1:25598981-25656935:+	-0.54	-9.36	7.09E-19	Erythrocyte sedimentation rate	
BLCA	cis	1	rs3099459	chr5:56137170	C5orf35	chr5:56205103-56213010:+	0.74	11.44	2.94E-26	Type 2 diabetes	
BLCA	cis	1	rs3099555	chr4:1725651	FAM53A	chr4:1641609-1685854:-	-0.34	-4.98	9.81E-7	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs3099899	chr4:129917368	C4orf33	chr4:130014829-130033842:+	-0.32	-5.31	1.83E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs3101443	chr15:43912372	ADAL	chr15:43622872-43646094:+	-0.39	-4.34	1.83E-5	Tumor biomarkers	
BLCA	cis	1	rs3101443	chr15:43912372	CATSPER2	chr15:43922774-43959900:-	-0.35	-5.1	5.28E-7	Tumor biomarkers	
BLCA	cis	1	rs3105369	chr4:130022448	C4orf33	chr4:130014829-130033842:+	-0.33	-5.42	1.04E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs3105593	chr15:50845018	SPPL2A	chr15:50999739-51057910:-	0.23	4.29	2.28E-5	QT interval	
BLCA	cis	1	rs3109878	chr15:50836243	SPPL2A	chr15:50999739-51057910:-	0.23	4.27	2.42E-5	QT interval	
BLCA	cis	1	rs3113489	chr4:129961179	C4orf33	chr4:130014829-130033842:+	-0.33	-5.43	9.9E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs3124510	chr9:131899690	CRAT	chr9:131857075-131873070:-	-0.32	-5.83	1.19E-8	Blood metabolite ratios	
BLCA	cis	1	rs3124512	chr9:131903881	CRAT	chr9:131857075-131873070:-	-0.35	-6.08	2.93E-9	Blood metabolite ratios	
BLCA	cis	1	rs313798	chr7:65493031	CCT6P1	chr7:65216092-65228661:+	0.32	4.4	1.43E-5	Diabetic kidney disease	
BLCA	cis	1	rs313799	chr7:65494330	CCT6P1	chr7:65216092-65228661:+	0.3	4.32	1.97E-5	Diabetic kidney disease	
BLCA	cis	1	rs313802	chr7:65516373	CCT6P1	chr7:65216092-65228661:+	0.31	4.19	3.41E-5	Diabetic kidney disease	
BLCA	cis	1	rs313803	chr7:65514731	CCT6P1	chr7:65216092-65228661:+	0.31	4.19	3.41E-5	Diabetic kidney disease	
BLCA	cis	1	rs313807	chr7:65499481	CCT6P1	chr7:65216092-65228661:+	0.3	4.32	1.97E-5	Diabetic kidney disease	
BLCA	cis	1	rs313809	chr7:65499983	CCT6P1	chr7:65216092-65228661:+	0.31	4.39	1.48E-5	Diabetic kidney disease	
BLCA	cis	1	rs313814	chr7:65503293	CCT6P1	chr7:65216092-65228661:+	0.31	4.23	2.93E-5	Diabetic kidney disease	
BLCA	cis	1	rs313820	chr7:65574466	CCT6P1	chr7:65216092-65228661:+	0.35	4.95	1.13E-6	Diabetic kidney disease	
BLCA	cis	1	rs313824	chr7:65581207	CCT6P1	chr7:65216092-65228661:+	0.35	4.95	1.13E-6	Diabetic kidney disease	
BLCA	cis	1	rs313831	chr7:65551226	CCT6P1	chr7:65216092-65228661:+	0.35	4.8	2.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs313832	chr7:65550891	CCT6P1	chr7:65216092-65228661:+	0.35	4.8	2.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs313839	chr19:47221557	FKRP	chr19:47249303-47261832:+	0.4	4.36	1.68E-5	Type 1 diabetes	
BLCA	cis	1	rs316304	chr7:65616894	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs316307	chr7:65570171	CCT6P1	chr7:65216092-65228661:+	0.33	4.68	3.98E-6	Diabetic kidney disease	
BLCA	cis	1	rs316312	chr7:65596491	CCT6P1	chr7:65216092-65228661:+	0.33	4.56	6.79E-6	Diabetic kidney disease	
BLCA	cis	1	rs316313	chr7:65593548	CCT6P1	chr7:65216092-65228661:+	0.33	4.56	6.79E-6	Diabetic kidney disease	
BLCA	cis	1	rs316315	chr7:65591205	CCT6P1	chr7:65216092-65228661:+	-0.3	-4.31	2.12E-5	Diabetic kidney disease	
BLCA	cis	1	rs316317	chr7:65613637	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs316318	chr7:65612904	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs316321	chr7:65611613	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs316322	chr7:65611233	CCT6P1	chr7:65216092-65228661:+	0.36	4.73	3.17E-6	Diabetic kidney disease	
BLCA	cis	1	rs316325	chr7:65609518	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs316326	chr7:65609453	CCT6P1	chr7:65216092-65228661:+	0.35	4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs316327	chr7:65609201	CCT6P1	chr7:65216092-65228661:+	-0.3	-4.21	3.13E-5	Diabetic kidney disease	
BLCA	cis	1	rs316329	chr7:65608416	CCT6P1	chr7:65216092-65228661:+	0.32	4.49	9.37E-6	Diabetic kidney disease	
BLCA	cis	1	rs316330	chr7:65605372	CCT6P1	chr7:65216092-65228661:+	0.36	4.95	1.13E-6	Diabetic kidney disease	
BLCA	cis	1	rs316331	chr7:65604622	CCT6P1	chr7:65216092-65228661:+	-0.33	-4.67	4.26E-6	Diabetic kidney disease	
BLCA	cis	1	rs316332	chr7:65604299	CCT6P1	chr7:65216092-65228661:+	0.33	4.66	4.41E-6	Diabetic kidney disease	
BLCA	cis	1	rs316334	chr7:65602126	CCT6P1	chr7:65216092-65228661:+	0.33	4.56	6.79E-6	Diabetic kidney disease	
BLCA	cis	1	rs3176766	chr19:10449778	KANK2	chr19:11274944-11308467:-	0.17	4.19	3.4E-5	Systemic lupus erythematosus or rheumatoid arthritis	
BLCA	cis	1	rs3204270	chr17:79682051	ARL16	chr17:79648234-79650954:-	-0.76	-10.24	6.52E-22	Dental caries	
BLCA	cis	1	rs3213861	chr19:41919944	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.06	5.97E-5	Height	
BLCA	cis	1	rs33322	chr5:56175226	C5orf35	chr5:56205103-56213010:+	0.75	11.44	2.76E-26	Type 2 diabetes	
BLCA	cis	1	rs33325	chr5:56142547	C5orf35	chr5:56205103-56213010:+	0.74	11.79	1.37E-27	Type 2 diabetes	
BLCA	cis	1	rs33326	chr5:56142601	C5orf35	chr5:56205103-56213010:+	0.75	11.66	4.12E-27	Type 2 diabetes	
BLCA	cis	1	rs333960	chr1:110439480	GSTM1	chr1:110230418-110236366:+	0.36	4.12	4.71E-5	Obesity-related traits	
BLCA	cis	1	rs33999310	chr3:52883332	TMEM110	chr3:52867139-52931547:-	0.41	3.95	9.47E-5	Immune reponse to smallpox (secreted IL-2)	
BLCA	cis	1	rs34102169	chr1:46424864	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.37	5.58E-10	Body mass index	
BLCA	cis	1	rs34106666	chr6:86676258	SNHG5	chr6:86386726-86388451:-	-0.5	-8.86	2.99E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs34128973	chr11:47851376	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.6	4.09E-8	Subjective well-being	
BLCA	cis	1	rs34136756	chr7:65381256	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs34156253	chr5:150226230	LOC134466	chr5:150310000-150326146:-	0.41	4.89	1.47E-6	Crohn's disease	
BLCA	cis	1	rs34180939	chr5:148618964	AFAP1L1	chr5:148651401-148721365:+	0.27	5.02	8.06E-7	Body mass index	
BLCA	cis	1	rs34192067	chr7:65887657	CCT6P1	chr7:65216092-65228661:+	0.37	4.98	9.6E-7	Diabetic kidney disease	
BLCA	cis	1	rs34193460	chr7:65393110	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs34281561	chr6:86701872	SNHG5	chr6:86386726-86388451:-	-0.52	-9.26	1.43E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs34305567	chr22:29853562	MTMR3	chr22:30279158-30426855:+	0.25	3.93	0.000101	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs34305567	chr22:29853562	NIPSNAP1	chr22:29950800-29977144:-	0.3	4.15	4.1E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs34344888	chr14:23387585	HAUS4	chr14:23415438-23426335:-	-0.21	-4.16	3.93E-5	Educational attainment (years of education)	
BLCA	cis	1	rs344081	chr3:156555984	LEKR1	chr3:156544076-156763918:+	-0.45	-6.31	7.51E-10	Bone mineral density	
BLCA	cis	1	rs344088	chr3:156561361	LEKR1	chr3:156544076-156763918:+	-0.45	-6.34	6.39E-10	Bone mineral density	
BLCA	cis	1	rs344090	chr3:156563140	LEKR1	chr3:156544076-156763918:+	-0.45	-6.34	6.39E-10	Bone mineral density	
BLCA	cis	1	rs34409160	chr2:28943865	TRMT61B	chr2:29072690-29093175:-	0.3	5.29	2.1E-7	Body mass index	
BLCA	cis	1	rs34473788	chr1:27271519	GPN2	chr1:27205873-27216869:-	0.48	4.1	5.14E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs34529418	chr7:65403209	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs34560516	chr7:65404092	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs34570071	chr15:85280212	LOC388152	chr15:84867600-84898920:-	-0.24	-4.17	3.84E-5	Schizophrenia	
BLCA	cis	1	rs34577383	chr7:65385726	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs34581302	chr6:86705948	SNHG5	chr6:86386726-86388451:-	-0.52	-9.2	2.39E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs34622557	chr6:86630852	SNHG5	chr6:86386726-86388451:-	-0.51	-9.04	7.68E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs34637256	chr7:65360131	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.03E-5	Diabetic kidney disease	
BLCA	cis	1	rs34702770	chr7:65344823	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.03E-5	Diabetic kidney disease	
BLCA	cis	1	rs34703416	chr7:65300642	CCT6P1	chr7:65216092-65228661:+	0.32	4.48	1.0E-5	Diabetic kidney disease	
BLCA	cis	1	rs34746918	chr19:18539744	LRRC25	chr19:18501955-18508421:-	-0.1	-3.84	0.000142	Breast cancer	
BLCA	cis	1	rs34751999	chr15:84758419	LOC388152	chr15:84867600-84898920:-	-0.26	-4.61	5.56E-6	Schizophrenia	
BLCA	cis	1	rs34812189	chr6:56806727	BEND6	chr6:56819773-56892138:+	-0.28	-3.87	0.00013	Menarche (age at onset)	
BLCA	cis	1	rs34815098	chr7:65292254	CCT6P1	chr7:65216092-65228661:+	0.31	4.39	1.49E-5	Diabetic kidney disease	
BLCA	cis	1	rs34817530	chr14:71228462	MAP3K9	chr14:71194856-71275888:-	0.4	4.18	3.65E-5	Response to antipsychotic treatment in schizophrenia (reasoning)	
BLCA	cis	1	rs34848593	chr1:113240106	ST7L	chr1:113066142-113162405:-	0.44	6.49	2.68E-10	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs34852683	chr6:86702330	SNHG5	chr6:86386726-86388451:-	-0.5	-8.76	6.51E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs34895954	chr10:52007016	FAM21A	chr10:51827684-51893268:+	-0.53	-4.62	5.34E-6	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs34897410	chr2:239182123	LOC151174	chr2:239133754-239140318:-	0.45	4.55	7.1E-6	Irritable bowel syndrome	
BLCA	cis	1	rs34900908	chr15:85257599	LOC388152	chr15:84867600-84898920:-	-0.24	-4.11	4.83E-5	Schizophrenia	
BLCA	cis	1	rs34910028	chr11:47758449	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.62	3.73E-8	Subjective well-being	
BLCA	cis	1	rs34933526	chr7:65383199	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs34964872	chr14:104448435	TDRD9	chr14:104394817-104519002:+	0.34	5.42	1.04E-7	Bipolar disorder	
BLCA	cis	1	rs34970380	chr7:65431493	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.05E-5	Diabetic kidney disease	
BLCA	cis	1	rs34974928	chr7:65364006	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs35006492	chr4:129878342	C4orf33	chr4:130014829-130033842:+	0.32	4.97	1.01E-6	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs35025342	chr6:151876661	C6orf97	chr6:151815175-151942327:+	0.28	4.07	5.63E-5	Bone mineral density (spine)	
BLCA	cis	1	rs35046236	chr7:65408613	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs35058610	chr7:65390925	CCT6P1	chr7:65216092-65228661:+	0.32	4.48	9.9E-6	Diabetic kidney disease	
BLCA	cis	1	rs35060985	chr11:43693110	HSD17B12	chr11:43702143-43878160:+	-0.42	-6.97	1.38E-11	Forced vital capacity	
BLCA	cis	1	rs35108146	chr1:27248440	GPN2	chr1:27205873-27216869:-	0.47	3.96	8.9E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs35141484	chr4:39088341	PDS5A	chr4:39824484-39979576:-	-0.56	-4.1	5.03E-5	Asthma (childhood onset)	
BLCA	cis	1	rs35141484	chr4:39088341	RFC1	chr4:39289076-39367995:-	-0.5	-4	7.54E-5	Asthma (childhood onset)	
BLCA	cis	1	rs35163227	chr3:53127876	SFMBT1	chr3:52938628-53080070:-	-0.45	-4.06	5.92E-5	Immune reponse to smallpox (secreted IL-2)	
BLCA	cis	1	rs35184688	chr17:40272406	DHX58	chr17:40253422-40264751:-	-0.25	-4.59	5.98E-6	Fibrinogen levels	
BLCA	cis	1	rs35202312	chr6:56788937	BEND6	chr6:56819773-56892138:+	-0.29	-4.16	3.9E-5	Menarche (age at onset)	
BLCA	cis	1	rs35283677	chr7:65359233	CCT6P1	chr7:65216092-65228661:+	0.33	4.45	1.11E-5	Diabetic kidney disease	
BLCA	cis	1	rs35297609	chr15:84772896	LOC388152	chr15:84867600-84898920:-	-0.27	-4.65	4.65E-6	Schizophrenia	
BLCA	cis	1	rs35316992	chr15:85248133	LOC388152	chr15:84867600-84898920:-	-0.25	-4.2	3.37E-5	Schizophrenia	
BLCA	cis	1	rs35372377	chr15:52882281	ARPP19	chr15:52839432-52861364:-	0.22	4.14	4.36E-5	Schizophrenia	
BLCA	cis	1	rs35385043	chr6:86648546	SNHG5	chr6:86386726-86388451:-	-0.55	-10.06	2.7E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs35391607	chr7:65360829	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs35396113	chr7:65495461	CCT6P1	chr7:65216092-65228661:+	0.31	4.39	1.48E-5	Diabetic kidney disease	
BLCA	cis	1	rs35419329	chr6:86702291	SNHG5	chr6:86386726-86388451:-	-0.52	-9.26	1.43E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs35421653	chr7:65363429	CCT6P1	chr7:65216092-65228661:+	0.33	4.45	1.11E-5	Diabetic kidney disease	
BLCA	cis	1	rs35432774	chr7:65393019	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs35435780	chr17:79579602	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs35454259	chr6:27254475	BTN3A2	chr6:26365398-26378546:+	-0.29	-4.71	3.51E-6	Schizophrenia	
BLCA	cis	1	rs35524990	chr15:85258203	LOC388152	chr15:84867600-84898920:-	-0.24	-4.11	4.83E-5	Schizophrenia	
BLCA	cis	1	rs35527216	chr6:56791278	BEND6	chr6:56819773-56892138:+	-0.27	-3.86	0.000134	Menarche (age at onset)	
BLCA	cis	1	rs35542501	chr7:65431215	CCT6P1	chr7:65216092-65228661:+	0.31	4.39	1.44E-5	Diabetic kidney disease	
BLCA	cis	1	rs35564624	chr6:151876494	C6orf97	chr6:151815175-151942327:+	0.28	4.1	5.13E-5	Bone mineral density (spine)	
BLCA	cis	1	rs35577967	chr15:75354621	SCAMP5	chr15:75287901-75313836:+	0.28	4.71	3.5E-6	Blood trace element (Zn levels)	
BLCA	cis	1	rs35624992	chr11:47615798	C1QTNF4	chr11:47611216-47615961:-	-0.29	-5.62	3.78E-8	Subjective well-being	
BLCA	cis	1	rs35630683	chr15:85349231	LOC388152	chr15:84867600-84898920:-	-0.22	-3.92	0.000105	Schizophrenia	
BLCA	cis	1	rs35648189	chr15:84740748	LOC388152	chr15:84867600-84898920:-	-0.26	-4.59	6.03E-6	Schizophrenia	
BLCA	cis	1	rs35658069	chr15:84780146	LOC388152	chr15:84867600-84898920:-	-0.27	-4.67	4.27E-6	Schizophrenia	
BLCA	cis	1	rs35718987	chr3:134272783	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs35718987	chr3:134272783	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs35726233	chr15:85337800	LOC388152	chr15:84867600-84898920:-	-0.23	-4.16	4.0E-5	Schizophrenia	
BLCA	cis	1	rs35734267	chr2:70281190	FAM136A	chr2:70523109-70529220:-	-0.26	-4.23	2.87E-5	Obesity-related traits	
BLCA	cis	1	rs35735127	chr7:65300423	CCT6P1	chr7:65216092-65228661:+	0.31	4.39	1.49E-5	Diabetic kidney disease	
BLCA	cis	1	rs35760725	chr6:86648985	SNHG5	chr6:86386726-86388451:-	-0.55	-10.06	2.7E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs35761942	chr6:86629504	SNHG5	chr6:86386726-86388451:-	-0.54	-9.57	1.33E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs35797755	chr6:86706554	SNHG5	chr6:86386726-86388451:-	-0.52	-9.13	4.08E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs35820085	chr7:65442758	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.05E-5	Diabetic kidney disease	
BLCA	cis	1	rs35825738	chr7:65318027	CCT6P1	chr7:65216092-65228661:+	0.31	4.39	1.49E-5	Diabetic kidney disease	
BLCA	cis	1	rs35902101	chr11:47795169	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.65	3.22E-8	Subjective well-being	
BLCA	cis	1	rs35960805	chr15:85343980	LOC388152	chr15:84867600-84898920:-	-0.23	-4.16	4.0E-5	Schizophrenia	
BLCA	cis	1	rs35962879	chr1:27283456	GPN2	chr1:27205873-27216869:-	0.47	4.05	6.12E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs36033484	chr7:65390558	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs36033486	chr15:85319692	LOC388152	chr15:84867600-84898920:-	-0.23	-4.18	3.68E-5	Schizophrenia	
BLCA	cis	1	rs36035949	chr6:109736614	SMPD2	chr6:109761931-109765121:+	0.21	3.98	8.34E-5	Height	
BLCA	cis	1	rs36068983	chr7:65408991	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs36096931	chr6:86693134	SNHG5	chr6:86386726-86388451:-	-0.49	-8.73	7.95E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs36216559	chr2:262335	SH3YL1	chr2:218138-264810:-	-0.45	-11.68	3.7E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs364283	chr6:167383750	RNASET2	chr6:167343008-167412795:-	-0.23	-4.95	1.14E-6	Crohn's disease	
BLCA	cis	1	rs364451	chr6:167384756	RNASET2	chr6:167343008-167412795:-	-0.23	-4.86	1.7E-6	Crohn's disease	
BLCA	cis	1	rs365189	chr6:167384545	RNASET2	chr6:167343008-167412795:-	-0.23	-4.95	1.14E-6	Crohn's disease	
BLCA	cis	1	rs3731714	chr2:202060820	PPIL3	chr2:201735680-201753999:-	0.32	4.98	9.6E-7	Trans fatty acid levels	
BLCA	cis	1	rs3732361	chr3:119542297	KTELC1	chr3:119187785-119213552:+	0.24	4.33	1.91E-5	HDL cholesterol	
BLCA	cis	1	rs3738483	chr1:150801466	HORMAD1	chr1:150670542-150693352:-	0.41	4.04	6.37E-5	Congenital left-sided heart lesions	
BLCA	cis	1	rs3738814	chr1:17331676	MST1P9	chr1:17081402-17090975:-	0.33	6.73	6.37E-11	Height	
BLCA	cis	1	rs3738848	chr2:73761881	ALMS1P	chr2:73872046-73912692:+	0.38	5.74	1.93E-8	Metabolite levels	
BLCA	cis	1	rs3740711	chr11:18379839	GTF2H1	chr11:18343816-18388590:+	0.29	5.51	6.75E-8	Pancreatic cancer	
BLCA	cis	1	rs3742500	chr14:24611978	FAM158A	chr14:24608175-24610797:-	-0.42	-8.32	1.53E-15	IgG glycosylation	
BLCA	cis	1	rs3745937	chr19:42071289	CEACAM21	chr19:42055886-42093196:+	0.34	7.76	7.88E-14	Schizophrenia	
BLCA	cis	1	rs3748656	chr1:113236681	ST7L	chr1:113066142-113162405:-	0.44	6.49	2.68E-10	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs3751972	chr17:26206414	C17orf108	chr17:26205341-26220409:-	0.24	4.71	3.41E-6	Fractional exhaled nitric oxide (childhood)	
BLCA	cis	1	rs3752749	chr4:1737262	FAM53A	chr4:1641609-1685854:-	-0.31	-4.49	9.51E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs3754439	chr1:110615094	ALX3	chr1:110602998-110613322:-	-0.21	-3.89	0.000118	Blood metabolite levels	
BLCA	cis	1	rs3754440	chr1:110613674	ALX3	chr1:110602998-110613322:-	-0.22	-4.06	5.97E-5	Blood metabolite levels	
BLCA	cis	1	rs3761959	chr1:157669278	FCRL3	chr1:157646278-157670775:-	0.31	9.76	3.11E-20	Type 1 diabetes autoantibodies	
BLCA	cis	1	rs376551	chr6:167384923	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs376574	chr6:167389956	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs3774372	chr3:41877414	ULK4	chr3:41288091-42003660:-	0.61	8.99	1.15E-17	Diastolic blood pressure	
BLCA	cis	1	rs3774808	chr3:48481647	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000134	Longevity	
BLCA	cis	1	rs3778483	chr6:46627100	SLC25A27	chr6:46620679-46645925:+	-0.25	-4.98	9.57E-7	QRS complex (Sokolow-Lyon)	
BLCA	cis	1	rs3782130	chr12:58161898	FAM119B	chr12:58166383-58176323:+	0.28	4.42	1.3E-5	Multiple sclerosis	
BLCA	cis	1	rs3782130	chr12:58161898	TSFM	chr12:58176536-58191367:+	-0.39	-6.92	1.87E-11	Multiple sclerosis	
BLCA	cis	1	rs3782130	chr12:58161898	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.09	5.28E-5	Multiple sclerosis	
BLCA	cis	1	rs3788545	chr22:39065172	JOSD1	chr22:39081549-39096459:-	-0.25	-4.08	5.55E-5	Resting heart rate	
BLCA	cis	1	rs3790012	chr13:36773489	SOHLH2	chr13:36742347-36871992:-	0.27	4.53	7.72E-6	Glucose homeostasis traits	
BLCA	cis	1	rs3791220	chr2:227066	SH3YL1	chr2:218138-264810:-	-0.44	-11.57	9.11E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs3791221	chr2:226933	SH3YL1	chr2:218138-264810:-	-0.44	-11.45	2.67E-26	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs3791223	chr2:222336	SH3YL1	chr2:218138-264810:-	-0.45	-11.82	1.11E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs3791224	chr2:221981	SH3YL1	chr2:218138-264810:-	-0.45	-11.79	1.37E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs3795819	chr1:113234179	ST7L	chr1:113066142-113162405:-	-0.43	-6.46	3.26E-10	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs3796352	chr3:52913279	TMEM110	chr3:52867139-52931547:-	0.47	4.35	1.76E-5	Immune reponse to smallpox (secreted IL-2)	
BLCA	cis	1	rs3796689	chr4:185649866	MLF1IP	chr4:185615220-185655286:-	-0.47	-11.04	9.0E-25	Kawasaki disease	
BLCA	cis	1	rs3806988	chr6:49431569	CENPQ	chr6:49431096-49460820:+	-0.27	-5.41	1.11E-7	Folate pathway vitamin levels	
BLCA	cis	1	rs3806988	chr6:49431569	MUT	chr6:49398994-49431031:-	0.29	5.66	2.95E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs3809868	chr17:45750596	C17orf57	chr17:45401142-45518675:+	-0.26	-5.75	1.79E-8	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs3810174	chr19:41904165	B3GNT8	chr19:41931265-41934635:-	-0.2	-3.84	0.000144	Height	
BLCA	cis	1	rs3810175	chr19:41904396	B3GNT8	chr19:41931265-41934635:-	0.21	3.87	0.000127	Height	
BLCA	cis	1	rs3812638	chr10:75896072	ADK	chr10:75910965-76469059:+	0.33	4.82	2.04E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs3812638	chr10:75896072	AP3M1	chr10:75880016-75910826:-	0.32	4.06	5.83E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs3813227	chr2:73651967	ALMS1P	chr2:73872046-73912692:+	-0.37	-5.45	8.95E-8	Metabolite levels	
BLCA	cis	1	rs3823114	chr6:49431720	CENPQ	chr6:49431096-49460820:+	-0.28	-5.65	3.17E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs3823114	chr6:49431720	MUT	chr6:49398994-49431031:-	0.28	5.51	6.48E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs3825079	chr12:58203354	FAM119B	chr12:58166383-58176323:+	0.28	4.45	1.12E-5	Multiple sclerosis	
BLCA	cis	1	rs3825079	chr12:58203354	TSFM	chr12:58176536-58191367:+	-0.39	-6.89	2.36E-11	Multiple sclerosis	
BLCA	cis	1	rs3825079	chr12:58203354	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.12	4.66E-5	Multiple sclerosis	
BLCA	cis	1	rs3826331	chr17:38150492	ZPBP2	chr17:38024455-38034144:+	0.22	4.06	6.02E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs3828165	chr2:220889	SH3YL1	chr2:218138-264810:-	-0.45	-11.84	9.03E-28	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs383402	chr7:65586653	CCT6P1	chr7:65216092-65228661:+	-0.31	-4.62	5.31E-6	Diabetic kidney disease	
BLCA	cis	1	rs3846055	chr3:134203973	ANAPC13	chr3:134196547-134204865:-	0.51	8.16	4.83E-15	Height	
BLCA	cis	1	rs3846055	chr3:134203973	CEP63	chr3:134204575-134293852:+	0.25	4.36	1.7E-5	Height	
BLCA	cis	1	rs3846056	chr3:134227292	ANAPC13	chr3:134196547-134204865:-	0.49	7.99	1.6E-14	Height	
BLCA	cis	1	rs3846056	chr3:134227292	CEP63	chr3:134204575-134293852:+	0.24	4.2	3.36E-5	Height	
BLCA	cis	1	rs3846926	chr6:56092186	COL21A1	chr6:55921389-56258892:-	0.36	6.65	1.01E-10	Pulse pressure	
BLCA	cis	1	rs385113	chr6:167403971	RNASET2	chr6:167343008-167412795:-	-0.25	-5.15	4.08E-7	Crohn's disease	
BLCA	cis	1	rs3857422	chr5:150268609	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs385863	chr6:167386615	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs386548	chr6:167385533	RNASET2	chr6:167343008-167412795:-	0.25	5.33	1.66E-7	Crohn's disease	
BLCA	cis	1	rs387676	chr7:65598220	CCT6P1	chr7:65216092-65228661:+	0.34	4.61	5.54E-6	Diabetic kidney disease	
BLCA	cis	1	rs3885839	chr7:65290403	CCT6P1	chr7:65216092-65228661:+	0.33	4.46	1.08E-5	Diabetic kidney disease	
BLCA	cis	1	rs3890604	chr3:41760625	ULK4	chr3:41288091-42003660:-	0.64	9.9	9.78E-21	Diastolic blood pressure	
BLCA	cis	1	rs3892761	chr12:54070445	ATP5G2	chr12:54058945-54070512:-	0.22	4.78	2.54E-6	Height	
BLCA	cis	1	rs389946	chr6:167407268	RNASET2	chr6:167343008-167412795:-	-0.25	-5.16	4.07E-7	Crohn's disease	
BLCA	cis	1	rs389956	chr6:167407254	RNASET2	chr6:167343008-167412795:-	-0.25	-5.16	4.07E-7	Crohn's disease	
BLCA	cis	1	rs3900064	chr5:150264414	LOC134466	chr5:150310000-150326146:-	-0.42	-5.48	7.88E-8	Crohn's disease	
BLCA	cis	1	rs3906527	chr5:150266392	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs3906528	chr5:150266718	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs391396	chr4:130037653	C4orf33	chr4:130014829-130033842:+	-0.35	-5.79	1.47E-8	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs3931020	chr1:75235317	CRYZ	chr1:75171175-75199092:-	-0.28	-4.46	1.07E-5	Resistin levels	
BLCA	cis	1	rs3932818	chr3:134206069	ANAPC13	chr3:134196547-134204865:-	0.47	7.39	9.45E-13	Height	
BLCA	cis	1	rs3934103	chr3:41977214	ULK4	chr3:41288091-42003660:-	-0.61	-9.43	3.93E-19	Diastolic blood pressure	
BLCA	cis	1	rs3935543	chr17:79579874	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs393558	chr6:167397750	RNASET2	chr6:167343008-167412795:-	-0.24	-5.1	5.43E-7	Crohn's disease	
BLCA	cis	1	rs393727	chr6:167398632	RNASET2	chr6:167343008-167412795:-	-0.24	-5.1	5.41E-7	Crohn's disease	
BLCA	cis	1	rs394522	chr6:167398071	RNASET2	chr6:167343008-167412795:-	-0.24	-5.1	5.43E-7	Crohn's disease	
BLCA	cis	1	rs3960018	chr15:90383307	AP3S2	chr15:90373832-90456222:-	-0.7	-10.62	2.88E-23	Type 2 diabetes	
BLCA	cis	1	rs396508	chr16:20682354	ACSM1	chr16:20634559-20709066:-	-0.22	-4.21	3.19E-5	Schizophrenia	
BLCA	cis	1	rs397713	chr6:167386714	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs398278	chr6:167388169	RNASET2	chr6:167343008-167412795:-	-0.23	-4.83	1.99E-6	Crohn's disease	
BLCA	cis	1	rs39841	chr5:96120170	ERAP1	chr5:96096515-96149837:-	-0.47	-8.87	2.75E-17	Inflammatory skin disease	
BLCA	cis	1	rs39841	chr5:96120170	ERAP2	chr5:96211644-96255398:+	0.35	5.43	1.03E-7	Inflammatory skin disease	
BLCA	cis	1	rs400063	chr6:167386592	RNASET2	chr6:167343008-167412795:-	-0.23	-4.95	1.11E-6	Crohn's disease	
BLCA	cis	1	rs400176	chr6:167406238	RNASET2	chr6:167343008-167412795:-	-0.25	-5.16	4.07E-7	Crohn's disease	
BLCA	cis	1	rs400837	chr6:167411008	RNASET2	chr6:167343008-167412795:-	-0.24	-5.05	7.0E-7	Crohn's disease	
BLCA	cis	1	rs402418	chr7:65509469	CCT6P1	chr7:65216092-65228661:+	0.32	4.38	1.51E-5	Diabetic kidney disease	
BLCA	cis	1	rs402749	chr6:167386104	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs4037	chr10:97365820	ENTPD1	chr10:97471536-97637022:+	0.2	5	8.71E-7	Blood metabolite levels	
BLCA	cis	1	rs404222	chr6:167402150	RNASET2	chr6:167343008-167412795:-	-0.24	-5.03	7.43E-7	Crohn's disease	
BLCA	cis	1	rs405553	chr6:167395058	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs406095	chr6:167409087	RNASET2	chr6:167343008-167412795:-	-0.24	-5.05	7.0E-7	Crohn's disease	
BLCA	cis	1	rs4073846	chr1:46462881	CCDC163P	chr1:45960581-45965646:-	0.34	6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs4074170	chr17:28381141	EFCAB5	chr17:28256874-28435469:+	-0.22	-3.84	0.000147	Coffee consumption (cups per day)	
BLCA	cis	1	rs4074915	chr17:79579230	TSPAN10	chr17:79609349-79615778:+	-0.49	-8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs4074916	chr17:79579248	TSPAN10	chr17:79609349-79615778:+	-0.49	-8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs407515	chr6:167407544	RNASET2	chr6:167343008-167412795:-	-0.24	-5.05	7.0E-7	Crohn's disease	
BLCA	cis	1	rs4075511	chr2:18243534	KCNS3	chr2:18059114-18114224:+	0.24	3.92	0.000106	Temperament (bipolar disorder)	
BLCA	cis	1	rs4075623	chr17:28386526	EFCAB5	chr17:28256874-28435469:+	-0.23	-4	7.57E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs4076006	chr1:46438076	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs408040	chr6:167398903	RNASET2	chr6:167343008-167412795:-	-0.24	-5.1	5.43E-7	Crohn's disease	
BLCA	cis	1	rs408080	chr6:167392522	RNASET2	chr6:167343008-167412795:-	-0.24	-4.96	1.04E-6	Crohn's disease	
BLCA	cis	1	rs408087	chr6:167398952	RNASET2	chr6:167343008-167412795:-	-0.24	-5.06	6.52E-7	Crohn's disease	
BLCA	cis	1	rs408918	chr6:167399282	RNASET2	chr6:167343008-167412795:-	-0.22	-4.62	5.33E-6	Crohn's disease	
BLCA	cis	1	rs409035	chr20:5943649	MCM8	chr20:5931298-5975829:+	-0.21	-4.39	1.45E-5	HIV-1 viral setpoint	
BLCA	cis	1	rs409356	chr6:167405226	RNASET2	chr6:167343008-167412795:-	-0.25	-5.15	4.08E-7	Crohn's disease	
BLCA	cis	1	rs410128	chr7:65603173	CCT6P1	chr7:65216092-65228661:+	0.31	4.13	4.46E-5	Diabetic kidney disease	
BLCA	cis	1	rs4129956	chr4:302008	ZNF718	chr4:53272-156488:+	0.35	4.61	5.42E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs413232	chr6:167400972	RNASET2	chr6:167343008-167412795:-	-0.25	-5.17	3.76E-7	Crohn's disease	
BLCA	cis	1	rs4134386	chr1:46395089	CCDC163P	chr1:45960581-45965646:-	-0.35	-6.56	1.75E-10	Body mass index	
BLCA	cis	1	rs4140574	chr6:56099424	COL21A1	chr6:55921389-56258892:-	0.36	6.51	2.31E-10	Pulse pressure	
BLCA	cis	1	rs4140575	chr6:56099222	COL21A1	chr6:55921389-56258892:-	0.36	6.62	1.2E-10	Pulse pressure	
BLCA	cis	1	rs4144937	chr6:46628516	SLC25A27	chr6:46620679-46645925:+	-0.25	-5.03	7.39E-7	QRS complex (Sokolow-Lyon)	
BLCA	cis	1	rs4145008	chr7:65647511	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs4148575	chr3:183702275	ABCC5	chr3:183637726-183735727:-	-0.2	-3.96	8.97E-5	Anterior chamber depth	
BLCA	cis	1	rs4149468	chr7:65825690	CCT6P1	chr7:65216092-65228661:+	0.37	4.94	1.2E-6	Diabetic kidney disease	
BLCA	cis	1	rs4150550	chr11:18350898	GTF2H1	chr11:18343816-18388590:+	0.32	6.12	2.28E-9	Pancreatic cancer	
BLCA	cis	1	rs4150562	chr11:18354995	GTF2H1	chr11:18343816-18388590:+	0.32	6.05	3.38E-9	Pancreatic cancer	
BLCA	cis	1	rs4150564	chr11:18355308	GTF2H1	chr11:18343816-18388590:+	0.31	5.94	6.24E-9	Pancreatic cancer	
BLCA	cis	1	rs4150566	chr11:18355599	GTF2H1	chr11:18343816-18388590:+	0.32	6.05	3.48E-9	Pancreatic cancer	
BLCA	cis	1	rs4150575	chr11:18356466	GTF2H1	chr11:18343816-18388590:+	0.31	6.02	4.03E-9	Pancreatic cancer	
BLCA	cis	1	rs4150579	chr11:18357180	GTF2H1	chr11:18343816-18388590:+	-0.32	-6.02	4.01E-9	Pancreatic cancer	
BLCA	cis	1	rs4150610	chr11:18364140	GTF2H1	chr11:18343816-18388590:+	0.3	5.73	1.99E-8	Pancreatic cancer	
BLCA	cis	1	rs4150612	chr11:18364358	GTF2H1	chr11:18343816-18388590:+	0.31	5.88	8.76E-9	Pancreatic cancer	
BLCA	cis	1	rs4150615	chr11:18365028	GTF2H1	chr11:18343816-18388590:+	-0.29	-5.36	1.47E-7	Pancreatic cancer	
BLCA	cis	1	rs4150622	chr11:18365710	GTF2H1	chr11:18343816-18388590:+	0.31	6.01	4.36E-9	Pancreatic cancer	
BLCA	cis	1	rs4150641	chr11:18370739	GTF2H1	chr11:18343816-18388590:+	0.31	6	4.6E-9	Pancreatic cancer	
BLCA	cis	1	rs4150650	chr11:18374279	GTF2H1	chr11:18343816-18388590:+	0.31	6.04	3.75E-9	Pancreatic cancer	
BLCA	cis	1	rs4150651	chr11:18374425	GTF2H1	chr11:18343816-18388590:+	0.31	6.04	3.75E-9	Pancreatic cancer	
BLCA	cis	1	rs4150655	chr11:18375164	GTF2H1	chr11:18343816-18388590:+	-0.28	-5.4	1.16E-7	Pancreatic cancer	
BLCA	cis	1	rs4150661	chr11:18379629	GTF2H1	chr11:18343816-18388590:+	0.29	5.52	6.15E-8	Pancreatic cancer	
BLCA	cis	1	rs4150673	chr11:18383449	GTF2H1	chr11:18343816-18388590:+	0.29	5.39	1.24E-7	Pancreatic cancer	
BLCA	cis	1	rs415842	chr6:167406681	RNASET2	chr6:167343008-167412795:-	-0.25	-5.16	4.07E-7	Crohn's disease	
BLCA	cis	1	rs415890	chr6:167406633	RNASET2	chr6:167343008-167412795:-	0.25	5.21	3.07E-7	Crohn's disease	
BLCA	cis	1	rs416131	chr6:167406544	RNASET2	chr6:167343008-167412795:-	0.23	4.89	1.52E-6	Crohn's disease	
BLCA	cis	1	rs419603	chr7:65597341	CCT6P1	chr7:65216092-65228661:+	0.33	4.56	6.79E-6	Diabetic kidney disease	
BLCA	cis	1	rs420259	chr16:23634026	EARS2	chr16:23533335-23568696:-	0.25	3.97	8.42E-5	Bipolar disorder	
BLCA	cis	1	rs421214	chr6:167396629	RNASET2	chr6:167343008-167412795:-	-0.24	-5.08	5.88E-7	Crohn's disease	
BLCA	cis	1	rs422094	chr6:167397033	RNASET2	chr6:167343008-167412795:-	-0.24	-5.08	5.88E-7	Crohn's disease	
BLCA	cis	1	rs422164	chr7:65586605	CCT6P1	chr7:65216092-65228661:+	0.35	4.95	1.13E-6	Diabetic kidney disease	
BLCA	cis	1	rs422562	chr6:167406318	RNASET2	chr6:167343008-167412795:-	-0.24	-4.99	9.3E-7	Crohn's disease	
BLCA	cis	1	rs422694	chr6:167406074	RNASET2	chr6:167343008-167412795:-	-0.25	-5.16	4.07E-7	Crohn's disease	
BLCA	cis	1	rs422780	chr6:167406209	RNASET2	chr6:167343008-167412795:-	-0.25	-5.16	4.07E-7	Crohn's disease	
BLCA	cis	1	rs4237643	chr11:43648368	HSD17B12	chr11:43702143-43878160:+	0.43	7.19	3.45E-12	Forced vital capacity	
BLCA	cis	1	rs4239227	chr17:28389103	EFCAB5	chr17:28256874-28435469:+	-0.23	-4	7.57E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs4253766	chr22:46623905	PKDREJ	chr22:46651561-46659219:-	-0.41	-4.22	3.04E-5	Cholesterol, total;LDL cholesterol	
BLCA	cis	1	rs4253772	chr22:46627603	PKDREJ	chr22:46651561-46659219:-	-0.43	-4.11	4.92E-5	Cholesterol, total;LDL cholesterol	
BLCA	cis	1	rs4256922	chr10:52568616	ASAH2B	chr10:52499696-52514567:+	-0.29	-3.83	0.000152	Urate levels in lean individuals	
BLCA	cis	1	rs4263408	chr4:39785276	RPL9	chr4:39455747-39460568:-	-0.42	-7.07	7.46E-12	Plasma amyloid beta peptide concentrations (ABx-40)	
BLCA	cis	1	rs4267943	chr6:49439805	CENPQ	chr6:49431096-49460820:+	0.3	6.07	3.08E-9	Folate pathway vitamin levels	
BLCA	cis	1	rs4267943	chr6:49439805	MUT	chr6:49398994-49431031:-	-0.25	-4.7	3.68E-6	Folate pathway vitamin levels	
BLCA	cis	1	rs427044	chr7:65508545	CCT6P1	chr7:65216092-65228661:+	0.32	4.4	1.39E-5	Diabetic kidney disease	
BLCA	cis	1	rs4272382	chr8:8433488	ERI1	chr8:8860314-8890849:+	-0.41	-3.96	8.86E-5	Response to cytidine analogues (gemcitabine)	
BLCA	cis	1	rs4272382	chr8:8433488	TNKS	chr8:9413445-9639855:+	-0.5	-6.17	1.74E-9	Response to cytidine analogues (gemcitabine)	
BLCA	cis	1	rs4281086	chr8:10352308	PINX1	chr8:10622884-10697299:-	-0.22	-4.17	3.84E-5	Obesity-related traits	
BLCA	cis	1	rs4281086	chr8:10352308	TNKS	chr8:9413445-9639855:+	-0.24	-4.83	1.97E-6	Obesity-related traits	
BLCA	cis	1	rs4282209	chr4:76919536	NAAA	chr4:76831809-76862166:-	-0.37	-6.05	3.38E-9	Longevity	
BLCA	cis	1	rs429083	chr6:167383972	RNASET2	chr6:167343008-167412795:-	-0.23	-4.95	1.14E-6	Crohn's disease	
BLCA	cis	1	rs4294134	chr7:135293128	PL-5283	chr7:135347221-135378160:+	0.6	8.26	2.34E-15	Paget's disease	
BLCA	cis	1	rs4297570	chr13:36755179	SOHLH2	chr13:36742347-36871992:-	-0.27	-4.59	5.89E-6	Glucose homeostasis traits	
BLCA	cis	1	rs430097	chr6:167405073	RNASET2	chr6:167343008-167412795:-	-0.25	-5.15	4.08E-7	Crohn's disease	
BLCA	cis	1	rs430293	chr6:167404958	RNASET2	chr6:167343008-167412795:-	-0.25	-5.15	4.08E-7	Crohn's disease	
BLCA	cis	1	rs430477	chr6:167389851	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs4309773	chr3:134277301	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs4309773	chr3:134277301	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs431076	chr7:65600320	CCT6P1	chr7:65216092-65228661:+	0.33	4.56	6.79E-6	Diabetic kidney disease	
BLCA	cis	1	rs431318	chr7:65511597	CCT6P1	chr7:65216092-65228661:+	0.32	4.38	1.51E-5	Diabetic kidney disease	
BLCA	cis	1	rs43184	chr5:56141777	C5orf35	chr5:56205103-56213010:+	0.75	11.66	4.12E-27	Type 2 diabetes	
BLCA	cis	1	rs4320897	chr10:76017732	ADK	chr10:75910965-76469059:+	0.28	4.37	1.57E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs4323544	chr9:123647377	LOC253039	chr9:123605320-123616644:+	-0.34	-5.81	1.3E-8	Rheumatoid arthritis	
BLCA	cis	1	rs4334685	chr3:134304335	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs433598	chr16:20680206	ACSM1	chr16:20634559-20709066:-	0.21	3.99	7.85E-5	Schizophrenia	
BLCA	cis	1	rs4350617	chr17:28423088	EFCAB5	chr17:28256874-28435469:+	0.23	3.91	0.000109	Coffee consumption (cups per day)	
BLCA	cis	1	rs4353250	chr11:18323517	GTF2H1	chr11:18343816-18388590:+	0.31	5.88	8.86E-9	Pancreatic cancer	
BLCA	cis	1	rs436707	chr6:167388843	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs4367113	chr3:134287975	ANAPC13	chr3:134196547-134204865:-	0.49	7.81	5.66E-14	Height	
BLCA	cis	1	rs4367113	chr3:134287975	CEP63	chr3:134204575-134293852:+	0.22	3.83	0.00015	Height	
BLCA	cis	1	rs4368544	chr3:134300014	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.94	2.24E-14	Height	
BLCA	cis	1	rs4368544	chr3:134300014	CEP63	chr3:134204575-134293852:+	-0.24	-4.14	4.32E-5	Height	
BLCA	cis	1	rs4372836	chr2:28973883	TRMT61B	chr2:29072690-29093175:-	-0.29	-5.13	4.54E-7	Body mass index	
BLCA	cis	1	rs4375701	chr17:45712218	C17orf57	chr17:45401142-45518675:+	0.25	5.57	4.69E-8	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs4376778	chr1:46288846	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs437889	chr7:65509234	CCT6P1	chr7:65216092-65228661:+	0.32	4.38	1.51E-5	Diabetic kidney disease	
BLCA	cis	1	rs4385527	chr9:97648587	C9orf130	chr9:98568372-98638259:-	-0.23	-3.83	0.00015	Urinary albumin-to-creatinine ratio	
BLCA	cis	1	rs439237	chr6:167391392	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs439295	chr3:156572455	LEKR1	chr3:156544076-156763918:+	-0.45	-6.35	6.02E-10	Bone mineral density	
BLCA	cis	1	rs4394010	chr4:129894649	C4orf33	chr4:130014829-130033842:+	0.31	5.15	4.17E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs439553	chr6:167391212	RNASET2	chr6:167343008-167412795:-	-0.23	-4.94	1.18E-6	Crohn's disease	
BLCA	cis	1	rs4407214	chr2:29118258	TRMT61B	chr2:29072690-29093175:-	0.33	5.06	6.67E-7	Breast cancer (estrogen-receptor negative);Breast cancer	
BLCA	cis	1	rs4408846	chr3:41753679	ULK4	chr3:41288091-42003660:-	0.67	10.14	1.45E-21	Diastolic blood pressure	
BLCA	cis	1	rs4417907	chr3:134291363	ANAPC13	chr3:134196547-134204865:-	0.51	8	1.45E-14	Height	
BLCA	cis	1	rs4417907	chr3:134291363	CEP63	chr3:134204575-134293852:+	0.24	4.14	4.32E-5	Height	
BLCA	cis	1	rs4423809	chr3:134300107	ANAPC13	chr3:134196547-134204865:-	-0.48	-7.73	9.49E-14	Height	
BLCA	cis	1	rs444988	chr6:167389674	RNASET2	chr6:167343008-167412795:-	-0.24	-4.96	1.04E-6	Crohn's disease	
BLCA	cis	1	rs4465649	chr17:28394747	EFCAB5	chr17:28256874-28435469:+	-0.22	-3.85	0.00014	Coffee consumption (cups per day)	
BLCA	cis	1	rs4466058	chr4:129923879	C4orf33	chr4:130014829-130033842:+	-0.32	-5.3	1.97E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs4469291	chr6:49440614	CENPQ	chr6:49431096-49460820:+	-0.28	-5.56	4.93E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs4469291	chr6:49440614	MUT	chr6:49398994-49431031:-	0.28	5.5	6.93E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs448060	chr6:167382622	RNASET2	chr6:167343008-167412795:-	-0.23	-4.95	1.14E-6	Crohn's disease	
BLCA	cis	1	rs4490383	chr3:48484683	TREX1	chr3:48501186-48509043:+	-0.19	-3.82	0.000153	Longevity	
BLCA	cis	1	rs4490669	chr6:56789465	BEND6	chr6:56819773-56892138:+	-0.28	-4.11	4.75E-5	Menarche (age at onset)	
BLCA	cis	1	rs4497901	chr2:239969	SH3YL1	chr2:218138-264810:-	-0.43	-11.33	7.28E-26	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs4498009	chr3:134198008	ANAPC13	chr3:134196547-134204865:-	0.51	8.23	2.91E-15	Height	
BLCA	cis	1	rs4498009	chr3:134198008	CEP63	chr3:134204575-134293852:+	0.26	4.44	1.16E-5	Height	
BLCA	cis	1	rs451396	chr7:65484074	CCT6P1	chr7:65216092-65228661:+	0.31	4.42	1.31E-5	Diabetic kidney disease	
BLCA	cis	1	rs4531856	chr19:18388383	KIAA1683	chr19:18367906-18385319:-	-0.23	-4.21	3.22E-5	Waist-to-hip ratio adjusted for body mass index	
BLCA	cis	1	rs4535272	chr3:134299916	ANAPC13	chr3:134196547-134204865:-	-0.49	-7.77	7.07E-14	Height	
BLCA	cis	1	rs4535272	chr3:134299916	CEP63	chr3:134204575-134293852:+	-0.23	-3.99	7.78E-5	Height	
BLCA	cis	1	rs454422	chr20:5943693	MCM8	chr20:5931298-5975829:+	-0.21	-4.43	1.26E-5	HIV-1 viral setpoint	
BLCA	cis	1	rs4545281	chr1:46360054	CCDC163P	chr1:45960581-45965646:-	-0.36	-6.74	6.01E-11	Body mass index	
BLCA	cis	1	rs4548056	chr7:65298873	CCT6P1	chr7:65216092-65228661:+	0.31	4.37	1.63E-5	Diabetic kidney disease	
BLCA	cis	1	rs4549034	chr2:28972579	TRMT61B	chr2:29072690-29093175:-	-0.29	-5.1	5.37E-7	Body mass index	
BLCA	cis	1	rs4549329	chr4:239785	ZNF718	chr4:53272-156488:+	0.31	4.3	2.16E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs4560537	chr5:150262586	LOC134466	chr5:150310000-150326146:-	0.47	6.2	1.42E-9	Crohn's disease	
BLCA	cis	1	rs4560868	chr9:115985499	CDC26	chr9:116029290-116037869:-	0.42	8.28	2.04E-15	Hematology traits	
BLCA	cis	1	rs4572812	chr3:134291177	ANAPC13	chr3:134196547-134204865:-	-0.51	-8	1.45E-14	Height	
BLCA	cis	1	rs4572812	chr3:134291177	CEP63	chr3:134204575-134293852:+	-0.24	-4.14	4.32E-5	Height	
BLCA	cis	1	rs4575590	chr17:28361969	EFCAB5	chr17:28256874-28435469:+	-0.23	-4	7.57E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs4578563	chr14:51159585	SAV1	chr14:51100360-51135023:-	-0.18	-4.02	6.92E-5	Plasma amyloid beta peptide concentrations (ABx-40)	
BLCA	cis	1	rs4579248	chr5:150268151	LOC134466	chr5:150310000-150326146:-	0.54	6.74	6.0E-11	Crohn's disease	
BLCA	cis	1	rs4581755	chr17:28427898	EFCAB5	chr17:28256874-28435469:+	0.23	3.91	0.000108	Coffee consumption (cups per day)	
BLCA	cis	1	rs4582105	chr4:246342	ZNF718	chr4:53272-156488:+	0.34	4.55	7.25E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs458291	chr7:65520479	CCT6P1	chr7:65216092-65228661:+	0.31	4.19	3.41E-5	Diabetic kidney disease	
BLCA	cis	1	rs4604732	chr1:247623872	LOC148824	chr1:247687982-247694106:-	0.26	4.06	5.91E-5	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid)	
BLCA	cis	1	rs4604928	chr11:117044203	PCSK7	chr11:117075789-117102811:-	-0.41	-5.13	4.63E-7	Protein quantitative trait loci	
BLCA	cis	1	rs4606360	chr1:173699007	ANKRD45	chr1:173577475-173639001:-	0.25	4.21	3.15E-5	Subjective well-being	
BLCA	cis	1	rs4627050	chr11:18822037	PTPN5	chr11:18749478-18813389:-	-0.23	-4.44	1.2E-5	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin)	
BLCA	cis	1	rs462853	chr7:65558167	CCT6P1	chr7:65216092-65228661:+	0.34	4.8	2.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs4640348	chr2:28965479	TRMT61B	chr2:29072690-29093175:-	-0.29	-5.03	7.45E-7	Body mass index	
BLCA	cis	1	rs4643294	chr15:85250253	LOC388152	chr15:84867600-84898920:-	-0.25	-4.2	3.37E-5	Schizophrenia	
BLCA	cis	1	rs4646536	chr12:58157988	FAM119B	chr12:58166383-58176323:+	0.31	4.79	2.38E-6	Multiple sclerosis	
BLCA	cis	1	rs4646536	chr12:58157988	TSFM	chr12:58176536-58191367:+	-0.38	-6.64	1.05E-10	Multiple sclerosis	
BLCA	cis	1	rs4646536	chr12:58157988	XRCC6BP1	chr12:58335445-58351051:+	-0.24	-4.17	3.73E-5	Multiple sclerosis	
BLCA	cis	1	rs464895	chr7:65527106	CCT6P1	chr7:65216092-65228661:+	0.3	3.9	0.000113	Diabetic kidney disease	
BLCA	cis	1	rs465359	chr7:65558164	CCT6P1	chr7:65216092-65228661:+	0.34	4.8	2.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs4660306	chr1:45978675	CCDC163P	chr1:45960581-45965646:-	0.8	16.28	1.11E-45	Homocysteine levels	
BLCA	cis	1	rs4660317	chr1:46326226	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs4660319	chr1:46341623	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs4660321	chr1:46366760	CCDC163P	chr1:45960581-45965646:-	-0.37	-6.96	1.44E-11	Body mass index	
BLCA	cis	1	rs4660870	chr1:45995231	CCDC163P	chr1:45960581-45965646:-	-0.72	-13.87	1.01E-35	Homocysteine levels	
BLCA	cis	1	rs4660898	chr1:46402171	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.23	1.26E-9	Body mass index	
BLCA	cis	1	rs4660910	chr1:46548402	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.17	1.71E-9	Body mass index	
BLCA	cis	1	rs4663300	chr2:239181491	LOC151174	chr2:239133754-239140318:-	0.46	4.5	8.92E-6	Irritable bowel syndrome	
BLCA	cis	1	rs4663865	chr2:239145960	LOC151174	chr2:239133754-239140318:-	-0.43	-4.52	8.07E-6	Irritable bowel syndrome	
BLCA	cis	1	rs4666118	chr2:28951698	TRMT61B	chr2:29072690-29093175:-	-0.28	-4.83	1.97E-6	Body mass index	
BLCA	cis	1	rs4666119	chr2:28975690	TRMT61B	chr2:29072690-29093175:-	-0.31	-5.39	1.26E-7	Body mass index	
BLCA	cis	1	rs466983	chr7:65520496	CCT6P1	chr7:65216092-65228661:+	0.3	4.19	3.43E-5	Diabetic kidney disease	
BLCA	cis	1	rs4677834	chr3:195093631	C3orf21	chr3:194789015-194991895:-	-0.28	-5.42	1.07E-7	Body mass index	
BLCA	cis	1	rs469758	chr5:96121715	ERAP1	chr5:96096515-96149837:-	-0.51	-10.95	1.77E-24	Ankylosing spondylitis	
BLCA	cis	1	rs469758	chr5:96121715	ERAP2	chr5:96211644-96255398:+	0.33	5.45	9.1E-8	Ankylosing spondylitis	
BLCA	cis	1	rs4699052	chr4:104137790	MANBA	chr4:103552644-103682151:-	0.26	4.15	4.05E-5	Testicular germ cell tumor	
BLCA	cis	1	rs4699055	chr4:104154500	MANBA	chr4:103552644-103682151:-	0.26	4.26	2.61E-5	Testicular germ cell tumor	
BLCA	cis	1	rs4706254	chr6:86602813	SNHG5	chr6:86386726-86388451:-	-0.57	-10.33	3.26E-22	Response to antipsychotic treatment	
BLCA	cis	1	rs4707239	chr6:86610717	SNHG5	chr6:86386726-86388451:-	-0.55	-10	4.56E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs4710147	chr6:167374239	RNASET2	chr6:167343008-167412795:-	0.22	4.7	3.57E-6	Crohn's disease	
BLCA	cis	1	rs4712120	chr6:56092916	COL21A1	chr6:55921389-56258892:-	0.33	5.88	8.79E-9	Pulse pressure	
BLCA	cis	1	rs4715129	chr6:49415043	CENPQ	chr6:49431096-49460820:+	-0.28	-5.82	1.22E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs4715129	chr6:49415043	MUT	chr6:49398994-49431031:-	0.27	5.44	9.37E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs4715130	chr6:49416825	CENPQ	chr6:49431096-49460820:+	-0.3	-6.07	3.05E-9	Folate pathway vitamin levels	
BLCA	cis	1	rs4715130	chr6:49416825	MUT	chr6:49398994-49431031:-	0.25	4.96	1.07E-6	Folate pathway vitamin levels	
BLCA	cis	1	rs4715590	chr6:56060017	COL21A1	chr6:55921389-56258892:-	0.32	5.77	1.68E-8	Pulse pressure	
BLCA	cis	1	rs4718269	chr7:65200778	CCT6P1	chr7:65216092-65228661:+	-0.3	-4.21	3.16E-5	Diabetic kidney disease	
BLCA	cis	1	rs4718270	chr7:65202407	CCT6P1	chr7:65216092-65228661:+	0.32	4.44	1.18E-5	Diabetic kidney disease	
BLCA	cis	1	rs4718309	chr7:65627764	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs4718315	chr7:65648541	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs4718316	chr7:65648731	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs4718317	chr7:65648901	CCT6P1	chr7:65216092-65228661:+	-0.33	-4.46	1.07E-5	Diabetic kidney disease	
BLCA	cis	1	rs4718333	chr7:65772758	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.72	3.24E-6	Diabetic kidney disease	
BLCA	cis	1	rs4718334	chr7:65789454	CCT6P1	chr7:65216092-65228661:+	-0.36	-4.92	1.29E-6	Diabetic kidney disease	
BLCA	cis	1	rs4726669	chr7:143758191	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.97	5.56E-9	Obesity-related traits	
BLCA	cis	1	rs4727443	chr7:99593346	TRIM4	chr7:99488037-99517154:-	-0.23	-4.09	5.18E-5	Interstitial lung disease	
BLCA	cis	1	rs4728142	chr7:128573967	IRF5	chr7:128577769-128590086:+	0.24	4.4	1.44E-5	Systemic lupus erythematosus;Ulcerative colitis;Inflammatory bowel disease	
BLCA	cis	1	rs473073	chr10:131429646	MGMT	chr10:131265454-131565783:+	0.23	4.93	1.25E-6	Response to temozolomide	
BLCA	cis	1	rs473188	chr11:116812029	PCSK7	chr11:117075789-117102811:-	-0.38	-4.86	1.74E-6	Protein quantitative trait loci	
BLCA	cis	1	rs473771	chr10:131408155	MGMT	chr10:131265454-131565783:+	0.21	4.49	9.37E-6	Response to temozolomide	
BLCA	cis	1	rs4745740	chr10:75942469	ADK	chr10:75910965-76469059:+	0.28	4.41	1.34E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs4750759	chr10:131436603	MGMT	chr10:131265454-131565783:+	-0.22	-4.83	1.93E-6	Response to temozolomide	
BLCA	cis	1	rs4752797	chr11:47874364	C1QTNF4	chr11:47611216-47615961:-	-0.29	-5.34	1.61E-7	Subjective well-being	
BLCA	cis	1	rs4752856	chr11:47648042	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.84	1.14E-8	Subjective well-being	
BLCA	cis	1	rs4752857	chr11:47655752	C1QTNF4	chr11:47611216-47615961:-	-0.29	-5.62	3.62E-8	Subjective well-being	
BLCA	cis	1	rs4752873	chr11:47857520	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.58	4.52E-8	Subjective well-being	
BLCA	cis	1	rs4755726	chr11:43642130	HSD17B12	chr11:43702143-43878160:+	-0.42	-7.01	1.1E-11	Forced vital capacity	
BLCA	cis	1	rs4759042	chr12:57377347	PRIM1	chr12:57125370-57146146:-	0.16	3.94	9.62E-5	Migraine	
BLCA	cis	1	rs4759229	chr12:56474480	RPS26	chr12:56435686-56438005:+	-0.47	-7.92	2.6E-14	Cognitive function	
BLCA	cis	1	rs4763879	chr12:9910164	CLECL1	chr12:9868457-9885860:-	-0.21	-5.21	3.11E-7	Type 1 diabetes	
BLCA	cis	1	rs4764124	chr12:14966604	C12orf60	chr12:14956506-14976789:+	-0.32	-4.89	1.47E-6	Pubertal anthropometrics	
BLCA	cis	1	rs4766646	chr12:110398145	TRPV4	chr12:110220894-110271212:-	-0.26	-4.08	5.52E-5	Metabolite levels (MHPG)	
BLCA	cis	1	rs4776058	chr15:52880263	ARPP19	chr15:52839432-52861364:-	0.22	4.06	5.93E-5	Schizophrenia	
BLCA	cis	1	rs477692	chr10:131426022	MGMT	chr10:131265454-131565783:+	0.25	5.43	1.02E-7	Response to temozolomide	
BLCA	cis	1	rs4788187	chr16:29845685	LOC440356	chr16:29875004-29879374:+	0.32	3.93	0.000102	Multiple sclerosis	
BLCA	cis	1	rs4788188	chr16:29860863	LOC440356	chr16:29875004-29879374:+	-0.33	-4.03	6.67E-5	Multiple sclerosis	
BLCA	cis	1	rs4789693	chr17:80421870	HEXDC	chr17:80376252-80400515:+	0.29	6.02	4.08E-9	Glucocorticoid-induced osteonecrosis	
BLCA	cis	1	rs4794016	chr17:45725931	C17orf57	chr17:45401142-45518675:+	-0.26	-5.87	9.26E-9	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs4794048	chr17:45763073	C17orf57	chr17:45401142-45518675:+	0.24	5.23	2.74E-7	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs4794202	chr17:45930539	SCRN2	chr17:45915049-45918699:-	-0.3	-4.58	6.24E-6	Alzheimer's disease (cognitive decline)	
BLCA	cis	1	rs479478	chr10:131428959	MGMT	chr10:131265454-131565783:+	0.23	5.01	8.13E-7	Response to temozolomide	
BLCA	cis	1	rs4794823	chr17:38166265	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.93	0.000101	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs4795415	chr17:38157995	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.94	9.66E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs4795416	chr17:38158133	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.94	9.66E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs4795418	chr17:38164851	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.93	0.000101	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs4795525	chr17:28388487	EFCAB5	chr17:28256874-28435469:+	-0.23	-4	7.57E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs4803463	chr19:41911040	B3GNT8	chr19:41931265-41934635:-	-0.21	-3.9	0.000114	Height	
BLCA	cis	1	rs4803468	chr19:41922352	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.09	5.33E-5	Height	
BLCA	cis	1	rs4803469	chr19:41922775	B3GNT8	chr19:41931265-41934635:-	-0.22	-4.09	5.33E-5	Height	
BLCA	cis	1	rs4803480	chr19:42066279	CEACAM21	chr19:42055886-42093196:+	0.35	7.88	3.41E-14	Schizophrenia	
BLCA	cis	1	rs4805834	chr19:33453659	SLC7A9	chr19:33321421-33360683:-	-0.34	-3.97	8.47E-5	Creatinine levels	
BLCA	cis	1	rs480643	chr10:131400308	MGMT	chr10:131265454-131565783:+	0.21	4.56	6.82E-6	Response to temozolomide	
BLCA	cis	1	rs4808200	chr19:19554803	YJEFN3	chr19:19639720-19648393:+	-0.27	-5.33	1.66E-7	Schizophrenia	
BLCA	cis	1	rs4819388	chr21:45647421	ICOSLG	chr21:45646724-45660834:-	-0.26	-4.36	1.7E-5	Celiac disease	
BLCA	cis	1	rs4838890	chr1:110616679	ALX3	chr1:110602998-110613322:-	-0.21	-3.83	0.000147	Blood metabolite levels	
BLCA	cis	1	rs4840351	chr8:8573148	CLDN23	chr8:8559666-8561616:+	-0.23	-3.95	9.25E-5	Obesity-related traits	
BLCA	cis	1	rs4840352	chr8:8573508	CLDN23	chr8:8559666-8561616:+	-0.22	-3.82	0.000154	Obesity-related traits	
BLCA	cis	1	rs4841016	chr8:8572561	CLDN23	chr8:8559666-8561616:+	-0.23	-3.94	9.88E-5	Obesity-related traits	
BLCA	cis	1	rs4853568	chr2:192126190	STAT4	chr2:191894306-192038902:-	0.14	3.87	0.000126	Obesity-related traits	
BLCA	cis	1	rs485576	chr10:131425496	MGMT	chr10:131265454-131565783:+	0.25	5.44	9.67E-8	Response to temozolomide	
BLCA	cis	1	rs4859413	chr4:76898250	NAAA	chr4:76831809-76862166:-	0.37	6.1	2.62E-9	Longevity	
BLCA	cis	1	rs4859581	chr4:76906974	NAAA	chr4:76831809-76862166:-	-0.37	-6.06	3.23E-9	Longevity	
BLCA	cis	1	rs4859582	chr4:76907213	NAAA	chr4:76831809-76862166:-	-0.38	-6.27	9.94E-10	Longevity	
BLCA	cis	1	rs4862406	chr4:185629339	MLF1IP	chr4:185615220-185655286:-	0.48	11.78	1.56E-27	Kawasaki disease	
BLCA	cis	1	rs486301	chr15:43836949	ADAL	chr15:43622872-43646094:+	-0.42	-5.24	2.69E-7	Tumor biomarkers	
BLCA	cis	1	rs486301	chr15:43836949	CATSPER2	chr15:43922774-43959900:-	-0.31	-4.83	1.98E-6	Tumor biomarkers	
BLCA	cis	1	rs4865463	chr4:1742400	FAM53A	chr4:1641609-1685854:-	-0.31	-4.5	9.09E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs4865467	chr4:1745500	FAM53A	chr4:1641609-1685854:-	0.31	4.47	1.01E-5	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs4869313	chr5:96223880	ERAP2	chr5:96211644-96255398:+	-0.91	-24.1	9.16E-79	Pediatric autoimmune diseases	
BLCA	cis	1	rs4886818	chr15:76880939	SCAPER	chr15:76640529-77197744:-	-0.21	-4.67	4.18E-6	Blood metabolite levels	
BLCA	cis	1	rs4903201	chr14:74659690	LIN52	chr14:74551656-74667117:+	-0.36	-8.09	7.93E-15	Common traits (Other)	
BLCA	cis	1	rs4903202	chr14:74660302	LIN52	chr14:74551656-74667117:+	-0.36	-8.09	7.85E-15	Common traits (Other)	
BLCA	cis	1	rs4903203	chr14:74660508	LIN52	chr14:74551656-74667117:+	-0.36	-8.09	7.85E-15	Common traits (Other)	
BLCA	cis	1	rs4919361	chr10:101363707	CNNM1	chr10:101088856-101154085:+	0.34	3.86	0.000135	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels	
BLCA	cis	1	rs4919367	chr10:101366816	CNNM1	chr10:101088856-101154085:+	0.34	3.99	7.95E-5	&beta;2-Glycoprotein I (&beta;2-GPI) plasma levels	
BLCA	cis	1	rs4919690	chr10:104616500	C10orf32	chr10:104613967-104624718:+	0.34	5.19	3.5E-7	Arsenic metabolism	
BLCA	cis	1	rs4932148	chr15:90394356	AP3S2	chr15:90373832-90456222:-	-0.69	-10.24	6.77E-22	Type 2 diabetes	
BLCA	cis	1	rs4935575	chr10:52006165	FAM21A	chr10:51827684-51893268:+	-0.33	-4.02	6.88E-5	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs4936613	chr11:121204601	SC5DL	chr11:121163388-121184117:+	-0.33	-4.25	2.72E-5	Response to taxane treatment (placlitaxel)	
BLCA	cis	1	rs4951261	chr1:205717823	PM20D1	chr1:205797154-205819245:-	0.22	4.21	3.16E-5	Menarche (age at onset)	
BLCA	cis	1	rs4951261	chr1:205717823	RAB7L1	chr1:205737115-205744610:-	-0.35	-5.98	5.12E-9	Menarche (age at onset)	
BLCA	cis	1	rs4955485	chr3:134295843	ANAPC13	chr3:134196547-134204865:-	0.47	7.51	4.32E-13	Height	
BLCA	cis	1	rs4955555	chr3:134286427	ANAPC13	chr3:134196547-134204865:-	0.49	7.81	5.66E-14	Height	
BLCA	cis	1	rs4955555	chr3:134286427	CEP63	chr3:134204575-134293852:+	0.22	3.83	0.00015	Height	
BLCA	cis	1	rs4958424	chr5:150225036	LOC134466	chr5:150310000-150326146:-	0.43	5.33	1.71E-7	Crohn's disease	
BLCA	cis	1	rs4958426	chr5:150278346	LOC134466	chr5:150310000-150326146:-	0.56	6.99	1.21E-11	Crohn's disease	
BLCA	cis	1	rs4958843	chr5:150224924	LOC134466	chr5:150310000-150326146:-	0.43	5.33	1.71E-7	Crohn's disease	
BLCA	cis	1	rs4958848	chr5:150271122	LOC134466	chr5:150310000-150326146:-	0.45	5.81	1.33E-8	Crohn's disease	
BLCA	cis	1	rs4958852	chr5:150330631	LOC134466	chr5:150310000-150326146:-	0.63	6.7	7.39E-11	Crohn's disease	
BLCA	cis	1	rs496584	chr15:43831923	ADAL	chr15:43622872-43646094:+	-0.39	-4.79	2.4E-6	Tumor biomarkers	
BLCA	cis	1	rs496584	chr15:43831923	CATSPER2	chr15:43922774-43959900:-	-0.29	-4.43	1.25E-5	Tumor biomarkers	
BLCA	cis	1	rs4973991	chr3:41927273	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs4974483	chr3:134219001	ANAPC13	chr3:134196547-134204865:-	0.47	7.5	4.62E-13	Height	
BLCA	cis	1	rs4974484	chr3:134219019	ANAPC13	chr3:134196547-134204865:-	0.51	8.25	2.62E-15	Height	
BLCA	cis	1	rs4974484	chr3:134219019	CEP63	chr3:134204575-134293852:+	0.26	4.55	7.27E-6	Height	
BLCA	cis	1	rs4974493	chr3:134219993	ANAPC13	chr3:134196547-134204865:-	0.51	8.18	4.34E-15	Height	
BLCA	cis	1	rs4974493	chr3:134219993	CEP63	chr3:134204575-134293852:+	0.26	4.46	1.07E-5	Height	
BLCA	cis	1	rs4975193	chr4:129980630	C4orf33	chr4:130014829-130033842:+	-0.33	-5.43	1.02E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs4975194	chr4:129982377	C4orf33	chr4:130014829-130033842:+	-0.33	-5.43	1.02E-7	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs503660	chr10:131418999	MGMT	chr10:131265454-131565783:+	0.23	5.05	6.77E-7	Response to temozolomide	
BLCA	cis	1	rs506274	chr10:131409392	MGMT	chr10:131265454-131565783:+	0.21	4.5	9.09E-6	Response to temozolomide	
BLCA	cis	1	rs508303	chr10:131424996	MGMT	chr10:131265454-131565783:+	-0.24	-5.29	2.05E-7	Response to temozolomide	
BLCA	cis	1	rs510988	chr11:116813804	PCSK7	chr11:117075789-117102811:-	-0.4	-5	8.65E-7	Protein quantitative trait loci	
BLCA	cis	1	rs511676	chr11:116824884	PCSK7	chr11:117075789-117102811:-	-0.41	-5.05	7.01E-7	Protein quantitative trait loci	
BLCA	cis	1	rs513736	chr10:131406489	MGMT	chr10:131265454-131565783:+	0.21	4.45	1.1E-5	Response to temozolomide	
BLCA	cis	1	rs516704	chr10:131419879	MGMT	chr10:131265454-131565783:+	0.21	4.61	5.51E-6	Response to temozolomide	
BLCA	cis	1	rs522891	chr10:131430916	MGMT	chr10:131265454-131565783:+	-0.23	-4.95	1.12E-6	Response to temozolomide	
BLCA	cis	1	rs530466	chr10:131427717	MGMT	chr10:131265454-131565783:+	0.25	5.62	3.67E-8	Response to temozolomide	
BLCA	cis	1	rs531572	chr10:131427569	MGMT	chr10:131265454-131565783:+	-0.25	-5.45	9.02E-8	Response to temozolomide	
BLCA	cis	1	rs534417	chr1:23784965	ASAP3	chr1:23755056-23811057:-	0.31	4.34	1.83E-5	Cholesterol, total	
BLCA	cis	1	rs534417	chr1:23784965	TCEA3	chr1:23707555-23751261:-	0.32	4.37	1.6E-5	Cholesterol, total	
BLCA	cis	1	rs538969	chr10:131410608	MGMT	chr10:131265454-131565783:+	0.21	4.57	6.58E-6	Response to temozolomide	
BLCA	cis	1	rs548181	chr11:125461709	DDX25	chr11:125774272-125793003:+	-0.29	-3.83	0.000148	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);Schizophrenia	
BLCA	cis	1	rs548390	chr10:131417427	MGMT	chr10:131265454-131565783:+	0.21	4.5	8.86E-6	Response to temozolomide	
BLCA	cis	1	rs553371	chr10:131413676	MGMT	chr10:131265454-131565783:+	0.21	4.66	4.36E-6	Response to temozolomide	
BLCA	cis	1	rs554792	chr10:131423181	MGMT	chr10:131265454-131565783:+	0.22	4.88	1.57E-6	Response to temozolomide	
BLCA	cis	1	rs55752096	chr18:48368918	MRO	chr18:48321491-48351754:-	0.26	4.63	5.09E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs55753056	chr2:243929	SH3YL1	chr2:218138-264810:-	-0.44	-11.65	4.86E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs55786720	chr6:56783647	BEND6	chr6:56819773-56892138:+	-0.29	-4.06	6.01E-5	Menarche (age at onset)	
BLCA	cis	1	rs55835850	chr2:28949296	TRMT61B	chr2:29072690-29093175:-	0.29	5.05	6.75E-7	Body mass index	
BLCA	cis	1	rs558764	chr10:131426957	MGMT	chr10:131265454-131565783:+	-0.21	-4.46	1.09E-5	Response to temozolomide	
BLCA	cis	1	rs55883249	chr2:9741535	ADAM17	chr2:9629413-9695917:-	-0.19	-3.98	8.35E-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	
BLCA	cis	1	rs55895244	chr7:65387678	CCT6P1	chr7:65216092-65228661:+	0.31	4.39	1.48E-5	Diabetic kidney disease	
BLCA	cis	1	rs55913793	chr3:134285968	ANAPC13	chr3:134196547-134204865:-	0.49	7.81	5.66E-14	Height	
BLCA	cis	1	rs55913793	chr3:134285968	CEP63	chr3:134204575-134293852:+	0.22	3.83	0.00015	Height	
BLCA	cis	1	rs55914901	chr19:50528346	SIGLEC16	chr19:50472912-50479075:+	0.53	5.14	4.33E-7	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs55936726	chr2:258210	SH3YL1	chr2:218138-264810:-	-0.45	-11.96	3.11E-28	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs55946380	chr2:268293	SH3YL1	chr2:218138-264810:-	-0.45	-11.79	1.36E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs55971458	chr17:28427016	EFCAB5	chr17:28256874-28435469:+	0.23	3.91	0.000109	Coffee consumption (cups per day)	
BLCA	cis	1	rs56016656	chr7:65383481	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs56030203	chr6:56783857	BEND6	chr6:56819773-56892138:+	-0.29	-4.06	6.01E-5	Menarche (age at onset)	
BLCA	cis	1	rs56040780	chr16:28861881	EIF3C	chr16:28722782-28747052:+;chr16	0.31	5.57	4.69E-8	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
BLCA	cis	1	rs56040780	chr16:28861881	EIF3CL	chr16:28699879-28747052:+;chr16	0.34	5.33	1.64E-7	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
BLCA	cis	1	rs56060232	chr14:104386165	TDRD9	chr14:104394817-104519002:+	0.34	5.41	1.11E-7	Bipolar disorder	
BLCA	cis	1	rs56098064	chr14:50105849	RPL36AL	chr14:50085407-50087349:-	0.21	3.84	0.000144	Carotid intima media thickness	
BLCA	cis	1	rs56121764	chr3:41883975	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs56139710	chr1:27269788	GPN2	chr1:27205873-27216869:-	0.48	4.1	5.14E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs56145559	chr2:73623439	ALMS1P	chr2:73872046-73912692:+	0.34	4.95	1.1E-6	Schizophrenia	
BLCA	cis	1	rs56154726	chr2:73721767	ALMS1P	chr2:73872046-73912692:+	0.34	4.94	1.2E-6	Metabolite levels	
BLCA	cis	1	rs56158380	chr3:41885588	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs56167434	chr2:282137	SH3YL1	chr2:218138-264810:-	-0.46	-12.24	2.68E-29	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs56207540	chr3:41976627	ULK4	chr3:41288091-42003660:-	0.63	8.28	2.12E-15	Diastolic blood pressure	
BLCA	cis	1	rs56291018	chr7:65390339	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs56321614	chr2:268191	SH3YL1	chr2:218138-264810:-	-0.44	-11.55	1.15E-26	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs56322409	chr10:97395962	ENTPD1	chr10:97471536-97637022:+	0.19	4.94	1.15E-6	Blood metabolite levels	
BLCA	cis	1	rs56372340	chr2:9741536	ADAM17	chr2:9629413-9695917:-	-0.19	-3.98	8.35E-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	
BLCA	cis	1	rs56400371	chr19:30299634	CCNE1	chr19:30302901-30315218:+	0.21	3.95	9.39E-5	Bladder cancer	
BLCA	cis	1	rs565974	chr10:131423274	MGMT	chr10:131265454-131565783:+	0.22	4.88	1.57E-6	Response to temozolomide	
BLCA	cis	1	rs56672945	chr2:73622663	ALMS1P	chr2:73872046-73912692:+	0.33	4.87	1.65E-6	Metabolite levels	
BLCA	cis	1	rs567700	chr10:131423126	MGMT	chr10:131265454-131565783:+	0.22	4.88	1.57E-6	Response to temozolomide	
BLCA	cis	1	rs56776628	chr3:41866856	ULK4	chr3:41288091-42003660:-	0.62	9.66	6.48E-20	Diastolic blood pressure	
BLCA	cis	1	rs568617	chr11:65653242	CTSW	chr11:65647284-65651212:+	-0.6	-9.06	6.99E-18	Crohn's disease	
BLCA	cis	1	rs568617	chr11:65653242	SNX32	chr11:65601410-65621170:+	0.34	4.75	2.91E-6	Crohn's disease	
BLCA	cis	1	rs56864281	chr15:85357649	LOC388152	chr15:84867600-84898920:-	-0.23	-4.09	5.29E-5	Schizophrenia	
BLCA	cis	1	rs56922390	chr17:38157021	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.94	9.66E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs569235	chr10:131411620	MGMT	chr10:131265454-131565783:+	0.21	4.66	4.38E-6	Response to temozolomide	
BLCA	cis	1	rs56985706	chr7:65394562	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs57001853	chr5:150272452	LOC134466	chr5:150310000-150326146:-	0.46	5.97	5.47E-9	Crohn's disease	
BLCA	cis	1	rs57057549	chr7:65405738	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs57075379	chr14:35577801	PPP2R3C	chr14:35554679-35591679:-	0.27	4.26	2.6E-5	Atopic dermatitis	
BLCA	cis	1	rs57479675	chr3:41798038	ULK4	chr3:41288091-42003660:-	0.62	9.52	1.95E-19	Diastolic blood pressure	
BLCA	cis	1	rs5750621	chr22:38956166	JOSD1	chr22:39081549-39096459:-	-0.23	-3.95	9.43E-5	Resting heart rate	
BLCA	cis	1	rs5750622	chr22:38956464	JOSD1	chr22:39081549-39096459:-	-0.23	-3.86	0.000135	Resting heart rate	
BLCA	cis	1	rs5750672	chr22:39104168	JOSD1	chr22:39081549-39096459:-	0.23	3.96	9.11E-5	Resting heart rate	
BLCA	cis	1	rs5751255	chr22:42648408	C22orf32	chr22:42475699-42480287:+	0.2	5.32	1.74E-7	Cognitive function	
BLCA	cis	1	rs5751255	chr22:42648408	CCDC134	chr22:42196678-42222303:+	0.26	4.26	2.6E-5	Cognitive function	
BLCA	cis	1	rs5751255	chr22:42648408	CYP2D6	chr22:42522502-42526883:-	-0.36	-7.61	2.12E-13	Cognitive function	
BLCA	cis	1	rs5751255	chr22:42648408	NAGA	chr22:42454339-42466846:-	0.3	5.39	1.25E-7	Cognitive function	
BLCA	cis	1	rs5753543	chr22:31685458	C22orf30	chr22:32072242-32146120:-	-0.21	-3.89	0.000117	Paclitaxel-induced neuropathy	
BLCA	cis	1	rs57542652	chr2:228088	SH3YL1	chr2:218138-264810:-	-0.44	-11.5	1.67E-26	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs5757141	chr22:38957483	JOSD1	chr22:39081549-39096459:-	-0.23	-3.85	0.000138	Resting heart rate	
BLCA	cis	1	rs5757673	chr22:39837920	NPTXR	chr22:39214458-39240017:-	-0.24	-3.93	0.000101	Post bronchodilator FEV1	
BLCA	cis	1	rs5758659	chr22:42622003	C22orf32	chr22:42475699-42480287:+	0.21	5.48	7.79E-8	Cognitive function	
BLCA	cis	1	rs5758659	chr22:42622003	CCDC134	chr22:42196678-42222303:+	0.26	4.25	2.66E-5	Cognitive function	
BLCA	cis	1	rs5758659	chr22:42622003	CYP2D6	chr22:42522502-42526883:-	-0.36	-7.7	1.17E-13	Cognitive function	
BLCA	cis	1	rs5758659	chr22:42622003	NAGA	chr22:42454339-42466846:-	0.31	5.6	4.01E-8	Cognitive function	
BLCA	cis	1	rs5758660	chr22:42623718	C22orf32	chr22:42475699-42480287:+	0.21	5.52	6.11E-8	Cognitive function	
BLCA	cis	1	rs5758660	chr22:42623718	CCDC134	chr22:42196678-42222303:+	0.25	4.16	3.92E-5	Cognitive function	
BLCA	cis	1	rs5758660	chr22:42623718	CYP2D6	chr22:42522502-42526883:-	-0.36	-7.72	1.05E-13	Cognitive function	
BLCA	cis	1	rs5758660	chr22:42623718	NAGA	chr22:42454339-42466846:-	0.32	5.67	2.88E-8	Cognitive function	
BLCA	cis	1	rs5758677	chr22:42643039	C22orf32	chr22:42475699-42480287:+	0.2	5.39	1.22E-7	Cognitive function	
BLCA	cis	1	rs5758677	chr22:42643039	CCDC134	chr22:42196678-42222303:+	0.25	4.07	5.6E-5	Cognitive function	
BLCA	cis	1	rs5758677	chr22:42643039	CYP2D6	chr22:42522502-42526883:-	-0.36	-7.56	2.92E-13	Cognitive function	
BLCA	cis	1	rs5758677	chr22:42643039	NAGA	chr22:42454339-42466846:-	0.31	5.58	4.52E-8	Cognitive function	
BLCA	cis	1	rs5760216	chr22:24539734	SUSD2	chr22:24577444-24585074:+	0.56	5.48	7.54E-8	Amyotrophic lateral sclerosis	
BLCA	cis	1	rs5760220	chr22:24542480	SUSD2	chr22:24577444-24585074:+	0.65	6.09	2.69E-9	Amyotrophic lateral sclerosis	
BLCA	cis	1	rs5760229	chr22:24560254	SUSD2	chr22:24577444-24585074:+	0.56	5.44	9.62E-8	Amyotrophic lateral sclerosis	
BLCA	cis	1	rs5763855	chr22:30578964	NIPSNAP1	chr22:29950800-29977144:-	-0.4	-3.95	9.2E-5	Dialysis-related mortality	
BLCA	cis	1	rs5763858	chr22:30579722	NIPSNAP1	chr22:29950800-29977144:-	-0.42	-4.16	3.97E-5	Dialysis-related mortality	
BLCA	cis	1	rs5770922	chr22:51023408	CPT1B	chr22:51007291-51017096:-	-0.38	-3.89	0.000119	Narcolepsy	
BLCA	cis	1	rs5770924	chr22:51024542	CPT1B	chr22:51007291-51017096:-	-0.38	-3.85	0.000139	Narcolepsy	
BLCA	cis	1	rs577227	chr10:131404528	MGMT	chr10:131265454-131565783:+	0.21	4.44	1.18E-5	Response to temozolomide	
BLCA	cis	1	rs57894940	chr19:30293462	CCNE1	chr19:30302901-30315218:+	0.21	3.97	8.72E-5	Bladder cancer	
BLCA	cis	1	rs579890	chr11:116798963	PCSK7	chr11:117075789-117102811:-	-0.38	-4.61	5.41E-6	Protein quantitative trait loci	
BLCA	cis	1	rs58062456	chr7:65394852	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs580745	chr10:131414401	MGMT	chr10:131265454-131565783:+	0.21	4.46	1.06E-5	Response to temozolomide	
BLCA	cis	1	rs58189451	chr6:149921388	NUP43	chr6:150045453-150067688:-	-0.27	-4.27	2.51E-5	Lung cancer	
BLCA	cis	1	rs58416181	chr15:85264461	LOC388152	chr15:84867600-84898920:-	-0.23	-4	7.56E-5	Schizophrenia	
BLCA	cis	1	rs58461606	chr2:267367	SH3YL1	chr2:218138-264810:-	-0.44	-11.68	3.47E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs58603761	chr2:73726605	ALMS1P	chr2:73872046-73912692:+	0.39	5.84	1.13E-8	Metabolite levels	
BLCA	cis	1	rs58669269	chr7:65951953	CCT6P1	chr7:65216092-65228661:+	0.37	4.81	2.22E-6	Diabetic kidney disease	
BLCA	cis	1	rs58717741	chr5:150284936	LOC134466	chr5:150310000-150326146:-	0.54	7.08	7.06E-12	Crohn's disease	
BLCA	cis	1	rs588918	chr11:116856642	PCSK7	chr11:117075789-117102811:-	-0.32	-4.28	2.32E-5	Protein quantitative trait loci	
BLCA	cis	1	rs59032271	chr5:148618749	AFAP1L1	chr5:148651401-148721365:+	0.27	5.02	8.06E-7	Body mass index	
BLCA	cis	1	rs59043558	chr5:150334662	LOC134466	chr5:150310000-150326146:-	0.52	5.93	6.83E-9	Crohn's disease	
BLCA	cis	1	rs59150578	chr11:18340862	GTF2H1	chr11:18343816-18388590:+	0.32	6.04	3.61E-9	Pancreatic cancer	
BLCA	cis	1	rs59226697	chr22:25870037	CRYBB2	chr22:25615612-25627836:+	0.99	8.03	1.23E-14	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs59227481	chr12:110007993	KCTD10	chr12:109886460-109915155:-	-0.21	-3.93	9.97E-5	Age-related nuclear cataracts	
BLCA	cis	1	rs59244547	chr3:156582997	LEKR1	chr3:156544076-156763918:+	-0.47	-6.39	4.95E-10	Bone mineral density	
BLCA	cis	1	rs59274738	chr17:28437635	EFCAB5	chr17:28256874-28435469:+	0.23	3.91	0.000108	Coffee consumption (cups per day)	
BLCA	cis	1	rs59376497	chr16:67681170	LRRC36	chr16:67360747-67419108:+	0.59	4.35	1.72E-5	Crohn's disease	
BLCA	cis	1	rs59468948	chr1:156288058	BGLAP	chr1:156182784-156213112:+	0.23	3.86	0.000132	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs59531858	chr5:150247063	LOC134466	chr5:150310000-150326146:-	0.54	6.52	2.24E-10	Crohn's disease	
BLCA	cis	1	rs59592823	chr19:30297516	CCNE1	chr19:30302901-30315218:+	0.21	4.03	6.86E-5	Bladder cancer	
BLCA	cis	1	rs59757169	chr5:148618752	AFAP1L1	chr5:148651401-148721365:+	0.27	5.02	8.06E-7	Body mass index	
BLCA	cis	1	rs59794892	chr7:65415873	CCT6P1	chr7:65216092-65228661:+	0.31	4.4	1.4E-5	Diabetic kidney disease	
BLCA	cis	1	rs59868991	chr19:30297577	CCNE1	chr19:30302901-30315218:+	0.21	4.03	6.86E-5	Bladder cancer	
BLCA	cis	1	rs59925331	chr17:38169273	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.95	9.21E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs59937473	chr2:271797	SH3YL1	chr2:218138-264810:-	-0.44	-11.7	3.03E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs5996946	chr22:25875988	CRYBB2	chr22:25615612-25627836:+	0.93	9.86	1.33E-20	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs59980321	chr5:150241813	LOC134466	chr5:150310000-150326146:-	0.45	5.62	3.62E-8	Crohn's disease	
BLCA	cis	1	rs6003958	chr22:24264089	GSTT1	chr22:24376141-24384284:-	-0.63	-9.02	9.47E-18	S-phenylmercapturic acid levels in smokers	
BLCA	cis	1	rs6003958	chr22:24264089	GSTT2	chr22:24322314-24326104:+;chr22	0.49	6.36	5.7E-10	S-phenylmercapturic acid levels in smokers	
BLCA	cis	1	rs6003958	chr22:24264089	LOC391322	chr22:24373117-24374043:+	-0.53	-8.05	1.06E-14	S-phenylmercapturic acid levels in smokers	
BLCA	cis	1	rs6004667	chr22:25874464	CRYBB2	chr22:25615612-25627836:+	-0.9	-9.22	2.0E-18	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs6004668	chr22:25874502	CRYBB2	chr22:25615612-25627836:+	-0.97	-10.49	8.42E-23	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs6004669	chr22:25875803	CRYBB2	chr22:25615612-25627836:+	0.95	10.08	2.42E-21	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs6004671	chr22:25879474	CRYBB2	chr22:25615612-25627836:+	0.91	9.5	2.28E-19	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs6004672	chr22:25881013	CRYBB2	chr22:25615612-25627836:+	0.91	9.5	2.28E-19	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs6004673	chr22:25885353	CRYBB2	chr22:25615612-25627836:+	0.8	8.38	1.02E-15	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs60111824	chr7:6774135	C7orf28B	chr7:6838572-6865861:-	-0.55	-4.67	4.18E-6	Ejection fraction in Tripanosoma cruzi seropositivity	
BLCA	cis	1	rs601338	chr19:49206674	FUT2	chr19:49199228-49209190:+	-0.24	-4.01	7.33E-5	Blood metabolite levels;Blood metabolite ratios	
BLCA	cis	1	rs60134818	chr5:150261043	LOC134466	chr5:150310000-150326146:-	0.46	6.06	3.18E-9	Crohn's disease	
BLCA	cis	1	rs60149603	chr2:285421	SH3YL1	chr2:218138-264810:-	-0.46	-11.73	2.24E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs60326618	chr7:66166358	CCT6P1	chr7:65216092-65228661:+	0.35	4.69	3.85E-6	Gout	
BLCA	cis	1	rs60417730	chr14:71228992	MAP3K9	chr14:71194856-71275888:-	0.43	4.54	7.39E-6	Response to antipsychotic treatment in schizophrenia (reasoning)	
BLCA	cis	1	rs60484953	chr2:221560	SH3YL1	chr2:218138-264810:-	-0.45	-11.8	1.32E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs6051080	chr20:25975674	FAM182B	chr20:25744102-25848786:-	0.46	7.42	7.55E-13	Colorectal or endometrial cancer	
BLCA	cis	1	rs6051713	chr20:3265779	ITPA	chr20:3190056-3204504:+	0.25	3.82	0.000154	IFN-related cytopenia	
BLCA	cis	1	rs6053815	chr20:5970438	MCM8	chr20:5931298-5975829:+	-0.19	-4.16	3.91E-5	HIV-1 viral setpoint	
BLCA	cis	1	rs6053816	chr20:5970750	MCM8	chr20:5931298-5975829:+	-0.21	-4.46	1.07E-5	HIV-1 viral setpoint	
BLCA	cis	1	rs6058352	chr20:30269179	COX4I2	chr20:30225691-30232800:+	0.21	4.43	1.22E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6058465	chr20:30397691	COX4I2	chr20:30225691-30232800:+	0.2	4.25	2.68E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6058468	chr20:30406448	COX4I2	chr20:30225691-30232800:+	0.2	4.21	3.25E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060599	chr20:30257754	COX4I2	chr20:30225691-30232800:+	0.22	4.6	5.73E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6060621	chr20:30261562	COX4I2	chr20:30225691-30232800:+	0.22	4.58	6.2E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6060716	chr20:30274847	COX4I2	chr20:30225691-30232800:+	0.21	4.41	1.35E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060857	chr20:30300222	COX4I2	chr20:30225691-30232800:+	0.22	4.59	6.11E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6060915	chr20:30330306	COX4I2	chr20:30225691-30232800:+	0.2	4.27	2.46E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060919	chr20:30331922	COX4I2	chr20:30225691-30232800:+	0.2	4.17	3.83E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060922	chr20:30333909	COX4I2	chr20:30225691-30232800:+	0.2	4.17	3.83E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060932	chr20:30350545	COX4I2	chr20:30225691-30232800:+	0.2	4.18	3.54E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060933	chr20:30351903	COX4I2	chr20:30225691-30232800:+	0.2	4.29	2.3E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060944	chr20:30372114	COX4I2	chr20:30225691-30232800:+	0.2	4.23	2.97E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060950	chr20:30378031	COX4I2	chr20:30225691-30232800:+	0.2	4.23	2.93E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6060962	chr20:30397847	COX4I2	chr20:30225691-30232800:+	0.2	4.25	2.68E-5	Subcortical brain region volumes	
BLCA	cis	1	rs60683927	chr7:65394768	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs60693825	chr14:35514456	PPP2R3C	chr14:35554679-35591679:-	0.25	3.93	9.92E-5	Atopic dermatitis	
BLCA	cis	1	rs60843830	chr2:286756	SH3YL1	chr2:218138-264810:-	-0.44	-11	1.18E-24	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs60844734	chr2:73623205	ALMS1P	chr2:73872046-73912692:+	0.33	4.87	1.65E-6	Metabolite levels	
BLCA	cis	1	rs6087771	chr20:30306724	COX4I2	chr20:30225691-30232800:+	0.22	4.66	4.29E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6087779	chr20:30370566	COX4I2	chr20:30225691-30232800:+	0.2	4.23	2.97E-5	Subcortical brain region volumes	
BLCA	cis	1	rs6087782	chr20:30391580	COX4I2	chr20:30225691-30232800:+	0.21	4.34	1.82E-5	Subcortical brain region volumes	
BLCA	cis	1	rs60957376	chr15:85280792	LOC388152	chr15:84867600-84898920:-	-0.24	-4.17	3.84E-5	Schizophrenia	
BLCA	cis	1	rs60982898	chr6:49385806	CENPQ	chr6:49431096-49460820:+	-0.28	-5.66	2.91E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs60982898	chr6:49385806	MUT	chr6:49398994-49431031:-	0.28	5.53	5.94E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs61037750	chr11:43681372	HSD17B12	chr11:43702143-43878160:+	-0.44	-7.23	2.69E-12	Forced vital capacity	
BLCA	cis	1	rs61041336	chr16:58733162	GOT2	chr16:58741035-58768246:-	0.3	3.94	9.67E-5	Neuritic plaque	
BLCA	cis	1	rs61102033	chr1:46382441	CCDC163P	chr1:45960581-45965646:-	-0.35	-6.56	1.75E-10	Body mass index	
BLCA	cis	1	rs6119650	chr20:30258480	COX4I2	chr20:30225691-30232800:+	0.22	4.56	6.89E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6119652	chr20:30259445	COX4I2	chr20:30225691-30232800:+	0.22	4.58	6.2E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6120974	chr20:34126827	CPNE1	chr20:34213968-34262539:-	-0.55	-6.66	9.49E-11	Triglycerides	
BLCA	cis	1	rs6121038	chr20:30254773	COX4I2	chr20:30225691-30232800:+	0.22	4.71	3.48E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6121172	chr20:30296095	COX4I2	chr20:30225691-30232800:+	0.22	4.59	6.11E-6	Subcortical brain region volumes	
BLCA	cis	1	rs6121243	chr20:30415094	COX4I2	chr20:30225691-30232800:+	0.2	4.18	3.63E-5	Subcortical brain region volumes	
BLCA	cis	1	rs61270113	chr5:150226263	LOC134466	chr5:150310000-150326146:-	0.43	5.25	2.55E-7	Crohn's disease	
BLCA	cis	1	rs61457762	chr1:27284157	GPN2	chr1:27205873-27216869:-	0.47	4.05	6.12E-5	HDL cholesterol;Triglycerides;LDL cholesterol	
BLCA	cis	1	rs6151429	chr22:51063477	ARSA	chr22:51063450-51066607:-	-0.92	-9.21	2.14E-18	Blood metabolite levels	
BLCA	cis	1	rs61524473	chr15:45646283	SPATA5L1	chr15:45694519-45713614:+	0.34	4.86	1.7E-6	Metabolite levels (small molecules and protein measures)	
BLCA	cis	1	rs61530785	chr5:150261364	LOC134466	chr5:150310000-150326146:-	0.55	7.03	9.29E-12	Crohn's disease	
BLCA	cis	1	rs61744385	chr3:41756986	ULK4	chr3:41288091-42003660:-	0.67	10.35	2.66E-22	Diastolic blood pressure	
BLCA	cis	1	rs61744388	chr3:41756965	ULK4	chr3:41288091-42003660:-	0.67	10.35	2.66E-22	Diastolic blood pressure	
BLCA	cis	1	rs61783200	chr1:46297403	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs61783220	chr1:46335312	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs61792114	chr4:289139	ZNF718	chr4:53272-156488:+	0.32	4.53	7.98E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61792116	chr4:301077	ZNF718	chr4:53272-156488:+	0.35	4.65	4.63E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61794996	chr4:209328	ZNF718	chr4:53272-156488:+	0.34	4.46	1.06E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61794997	chr4:222103	ZNF718	chr4:53272-156488:+	0.34	4.49	9.44E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61795001	chr4:242057	ZNF718	chr4:53272-156488:+	0.34	4.54	7.4E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61795002	chr4:242797	ZNF718	chr4:53272-156488:+	0.34	4.55	7.29E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61795006	chr4:253601	ZNF718	chr4:53272-156488:+	0.29	4.06	5.94E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61795007	chr4:255264	ZNF718	chr4:53272-156488:+	0.28	4.03	6.69E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs61818802	chr1:113181739	ST7L	chr1:113066142-113162405:-	0.41	5.91	7.39E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs61826828	chr1:174015261	ANKRD45	chr1:173577475-173639001:-	0.29	3.94	9.77E-5	Schizophrenia	
BLCA	cis	1	rs61871790	chr10:97391223	ENTPD1	chr10:97471536-97637022:+	0.19	4.84	1.87E-6	Blood metabolite levels	
BLCA	cis	1	rs61871792	chr10:97397586	ENTPD1	chr10:97471536-97637022:+	0.19	4.94	1.15E-6	Blood metabolite levels	
BLCA	cis	1	rs61871793	chr10:97407738	ENTPD1	chr10:97471536-97637022:+	0.2	4.89	1.46E-6	Blood metabolite levels	
BLCA	cis	1	rs62019464	chr15:85294469	LOC388152	chr15:84867600-84898920:-	-0.24	-4.12	4.63E-5	Schizophrenia	
BLCA	cis	1	rs62019469	chr15:85321220	LOC388152	chr15:84867600-84898920:-	-0.23	-4.18	3.68E-5	Schizophrenia	
BLCA	cis	1	rs62021219	chr15:85256159	LOC388152	chr15:84867600-84898920:-	-0.24	-4.17	3.71E-5	Schizophrenia	
BLCA	cis	1	rs62023352	chr15:52889448	ARPP19	chr15:52839432-52861364:-	0.21	3.84	0.000146	Schizophrenia	
BLCA	cis	1	rs62026530	chr15:84775840	LOC388152	chr15:84867600-84898920:-	-0.27	-4.65	4.65E-6	Schizophrenia	
BLCA	cis	1	rs62070312	chr17:28438877	EFCAB5	chr17:28256874-28435469:+	0.23	3.91	0.000109	Coffee consumption (cups per day)	
BLCA	cis	1	rs62104478	chr19:30295306	CCNE1	chr19:30302901-30315218:+	0.21	4.02	6.98E-5	Bladder cancer	
BLCA	cis	1	rs62114497	chr2:214837	SH3YL1	chr2:218138-264810:-	-0.42	-10.8	6.68E-24	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs62114501	chr2:231741	SH3YL1	chr2:218138-264810:-	-0.45	-11.66	4.4E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs62114505	chr2:242426	SH3YL1	chr2:218138-264810:-	-0.45	-11.78	1.53E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs62114544	chr2:269679	SH3YL1	chr2:218138-264810:-	-0.45	-11.79	1.36E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs62114548	chr2:274672	SH3YL1	chr2:218138-264810:-	-0.45	-11.71	2.68E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs62119428	chr2:9743332	ADAM17	chr2:9629413-9695917:-	-0.19	-3.98	8.15E-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	
BLCA	cis	1	rs62119429	chr2:9743585	ADAM17	chr2:9629413-9695917:-	-0.19	-3.98	8.15E-5	3-hydroxy-1-methylpropylmercapturic acid levels in smokers	
BLCA	cis	1	rs62136864	chr2:46829124	ATP6V1E2	chr2:46738988-46769696:-	-0.27	-4.35	1.77E-5	Height	
BLCA	cis	1	rs62151174	chr2:70363968	FAM136A	chr2:70523109-70529220:-	-0.23	-3.88	0.000125	Obesity-related traits	
BLCA	cis	1	rs62151652	chr2:73700131	ALMS1P	chr2:73872046-73912692:+	0.35	5.22	2.91E-7	Metabolite levels	
BLCA	cis	1	rs62269547	chr3:134214042	ANAPC13	chr3:134196547-134204865:-	0.49	7.74	8.8E-14	Height	
BLCA	cis	1	rs62269547	chr3:134214042	CEP63	chr3:134204575-134293852:+	0.23	4.02	7.02E-5	Height	
BLCA	cis	1	rs62271513	chr3:134298412	ANAPC13	chr3:134196547-134204865:-	-0.48	-7.73	9.49E-14	Height	
BLCA	cis	1	rs62271514	chr3:134298554	ANAPC13	chr3:134196547-134204865:-	-0.48	-7.73	9.49E-14	Height	
BLCA	cis	1	rs62271515	chr3:134300507	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs62402013	chr6:26915000	LOC100270746	chr6:26987146-26988085:-	-0.27	-4.79	2.4E-6	Schizophrenia	
BLCA	cis	1	rs62451154	chr7:28007650	HIBADH	chr7:27565063-27702602:-	-0.38	-3.87	0.000127	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs62451158	chr7:28012032	HIBADH	chr7:27565063-27702602:-	-0.37	-3.82	0.000153	Thiazide-induced adverse metabolic effects in hypertensive patients	
BLCA	cis	1	rs627460	chr6:132640030	ENPP1	chr6:132129156-132216293:+	-0.23	-3.93	0.000103	Obesity-related traits	
BLCA	cis	1	rs641018	chr11:65655393	CTSW	chr11:65647284-65651212:+	-0.6	-9.06	6.99E-18	Crohn's disease	
BLCA	cis	1	rs641018	chr11:65655393	SNX32	chr11:65601410-65621170:+	0.34	4.75	2.91E-6	Crohn's disease	
BLCA	cis	1	rs641862	chr13:110790232	CARS2	chr13:111293757-111365950:-	0.57	4.09	5.17E-5	Obesity-related traits	
BLCA	cis	1	rs6429567	chr1:45956700	CCDC163P	chr1:45960581-45965646:-	-0.81	-16.82	5.97E-48	Homocysteine levels	
BLCA	cis	1	rs6429569	chr1:46001330	CCDC163P	chr1:45960581-45965646:-	-0.73	-14.41	6.33E-38	Homocysteine levels	
BLCA	cis	1	rs6429582	chr1:46321843	CCDC163P	chr1:45960581-45965646:-	0.36	7.04	9.0E-12	Body mass index	
BLCA	cis	1	rs6430585	chr2:136506927	DARS	chr2:136664254-136743222:-	-0.25	-4.15	4.07E-5	Corneal structure	
BLCA	cis	1	rs6439484	chr3:134249899	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs6439484	chr3:134249899	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs6439487	chr3:134260860	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs6439487	chr3:134260860	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs6441104	chr3:156681441	LEKR1	chr3:156544076-156763918:+	-0.46	-6.47	3.03E-10	Bone mineral density	
BLCA	cis	1	rs6442119	chr3:48440178	TREX1	chr3:48501186-48509043:+	-0.2	-4	7.48E-5	Longevity	
BLCA	cis	1	rs6442120	chr3:48464503	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000134	Longevity	
BLCA	cis	1	rs6443927	chr3:183718864	ABCC5	chr3:183637726-183735727:-	-0.19	-3.83	0.00015	Anterior chamber depth	
BLCA	cis	1	rs6450408	chr5:56098146	C5orf35	chr5:56205103-56213010:+	0.71	10.45	1.17E-22	Type 2 diabetes	
BLCA	cis	1	rs6450409	chr5:56101399	C5orf35	chr5:56205103-56213010:+	0.65	9.93	7.97E-21	Type 2 diabetes	
BLCA	cis	1	rs6454513	chr6:86720049	SNHG5	chr6:86386726-86388451:-	0.55	9.8	2.22E-20	Response to antipsychotic treatment	
BLCA	cis	1	rs6458307	chr6:42731115	PEX6	chr6:42931613-42946981:-	-0.31	-4.51	8.62E-6	Bipolar disorder	
BLCA	cis	1	rs6458685	chr6:49379536	CENPQ	chr6:49431096-49460820:+	-0.4	-8.67	1.24E-16	Homocysteine levels	
BLCA	cis	1	rs6458688	chr6:49406056	CENPQ	chr6:49431096-49460820:+	-0.39	-8.57	2.55E-16	Homocysteine levels	
BLCA	cis	1	rs6458690	chr6:49411619	CENPQ	chr6:49431096-49460820:+	-0.29	-5.87	9.23E-9	Folate pathway vitamin levels	
BLCA	cis	1	rs6458690	chr6:49411619	MUT	chr6:49398994-49431031:-	0.28	5.46	8.45E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs6458694	chr6:49445306	CENPQ	chr6:49431096-49460820:+	-0.28	-5.56	4.93E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs6458694	chr6:49445306	MUT	chr6:49398994-49431031:-	0.28	5.5	6.93E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs6460260	chr7:65215455	CCT6P1	chr7:65216092-65228661:+	-0.32	-4.49	9.5E-6	Diabetic kidney disease	
BLCA	cis	1	rs6460261	chr7:65215580	CCT6P1	chr7:65216092-65228661:+	-0.32	-4.49	9.5E-6	Diabetic kidney disease	
BLCA	cis	1	rs6460274	chr7:65628484	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs6464573	chr7:143748098	ARHGEF35	chr7:143883677-143892736:-	0.32	5.71	2.26E-8	Obesity-related traits	
BLCA	cis	1	rs6464574	chr7:143748257	ARHGEF35	chr7:143883677-143892736:-	-0.36	-6.38	5.22E-10	Obesity-related traits	
BLCA	cis	1	rs646867	chr1:25709258	RHCE	chr1:25688741-25756683:-	0.23	3.85	0.000139	Erythrocyte sedimentation rate	
BLCA	cis	1	rs646867	chr1:25709258	RHD	chr1:25598981-25656935:+	-0.49	-8.44	6.76E-16	Erythrocyte sedimentation rate	
BLCA	cis	1	rs6474359	chr8:41549194	AGPAT6	chr8:41435707-41482520:+	-0.48	-4.75	2.83E-6	Glycated hemoglobin levels	
BLCA	cis	1	rs6474359	chr8:41549194	AP3M2	chr8:42010464-42028702:+	-0.47	-4.41	1.34E-5	Glycated hemoglobin levels	
BLCA	cis	1	rs6474359	chr8:41549194	C8orf40	chr8:42396298-42408139:+	-0.46	-4.3	2.19E-5	Glycated hemoglobin levels	
BLCA	cis	1	rs6474359	chr8:41549194	GINS4	chr8:41386725-41402563:+	-0.45	-4.97	1.02E-6	Glycated hemoglobin levels	
BLCA	cis	1	rs6474359	chr8:41549194	GOLGA7	chr8:41348081-41368497:+	-0.61	-5.28	2.2E-7	Glycated hemoglobin levels	
BLCA	cis	1	rs6474359	chr8:41549194	MYST3	chr8:41786998-41909505:-	-0.42	-4.5	9.12E-6	Glycated hemoglobin levels	
BLCA	cis	1	rs6474359	chr8:41549194	VDAC3	chr8:42249346-42263413:+	-0.45	-3.95	9.36E-5	Glycated hemoglobin levels	
BLCA	cis	1	rs6478484	chr9:123652380	LOC253039	chr9:123605320-123616644:+	-0.35	-5.97	5.46E-9	Rheumatoid arthritis	
BLCA	cis	1	rs6478486	chr9:123655329	LOC253039	chr9:123605320-123616644:+	-0.36	-6.09	2.72E-9	Rheumatoid arthritis	
BLCA	cis	1	rs6478867	chr9:131903923	CRAT	chr9:131857075-131873070:-	-0.31	-5.4	1.16E-7	Blood metabolite ratios	
BLCA	cis	1	rs6480723	chr10:75966366	ADK	chr10:75910965-76469059:+	0.3	4.62	5.23E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs6485438	chr11:43686618	HSD17B12	chr11:43702143-43878160:+	-0.44	-7.37	1.05E-12	Forced vital capacity	
BLCA	cis	1	rs6485443	chr11:43696316	HSD17B12	chr11:43702143-43878160:+	0.43	7.28	1.9E-12	Forced vital capacity	
BLCA	cis	1	rs6488051	chr12:32532733	FGD4	chr12:32638906-32798982:+	-0.33	-5.36	1.47E-7	Response to tocilizumab in rheumatoid arthritis	
BLCA	cis	1	rs649338	chr11:118705654	NLRX1	chr11:119039437-119054723:+	-0.37	-3.91	0.000108	Vitiligo	
BLCA	cis	1	rs6495206	chr15:76870963	SCAPER	chr15:76640529-77197744:-	-0.2	-4.47	1.03E-5	Blood metabolite levels	
BLCA	cis	1	rs6502677	chr17:18803658	FAM18B	chr17:18684582-18710026:+	-0.22	-4.06	6.05E-5	Educational attainment (years of education)	
BLCA	cis	1	rs6503530	chr17:38161823	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.95	9.31E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs6503877	chr17:56841948	RAD51C	chr17:56769963-56811690:+	0.29	5.15	4.09E-7	Cognitive test performance	
BLCA	cis	1	rs6503882	chr17:56915761	RAD51C	chr17:56769963-56811690:+	0.28	4.9	1.43E-6	Cognitive test performance	
BLCA	cis	1	rs6504661	chr17:48580126	MYCBPAP	chr17:48585745-48608861:+	0.27	3.87	0.000126	Visceral fat	
BLCA	cis	1	rs6505152	chr17:28331466	EFCAB5	chr17:28256874-28435469:+	-0.23	-4	7.57E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs6505158	chr17:28403348	EFCAB5	chr17:28256874-28435469:+	-0.23	-3.97	8.64E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs6508977	chr19:41909346	B3GNT8	chr19:41931265-41934635:-	-0.21	-3.9	0.000114	Height	
BLCA	cis	1	rs6519120	chr22:38991393	JOSD1	chr22:39081549-39096459:-	0.24	3.88	0.000122	Resting heart rate	
BLCA	cis	1	rs6532078	chr4:76920809	NAAA	chr4:76831809-76862166:-	-0.37	-6.05	3.38E-9	Longevity	
BLCA	cis	1	rs6533059	chr4:104133376	MANBA	chr4:103552644-103682151:-	0.28	4.49	9.34E-6	Testicular germ cell tumor	
BLCA	cis	1	rs6533060	chr4:104139996	MANBA	chr4:103552644-103682151:-	0.26	4.22	2.99E-5	Testicular germ cell tumor	
BLCA	cis	1	rs6545883	chr2:61772257	AHSA2	chr2:61404553-61414058:+	-0.17	-4.75	2.85E-6	Tuberculosis	
BLCA	cis	1	rs6545883	chr2:61772257	C2orf74	chr2:61372243-61391964:+	0.33	5.71	2.32E-8	Tuberculosis	
BLCA	cis	1	rs6546835	chr2:73664715	ALMS1P	chr2:73872046-73912692:+	0.4	5.93	6.67E-9	Metabolite levels	
BLCA	cis	1	rs6546836	chr2:73677833	ALMS1P	chr2:73872046-73912692:+	0.38	5.79	1.47E-8	Metabolite levels	
BLCA	cis	1	rs6546837	chr2:73677898	ALMS1P	chr2:73872046-73912692:+	0.39	5.82	1.23E-8	Metabolite levels	
BLCA	cis	1	rs6546838	chr2:73679280	ALMS1P	chr2:73872046-73912692:+	0.39	5.82	1.23E-8	Metabolite levels	
BLCA	cis	1	rs6546839	chr2:73680508	ALMS1P	chr2:73872046-73912692:+	0.39	5.82	1.23E-8	Metabolite levels	
BLCA	cis	1	rs6547734	chr2:27830990	C2orf16	chr2:27799389-27805588:+	0.23	4.04	6.46E-5	Oral cavity cancer	
BLCA	cis	1	rs6547872	chr2:28978074	TRMT61B	chr2:29072690-29093175:-	-0.32	-5.68	2.7E-8	Body mass index	
BLCA	cis	1	rs6563380	chr13:36770422	SOHLH2	chr13:36742347-36871992:-	0.26	4.43	1.23E-5	Glucose homeostasis traits	
BLCA	cis	1	rs6563389	chr13:36777536	SOHLH2	chr13:36742347-36871992:-	-0.39	-5.2	3.19E-7	Economic and political preferences	
BLCA	cis	1	rs656980	chr11:65656282	CTSW	chr11:65647284-65651212:+	-0.6	-9.06	6.99E-18	Crohn's disease	
BLCA	cis	1	rs656980	chr11:65656282	SNX32	chr11:65601410-65621170:+	0.34	4.75	2.91E-6	Crohn's disease	
BLCA	cis	1	rs6570043	chr6:136134098	PDE7B	chr6:136172834-136516708:+	0.21	3.86	0.000135	Phosphorus levels	
BLCA	cis	1	rs6579245	chr20:34125271	CPNE1	chr20:34213968-34262539:-	-0.54	-6.66	9.54E-11	Cholesterol, total	
BLCA	cis	1	rs6579803	chr5:150255559	LOC134466	chr5:150310000-150326146:-	0.48	6.27	9.54E-10	Crohn's disease	
BLCA	cis	1	rs6579804	chr5:150255931	LOC134466	chr5:150310000-150326146:-	0.48	6.27	9.54E-10	Crohn's disease	
BLCA	cis	1	rs6579806	chr5:150271084	LOC134466	chr5:150310000-150326146:-	0.45	5.81	1.33E-8	Crohn's disease	
BLCA	cis	1	rs6581155	chr12:58178162	FAM119B	chr12:58166383-58176323:+	0.27	4.34	1.83E-5	Multiple sclerosis	
BLCA	cis	1	rs6581155	chr12:58178162	TSFM	chr12:58176536-58191367:+	-0.36	-6.55	1.91E-10	Multiple sclerosis	
BLCA	cis	1	rs6581155	chr12:58178162	XRCC6BP1	chr12:58335445-58351051:+	-0.23	-4.12	4.74E-5	Multiple sclerosis	
BLCA	cis	1	rs6589575	chr11:116733310	PCSK7	chr11:117075789-117102811:-	-0.44	-5.68	2.73E-8	Protein quantitative trait loci	
BLCA	cis	1	rs6589576	chr11:116735788	PCSK7	chr11:117075789-117102811:-	0.41	5.49	7.46E-8	Protein quantitative trait loci	
BLCA	cis	1	rs6589589	chr11:116932428	PCSK7	chr11:117075789-117102811:-	-0.4	-5.21	3.05E-7	Protein quantitative trait loci	
BLCA	cis	1	rs6598955	chr1:26619649	ZNF593	chr1:26496388-26497362:+	0.21	4.47	1.02E-5	Obesity-related traits	
BLCA	cis	1	rs6599170	chr3:41772718	ULK4	chr3:41288091-42003660:-	0.63	9.74	3.64E-20	Diastolic blood pressure	
BLCA	cis	1	rs6599175	chr3:41786009	ULK4	chr3:41288091-42003660:-	-0.6	-9.51	2.14E-19	Diastolic blood pressure	
BLCA	cis	1	rs6599176	chr3:41788492	ULK4	chr3:41288091-42003660:-	-0.62	-9.75	3.3E-20	Diastolic blood pressure	
BLCA	cis	1	rs6599178	chr3:41842129	ULK4	chr3:41288091-42003660:-	0.64	9.96	6.41E-21	Diastolic blood pressure	
BLCA	cis	1	rs6599179	chr3:41855284	ULK4	chr3:41288091-42003660:-	0.64	10	4.42E-21	Diastolic blood pressure	
BLCA	cis	1	rs6599318	chr4:243968	ZNF718	chr4:53272-156488:+	0.34	4.55	7.25E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs6656992	chr1:46333068	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs6661910	chr1:46290632	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs6662641	chr1:46571509	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.21	1.42E-9	Body mass index	
BLCA	cis	1	rs6667191	chr1:45982844	CCDC163P	chr1:45960581-45965646:-	-0.81	-16.62	4.15E-47	Homocysteine levels	
BLCA	cis	1	rs6668284	chr1:46354510	CCDC163P	chr1:45960581-45965646:-	-0.37	-7.03	9.62E-12	Body mass index	
BLCA	cis	1	rs6669522	chr1:46397941	CCDC163P	chr1:45960581-45965646:-	-0.35	-6.56	1.75E-10	Body mass index	
BLCA	cis	1	rs6672898	chr1:46290588	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs6675726	chr1:46560643	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.8E-10	Body mass index	
BLCA	cis	1	rs6675726	chr1:46560643	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000117	Body mass index	
BLCA	cis	1	rs6675946	chr1:46371774	CCDC163P	chr1:45960581-45965646:-	-0.36	-6.79	4.3E-11	Body mass index	
BLCA	cis	1	rs6677007	chr1:46400590	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs66775662	chr6:151876216	C6orf97	chr6:151815175-151942327:+	0.27	3.99	7.84E-5	Bone mineral density (spine)	
BLCA	cis	1	rs6679	chr1:113243048	ST7L	chr1:113066142-113162405:-	0.43	6.19	1.55E-9	Diastolic blood pressure;Blood pressure	
BLCA	cis	1	rs6680380	chr1:46300189	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs6695809	chr1:46285461	CCDC163P	chr1:45960581-45965646:-	-0.37	-6.99	1.19E-11	Body mass index	
BLCA	cis	1	rs66965793	chr1:156285814	BGLAP	chr1:156182784-156213112:+	0.23	3.91	0.000109	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs6700597	chr1:46284246	CCDC163P	chr1:45960581-45965646:-	-0.37	-6.99	1.19E-11	Body mass index	
BLCA	cis	1	rs6701614	chr1:46309420	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs6705489	chr2:73648811	ALMS1P	chr2:73872046-73912692:+	0.34	4.93	1.24E-6	Metabolite levels	
BLCA	cis	1	rs6706610	chr2:27778091	C2orf16	chr2:27799389-27805588:+	0.22	3.83	0.000152	Oral cavity cancer	
BLCA	cis	1	rs67073037	chr2:29119585	TRMT61B	chr2:29072690-29093175:-	0.33	5.04	7.05E-7	Breast cancer (estrogen-receptor negative);Breast cancer	
BLCA	cis	1	rs6707722	chr2:73654363	ALMS1P	chr2:73872046-73912692:+	0.38	5.71	2.23E-8	Metabolite levels	
BLCA	cis	1	rs6707848	chr2:28988083	TRMT61B	chr2:29072690-29093175:-	-0.33	-5.77	1.66E-8	Body mass index	
BLCA	cis	1	rs6708328	chr2:24412413	LOC375190	chr2:24299728-24397519:+	-0.24	-4.07	5.63E-5	Venous thromboembolism (SNP x SNP interaction)	
BLCA	cis	1	rs6709534	chr2:217334	SH3YL1	chr2:218138-264810:-	-0.44	-11.56	1.05E-26	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs6710438	chr2:73820108	ALMS1P	chr2:73872046-73912692:+	-0.35	-5.12	4.78E-7	Metabolite levels	
BLCA	cis	1	rs6710959	chr2:28958603	TRMT61B	chr2:29072690-29093175:-	-0.29	-5.03	7.45E-7	Body mass index	
BLCA	cis	1	rs6711033	chr2:73746643	ALMS1P	chr2:73872046-73912692:+	0.34	4.99	9.15E-7	Metabolite levels	
BLCA	cis	1	rs6711127	chr2:202213515	PPIL3	chr2:201735680-201753999:-	-0.44	-3.88	0.000125	Rheumatoid arthritis	
BLCA	cis	1	rs6711941	chr2:202178130	PPIL3	chr2:201735680-201753999:-	-0.53	-5.3	1.93E-7	Rheumatoid arthritis	
BLCA	cis	1	rs6715284	chr2:202154397	PPIL3	chr2:201735680-201753999:-	-0.45	-5	8.61E-7	Rheumatoid arthritis	
BLCA	cis	1	rs6715380	chr2:202214505	PPIL3	chr2:201735680-201753999:-	-0.46	-4.11	4.92E-5	Rheumatoid arthritis	
BLCA	cis	1	rs6715819	chr2:73772309	ALMS1P	chr2:73872046-73912692:+	0.36	5.34	1.63E-7	Metabolite levels	
BLCA	cis	1	rs6720809	chr2:88528943	THNSL2	chr2:88469835-88486145:+	-0.53	-5.36	1.45E-7	Plasma clusterin levels	
BLCA	cis	1	rs6722069	chr2:88533151	THNSL2	chr2:88469835-88486145:+	-0.56	-5.77	1.61E-8	Plasma clusterin levels	
BLCA	cis	1	rs67239267	chr7:143745116	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.92	7.15E-9	Obesity-related traits	
BLCA	cis	1	rs6724782	chr2:73679990	ALMS1P	chr2:73872046-73912692:+	0.39	5.82	1.23E-8	Metabolite levels	
BLCA	cis	1	rs6732236	chr2:136501509	DARS	chr2:136664254-136743222:-	0.27	4.48	1.01E-5	Corneal structure	
BLCA	cis	1	rs6736866	chr2:73661986	ALMS1P	chr2:73872046-73912692:+	0.34	4.97	1.0E-6	Metabolite levels	
BLCA	cis	1	rs6740223	chr2:73653332	ALMS1P	chr2:73872046-73912692:+	0.38	5.71	2.23E-8	Metabolite levels	
BLCA	cis	1	rs6741269	chr2:239179418	LOC151174	chr2:239133754-239140318:-	0.46	4.5	9.06E-6	Irritable bowel syndrome	
BLCA	cis	1	rs6742276	chr2:61768745	AHSA2	chr2:61404553-61414058:+	-0.19	-5.04	7.34E-7	Tuberculosis	
BLCA	cis	1	rs6742276	chr2:61768745	C2orf74	chr2:61372243-61391964:+	0.37	6.05	3.53E-9	Tuberculosis	
BLCA	cis	1	rs67445790	chr6:151876730	C6orf97	chr6:151815175-151942327:+	0.27	3.89	0.000116	Bone mineral density (spine)	
BLCA	cis	1	rs67446674	chr14:71217852	MAP3K9	chr14:71194856-71275888:-	0.44	4.25	2.73E-5	Response to antipsychotic treatment in schizophrenia (reasoning)	
BLCA	cis	1	rs6745368	chr2:73809974	ALMS1P	chr2:73872046-73912692:+	0.35	5.12	4.75E-7	Metabolite levels	
BLCA	cis	1	rs6749052	chr2:27772879	C2orf16	chr2:27799389-27805588:+	0.22	3.83	0.000152	Oral cavity cancer	
BLCA	cis	1	rs6750943	chr2:27777904	C2orf16	chr2:27799389-27805588:+	0.23	3.97	8.5E-5	Oral cavity cancer	
BLCA	cis	1	rs6753344	chr2:73653138	ALMS1P	chr2:73872046-73912692:+	-0.33	-4.96	1.05E-6	Metabolite levels	
BLCA	cis	1	rs67536397	chr7:65947917	CCT6P1	chr7:65216092-65228661:+	0.36	4.72	3.38E-6	Diabetic kidney disease	
BLCA	cis	1	rs6755217	chr2:73641285	ALMS1P	chr2:73872046-73912692:+	0.32	4.57	6.57E-6	Metabolite levels	
BLCA	cis	1	rs6755241	chr2:73641364	ALMS1P	chr2:73872046-73912692:+	0.33	4.78	2.53E-6	Metabolite levels	
BLCA	cis	1	rs6756987	chr2:73687077	ALMS1P	chr2:73872046-73912692:+	0.39	5.82	1.23E-8	Metabolite levels	
BLCA	cis	1	rs6759004	chr2:202004676	CFLAR	chr2:201980816-202029001:+	-0.27	-4.85	1.8E-6	Triptolide cytotoxicity	
BLCA	cis	1	rs6759004	chr2:202004676	PPIL3	chr2:201735680-201753999:-	-0.63	-8.91	2.06E-17	Triptolide cytotoxicity	
BLCA	cis	1	rs6763088	chr3:134254989	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs6763088	chr3:134254989	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs6763093	chr3:134254995	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.96	2.01E-14	Height	
BLCA	cis	1	rs6763093	chr3:134254995	CEP63	chr3:134204575-134293852:+	-0.24	-4.2	3.39E-5	Height	
BLCA	cis	1	rs6763829	chr3:41897046	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs6765505	chr3:134208132	ANAPC13	chr3:134196547-134204865:-	0.48	7.71	1.1E-13	Height	
BLCA	cis	1	rs6765505	chr3:134208132	CEP63	chr3:134204575-134293852:+	0.24	4.11	4.93E-5	Height	
BLCA	cis	1	rs6766818	chr3:134226159	ANAPC13	chr3:134196547-134204865:-	0.51	8.28	2.13E-15	Height	
BLCA	cis	1	rs6766818	chr3:134226159	CEP63	chr3:134204575-134293852:+	0.26	4.53	7.95E-6	Height	
BLCA	cis	1	rs6766897	chr3:134191303	ANAPC13	chr3:134196547-134204865:-	0.47	7.23	2.7E-12	Height	
BLCA	cis	1	rs6767013	chr3:183680102	ABCC5	chr3:183637726-183735727:-	-0.2	-3.84	0.000142	Anterior chamber depth	
BLCA	cis	1	rs6767013	chr3:183680102	VWA5B2	chr3:183948317-183960116:+	-0.24	-3.85	0.00014	Anterior chamber depth	
BLCA	cis	1	rs6768128	chr3:41865080	ULK4	chr3:41288091-42003660:-	0.62	9.66	6.48E-20	Diastolic blood pressure	
BLCA	cis	1	rs6768542	chr3:41865474	ULK4	chr3:41288091-42003660:-	0.62	9.66	6.48E-20	Diastolic blood pressure	
BLCA	cis	1	rs6768563	chr3:41865541	ULK4	chr3:41288091-42003660:-	0.62	9.66	6.48E-20	Diastolic blood pressure	
BLCA	cis	1	rs6769885	chr3:134286913	ANAPC13	chr3:134196547-134204865:-	0.49	7.81	5.66E-14	Height	
BLCA	cis	1	rs6769885	chr3:134286913	CEP63	chr3:134204575-134293852:+	0.22	3.83	0.00015	Height	
BLCA	cis	1	rs67728539	chr7:65378124	CCT6P1	chr7:65216092-65228661:+	0.31	4.37	1.61E-5	Diabetic kidney disease	
BLCA	cis	1	rs6772896	chr3:134203347	ANAPC13	chr3:134196547-134204865:-	0.51	8.23	2.91E-15	Height	
BLCA	cis	1	rs6772896	chr3:134203347	CEP63	chr3:134204575-134293852:+	0.26	4.44	1.16E-5	Height	
BLCA	cis	1	rs6776700	chr3:48496758	TREX1	chr3:48501186-48509043:+	-0.19	-3.92	0.000105	Longevity	
BLCA	cis	1	rs6781326	chr3:41777028	ULK4	chr3:41288091-42003660:-	0.63	9.77	2.83E-20	Diastolic blood pressure	
BLCA	cis	1	rs6782563	chr3:134295959	ANAPC13	chr3:134196547-134204865:-	-0.47	-7.51	4.32E-13	Height	
BLCA	cis	1	rs6783001	chr3:41862232	ULK4	chr3:41288091-42003660:-	0.64	9.92	8.26E-21	Diastolic blood pressure	
BLCA	cis	1	rs6784421	chr3:156655494	LEKR1	chr3:156544076-156763918:+	0.24	4.53	7.96E-6	Multiple sclerosis (severity)	
BLCA	cis	1	rs6785027	chr3:134211649	ANAPC13	chr3:134196547-134204865:-	-0.48	-7.74	9.22E-14	Height	
BLCA	cis	1	rs6787371	chr3:134254991	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs6787371	chr3:134254991	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs6787952	chr3:156609375	LEKR1	chr3:156544076-156763918:+	-0.46	-6.35	6.01E-10	Bone mineral density	
BLCA	cis	1	rs6789260	chr3:41776350	ULK4	chr3:41288091-42003660:-	0.64	9.46	3.23E-19	Diastolic blood pressure	
BLCA	cis	1	rs6790466	chr3:134197740	ANAPC13	chr3:134196547-134204865:-	0.51	8.15	5.16E-15	Height	
BLCA	cis	1	rs6790466	chr3:134197740	CEP63	chr3:134204575-134293852:+	0.25	4.41	1.33E-5	Height	
BLCA	cis	1	rs6790732	chr3:41864872	ULK4	chr3:41288091-42003660:-	0.64	9.96	6.34E-21	Diastolic blood pressure	
BLCA	cis	1	rs6791806	chr3:41889995	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs6793487	chr3:134299426	ANAPC13	chr3:134196547-134204865:-	-0.47	-7.51	4.32E-13	Height	
BLCA	cis	1	rs6796210	chr3:41851718	ULK4	chr3:41288091-42003660:-	0.65	10.07	2.66E-21	Diastolic blood pressure	
BLCA	cis	1	rs6797165	chr3:41887777	ULK4	chr3:41288091-42003660:-	0.65	10.01	4.27E-21	Diastolic blood pressure	
BLCA	cis	1	rs6800862	chr3:134228628	ANAPC13	chr3:134196547-134204865:-	0.47	7.68	1.39E-13	Height	
BLCA	cis	1	rs6801343	chr3:41767234	ULK4	chr3:41288091-42003660:-	0.63	9.78	2.69E-20	Diastolic blood pressure	
BLCA	cis	1	rs6801596	chr3:134252114	ANAPC13	chr3:134196547-134204865:-	0.47	7.54	3.54E-13	Height	
BLCA	cis	1	rs6802340	chr3:41894034	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs6802654	chr3:134217072	ANAPC13	chr3:134196547-134204865:-	0.49	7.8	6.04E-14	Height	
BLCA	cis	1	rs6802654	chr3:134217072	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.17E-5	Height	
BLCA	cis	1	rs6802849	chr3:183698943	ABCC5	chr3:183637726-183735727:-	-0.21	-4.1	4.97E-5	Anterior chamber depth	
BLCA	cis	1	rs6803560	chr3:41824480	ULK4	chr3:41288091-42003660:-	0.63	9.72	4.23E-20	Diastolic blood pressure	
BLCA	cis	1	rs6803652	chr3:41824556	ULK4	chr3:41288091-42003660:-	0.63	9.72	4.23E-20	Diastolic blood pressure	
BLCA	cis	1	rs6804242	chr3:183659463	ABCC5	chr3:183637726-183735727:-	-0.2	-3.88	0.000123	Anterior chamber depth	
BLCA	cis	1	rs6804242	chr3:183659463	VWA5B2	chr3:183948317-183960116:+	-0.26	-4.16	3.94E-5	Anterior chamber depth	
BLCA	cis	1	rs6804770	chr3:134230234	ANAPC13	chr3:134196547-134204865:-	0.49	7.99	1.6E-14	Height	
BLCA	cis	1	rs6804770	chr3:134230234	CEP63	chr3:134204575-134293852:+	0.24	4.2	3.36E-5	Height	
BLCA	cis	1	rs6805251	chr3:119560606	KTELC1	chr3:119187785-119213552:+	-0.23	-4.03	6.73E-5	HDL cholesterol	
BLCA	cis	1	rs6805880	chr3:41865397	ULK4	chr3:41288091-42003660:-	0.62	9.66	6.48E-20	Diastolic blood pressure	
BLCA	cis	1	rs6805913	chr3:183662924	VWA5B2	chr3:183948317-183960116:+	-0.25	-3.96	9.11E-5	Anterior chamber depth	
BLCA	cis	1	rs6806417	chr3:134211446	ANAPC13	chr3:134196547-134204865:-	-0.49	-7.88	3.34E-14	Height	
BLCA	cis	1	rs6806417	chr3:134211446	CEP63	chr3:134204575-134293852:+	-0.23	-4.03	6.72E-5	Height	
BLCA	cis	1	rs6807015	chr3:41754514	ULK4	chr3:41288091-42003660:-	0.66	10.08	2.35E-21	Diastolic blood pressure	
BLCA	cis	1	rs68141011	chr6:28217797	ZNF389	chr6:28129551-28137375:+	-0.33	-4.07	5.63E-5	Depression	
BLCA	cis	1	rs68171315	chr6:86707400	SNHG5	chr6:86386726-86388451:-	-0.52	-9.13	4.02E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs68189316	chr7:65409169	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs6827617	chr4:76916146	NAAA	chr4:76831809-76862166:-	-0.37	-6.07	3.06E-9	Longevity	
BLCA	cis	1	rs6862814	chr5:150245259	LOC134466	chr5:150310000-150326146:-	0.43	5.77	1.66E-8	Crohn's disease	
BLCA	cis	1	rs687672	chr11:65649984	CTSW	chr11:65647284-65651212:+	0.59	8.99	1.14E-17	Crohn's disease	
BLCA	cis	1	rs687672	chr11:65649984	SNX32	chr11:65601410-65621170:+	-0.34	-4.75	2.93E-6	Crohn's disease	
BLCA	cis	1	rs6885541	chr5:56110857	C5orf35	chr5:56205103-56213010:+	0.72	10.68	1.81E-23	Type 2 diabetes	
BLCA	cis	1	rs6902429	chr6:49393500	CENPQ	chr6:49431096-49460820:+	-0.4	-8.67	1.24E-16	Homocysteine levels	
BLCA	cis	1	rs6904133	chr6:151881805	C6orf97	chr6:151815175-151942327:+	0.29	4.46	1.09E-5	Bone mineral density (spine)	
BLCA	cis	1	rs6910233	chr6:33534726	BAK1	chr6:33540324-33548070:-	0.2	4.79	2.4E-6	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity	
BLCA	cis	1	rs6914463	chr6:86653415	SNHG5	chr6:86386726-86388451:-	-0.55	-10.04	3.3E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs6915187	chr6:49423547	CENPQ	chr6:49431096-49460820:+	-0.41	-8.83	3.75E-17	Homocysteine levels	
BLCA	cis	1	rs6916888	chr6:49383804	CENPQ	chr6:49431096-49460820:+	-0.4	-8.67	1.24E-16	Homocysteine levels	
BLCA	cis	1	rs6918347	chr6:49406348	CENPQ	chr6:49431096-49460820:+	-0.39	-8.57	2.55E-16	Homocysteine levels	
BLCA	cis	1	rs6918586	chr6:26097384	BTN3A2	chr6:26365398-26378546:+	-0.22	-4.52	8.19E-6	Schizophrenia	
BLCA	cis	1	rs6923124	chr6:49419864	CENPQ	chr6:49431096-49460820:+	-0.27	-5.47	8.32E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs6923124	chr6:49419864	MUT	chr6:49398994-49431031:-	0.29	5.76	1.68E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs6923148	chr6:86767786	SNHG5	chr6:86386726-86388451:-	0.56	9.97	5.7E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs6927188	chr6:42912589	PEX6	chr6:42931613-42946981:-	-0.58	-8.09	8.22E-15	Diabetic kidney disease	
BLCA	cis	1	rs6932590	chr6:27248931	BTN3A2	chr6:26365398-26378546:+	-0.23	-4.06	5.87E-5	Schizophrenia	
BLCA	cis	1	rs6932936	chr6:14115090	CD83	chr6:14117865-14137146:+	-0.3	-3.9	0.000113	Rheumatoid arthritis	
BLCA	cis	1	rs6933377	chr6:86705255	SNHG5	chr6:86386726-86388451:-	0.46	8.31	1.7E-15	Response to antipsychotic treatment	
BLCA	cis	1	rs6936048	chr6:86702608	SNHG5	chr6:86386726-86388451:-	-0.5	-8.78	5.32E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs693824	chr11:65654783	CTSW	chr11:65647284-65651212:+	-0.6	-9.06	6.99E-18	Crohn's disease	
BLCA	cis	1	rs693824	chr11:65654783	SNX32	chr11:65601410-65621170:+	0.34	4.75	2.91E-6	Crohn's disease	
BLCA	cis	1	rs6940458	chr6:86644992	SNHG5	chr6:86386726-86388451:-	-0.52	-9.16	3.09E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs6949812	chr7:65387101	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs694994	chr11:65653309	CTSW	chr11:65647284-65651212:+	-0.6	-9.14	3.8E-18	Crohn's disease	
BLCA	cis	1	rs694994	chr11:65653309	SNX32	chr11:65601410-65621170:+	0.34	4.75	2.83E-6	Crohn's disease	
BLCA	cis	1	rs6958289	chr7:65657111	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.75	2.86E-6	Diabetic kidney disease	
BLCA	cis	1	rs6958420	chr7:65751171	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.72	3.27E-6	Diabetic kidney disease	
BLCA	cis	1	rs6959002	chr7:65650496	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs6964245	chr7:65718717	CCT6P1	chr7:65216092-65228661:+	-0.33	-4.52	8.25E-6	Diabetic kidney disease	
BLCA	cis	1	rs6964530	chr7:65718851	CCT6P1	chr7:65216092-65228661:+	-0.29	-3.93	0.000101	Diabetic kidney disease	
BLCA	cis	1	rs6966322	chr7:65646754	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs6967385	chr7:12391319	VWDE	chr7:12370509-12443852:-	-0.31	-5.17	3.79E-7	Response to taxane treatment (placlitaxel)	
BLCA	cis	1	rs6970243	chr7:65388490	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs6970597	chr7:21583519	DNAH11	chr7:21582833-21941455:+	-0.3	-4.99	9.08E-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs6970985	chr7:21583597	DNAH11	chr7:21582833-21941455:+	-0.3	-4.98	9.83E-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs6974373	chr7:99590893	TRIM4	chr7:99488037-99517154:-	-0.22	-4.08	5.56E-5	Interstitial lung disease	
BLCA	cis	1	rs6974723	chr7:65637939	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs6976053	chr7:100512119	UFSP1	chr7:100486346-100487339:-	-0.24	-4	7.64E-5	Plasminogen activator inhibitor type 1 levels (PAI-1)	
BLCA	cis	1	rs6980323	chr7:3356207	SDK1	chr7:3341080-4308629:+	0.24	3.88	0.000124	Motion sickness	
BLCA	cis	1	rs6989010	chr8:12772755	FAM86B1	chr8:12039614-12051624:-	-0.56	-4.09	5.2E-5	Colorectal cancer (diet interaction)	
BLCA	cis	1	rs7007450	chr8:71640269	XKR9	chr8:71581600-71648176:+	0.82	17.69	1.34E-51	Bone mineral density	
BLCA	cis	1	rs7017914	chr8:71591203	XKR9	chr8:71581600-71648176:+	0.82	18.12	1.88E-53	Bone mineral density	
BLCA	cis	1	rs7029536	chr9:130110411	SLC2A8	chr9:130159465-130170161:+	-0.29	-5.42	1.04E-7	Metabolite levels (HVA)	
BLCA	cis	1	rs7033675	chr9:2969877	KIAA0020	chr9:2804155-2844130:-	-0.49	-4.87	1.66E-6	Systolic blood pressure in sickle cell anemia	
BLCA	cis	1	rs7037140	chr9:123656327	LOC253039	chr9:123605320-123616644:+	-0.36	-6.07	3.13E-9	Rheumatoid arthritis	
BLCA	cis	1	rs703842	chr12:58162739	FAM119B	chr12:58166383-58176323:+	-0.27	-4.32	1.96E-5	Multiple sclerosis	
BLCA	cis	1	rs703842	chr12:58162739	TSFM	chr12:58176536-58191367:+	0.38	6.86	2.79E-11	Multiple sclerosis	
BLCA	cis	1	rs703842	chr12:58162739	XRCC6BP1	chr12:58335445-58351051:+	0.23	4.03	6.86E-5	Multiple sclerosis	
BLCA	cis	1	rs705696	chr12:56480648	RPS26	chr12:56435686-56438005:+	0.45	7.32	1.46E-12	Cognitive function	
BLCA	cis	1	rs7061710	chr1:171080615	FMO2	chr1:171154388-171181822:+	-0.24	-4.69	3.89E-6	Blood metabolite levels	
BLCA	cis	1	rs7072216	chr10:100156853	PYROXD2	chr10:100143323-100174978:-	0.29	6.67	8.78E-11	Metabolite levels	
BLCA	cis	1	rs7073432	chr10:75953350	ADK	chr10:75910965-76469059:+	0.33	4.82	2.06E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7073432	chr10:75953350	AP3M1	chr10:75880016-75910826:-	0.31	3.94	9.76E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7076721	chr10:75996682	ADK	chr10:75910965-76469059:+	0.29	4.39	1.47E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7081350	chr10:75990328	ADK	chr10:75910965-76469059:+	0.3	4.55	7.23E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7083534	chr10:75955672	ADK	chr10:75910965-76469059:+	0.31	4.71	3.41E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7096553	chr10:75957835	ADK	chr10:75910965-76469059:+	0.31	4.73	3.2E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7105282	chr11:47805614	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.58	4.62E-8	Subjective well-being	
BLCA	cis	1	rs7111	chr15:90373873	AP3S2	chr15:90373832-90456222:-	-0.7	-10.63	2.6E-23	Type 2 diabetes	
BLCA	cis	1	rs7112513	chr11:117037361	PCSK7	chr11:117075789-117102811:-	-0.39	-5	8.81E-7	Protein quantitative trait loci	
BLCA	cis	1	rs7114252	chr11:71237606	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.88	0.000123	Vitamin D levels	
BLCA	cis	1	rs7114963	chr11:116875983	PCSK7	chr11:117075789-117102811:-	-0.4	-5.15	4.22E-7	Protein quantitative trait loci	
BLCA	cis	1	rs7115737	chr11:43681249	HSD17B12	chr11:43702143-43878160:+	-0.44	-7.23	2.69E-12	Forced vital capacity	
BLCA	cis	1	rs7120333	chr11:47817441	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.61	3.9E-8	Subjective well-being	
BLCA	cis	1	rs7121347	chr11:116867209	PCSK7	chr11:117075789-117102811:-	-0.4	-5.15	4.22E-7	Protein quantitative trait loci	
BLCA	cis	1	rs7122944	chr11:117034619	PCSK7	chr11:117075789-117102811:-	-0.41	-5.13	4.63E-7	Protein quantitative trait loci	
BLCA	cis	1	rs7123517	chr11:117027755	PCSK7	chr11:117075789-117102811:-	-0.41	-5.13	4.63E-7	Protein quantitative trait loci	
BLCA	cis	1	rs7124741	chr11:116752219	PCSK7	chr11:117075789-117102811:-	-0.45	-5.61	3.94E-8	Protein quantitative trait loci	
BLCA	cis	1	rs71299622	chr3:52917038	TMEM110	chr3:52867139-52931547:-	0.46	4.22	3.0E-5	Immune reponse to smallpox (secreted IL-2)	
BLCA	cis	1	rs7130588	chr11:76270683	CAPN5	chr11:76777992-76837196:+	-0.16	-3.92	0.000105	Crohn's disease;Gut microbiota (functional units)	
BLCA	cis	1	rs7130829	chr11:71237702	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.86	0.000132	Vitamin D levels	
BLCA	cis	1	rs71324766	chr22:29839659	NIPSNAP1	chr22:29950800-29977144:-	0.29	3.95	9.15E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs71327718	chr3:125592857	ALG1L	chr3:125648118-125655882:-	-0.4	-5.67	2.86E-8	Metabolite levels (HVA/5-HIAA ratio)	
BLCA	cis	1	rs71327718	chr3:125592857	LOC100125556	chr3:125635444-125648865:+	0.31	3.84	0.000146	Metabolite levels (HVA/5-HIAA ratio)	
BLCA	cis	1	rs71426510	chr2:239178909	LOC151174	chr2:239133754-239140318:-	0.46	4.51	8.67E-6	Irritable bowel syndrome	
BLCA	cis	1	rs7143682	chr14:104413455	TDRD9	chr14:104394817-104519002:+	0.34	5.4	1.15E-7	Bipolar disorder	
BLCA	cis	1	rs7144423	chr14:35572547	PPP2R3C	chr14:35554679-35591679:-	0.28	4.25	2.73E-5	Atopic dermatitis	
BLCA	cis	1	rs7153160	chr14:74509377	LIN52	chr14:74551656-74667117:+	0.34	7.89	3.14E-14	Common traits (Other)	
BLCA	cis	1	rs7153587	chr14:74509660	LIN52	chr14:74551656-74667117:+	0.35	8.03	1.23E-14	Common traits (Other)	
BLCA	cis	1	rs7154306	chr14:35540499	PPP2R3C	chr14:35554679-35591679:-	0.25	3.85	0.000138	Atopic dermatitis	
BLCA	cis	1	rs71550519	chr6:56780272	BEND6	chr6:56819773-56892138:+	-0.31	-4.31	2.05E-5	Menarche (age at onset)	
BLCA	cis	1	rs715510	chr22:31690528	C22orf30	chr22:32072242-32146120:-	-0.2	-3.83	0.000151	Paclitaxel-induced neuropathy	
BLCA	cis	1	rs7156322	chr14:35544330	PPP2R3C	chr14:35554679-35591679:-	0.26	3.99	8.01E-5	Atopic dermatitis	
BLCA	cis	1	rs71563547	chr7:97615831	MGC72080	chr7:97503667-97601638:-	0.44	3.96	9.03E-5	Sudden cardiac arrest	
BLCA	cis	1	rs71564866	chr6:56771207	BEND6	chr6:56819773-56892138:+	-0.31	-4.28	2.36E-5	Menarche (age at onset)	
BLCA	cis	1	rs71564868	chr6:56798441	BEND6	chr6:56819773-56892138:+	-0.29	-4.01	7.16E-5	Menarche (age at onset)	
BLCA	cis	1	rs7157566	chr14:74649129	LIN52	chr14:74551656-74667117:+	-0.34	-8.11	7.02E-15	Common traits (Other)	
BLCA	cis	1	rs7157595	chr14:24696238	TGM1	chr14:24718322-24732416:-	0.29	3.93	0.000103	Systolic blood pressure (cigarette smoking interaction)	
BLCA	cis	1	rs71636213	chr5:79581768	CKMT2	chr5:80529139-80562216:+	-0.41	-4.15	4.16E-5	Alzheimer's disease in APOE e4- carriers	
BLCA	cis	1	rs7164132	chr15:40675155	C15orf23	chr15:40674922-40686488:+	0.32	5.58	4.67E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs7166991	chr15:40671957	C15orf23	chr15:40674922-40686488:+	0.3	5.29	2.04E-7	Heschl's gyrus morphology	
BLCA	cis	1	rs7169404	chr15:40675443	C15orf23	chr15:40674922-40686488:+	0.33	5.69	2.51E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs7173833	chr15:75369618	SCAMP5	chr15:75287901-75313836:+	0.26	4.46	1.07E-5	Blood trace element (Zn levels)	
BLCA	cis	1	rs7175720	chr15:75348962	SCAMP5	chr15:75287901-75313836:+	-0.29	-4.8	2.29E-6	Blood trace element (Zn levels)	
BLCA	cis	1	rs717658	chr7:150503637	TMEM176A	chr7:150497854-150502208:+	0.16	4.23	2.94E-5	Forced expiratory volume in 1 second (environmental interaction)	
BLCA	cis	1	rs718847	chr11:116734146	PCSK7	chr11:117075789-117102811:-	-0.44	-5.68	2.73E-8	Protein quantitative trait loci	
BLCA	cis	1	rs7205409	chr16:642610	WFIKKN1	chr16:679239-684116:+	0.27	4.94	1.16E-6	Height	
BLCA	cis	1	rs7209180	chr17:79581519	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs7210738	chr17:45757598	C17orf57	chr17:45401142-45518675:+	-0.26	-5.74	1.96E-8	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs7212497	chr17:28335949	EFCAB5	chr17:28256874-28435469:+	-0.23	-3.94	9.84E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs7213129	chr17:79581573	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs7214085	chr17:38169095	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.95	9.21E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs7214743	chr17:59498052	C17orf82	chr17:59489112-59490641:+	0.2	4.3	2.15E-5	Sitting height ratio	
BLCA	cis	1	rs7216660	chr17:64147376	AXIN2	chr17:63524685-63637183:-	0.54	4.63	4.94E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs7218362	chr17:56888299	RAD51C	chr17:56769963-56811690:+	0.29	5.15	4.09E-7	Cognitive test performance	
BLCA	cis	1	rs7221109	chr17:38770286	KRT24	chr17:38854244-38860002:-	0.3	5.62	3.61E-8	Type 1 diabetes	
BLCA	cis	1	rs7222241	chr17:79574714	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs7223231	chr17:18811846	FAM18B	chr17:18684582-18710026:+	-0.23	-4.23	2.92E-5	Educational attainment (years of education)	
BLCA	cis	1	rs7223613	chr17:79574803	TSPAN10	chr17:79609349-79615778:+	-0.49	-8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs7223786	chr17:28332107	EFCAB5	chr17:28256874-28435469:+	-0.23	-3.94	9.84E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs7238284	chr18:48373876	MRO	chr18:48321491-48351754:-	0.23	4.15	4.12E-5	Entorhinal cortical thickness	
BLCA	cis	1	rs7246967	chr19:23056346	ZNF492	chr19:22817126-22850472:+	-0.3	-4.03	6.82E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs7247779	chr19:30297919	CCNE1	chr19:30302901-30315218:+	0.21	4.08	5.38E-5	Bladder cancer	
BLCA	cis	1	rs7250300	chr19:10448660	QTRT1	chr19:10812112-10824042:+	0.2	3.84	0.000146	Systemic lupus erythematosus or rheumatoid arthritis	
BLCA	cis	1	rs7250300	chr19:10448660	YIPF2	chr19:11033446-11039357:-	0.27	4.22	3.1E-5	Systemic lupus erythematosus or rheumatoid arthritis	
BLCA	cis	1	rs7252707	chr19:18612257	LRRC25	chr19:18501955-18508421:-	-0.1	-3.84	0.000141	Breast cancer	
BLCA	cis	1	rs725310	chr3:48418571	TREX1	chr3:48501186-48509043:+	0.19	3.96	9.04E-5	Longevity	
BLCA	cis	1	rs7254041	chr19:10448636	YIPF2	chr19:11033446-11039357:-	0.25	3.97	8.51E-5	Systemic lupus erythematosus or rheumatoid arthritis	
BLCA	cis	1	rs7255679	chr19:42063981	CEACAM21	chr19:42055886-42093196:+	0.35	7.77	7.32E-14	Schizophrenia	
BLCA	cis	1	rs7257127	chr19:23056699	ZNF492	chr19:22817126-22850472:+	-0.31	-4.16	3.95E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs7257871	chr19:10449252	YIPF2	chr19:11033446-11039357:-	0.24	3.9	0.000114	Systemic lupus erythematosus or rheumatoid arthritis	
BLCA	cis	1	rs7258015	chr19:10449358	YIPF2	chr19:11033446-11039357:-	0.24	3.9	0.000114	Systemic lupus erythematosus or rheumatoid arthritis	
BLCA	cis	1	rs72644213	chr10:81783660	LOC219347	chr10:81805991-81838949:-	0.35	4.14	4.36E-5	Chronic obstructive pulmonary disease-related biomarkers	
BLCA	cis	1	rs72645460	chr11:116771375	PCSK7	chr11:117075789-117102811:-	0.45	5.5	7.0E-8	Protein quantitative trait loci	
BLCA	cis	1	rs72782294	chr2:28953390	TRMT61B	chr2:29072690-29093175:-	0.29	5.09	5.59E-7	Body mass index	
BLCA	cis	1	rs72840063	chr2:85550396	TGOLN2	chr2:85545147-85555374:-	-0.22	-5.33	1.66E-7	Ear protrusion	
BLCA	cis	1	rs72843784	chr6:26498758	BTN3A2	chr6:26365398-26378546:+	-0.77	-7.63	1.86E-13	Schizophrenia	
BLCA	cis	1	rs7285549	chr22:25874580	CRYBB2	chr22:25615612-25627836:+	0.93	9.86	1.33E-20	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs7290684	chr22:29857664	NIPSNAP1	chr22:29950800-29977144:-	0.28	4.03	6.64E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs7290855	chr22:29852474	MTMR3	chr22:30279158-30426855:+	0.25	3.95	9.17E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs7290855	chr22:29852474	NIPSNAP1	chr22:29950800-29977144:-	0.27	3.85	0.000137	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs72929710	chr18:48372427	MRO	chr18:48321491-48351754:-	0.25	4.42	1.29E-5	Entorhinal cortical thickness	
BLCA	cis	1	rs72929734	chr18:48381990	MRO	chr18:48321491-48351754:-	0.25	4.39	1.5E-5	Entorhinal cortical thickness	
BLCA	cis	1	rs72934944	chr2:202190610	PPIL3	chr2:201735680-201753999:-	-0.5	-4.89	1.5E-6	Rheumatoid arthritis	
BLCA	cis	1	rs72934960	chr2:202204749	PPIL3	chr2:201735680-201753999:-	-0.44	-3.89	0.000117	Rheumatoid arthritis	
BLCA	cis	1	rs72934973	chr2:202213934	PPIL3	chr2:201735680-201753999:-	-0.44	-3.88	0.000125	Rheumatoid arthritis	
BLCA	cis	1	rs72934999	chr2:202223524	PPIL3	chr2:201735680-201753999:-	-0.44	-4.14	4.27E-5	Rheumatoid arthritis	
BLCA	cis	1	rs72937106	chr2:202225520	PPIL3	chr2:201735680-201753999:-	-0.44	-4.14	4.27E-5	Rheumatoid arthritis	
BLCA	cis	1	rs72937118	chr2:202229527	PPIL3	chr2:201735680-201753999:-	-0.44	-4.14	4.27E-5	Rheumatoid arthritis	
BLCA	cis	1	rs72937120	chr2:202232611	PPIL3	chr2:201735680-201753999:-	-0.44	-4	7.67E-5	Rheumatoid arthritis	
BLCA	cis	1	rs73069392	chr3:41787009	ULK4	chr3:41288091-42003660:-	0.61	9.06	6.68E-18	Diastolic blood pressure	
BLCA	cis	1	rs73069394	chr3:41787233	ULK4	chr3:41288091-42003660:-	0.62	9.53	1.83E-19	Diastolic blood pressure	
BLCA	cis	1	rs73069396	chr3:41787236	ULK4	chr3:41288091-42003660:-	0.62	9.53	1.83E-19	Diastolic blood pressure	
BLCA	cis	1	rs73071329	chr3:41810539	ULK4	chr3:41288091-42003660:-	0.63	9.57	1.39E-19	Diastolic blood pressure	
BLCA	cis	1	rs73077367	chr3:41851959	ULK4	chr3:41288091-42003660:-	0.64	9.88	1.13E-20	Diastolic blood pressure	
BLCA	cis	1	rs73079316	chr3:41863859	ULK4	chr3:41288091-42003660:-	0.64	9.53	1.84E-19	Diastolic blood pressure	
BLCA	cis	1	rs73079321	chr3:41863910	ULK4	chr3:41288091-42003660:-	0.62	9.63	8.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs73081353	chr3:41906448	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs73081364	chr3:41913616	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs731152	chr17:40279680	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs73140069	chr7:75986790	UPK3B	chr7:76139745-76157197:+	-0.3	-6.33	6.76E-10	Multiple sclerosis	
BLCA	cis	1	rs73142121	chr7:65311206	CCT6P1	chr7:65216092-65228661:+	0.32	4.48	1.0E-5	Diabetic kidney disease	
BLCA	cis	1	rs73142122	chr7:65311298	CCT6P1	chr7:65216092-65228661:+	0.33	4.46	1.08E-5	Diabetic kidney disease	
BLCA	cis	1	rs73142162	chr7:65374296	CCT6P1	chr7:65216092-65228661:+	0.33	4.45	1.11E-5	Diabetic kidney disease	
BLCA	cis	1	rs73142166	chr7:65375832	CCT6P1	chr7:65216092-65228661:+	0.33	4.46	1.07E-5	Diabetic kidney disease	
BLCA	cis	1	rs73150014	chr7:65450919	CCT6P1	chr7:65216092-65228661:+	0.32	4.36	1.7E-5	Diabetic kidney disease	
BLCA	cis	1	rs7324557	chr13:24296862	PCOTH	chr13:24463028-24466241:+	0.38	5.95	6.11E-9	Visceral adipose tissue adjusted for BMI	
BLCA	cis	1	rs732528	chr18:48378234	MRO	chr18:48321491-48351754:-	0.25	4.39	1.5E-5	Entorhinal cortical thickness	
BLCA	cis	1	rs7327064	chr13:36771017	SOHLH2	chr13:36742347-36871992:-	0.4	5.12	4.77E-7	Economic and political preferences	
BLCA	cis	1	rs73282234	chr5:150195924	LOC134466	chr5:150310000-150326146:-	0.59	6.99	1.23E-11	Crohn's disease	
BLCA	cis	1	rs73282255	chr5:150223647	LOC134466	chr5:150310000-150326146:-	0.45	5.61	3.98E-8	Crohn's disease	
BLCA	cis	1	rs73284126	chr5:150261307	LOC134466	chr5:150310000-150326146:-	0.47	6.2	1.42E-9	Crohn's disease	
BLCA	cis	1	rs73284141	chr5:150266086	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs73284257	chr10:76000710	ADK	chr10:75910965-76469059:+	0.28	4.19	3.41E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7331697	chr13:36763345	SOHLH2	chr13:36742347-36871992:-	-0.39	-5.08	6.03E-7	Economic and political preferences	
BLCA	cis	1	rs7332189	chr13:36755610	SOHLH2	chr13:36742347-36871992:-	-0.26	-4.35	1.72E-5	Glucose homeostasis traits	
BLCA	cis	1	rs7332932	chr13:36755636	SOHLH2	chr13:36742347-36871992:-	-0.26	-4.35	1.72E-5	Glucose homeostasis traits	
BLCA	cis	1	rs73405097	chr22:29855836	MTMR3	chr22:30279158-30426855:+	0.24	3.84	0.000142	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs73405097	chr22:29855836	NIPSNAP1	chr22:29950800-29977144:-	0.28	4.02	6.98E-5	Carotid atherosclerosis in HIV infection	
BLCA	cis	1	rs73543347	chr16:20385774	DCUN1D3	chr16:20869403-20911561:-	-0.41	-3.89	0.00012	Urinary uromodulin levels	
BLCA	cis	1	rs73543347	chr16:20385774	THUMPD1	chr16:20744991-20753199:-	-0.39	-4.08	5.58E-5	Urinary uromodulin levels	
BLCA	cis	1	rs7356093	chr3:134238753	ANAPC13	chr3:134196547-134204865:-	0.5	7.88	3.42E-14	Height	
BLCA	cis	1	rs7356093	chr3:134238753	CEP63	chr3:134204575-134293852:+	0.24	4.04	6.44E-5	Height	
BLCA	cis	1	rs737008	chr16:11374866	C16orf75	chr16:11343506-11445617:+	0.2	3.88	0.000124	Obesity-related traits	
BLCA	cis	1	rs7371896	chr3:134249769	ANAPC13	chr3:134196547-134204865:-	0.49	7.77	7.23E-14	Height	
BLCA	cis	1	rs7372217	chr3:41990122	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs7374158	chr3:134270156	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs7374158	chr3:134270156	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs7374325	chr3:134275601	ANAPC13	chr3:134196547-134204865:-	0.5	7.97	1.89E-14	Height	
BLCA	cis	1	rs7374325	chr3:134275601	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.33E-5	Height	
BLCA	cis	1	rs7374952	chr3:128001367	EEFSEC	chr3:127872313-128127488:+	-0.33	-3.82	0.000153	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs739310	chr22:27051299	ASPHD2	chr22:26825280-26840978:+	-0.28	-4.57	6.53E-6	Obesity-related traits	
BLCA	cis	1	rs7395213	chr11:87869579	RAB38	chr11:87846431-87908599:-	-0.24	-4.15	4.09E-5	Frontotemporal dementia	
BLCA	cis	1	rs73958618	chr2:136500475	DARS	chr2:136664254-136743222:-	0.27	4.51	8.61E-6	Corneal structure	
BLCA	cis	1	rs739637	chr17:40280944	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs73992250	chr17:64132167	AXIN2	chr17:63524685-63637183:-	0.56	4.92	1.3E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs73992258	chr17:64165083	AXIN2	chr17:63524685-63637183:-	0.53	4.6	5.8E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs73992265	chr17:64181796	AXIN2	chr17:63524685-63637183:-	0.53	4.51	8.77E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs73992267	chr17:64183713	AXIN2	chr17:63524685-63637183:-	0.53	4.5	8.9E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs7404095	chr16:23864590	CHP2	chr16:23765948-23770256:+	0.22	4.06	5.94E-5	Ulcerative colitis;Inflammatory bowel disease	
BLCA	cis	1	rs7406003	chr17:79597597	TSPAN10	chr17:79609349-79615778:+	0.49	8.59	2.28E-16	Eye color traits	
BLCA	cis	1	rs740755	chr17:59496797	C17orf82	chr17:59489112-59490641:+	-0.21	-4.09	5.22E-5	Sitting height ratio	
BLCA	cis	1	rs74209810	chr16:20402466	C16orf88	chr16:19717676-19729492:-	-0.39	-3.85	0.000136	Urinary uromodulin levels	
BLCA	cis	1	rs74209810	chr16:20402466	DCUN1D3	chr16:20869403-20911561:-	-0.41	-4	7.61E-5	Urinary uromodulin levels	
BLCA	cis	1	rs74209810	chr16:20402466	THUMPD1	chr16:20744991-20753199:-	-0.36	-3.89	0.000116	Urinary uromodulin levels	
BLCA	cis	1	rs7425670	chr2:88522028	THNSL2	chr2:88469835-88486145:+	-0.61	-6.18	1.68E-9	Plasma clusterin levels	
BLCA	cis	1	rs7426847	chr3:134267519	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.97	1.89E-14	Height	
BLCA	cis	1	rs7426847	chr3:134267519	CEP63	chr3:134204575-134293852:+	-0.24	-4.09	5.33E-5	Height	
BLCA	cis	1	rs7427492	chr3:134261654	ANAPC13	chr3:134196547-134204865:-	0.5	7.97	1.89E-14	Height	
BLCA	cis	1	rs7427492	chr3:134261654	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.33E-5	Height	
BLCA	cis	1	rs7428326	chr3:134251184	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs7428326	chr3:134251184	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs7428	chr2:85545490	TGOLN2	chr2:85545147-85555374:-	0.22	5.16	3.96E-7	Ear protrusion	
BLCA	cis	1	rs7429866	chr3:134236306	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.88	3.42E-14	Height	
BLCA	cis	1	rs7429866	chr3:134236306	CEP63	chr3:134204575-134293852:+	-0.24	-4.04	6.44E-5	Height	
BLCA	cis	1	rs7432268	chr3:134242051	ANAPC13	chr3:134196547-134204865:-	0.5	7.97	1.89E-14	Height	
BLCA	cis	1	rs7432268	chr3:134242051	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.33E-5	Height	
BLCA	cis	1	rs7433663	chr3:134235790	ANAPC13	chr3:134196547-134204865:-	0.48	7.66	1.58E-13	Height	
BLCA	cis	1	rs7433663	chr3:134235790	CEP63	chr3:134204575-134293852:+	0.22	3.87	0.000127	Height	
BLCA	cis	1	rs7433991	chr3:134312292	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs74347384	chr7:1072440	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7436021	chr4:76905472	NAAA	chr4:76831809-76862166:-	-0.39	-6.41	4.28E-10	Longevity	
BLCA	cis	1	rs74366004	chr7:1088630	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.53	7.9E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs74369356	chr7:1071711	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7444	chr22:21976934	CCDC116	chr22:21987086-21991615:+	-0.25	-3.88	0.000121	Systemic lupus erythematosus	
BLCA	cis	1	rs74531840	chr17:64176115	AXIN2	chr17:63524685-63637183:-	0.54	4.54	7.41E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs74544416	chr8:82657745	CHMP4C	chr8:82644688-82671746:+	-0.78	-7.43	7.2E-13	Epithelial ovarian cancer;Ovarian cancer	
BLCA	cis	1	rs7456042	chr7:65299778	CCT6P1	chr7:65216092-65228661:+	0.32	4.48	1.0E-5	Diabetic kidney disease	
BLCA	cis	1	rs74607112	chr2:86305534	LOC90784	chr2:86247339-86250991:-	-0.38	-3.92	0.000106	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
BLCA	cis	1	rs74652290	chr7:1090109	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.35	1.76E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7475154	chr10:131440584	MGMT	chr10:131265454-131565783:+	-0.23	-4.92	1.27E-6	Response to temozolomide	
BLCA	cis	1	rs74758321	chr8:82667320	CHMP4C	chr8:82644688-82671746:+	-0.76	-7.15	4.34E-12	Epithelial ovarian cancer;Ovarian cancer	
BLCA	cis	1	rs74785791	chr7:1088494	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.53	7.9E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs74887741	chr7:1110658	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.47	1.05E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs749050	chr10:97376115	ENTPD1	chr10:97471536-97637022:+	0.19	4.93	1.21E-6	Blood metabolite levels	
BLCA	cis	1	rs74984113	chr4:250522	ZNF718	chr4:53272-156488:+	0.34	4.55	7.25E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs75016635	chr7:1094121	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.41	1.32E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7503679	chr17:79583843	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs75071288	chr5:150224379	LOC134466	chr5:150310000-150326146:-	0.43	5.33	1.71E-7	Crohn's disease	
BLCA	cis	1	rs75128809	chr21:43418210	C21orf121	chr21:43442113-43445060:+	0.32	4.5	9.03E-6	Hand grip strength	
BLCA	cis	1	rs7515491	chr1:46355079	CCDC163P	chr1:45960581-45965646:-	-0.36	-6.71	6.87E-11	Body mass index	
BLCA	cis	1	rs7517	chr1:150596411	HORMAD1	chr1:150670542-150693352:-	0.4	3.97	8.53E-5	Congenital left-sided heart lesions	
BLCA	cis	1	rs75181745	chr2:88520408	THNSL2	chr2:88469835-88486145:+	-0.58	-5.75	1.87E-8	Plasma clusterin levels	
BLCA	cis	1	rs751984	chr11:61278246	CD6	chr11:60739115-60787846:+	0.22	4.4	1.4E-5	Mean arterial pressure	
BLCA	cis	1	rs7520516	chr1:150659695	HORMAD1	chr1:150670542-150693352:-	0.38	3.91	0.00011	Congenital left-sided heart lesions	
BLCA	cis	1	rs7522601	chr1:46419021	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs7522705	chr1:45992300	CCDC163P	chr1:45960581-45965646:-	0.68	13.43	5.59E-34	Homocysteine levels	
BLCA	cis	1	rs7522948	chr1:156275308	BGLAP	chr1:156182784-156213112:+	0.25	4.08	5.59E-5	Mean corpuscular hemoglobin concentration;Glycated hemoglobin levels	
BLCA	cis	1	rs7524495	chr1:46266932	CCDC163P	chr1:45960581-45965646:-	-0.37	-6.99	1.19E-11	Body mass index	
BLCA	cis	1	rs75278386	chr15:40678312	C15orf23	chr15:40674922-40686488:+	0.33	5.7	2.34E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs7528684	chr1:157670816	FCRL3	chr1:157646278-157670775:-	0.26	8.49	4.56E-16	Type 1 diabetes autoantibodies	
BLCA	cis	1	rs75309929	chr2:88524377	THNSL2	chr2:88469835-88486145:+	-0.57	-5.69	2.53E-8	Plasma clusterin levels	
BLCA	cis	1	rs7531202	chr1:110616474	ALX3	chr1:110602998-110613322:-	-0.21	-3.87	0.000129	Blood metabolite levels	
BLCA	cis	1	rs7534467	chr1:45988691	CCDC163P	chr1:45960581-45965646:-	-0.79	-16.21	2.35E-45	Homocysteine levels	
BLCA	cis	1	rs7536557	chr1:45992114	CCDC163P	chr1:45960581-45965646:-	-0.73	-14.77	2.15E-39	Homocysteine levels	
BLCA	cis	1	rs7539932	chr1:46292354	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs75399471	chr1:76339092	RABGGTB	chr1:76251886-76260764:+	0.4	4.24	2.8E-5	Attention function in attention deficit hyperactive disorder	
BLCA	cis	1	rs7540325	chr1:46338217	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.18E-11	Body mass index	
BLCA	cis	1	rs75488469	chr7:1102122	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.48	9.73E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7550746	chr1:46351719	CCDC163P	chr1:45960581-45965646:-	-0.37	-7	1.15E-11	Body mass index	
BLCA	cis	1	rs7551124	chr1:23785760	ASAP3	chr1:23755056-23811057:-	0.3	4.25	2.66E-5	Cholesterol, total	
BLCA	cis	1	rs7551124	chr1:23785760	TCEA3	chr1:23707555-23751261:-	0.33	4.51	8.49E-6	Cholesterol, total	
BLCA	cis	1	rs7556436	chr1:46363880	CCDC163P	chr1:45960581-45965646:-	0.37	7.12	5.27E-12	Body mass index	
BLCA	cis	1	rs7556615	chr1:46461369	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.87E-10	Body mass index	
BLCA	cis	1	rs7558944	chr2:73810909	ALMS1P	chr2:73872046-73912692:+	0.36	5.22	2.93E-7	Metabolite levels	
BLCA	cis	1	rs7560267	chr2:18239971	KCNS3	chr2:18059114-18114224:+	0.26	4.26	2.52E-5	Temperament (bipolar disorder)	
BLCA	cis	1	rs7560357	chr2:99247820	REV1	chr2:100016939-100106480:-	0.27	4.34	1.81E-5	Bipolar disorder	
BLCA	cis	1	rs7560357	chr2:99247820	UNC50	chr2:99225042-99234975:+	0.39	5.29	2.1E-7	Bipolar disorder	
BLCA	cis	1	rs7562170	chr2:28943516	TRMT61B	chr2:29072690-29093175:-	0.29	5.11	5.05E-7	Body mass index	
BLCA	cis	1	rs7564890	chr2:73641853	ALMS1P	chr2:73872046-73912692:+	0.35	5.07	6.32E-7	Metabolite levels	
BLCA	cis	1	rs7566279	chr2:281178	SH3YL1	chr2:218138-264810:-	-0.46	-12.05	1.47E-28	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs7572722	chr2:73724675	ALMS1P	chr2:73872046-73912692:+	0.33	4.85	1.79E-6	Metabolite levels	
BLCA	cis	1	rs757608	chr17:59497277	C17orf82	chr17:59489112-59490641:+	0.19	4.18	3.67E-5	Sitting height ratio	
BLCA	cis	1	rs7576245	chr2:73829678	ALMS1P	chr2:73872046-73912692:+	0.38	5.68	2.68E-8	Metabolite levels	
BLCA	cis	1	rs75774363	chr5:150223722	LOC134466	chr5:150310000-150326146:-	0.46	5.54	5.76E-8	Crohn's disease	
BLCA	cis	1	rs7579277	chr2:28996295	TRMT61B	chr2:29072690-29093175:-	-0.33	-5.86	1.02E-8	Body mass index	
BLCA	cis	1	rs7580240	chr2:29114372	TRMT61B	chr2:29072690-29093175:-	0.31	4.78	2.56E-6	Breast cancer (estrogen-receptor negative);Breast cancer	
BLCA	cis	1	rs7580825	chr2:73635148	ALMS1P	chr2:73872046-73912692:+	0.33	4.83	1.94E-6	Metabolite levels	
BLCA	cis	1	rs7581224	chr2:84709215	DNAH6	chr2:84743579-85046711:+	0.42	7.71	1.11E-13	Coronary artery calcification	
BLCA	cis	1	rs75824542	chr14:74523047	LIN52	chr14:74551656-74667117:+	0.34	7.84	4.54E-14	Common traits (Other)	
BLCA	cis	1	rs7582606	chr2:73813945	ALMS1P	chr2:73872046-73912692:+	0.36	5.21	3.04E-7	Metabolite levels	
BLCA	cis	1	rs7583255	chr2:73797996	ALMS1P	chr2:73872046-73912692:+	0.35	5.1	5.44E-7	Metabolite levels	
BLCA	cis	1	rs7584575	chr2:73666402	ALMS1P	chr2:73872046-73912692:+	0.39	5.93	6.88E-9	Metabolite levels	
BLCA	cis	1	rs7585004	chr2:73666645	ALMS1P	chr2:73872046-73912692:+	0.41	6.13	2.25E-9	Metabolite levels	
BLCA	cis	1	rs758598	chr17:59492714	C17orf82	chr17:59489112-59490641:+	0.2	4.46	1.1E-5	Sitting height ratio	
BLCA	cis	1	rs758599	chr17:59492268	C17orf82	chr17:59489112-59490641:+	0.21	4.61	5.57E-6	Sitting height ratio	
BLCA	cis	1	rs7586463	chr2:73798476	ALMS1P	chr2:73872046-73912692:+	0.34	5.08	5.97E-7	Metabolite levels	
BLCA	cis	1	rs75889859	chr14:35539054	PPP2R3C	chr14:35554679-35591679:-	0.25	3.98	8.27E-5	Atopic dermatitis	
BLCA	cis	1	rs758944	chr7:75953297	UPK3B	chr7:76139745-76157197:+	-0.31	-6.43	3.81E-10	Multiple sclerosis	
BLCA	cis	1	rs7589728	chr2:88518440	THNSL2	chr2:88469835-88486145:+	-0.57	-5.54	5.49E-8	Plasma clusterin levels	
BLCA	cis	1	rs75913297	chr10:81789845	LOC219347	chr10:81805991-81838949:-	0.35	4.34	1.81E-5	Chronic obstructive pulmonary disease-related biomarkers	
BLCA	cis	1	rs7591472	chr2:201889751	CFLAR	chr2:201980816-202029001:+	-0.24	-4.42	1.27E-5	Triptolide cytotoxicity	
BLCA	cis	1	rs7591472	chr2:201889751	PPIL3	chr2:201735680-201753999:-	-0.64	-9.21	2.23E-18	Triptolide cytotoxicity	
BLCA	cis	1	rs7594511	chr2:73681639	ALMS1P	chr2:73872046-73912692:+	0.35	5.17	3.85E-7	Metabolite levels	
BLCA	cis	1	rs7595075	chr2:264019	SH3YL1	chr2:218138-264810:-	-0.45	-11.68	3.7E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs7598396	chr2:73652628	ALMS1P	chr2:73872046-73912692:+	0.36	5.33	1.68E-7	Metabolite levels	
BLCA	cis	1	rs7598419	chr2:73798223	ALMS1P	chr2:73872046-73912692:+	0.32	4.7	3.68E-6	Metabolite levels	
BLCA	cis	1	rs7598876	chr2:28974466	TRMT61B	chr2:29072690-29093175:-	-0.29	-5.13	4.54E-7	Body mass index	
BLCA	cis	1	rs76024966	chr7:75995021	UPK3B	chr7:76139745-76157197:+	-0.32	-6.51	2.36E-10	Multiple sclerosis	
BLCA	cis	1	rs7604682	chr2:73788026	ALMS1P	chr2:73872046-73912692:+	0.39	5.8	1.43E-8	Metabolite levels	
BLCA	cis	1	rs7604798	chr2:27824940	C2orf16	chr2:27799389-27805588:+	0.23	4.03	6.8E-5	Oral cavity cancer	
BLCA	cis	1	rs760555	chr22:25872837	CRYBB2	chr22:25615612-25627836:+	0.93	9.62	9.23E-20	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs7605824	chr2:280819	SH3YL1	chr2:218138-264810:-	0.46	12.14	6.28E-29	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs7607014	chr2:73730174	ALMS1P	chr2:73872046-73912692:+	-0.34	-5.05	6.84E-7	Metabolite levels	
BLCA	cis	1	rs7609851	chr3:156638503	LEKR1	chr3:156544076-156763918:+	-0.44	-6.19	1.52E-9	Bone mineral density	
BLCA	cis	1	rs7611238	chr3:195072918	C3orf21	chr3:194789015-194991895:-	0.27	5.52	6.34E-8	Body mass index	
BLCA	cis	1	rs7611611	chr3:134307877	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs7611828	chr3:134250325	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs7611828	chr3:134250325	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs76129108	chr7:1089159	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.53	8.04E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7615952	chr3:125649403	ALG1L	chr3:125648118-125655882:-	0.37	6.56	1.77E-10	Blood pressure (smoking interaction)	
BLCA	cis	1	rs7615952	chr3:125649403	LOC100125556	chr3:125635444-125648865:+	-0.35	-5.31	1.9E-7	Blood pressure (smoking interaction)	
BLCA	cis	1	rs7616044	chr3:125649354	ALG1L	chr3:125648118-125655882:-	-0.38	-6.67	8.89E-11	Blood pressure (smoking interaction)	
BLCA	cis	1	rs7616044	chr3:125649354	LOC100125556	chr3:125635444-125648865:+	0.33	5.06	6.37E-7	Blood pressure (smoking interaction)	
BLCA	cis	1	rs7616844	chr3:41874343	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs7617397	chr3:41959037	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs7617912	chr3:156576412	LEKR1	chr3:156544076-156763918:+	-0.46	-6.34	6.48E-10	Bone mineral density	
BLCA	cis	1	rs7619451	chr3:134233238	ANAPC13	chr3:134196547-134204865:-	0.5	7.63	1.86E-13	Height	
BLCA	cis	1	rs7620458	chr3:156576850	LEKR1	chr3:156544076-156763918:+	-0.46	-6.36	5.8E-10	Bone mineral density	
BLCA	cis	1	rs76214082	chr7:1102097	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.41	1.36E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7622259	chr3:41881351	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs7624372	chr3:41881107	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs763014	chr16:675680	WFIKKN1	chr16:679239-684116:+	0.28	5.27	2.23E-7	Height	
BLCA	cis	1	rs7630874	chr3:134293291	ANAPC13	chr3:134196547-134204865:-	-0.5	-7.96	1.97E-14	Height	
BLCA	cis	1	rs7630874	chr3:134293291	CEP63	chr3:134204575-134293852:+	-0.24	-4.12	4.57E-5	Height	
BLCA	cis	1	rs7631057	chr3:41817951	ULK4	chr3:41288091-42003660:-	0.65	9.85	1.54E-20	Diastolic blood pressure	
BLCA	cis	1	rs7632387	chr3:41853161	ULK4	chr3:41288091-42003660:-	0.64	9.72	4.04E-20	Diastolic blood pressure	
BLCA	cis	1	rs7632670	chr3:183713877	ABCC5	chr3:183637726-183735727:-	-0.2	-3.9	0.000113	Anterior chamber depth	
BLCA	cis	1	rs7633265	chr3:195048814	C3orf21	chr3:194789015-194991895:-	0.29	5.71	2.32E-8	Body mass index	
BLCA	cis	1	rs7634345	chr3:195073403	C3orf21	chr3:194789015-194991895:-	0.28	5.33	1.66E-7	Body mass index	
BLCA	cis	1	rs7636044	chr3:48484560	TREX1	chr3:48501186-48509043:+	-0.19	-3.82	0.000153	Longevity	
BLCA	cis	1	rs7637227	chr3:134244155	ANAPC13	chr3:134196547-134204865:-	0.49	7.75	8.37E-14	Height	
BLCA	cis	1	rs76375367	chr17:64138784	AXIN2	chr17:63524685-63637183:-	0.54	4.63	4.91E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs76388414	chr7:1100694	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.45	1.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7639514	chr3:156576067	LEKR1	chr3:156544076-156763918:+	-0.45	-6.37	5.45E-10	Bone mineral density	
BLCA	cis	1	rs7640320	chr3:187430530	ST6GAL1	chr3:186648516-186796339:+	-0.41	-4.27	2.51E-5	Response to citalopram treatment	
BLCA	cis	1	rs76433514	chr5:150306532	LOC134466	chr5:150310000-150326146:-	0.55	6.87	2.64E-11	Crohn's disease	
BLCA	cis	1	rs7645295	chr3:134307734	ANAPC13	chr3:134196547-134204865:-	0.48	7.59	2.51E-13	Height	
BLCA	cis	1	rs7646144	chr3:41853125	ULK4	chr3:41288091-42003660:-	0.64	9.72	4.04E-20	Diastolic blood pressure	
BLCA	cis	1	rs76471037	chr3:41799414	ULK4	chr3:41288091-42003660:-	0.62	9.52	1.95E-19	Diastolic blood pressure	
BLCA	cis	1	rs7648357	chr3:41849670	ULK4	chr3:41288091-42003660:-	0.63	9.79	2.36E-20	Diastolic blood pressure	
BLCA	cis	1	rs7648578	chr3:41858731	ULK4	chr3:41288091-42003660:-	0.62	9.72	4.27E-20	Diastolic blood pressure	
BLCA	cis	1	rs7648990	chr3:134244390	ANAPC13	chr3:134196547-134204865:-	0.49	7.74	9.0E-14	Height	
BLCA	cis	1	rs7648990	chr3:134244390	CEP63	chr3:134204575-134293852:+	0.23	3.92	0.000106	Height	
BLCA	cis	1	rs7650227	chr3:41794937	ULK4	chr3:41288091-42003660:-	0.61	9.47	2.99E-19	Diastolic blood pressure	
BLCA	cis	1	rs7651039	chr3:15648004	ANKRD28	chr3:15708744-15901053:-	-0.24	-4.48	9.65E-6	Coronary heart disease	
BLCA	cis	1	rs7651407	chr3:48443816	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000136	Longevity	
BLCA	cis	1	rs7651757	chr3:195077305	C3orf21	chr3:194789015-194991895:-	0.28	5.54	5.57E-8	Body mass index	
BLCA	cis	1	rs76542740	chr15:43891512	ADAL	chr15:43622872-43646094:+	-0.38	-4.3	2.21E-5	Tumor biomarkers	
BLCA	cis	1	rs76542740	chr15:43891512	CATSPER2	chr15:43922774-43959900:-	-0.33	-4.77	2.65E-6	Tumor biomarkers	
BLCA	cis	1	rs76548544	chr5:150223515	LOC134466	chr5:150310000-150326146:-	0.48	6.14	2.09E-9	Crohn's disease	
BLCA	cis	1	rs7655841	chr4:129890790	C4orf33	chr4:130014829-130033842:+	0.31	4.85	1.83E-6	Chronic obstructive pulmonary disease (moderate to severe)	
BLCA	cis	1	rs7656037	chr4:39717965	RPL9	chr4:39455747-39460568:-	-0.43	-7.13	5.13E-12	Plasma amyloid beta peptide concentrations (ABx-40)	
BLCA	cis	1	rs7661070	chr4:39724365	RPL9	chr4:39455747-39460568:-	-0.45	-7.39	9.36E-13	Plasma amyloid beta peptide concentrations (ABx-40)	
BLCA	cis	1	rs7661702	chr4:104140129	MANBA	chr4:103552644-103682151:-	0.26	4.23	2.92E-5	Testicular germ cell tumor	
BLCA	cis	1	rs7665727	chr4:277057	ZNF718	chr4:53272-156488:+	0.34	4.66	4.33E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs7674560	chr4:263319	ZNF718	chr4:53272-156488:+	0.29	4.2	3.27E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs76784350	chr2:27764278	C2orf16	chr2:27799389-27805588:+	0.23	3.92	0.000103	Oral cavity cancer	
BLCA	cis	1	rs76804143	chr7:1082021	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs76812330	chr19:50531860	SIGLEC16	chr19:50472912-50479075:+	0.51	4.97	1.03E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs7682402	chr4:1743343	FAM53A	chr4:1641609-1685854:-	-0.31	-4.5	8.9E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs76833820	chr7:1070278	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7686546	chr4:240614	ZNF718	chr4:53272-156488:+	0.34	4.54	7.4E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs7687557	chr4:39769260	RPL9	chr4:39455747-39460568:-	-0.42	-7.14	4.68E-12	Plasma amyloid beta peptide concentrations (ABx-40)	
BLCA	cis	1	rs76878669	chr11:66092567	CTSW	chr11:65647284-65651212:+	0.25	3.89	0.000117	Educational attainment (years of education)	
BLCA	cis	1	rs76994419	chr15:40714150	C15orf23	chr15:40674922-40686488:+	0.34	5.63	3.51E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs7705093	chr5:96290647	ERAP2	chr5:96211644-96255398:+	0.98	27.18	2.03E-91	Birdshot chorioretinopathy	
BLCA	cis	1	rs7705542	chr5:150228318	LOC134466	chr5:150310000-150326146:-	0.43	5.35	1.52E-7	Crohn's disease	
BLCA	cis	1	rs77078697	chr4:252048	ZNF718	chr4:53272-156488:+	0.29	4.06	5.94E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs77083167	chr7:1071823	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.31	2.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7709388	chr5:150246539	LOC134466	chr5:150310000-150326146:-	0.43	5.77	1.66E-8	Crohn's disease	
BLCA	cis	1	rs7709464	chr5:150269441	LOC134466	chr5:150310000-150326146:-	0.47	6.24	1.17E-9	Crohn's disease	
BLCA	cis	1	rs7709650	chr5:150246685	LOC134466	chr5:150310000-150326146:-	0.45	5.83	1.2E-8	Crohn's disease	
BLCA	cis	1	rs7714415	chr5:150270292	LOC134466	chr5:150310000-150326146:-	0.46	6.1	2.61E-9	Crohn's disease	
BLCA	cis	1	rs7714584	chr5:150270420	LOC134466	chr5:150310000-150326146:-	0.48	6.28	9.26E-10	Crohn's disease	
BLCA	cis	1	rs7715981	chr5:150258107	LOC134466	chr5:150310000-150326146:-	0.49	6.4	4.65E-10	Crohn's disease	
BLCA	cis	1	rs7716903	chr5:150258574	LOC134466	chr5:150310000-150326146:-	0.47	6.22	1.33E-9	Crohn's disease	
BLCA	cis	1	rs77187281	chr19:50507667	SIGLEC16	chr19:50472912-50479075:+	0.59	5.55	5.41E-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs77234191	chr4:258294	ZNF718	chr4:53272-156488:+	0.33	4.42	1.27E-5	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs7724036	chr5:150284808	LOC134466	chr5:150310000-150326146:-	-0.46	-6.11	2.42E-9	Crohn's disease	
BLCA	cis	1	rs7724558	chr5:150328866	LOC134466	chr5:150310000-150326146:-	0.58	6.36	5.92E-10	Crohn's disease	
BLCA	cis	1	rs7726839	chr5:618586	SLC9A3	chr5:473334-524549:-	0.27	4.02	6.87E-5	Obesity-related traits	
BLCA	cis	1	rs77305932	chr7:1100861	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.45	1.12E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7732643	chr5:150261436	LOC134466	chr5:150310000-150326146:-	0.46	6.12	2.36E-9	Crohn's disease	
BLCA	cis	1	rs7732945	chr5:150261601	LOC134466	chr5:150310000-150326146:-	0.47	6.2	1.42E-9	Crohn's disease	
BLCA	cis	1	rs77346188	chr7:1114023	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.43	1.26E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7734778	chr5:150256556	LOC134466	chr5:150310000-150326146:-	0.46	6.06	3.23E-9	Crohn's disease	
BLCA	cis	1	rs7734928	chr5:150256613	LOC134466	chr5:150310000-150326146:-	0.48	6.27	9.54E-10	Crohn's disease	
BLCA	cis	1	rs7736554	chr5:150258308	LOC134466	chr5:150310000-150326146:-	0.47	6.22	1.33E-9	Crohn's disease	
BLCA	cis	1	rs7736873	chr5:150258482	LOC134466	chr5:150310000-150326146:-	0.47	6.22	1.33E-9	Crohn's disease	
BLCA	cis	1	rs7740487	chr6:28216486	ZNF389	chr6:28129551-28137375:+	-0.33	-4.07	5.63E-5	Depression	
BLCA	cis	1	rs7747061	chr6:4381445	CDYL	chr6:4706393-4955777:+	-0.34	-3.88	0.000123	Obesity-related traits	
BLCA	cis	1	rs7747824	chr6:86647106	SNHG5	chr6:86386726-86388451:-	-0.56	-10.22	7.52E-22	Response to antipsychotic treatment	
BLCA	cis	1	rs7750918	chr6:49430082	CENPQ	chr6:49431096-49460820:+	-0.28	-5.67	2.85E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs7750918	chr6:49430082	MUT	chr6:49398994-49431031:-	0.26	5.05	6.69E-7	Folate pathway vitamin levels	
BLCA	cis	1	rs77531164	chr15:40673466	C15orf23	chr15:40674922-40686488:+	0.32	5.57	4.84E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs7756203	chr6:86627707	SNHG5	chr6:86386726-86388451:-	-0.51	-9.01	9.54E-18	Response to antipsychotic treatment	
BLCA	cis	1	rs7759071	chr6:49433198	CENPQ	chr6:49431096-49460820:+	-0.41	-8.97	1.37E-17	Homocysteine levels	
BLCA	cis	1	rs7760207	chr6:86721700	SNHG5	chr6:86386726-86388451:-	-0.54	-9.4	5.22E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs77620153	chr17:64130794	AXIN2	chr17:63524685-63637183:-	0.56	4.89	1.5E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs7766645	chr6:86622238	SNHG5	chr6:86386726-86388451:-	-0.55	-10.06	2.88E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs77698001	chr5:150250367	LOC134466	chr5:150310000-150326146:-	0.44	5.86	1.0E-8	Crohn's disease	
BLCA	cis	1	rs77702926	chr7:1088838	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.53	7.9E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7771342	chr6:86631936	SNHG5	chr6:86386726-86388451:-	-0.51	-9	1.03E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs7774688	chr6:49387292	CENPQ	chr6:49431096-49460820:+	-0.4	-8.67	1.24E-16	Homocysteine levels	
BLCA	cis	1	rs77760339	chr7:1083927	ZFAND2A	chr7:1192544-1199855:-	-0.39	-4.55	7.23E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7776797	chr7:107493598	DLD	chr7:107531586-107561642:+	0.22	4.06	5.97E-5	Ulcerative colitis	
BLCA	cis	1	rs7777389	chr7:143744802	ARHGEF35	chr7:143883677-143892736:-	-0.34	-5.92	7.15E-9	Obesity-related traits	
BLCA	cis	1	rs7778911	chr7:65694506	CCT6P1	chr7:65216092-65228661:+	-0.33	-4.52	8.25E-6	Diabetic kidney disease	
BLCA	cis	1	rs7781669	chr7:21584820	DNAH11	chr7:21582833-21941455:+	-0.31	-5.04	7.07E-7	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma)	
BLCA	cis	1	rs778679	chr7:65840911	CCT6P1	chr7:65216092-65228661:+	0.37	4.94	1.2E-6	Diabetic kidney disease	
BLCA	cis	1	rs77868187	chr7:1093968	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.41	1.32E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs778691	chr7:65873092	CCT6P1	chr7:65216092-65228661:+	0.37	4.98	9.6E-7	Diabetic kidney disease	
BLCA	cis	1	rs778704	chr7:65863467	CCT6P1	chr7:65216092-65228661:+	0.37	4.98	9.6E-7	Diabetic kidney disease	
BLCA	cis	1	rs7787230	chr7:65629099	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs778729	chr7:65824419	CCT6P1	chr7:65216092-65228661:+	0.36	4.92	1.29E-6	Diabetic kidney disease	
BLCA	cis	1	rs778758	chr2:61782161	AHSA2	chr2:61404553-61414058:+	-0.2	-5.49	7.31E-8	Tuberculosis	
BLCA	cis	1	rs778758	chr2:61782161	C2orf74	chr2:61372243-61391964:+	0.38	6.37	5.4E-10	Tuberculosis	
BLCA	cis	1	rs778762	chr2:61782921	AHSA2	chr2:61404553-61414058:+	-0.19	-5.2	3.33E-7	Tuberculosis	
BLCA	cis	1	rs778762	chr2:61782921	C2orf74	chr2:61372243-61391964:+	0.38	6.37	5.33E-10	Tuberculosis	
BLCA	cis	1	rs778763	chr2:61785639	AHSA2	chr2:61404553-61414058:+	-0.2	-5.41	1.14E-7	Tuberculosis	
BLCA	cis	1	rs778763	chr2:61785639	C2orf74	chr2:61372243-61391964:+	0.38	6.36	5.62E-10	Tuberculosis	
BLCA	cis	1	rs7789940	chr7:75951230	UPK3B	chr7:76139745-76157197:+	-0.28	-5.63	3.57E-8	Multiple sclerosis	
BLCA	cis	1	rs7792391	chr7:65773429	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.72	3.24E-6	Diabetic kidney disease	
BLCA	cis	1	rs7794661	chr7:65389730	CCT6P1	chr7:65216092-65228661:+	0.32	4.47	1.02E-5	Diabetic kidney disease	
BLCA	cis	1	rs7795242	chr7:65390094	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs7804223	chr7:65664559	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.75	2.86E-6	Diabetic kidney disease	
BLCA	cis	1	rs781149	chr7:65481284	CCT6P1	chr7:65216092-65228661:+	0.3	4.33	1.9E-5	Diabetic kidney disease	
BLCA	cis	1	rs781150	chr7:65480973	CCT6P1	chr7:65216092-65228661:+	0.32	4.4	1.43E-5	Diabetic kidney disease	
BLCA	cis	1	rs781156	chr7:65479141	CCT6P1	chr7:65216092-65228661:+	0.31	4.42	1.31E-5	Diabetic kidney disease	
BLCA	cis	1	rs781157	chr7:65478311	CCT6P1	chr7:65216092-65228661:+	0.3	4.34	1.8E-5	Diabetic kidney disease	
BLCA	cis	1	rs78143408	chr7:1096846	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs78153629	chr15:40673465	C15orf23	chr15:40674922-40686488:+	0.32	5.57	4.84E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs78158942	chr7:1090440	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.5	9.13E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs78185558	chr7:1090183	ZFAND2A	chr7:1192544-1199855:-	-0.36	-4.28	2.39E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs78185801	chr7:1096367	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs78300366	chr11:71205514	KRTAP5-10	chr11:71276609-71277666:+	0.2	3.86	0.000135	Vitamin D levels	
BLCA	cis	1	rs78308415	chr7:1072634	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.37	1.6E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs78343340	chr4:267437	ZNF718	chr4:53272-156488:+	0.35	4.72	3.37E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs78523927	chr7:1089458	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.5	9.13E-6	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs785464	chr1:46523089	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.25	1.1E-9	Body mass index	
BLCA	cis	1	rs785471	chr1:46518677	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.14	2.02E-9	Body mass index	
BLCA	cis	1	rs785479	chr1:46492144	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.89E-10	Body mass index	
BLCA	cis	1	rs785481	chr1:46554518	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.8E-10	Body mass index	
BLCA	cis	1	rs785481	chr1:46554518	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000117	Body mass index	
BLCA	cis	1	rs785485	chr1:46574424	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.75E-10	Body mass index	
BLCA	cis	1	rs785485	chr1:46574424	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000119	Body mass index	
BLCA	cis	1	rs785488	chr1:46576095	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.75E-10	Body mass index	
BLCA	cis	1	rs785488	chr1:46576095	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000119	Body mass index	
BLCA	cis	1	rs785489	chr1:46576390	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.35	6.0E-10	Body mass index	
BLCA	cis	1	rs785489	chr1:46576390	MUTYH	chr1:45794915-45806142:-	0.2	3.94	9.57E-5	Body mass index	
BLCA	cis	1	rs785491	chr1:46583418	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.69E-10	Body mass index	
BLCA	cis	1	rs785491	chr1:46583418	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000119	Body mass index	
BLCA	cis	1	rs785492	chr1:46583607	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.21	1.4E-9	Body mass index	
BLCA	cis	1	rs785494	chr1:46586626	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.69E-10	Body mass index	
BLCA	cis	1	rs785494	chr1:46586626	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000119	Body mass index	
BLCA	cis	1	rs785495	chr1:46587887	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.27	9.9E-10	Body mass index	
BLCA	cis	1	rs785503	chr1:46595868	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.69E-10	Body mass index	
BLCA	cis	1	rs785503	chr1:46595868	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000119	Body mass index	
BLCA	cis	1	rs785520	chr1:46568836	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.31	7.8E-10	Body mass index	
BLCA	cis	1	rs785520	chr1:46568836	MUTYH	chr1:45794915-45806142:-	0.2	3.89	0.000117	Body mass index	
BLCA	cis	1	rs78604110	chr15:40681854	C15orf23	chr15:40674922-40686488:+	0.33	5.67	2.88E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs78628466	chr7:1068453	ZFAND2A	chr7:1192544-1199855:-	-0.36	-4.3	2.15E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs786425	chr12:124085502	ATP6V0A2	chr12:124196865-124246299:+	-0.29	-4.31	2.07E-5	Pubertal anthropometrics	
BLCA	cis	1	rs78646493	chr2:86283195	LOC90784	chr2:86247339-86250991:-	-0.41	-4.21	3.18E-5	Response to methylphenidate treatment in attention-deficit/hyperactivity disorder (blood pressure)	
BLCA	cis	1	rs78679088	chr21:33910827	TCP10L	chr21:33947152-33957845:-	-0.37	-4.87	1.62E-6	Gastritis	
BLCA	cis	1	rs7868228	chr9:21667762	LOC554202	chr9:21454267-21559832:-	0.26	3.96	8.99E-5	Gut microbiome composition (winter)	
BLCA	cis	1	rs7868333	chr9:21667825	KLHL9	chr9:21324054-21335429:-	-0.3	-4.56	7.01E-6	Gut microbiome composition (winter)	
BLCA	cis	1	rs7868333	chr9:21667825	LOC554202	chr9:21454267-21559832:-	-0.26	-3.92	0.000105	Gut microbiome composition (winter)	
BLCA	cis	1	rs78724141	chr8:82659661	CHMP4C	chr8:82644688-82671746:+	-0.78	-7.44	6.8E-13	Epithelial ovarian cancer;Ovarian cancer	
BLCA	cis	1	rs78740005	chr8:82659306	CHMP4C	chr8:82644688-82671746:+	-0.78	-7.43	7.2E-13	Epithelial ovarian cancer;Ovarian cancer	
BLCA	cis	1	rs78803505	chr7:65382572	CCT6P1	chr7:65216092-65228661:+	0.31	4.38	1.53E-5	Diabetic kidney disease	
BLCA	cis	1	rs78861357	chr7:1095418	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.4	1.41E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs78896566	chr7:1080182	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7897778	chr10:75916105	ADK	chr10:75910965-76469059:+	0.28	4.25	2.74E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7904207	chr10:75884474	ADK	chr10:75910965-76469059:+	0.3	4.63	5.07E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs79044944	chr15:40676285	C15orf23	chr15:40674922-40686488:+	0.33	5.69	2.51E-8	Heschl's gyrus morphology	
BLCA	cis	1	rs7905536	chr10:75997209	ADK	chr10:75910965-76469059:+	0.27	4.16	3.93E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7907801	chr10:75976638	ADK	chr10:75910965-76469059:+	0.32	4.84	1.9E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7909664	chr10:75869754	ADK	chr10:75910965-76469059:+	0.27	4.1	5.01E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7909915	chr10:75960942	ADK	chr10:75910965-76469059:+	0.31	4.71	3.41E-6	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs7916697	chr10:69991853	PBLD	chr10:70042417-70092684:-	-0.25	-4.43	1.21E-5	Optic disc area	
BLCA	cis	1	rs7917792	chr10:97365627	ENTPD1	chr10:97471536-97637022:+	0.19	4.97	1.03E-6	Blood metabolite levels	
BLCA	cis	1	rs791856	chr6:86681841	SNHG5	chr6:86386726-86388451:-	0.54	9.72	4.2E-20	Response to antipsychotic treatment	
BLCA	cis	1	rs79199019	chr14:35581125	PPP2R3C	chr14:35554679-35591679:-	0.27	4.24	2.8E-5	Atopic dermatitis	
BLCA	cis	1	rs7927771	chr11:47781306	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.58	4.59E-8	Subjective well-being	
BLCA	cis	1	rs79318564	chr15:84786150	LOC388152	chr15:84867600-84898920:-	-0.28	-4.83	1.94E-6	Schizophrenia	
BLCA	cis	1	rs79327308	chr7:1108141	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.48	1.0E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs79366248	chr4:266659	ZNF718	chr4:53272-156488:+	0.34	4.66	4.33E-6	Immune response to smallpox vaccine (IL-6)	
BLCA	cis	1	rs793834	chr6:24234933	KAAG1	chr6:24357131-24358512:+	-0.25	-4.19	3.51E-5	Information processing speed	
BLCA	cis	1	rs7940310	chr11:117024481	PCSK7	chr11:117075789-117102811:-	-0.4	-5.02	7.91E-7	Protein quantitative trait loci	
BLCA	cis	1	rs79422648	chr7:1080241	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs79436302	chr14:35578797	PPP2R3C	chr14:35554679-35591679:-	0.27	4.26	2.6E-5	Atopic dermatitis	
BLCA	cis	1	rs79443843	chr7:1075245	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.36	1.69E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7947378	chr11:18381327	GTF2H1	chr11:18343816-18388590:+	0.28	5.24	2.62E-7	Pancreatic cancer	
BLCA	cis	1	rs7947730	chr11:47786184	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.58	4.59E-8	Subjective well-being	
BLCA	cis	1	rs7950364	chr11:116898886	PCSK7	chr11:117075789-117102811:-	-0.4	-5.15	4.22E-7	Protein quantitative trait loci	
BLCA	cis	1	rs7954638	chr12:96314795	AMDHD1	chr12:96337071-96362369:+	0.25	4.41	1.34E-5	Metabolite levels (small molecules and protein measures)	
BLCA	cis	1	rs79548696	chr3:41803385	ULK4	chr3:41288091-42003660:-	0.64	9.73	3.79E-20	Diastolic blood pressure	
BLCA	cis	1	rs7956611	chr12:66904523	CAND1	chr12:67663061-67708388:+	0.21	3.93	0.000102	Age of smoking initiation	
BLCA	cis	1	rs79617366	chr7:1111958	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.47	1.05E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs79683221	chr7:1096139	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs79702597	chr14:35558856	PPP2R3C	chr14:35554679-35591679:-	0.28	4.46	1.08E-5	Atopic dermatitis	
BLCA	cis	1	rs79716074	chr2:277003	SH3YL1	chr2:218138-264810:-	-0.45	-11.81	1.2E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs79765398	chr7:1073764	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.35	1.78E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs7980687	chr12:123822711	ABCB9	chr12:123413540-123459752:-	0.32	3.96	8.78E-5	Educational attainment;Height;Head circumference (infant)	
BLCA	cis	1	rs7980687	chr12:123822711	CDK2AP1	chr12:123745542-123756687:-	-0.34	-4.76	2.76E-6	Educational attainment;Height;Head circumference (infant)	
BLCA	cis	1	rs798719	chr4:1698183	FAM53A	chr4:1641609-1685854:-	-0.32	-4.63	4.99E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798724	chr4:1704643	FAM53A	chr4:1641609-1685854:-	-0.29	-4.29	2.3E-5	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798741	chr4:1712413	FAM53A	chr4:1641609-1685854:-	-0.29	-4.26	2.54E-5	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798744	chr4:1714684	FAM53A	chr4:1641609-1685854:-	-0.35	-5.06	6.58E-7	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798754	chr4:1720757	FAM53A	chr4:1641609-1685854:-	-0.33	-4.94	1.16E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798755	chr4:1720824	FAM53A	chr4:1641609-1685854:-	-0.33	-4.93	1.22E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798756	chr4:1707447	FAM53A	chr4:1641609-1685854:-	-0.32	-4.57	6.73E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798762	chr4:1731150	FAM53A	chr4:1641609-1685854:-	-0.31	-4.58	6.42E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798766	chr4:1734239	FAM53A	chr4:1641609-1685854:-	0.31	4.55	7.06E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs798767	chr4:1734281	FAM53A	chr4:1641609-1685854:-	-0.32	-4.7	3.62E-6	Urinary bladder cancer;Bladder cancer	
BLCA	cis	1	rs7995669	chr13:36762986	SOHLH2	chr13:36742347-36871992:-	-0.39	-5.08	6.03E-7	Economic and political preferences	
BLCA	cis	1	rs80031817	chr7:1096793	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.41	1.33E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs80075680	chr5:150223737	LOC134466	chr5:150310000-150326146:-	0.44	5.43	1.01E-7	Crohn's disease	
BLCA	cis	1	rs80094748	chr7:1103958	ZFAND2A	chr7:1192544-1199855:-	-0.37	-4.37	1.62E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs8010715	chr14:24609147	FAM158A	chr14:24608175-24610797:-	-0.42	-8.03	1.2E-14	IgG glycosylation	
BLCA	cis	1	rs8013540	chr14:35513760	PPP2R3C	chr14:35554679-35591679:-	0.25	3.86	0.000131	Atopic dermatitis	
BLCA	cis	1	rs8014170	chr14:50071694	RPL36AL	chr14:50085407-50087349:-	0.26	4.65	4.66E-6	Carotid intima media thickness	
BLCA	cis	1	rs8015636	chr14:71226559	MAP3K9	chr14:71194856-71275888:-	0.42	4.43	1.25E-5	Response to antipsychotic treatment in schizophrenia (reasoning)	
BLCA	cis	1	rs8018967	chr14:73976934	HEATR4	chr14:73945193-74025651:-	-0.23	-4.03	6.77E-5	Blood metabolite ratios	
BLCA	cis	1	rs80202648	chr19:50494386	SIGLEC16	chr19:50472912-50479075:+	0.59	5.59	4.42E-8	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs80212261	chr7:1114012	ZFAND2A	chr7:1192544-1199855:-	-0.38	-4.43	1.26E-5	C-reactive protein levels or total cholesterol levels (pleiotropy)	
BLCA	cis	1	rs8021692	chr14:104428576	TDRD9	chr14:104394817-104519002:+	0.31	4.7	3.57E-6	Bipolar disorder	
BLCA	cis	1	rs80285556	chr19:50540170	SIGLEC16	chr19:50472912-50479075:+	0.48	4.68	4.04E-6	antipsychotic drug dosage in schizophrenia or schizoaffective disorder	
BLCA	cis	1	rs8033837	chr15:75353975	SCAMP5	chr15:75287901-75313836:+	0.29	4.83	1.97E-6	Blood trace element (Zn levels)	
BLCA	cis	1	rs8033938	chr15:40703114	C15orf23	chr15:40674922-40686488:+	0.35	5.94	6.5E-9	Heschl's gyrus morphology	
BLCA	cis	1	rs8034191	chr15:78806023	CHRNA5	chr15:78857906-78886458:+	-0.26	-4.12	4.73E-5	Post bronchodilator FEV1;Emphysema imaging phenotypes;Local histogram emphysema pattern;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio	
BLCA	cis	1	rs8049173	chr16:11436882	C16orf75	chr16:11343506-11445617:+	0.25	3.98	8.34E-5	Vein graft stenosis in coronary artery bypass grafting	
BLCA	cis	1	rs8049439	chr16:28837515	EIF3C	chr16:28722782-28747052:+;chr16	0.26	4.68	3.97E-6	Educational attainment;Inflammatory bowel disease (early onset);Educational attainment (years of education)	
BLCA	cis	1	rs8054842	chr16:672799	WFIKKN1	chr16:679239-684116:+	0.28	5.31	1.85E-7	Height	
BLCA	cis	1	rs8055427	chr16:11436883	C16orf75	chr16:11343506-11445617:+	0.25	3.98	8.34E-5	Vein graft stenosis in coronary artery bypass grafting	
BLCA	cis	1	rs8065437	chr17:45721653	C17orf57	chr17:45401142-45518675:+	0.26	5.63	3.58E-8	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs8065669	chr17:45724996	C17orf57	chr17:45401142-45518675:+	0.25	5.58	4.51E-8	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs8070446	chr17:40285879	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs8070454	chr17:38160754	ZPBP2	chr17:38024455-38034144:+	-0.21	-3.95	9.46E-5	Neutrophil count;White blood cell count;C-reactive protein and white blood cell count	
BLCA	cis	1	rs8071789	chr17:38006333	ZPBP2	chr17:38024455-38034144:+	0.41	8.18	4.36E-15	Selective IgA deficiency	
BLCA	cis	1	rs8072100	chr17:45674687	C17orf57	chr17:45401142-45518675:+	-0.27	-6.04	3.63E-9	Very long-chain saturated fatty acid levels (fatty acid 20:0)	
BLCA	cis	1	rs8074708	chr17:40286354	DHX58	chr17:40253422-40264751:-	0.25	4.63	4.92E-6	Fibrinogen levels	
BLCA	cis	1	rs807669	chr22:19154522	SLC25A1	chr22:19163095-19166301:-	-0.32	-5.67	2.87E-8	Metabolite levels	
BLCA	cis	1	rs807670	chr22:19154608	SLC25A1	chr22:19163095-19166301:-	-0.26	-5.1	5.42E-7	Metabolite levels	
BLCA	cis	1	rs8081267	chr17:27763910	CCDC55	chr17:28443834-28513485:+	0.25	3.93	0.000101	Mean platelet volume	
BLCA	cis	1	rs8093534	chr18:48368020	MRO	chr18:48321491-48351754:-	0.27	4.69	3.82E-6	Entorhinal cortical thickness	
BLCA	cis	1	rs809775	chr1:46538040	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.22	1.28E-9	Body mass index	
BLCA	cis	1	rs809775	chr1:46538040	MUTYH	chr1:45794915-45806142:-	0.2	3.9	0.000115	Body mass index	
BLCA	cis	1	rs8102137	chr19:30296853	CCNE1	chr19:30302901-30315218:+	0.21	3.9	0.000112	Bladder cancer	
BLCA	cis	1	rs8113312	chr19:23061182	ZNF492	chr19:22817126-22850472:+	-0.3	-4.1	5.0E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs8133949	chr21:43421114	C21orf121	chr21:43442113-43445060:+	0.32	4.57	6.52E-6	Hand grip strength	
BLCA	cis	1	rs8138799	chr22:24556902	SUSD2	chr22:24577444-24585074:+	0.53	5.37	1.35E-7	Amyotrophic lateral sclerosis	
BLCA	cis	1	rs8140617	chr22:38970439	JOSD1	chr22:39081549-39096459:-	0.23	3.89	0.000116	Resting heart rate	
BLCA	cis	1	rs8141797	chr22:24582041	SUSD2	chr22:24577444-24585074:+	-0.52	-5.69	2.53E-8	Amyotrophic lateral sclerosis	
BLCA	cis	1	rs8181644	chr12:58173466	FAM119B	chr12:58166383-58176323:+	0.27	4.21	3.22E-5	Multiple sclerosis	
BLCA	cis	1	rs8181644	chr12:58173466	TSFM	chr12:58176536-58191367:+	-0.41	-7.17	3.82E-12	Multiple sclerosis	
BLCA	cis	1	rs8181644	chr12:58173466	XRCC6BP1	chr12:58335445-58351051:+	-0.25	-4.26	2.62E-5	Multiple sclerosis	
BLCA	cis	1	rs823301	chr3:195123495	C3orf21	chr3:194789015-194991895:-	-0.28	-5.38	1.28E-7	Body mass index	
BLCA	cis	1	rs823302	chr3:195104741	C3orf21	chr3:194789015-194991895:-	-0.29	-5.66	2.93E-8	Body mass index	
BLCA	cis	1	rs823306	chr3:195108320	C3orf21	chr3:194789015-194991895:-	-0.29	-5.54	5.62E-8	Body mass index	
BLCA	cis	1	rs823310	chr3:195127093	C3orf21	chr3:194789015-194991895:-	-0.29	-5.54	5.62E-8	Body mass index	
BLCA	cis	1	rs823311	chr3:195141029	C3orf21	chr3:194789015-194991895:-	-0.28	-5.38	1.28E-7	Body mass index	
BLCA	cis	1	rs823314	chr3:195132402	C3orf21	chr3:194789015-194991895:-	-0.29	-5.54	5.62E-8	Body mass index	
BLCA	cis	1	rs8255	chr10:75879750	ADK	chr10:75910965-76469059:+	0.28	4.33	1.89E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs832551	chr5:56180112	C5orf35	chr5:56205103-56213010:+	0.75	11.53	1.32E-26	Type 2 diabetes	
BLCA	cis	1	rs832553	chr5:56114786	C5orf35	chr5:56205103-56213010:+	0.73	11.16	3.06E-25	Type 2 diabetes	
BLCA	cis	1	rs832554	chr5:56115036	C5orf35	chr5:56205103-56213010:+	0.71	10.97	1.51E-24	Type 2 diabetes	
BLCA	cis	1	rs832565	chr5:56150803	C5orf35	chr5:56205103-56213010:+	0.75	11.66	4.12E-27	Type 2 diabetes	
BLCA	cis	1	rs832568	chr5:56153776	C5orf35	chr5:56205103-56213010:+	0.74	11.25	1.5E-25	Type 2 diabetes	
BLCA	cis	1	rs832569	chr5:56154584	C5orf35	chr5:56205103-56213010:+	0.74	11.25	1.5E-25	Type 2 diabetes	
BLCA	cis	1	rs832578	chr5:56164223	C5orf35	chr5:56205103-56213010:+	0.74	11.69	3.42E-27	Type 2 diabetes	
BLCA	cis	1	rs832582	chr5:56177743	C5orf35	chr5:56205103-56213010:+	0.74	11.45	2.62E-26	Type 2 diabetes	
BLCA	cis	1	rs832583	chr5:56178217	C5orf35	chr5:56205103-56213010:+	0.74	11.45	2.62E-26	Type 2 diabetes	
BLCA	cis	1	rs832584	chr5:56179212	C5orf35	chr5:56205103-56213010:+	-0.73	-11.03	9.55E-25	Type 2 diabetes	
BLCA	cis	1	rs853678	chr6:28297313	ZNF389	chr6:28129551-28137375:+	-0.31	-3.89	0.000117	Depression	
BLCA	cis	1	rs853679	chr6:28296863	ZNF389	chr6:28129551-28137375:+	-0.31	-3.89	0.000117	Depression	
BLCA	cis	1	rs858239	chr7:23286315	GPNMB	chr7:23286316-23314728:+	-0.26	-4.27	2.48E-5	Parkinson's disease	
BLCA	cis	1	rs858240	chr7:23284237	GPNMB	chr7:23286316-23314728:+	-0.25	-4.15	4.09E-5	Parkinson's disease	
BLCA	cis	1	rs8589	chr6:49403282	CENPQ	chr6:49431096-49460820:+	-0.39	-8.57	2.55E-16	Homocysteine levels	
BLCA	cis	1	rs860580	chr5:56149429	C5orf35	chr5:56205103-56213010:+	-0.73	-11.67	3.82E-27	Type 2 diabetes	
BLCA	cis	1	rs861283	chr5:56184610	C5orf35	chr5:56205103-56213010:+	0.75	11.53	1.32E-26	Type 2 diabetes	
BLCA	cis	1	rs863840	chr5:56128999	C5orf35	chr5:56205103-56213010:+	0.71	11.05	7.82E-25	Type 2 diabetes	
BLCA	cis	1	rs866222	chr5:56184444	C5orf35	chr5:56205103-56213010:+	0.75	11.53	1.32E-26	Type 2 diabetes	
BLCA	cis	1	rs871546	chr21:43413553	C21orf121	chr21:43442113-43445060:+	0.29	4.13	4.49E-5	Hand grip strength	
BLCA	cis	1	rs873063	chr8:8572447	CLDN23	chr8:8559666-8561616:+	-0.23	-3.94	9.88E-5	Obesity-related traits	
BLCA	cis	1	rs873064	chr8:8572380	CLDN23	chr8:8559666-8561616:+	-0.23	-3.94	9.88E-5	Obesity-related traits	
BLCA	cis	1	rs873686	chr4:185638876	MLF1IP	chr4:185615220-185655286:-	0.48	11.15	3.49E-25	Kawasaki disease	
BLCA	cis	1	rs8758	chr10:97366107	ENTPD1	chr10:97471536-97637022:+	0.2	5	8.71E-7	Blood metabolite levels	
BLCA	cis	1	rs877636	chr12:56480583	RPS26	chr12:56435686-56438005:+	-0.46	-7.82	5.14E-14	Cognitive function	
BLCA	cis	1	rs879620	chr16:4015729	CREBBP	chr16:3775058-3930121:-	0.19	3.85	0.000139	Body mass index;Obesity	
BLCA	cis	1	rs881375	chr9:123652898	LOC253039	chr9:123605320-123616644:+	-0.35	-5.95	6.1E-9	Rheumatoid arthritis	
BLCA	cis	1	rs881827	chr21:48019868	C21orf56	chr21:47581063-47604373:-	-0.25	-4.03	6.69E-5	Lymphocyte counts	
BLCA	cis	1	rs882367	chr17:59494574	C17orf82	chr17:59489112-59490641:+	0.2	4.4	1.39E-5	Sitting height ratio	
BLCA	cis	1	rs882803	chr1:45976147	CCDC163P	chr1:45960581-45965646:-	-0.74	-14.99	2.75E-40	Homocysteine levels	
BLCA	cis	1	rs884841	chr6:86680300	SNHG5	chr6:86386726-86388451:-	-0.5	-8.85	3.22E-17	Response to antipsychotic treatment	
BLCA	cis	1	rs889312	chr5:56031884	C5orf35	chr5:56205103-56213010:+	0.3	4.75	2.85E-6	Breast cancer (early onset);Breast cancer	
BLCA	cis	1	rs898225	chr3:48413179	TREX1	chr3:48501186-48509043:+	0.19	3.84	0.000145	Longevity	
BLCA	cis	1	rs900012	chr11:116966435	PCSK7	chr11:117075789-117102811:-	-0.43	-5.32	1.74E-7	Protein quantitative trait loci	
BLCA	cis	1	rs906134	chr7:65444288	CCT6P1	chr7:65216092-65228661:+	0.33	4.47	1.05E-5	Diabetic kidney disease	
BLCA	cis	1	rs917911	chr12:9905851	CLECL1	chr12:9868457-9885860:-	0.23	5.66	2.9E-8	Type 1 diabetes	
BLCA	cis	1	rs919586	chr8:13174671	LONRF1	chr8:12579406-12612992:-	0.35	5.14	4.31E-7	Obesity-related traits	
BLCA	cis	1	rs9213	chr2:218386	SH3YL1	chr2:218138-264810:-	-0.45	-11.72	2.65E-27	Spherical equivalent (joint main effects and education interaction)	
BLCA	cis	1	rs922075	chr3:48489398	TREX1	chr3:48501186-48509043:+	0.2	4.04	6.42E-5	Longevity	
BLCA	cis	1	rs925098	chr4:17919811	LCORL	chr4:17844844-18023385:-	0.28	4.19	3.53E-5	Height	
BLCA	cis	1	rs9283717	chr5:56078659	C5orf35	chr5:56205103-56213010:+	0.73	11.23	1.75E-25	Type 2 diabetes	
BLCA	cis	1	rs9289275	chr3:125648659	ALG1L	chr3:125648118-125655882:-	-0.38	-6.49	2.65E-10	Blood pressure (smoking interaction)	
BLCA	cis	1	rs9289275	chr3:125648659	LOC100125556	chr3:125635444-125648865:+	0.36	5.33	1.71E-7	Blood pressure (smoking interaction)	
BLCA	cis	1	rs9289471	chr3:134230811	ANAPC13	chr3:134196547-134204865:-	0.5	8.07	8.91E-15	Height	
BLCA	cis	1	rs9289471	chr3:134230811	CEP63	chr3:134204575-134293852:+	0.25	4.29	2.26E-5	Height	
BLCA	cis	1	rs9289475	chr3:134236459	ANAPC13	chr3:134196547-134204865:-	0.48	7.66	1.58E-13	Height	
BLCA	cis	1	rs9289475	chr3:134236459	CEP63	chr3:134204575-134293852:+	0.22	3.87	0.000127	Height	
BLCA	cis	1	rs9289476	chr3:134237103	ANAPC13	chr3:134196547-134204865:-	0.47	7.49	4.72E-13	Height	
BLCA	cis	1	rs9289478	chr3:134268619	ANAPC13	chr3:134196547-134204865:-	0.47	7.54	3.54E-13	Height	
BLCA	cis	1	rs9296404	chr6:42925803	GNMT	chr6:42928500-42931617:+	-0.46	-8.11	6.92E-15	Plasma homocysteine levels (post-methionine load test)	
BLCA	cis	1	rs9296404	chr6:42925803	PEX6	chr6:42931613-42946981:-	0.67	11.59	7.59E-27	Plasma homocysteine levels (post-methionine load test)	
BLCA	cis	1	rs9296504	chr6:46629505	SLC25A27	chr6:46620679-46645925:+	0.24	4.9	1.4E-6	QRS complex (Sokolow-Lyon)	
BLCA	cis	1	rs9296505	chr6:46629841	SLC25A27	chr6:46620679-46645925:+	0.23	4.71	3.42E-6	QRS complex (Sokolow-Lyon)	
BLCA	cis	1	rs9296616	chr6:49414235	CENPQ	chr6:49431096-49460820:+	-0.3	-6.07	3.05E-9	Folate pathway vitamin levels	
BLCA	cis	1	rs9296616	chr6:49414235	MUT	chr6:49398994-49431031:-	0.25	4.96	1.07E-6	Folate pathway vitamin levels	
BLCA	cis	1	rs9296617	chr6:49428360	CENPQ	chr6:49431096-49460820:+	-0.28	-5.65	3.17E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9296617	chr6:49428360	MUT	chr6:49398994-49431031:-	0.28	5.51	6.48E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9296832	chr6:56100909	COL21A1	chr6:55921389-56258892:-	0.36	6.58	1.54E-10	Pulse pressure	
BLCA	cis	1	rs929843	chr16:70045748	CLEC18A	chr16:69984626-69997887:+	-0.39	-5.16	3.88E-7	Menarche (age at onset)	
BLCA	cis	1	rs929843	chr16:70045748	PDXDC2	chr16:70010210-70099851:-	-0.24	-4.67	4.08E-6	Menarche (age at onset)	
BLCA	cis	1	rs9303401	chr17:56847945	RAD51C	chr17:56769963-56811690:+	0.29	5.15	4.09E-7	Cognitive test performance	
BLCA	cis	1	rs9307050	chr4:76905649	NAAA	chr4:76831809-76862166:-	-0.39	-6.41	4.28E-10	Longevity	
BLCA	cis	1	rs9309473	chr2:73743982	ALMS1P	chr2:73872046-73912692:+	0.35	5.15	4.19E-7	Metabolite levels	
BLCA	cis	1	rs931058	chr5:150333698	LOC134466	chr5:150310000-150326146:-	0.68	7.36	1.15E-12	Crohn's disease	
BLCA	cis	1	rs9311288	chr3:41804581	ULK4	chr3:41288091-42003660:-	0.63	9.7	4.95E-20	Diastolic blood pressure	
BLCA	cis	1	rs9311676	chr3:58470351	PDHB	chr3:58413355-58419565:-	-0.24	-3.9	0.000114	Systemic lupus erythematosus	
BLCA	cis	1	rs9316278	chr13:47841469	ESD	chr13:47345392-47371367:-	0.36	4.26	2.58E-5	Cannabis use (initiation)	
BLCA	cis	1	rs9316278	chr13:47841469	SUCLA2	chr13:48516792-48612125:-	0.38	4.47	1.04E-5	Cannabis use (initiation)	
BLCA	cis	1	rs9318086	chr13:24432467	PCOTH	chr13:24463028-24466241:+	0.28	4.26	2.56E-5	Myopia (pathological)	
BLCA	cis	1	rs9322193	chr6:149919143	NUP43	chr6:150045453-150067688:-	-0.28	-4.52	8.44E-6	Lung cancer	
BLCA	cis	1	rs9324660	chr5:150257054	LOC134466	chr5:150310000-150326146:-	0.46	5.96	5.61E-9	Crohn's disease	
BLCA	cis	1	rs932644	chr6:167404187	RNASET2	chr6:167343008-167412795:-	-0.25	-5.15	4.08E-7	Crohn's disease	
BLCA	cis	1	rs9329165	chr8:8576642	CLDN23	chr8:8559666-8561616:+	0.22	3.88	0.000124	Obesity-related traits	
BLCA	cis	1	rs934093	chr3:134195885	ANAPC13	chr3:134196547-134204865:-	0.51	8.15	5.16E-15	Height	
BLCA	cis	1	rs934093	chr3:134195885	CEP63	chr3:134204575-134293852:+	0.25	4.41	1.33E-5	Height	
BLCA	cis	1	rs9349804	chr6:56098876	COL21A1	chr6:55921389-56258892:-	0.36	6.56	1.79E-10	Pulse pressure	
BLCA	cis	1	rs936525	chr19:23056189	ZNF492	chr19:22817126-22850472:+	-0.3	-4.2	3.34E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs936526	chr19:23055987	ZNF492	chr19:22817126-22850472:+	-0.3	-4.03	6.82E-5	Bronchopulmonary dysplasia	
BLCA	cis	1	rs9369898	chr6:49382193	CENPQ	chr6:49431096-49460820:+	-0.4	-8.67	1.24E-16	Homocysteine levels	
BLCA	cis	1	rs937108	chr7:65428452	CCT6P1	chr7:65216092-65228661:+	0.33	4.53	7.78E-6	Diabetic kidney disease	
BLCA	cis	1	rs9371221	chr6:151885986	C6orf97	chr6:151815175-151942327:+	0.28	4.21	3.14E-5	Bone mineral density (spine)	
BLCA	cis	1	rs9377229	chr6:149928791	NUP43	chr6:150045453-150067688:-	-0.29	-4.65	4.67E-6	Lung cancer	
BLCA	cis	1	rs9381040	chr6:41154650	LOC221442	chr6:41068773-41108567:+	0.24	4.27	2.47E-5	Alzheimer's disease (late onset)	
BLCA	cis	1	rs9381469	chr6:46630068	SLC25A27	chr6:46620679-46645925:+	-0.24	-4.83	1.94E-6	QRS complex (Sokolow-Lyon)	
BLCA	cis	1	rs9381784	chr6:49398115	CENPQ	chr6:49431096-49460820:+	0.38	8.03	1.23E-14	Homocysteine levels	
BLCA	cis	1	rs939337	chr3:183701147	ABCC5	chr3:183637726-183735727:-	-0.21	-4.1	4.97E-5	Anterior chamber depth	
BLCA	cis	1	rs939338	chr3:183704068	VWA5B2	chr3:183948317-183960116:+	0.23	3.86	0.000131	Anterior chamber depth	
BLCA	cis	1	rs9394931	chr6:42873245	PEX6	chr6:42931613-42946981:-	-0.44	-7.19	3.4E-12	Plasma omega-6 polyunsaturated fatty acid levels (arachidonic acid)	
BLCA	cis	1	rs9395493	chr6:49427409	CENPQ	chr6:49431096-49460820:+	-0.41	-8.83	3.75E-17	Homocysteine levels	
BLCA	cis	1	rs939558	chr3:41976040	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs9397425	chr6:151873024	C6orf97	chr6:151815175-151942327:+	0.26	3.91	0.000111	Bone mineral density (spine)	
BLCA	cis	1	rs9397428	chr6:151875080	C6orf97	chr6:151815175-151942327:+	0.26	3.91	0.000111	Bone mineral density (spine)	
BLCA	cis	1	rs9397429	chr6:151877569	C6orf97	chr6:151815175-151942327:+	0.29	4.23	2.88E-5	Bone mineral density (spine)	
BLCA	cis	1	rs9397431	chr6:151883930	C6orf97	chr6:151815175-151942327:+	0.3	4.47	1.05E-5	Bone mineral density (spine)	
BLCA	cis	1	rs9399693	chr6:149933854	NUP43	chr6:150045453-150067688:-	-0.25	-4.09	5.29E-5	Lung cancer	
BLCA	cis	1	rs941653	chr14:35592538	PPP2R3C	chr14:35554679-35591679:-	0.25	4.05	6.12E-5	Atopic dermatitis	
BLCA	cis	1	rs9425766	chr1:173853127	ANKRD45	chr1:173577475-173639001:-	0.26	4.31	2.07E-5	Life satisfaction	
BLCA	cis	1	rs9429183	chr1:46524582	CCDC163P	chr1:45960581-45965646:-	-0.33	-6.25	1.1E-9	Body mass index	
BLCA	cis	1	rs945635	chr1:157670290	FCRL3	chr1:157646278-157670775:-	0.29	9.27	1.4E-18	Type 1 diabetes autoantibodies	
BLCA	cis	1	rs9457247	chr6:167392174	RNASET2	chr6:167343008-167412795:-	-0.24	-5.04	7.23E-7	Crohn's disease	
BLCA	cis	1	rs9463473	chr6:49380121	CENPQ	chr6:49431096-49460820:+	-0.27	-5.63	3.5E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463473	chr6:49380121	MUT	chr6:49398994-49431031:-	0.28	5.53	5.97E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463474	chr6:49380199	CENPQ	chr6:49431096-49460820:+	-0.27	-5.63	3.5E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463474	chr6:49380199	MUT	chr6:49398994-49431031:-	0.28	5.53	5.97E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463475	chr6:49380899	CENPQ	chr6:49431096-49460820:+	0.28	5.61	3.79E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463475	chr6:49380899	MUT	chr6:49398994-49431031:-	-0.28	-5.58	4.67E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463477	chr6:49386446	CENPQ	chr6:49431096-49460820:+	-0.28	-5.66	2.91E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463477	chr6:49386446	MUT	chr6:49398994-49431031:-	0.28	5.53	5.94E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463478	chr6:49386564	CENPQ	chr6:49431096-49460820:+	-0.4	-8.67	1.24E-16	Homocysteine levels	
BLCA	cis	1	rs9463479	chr6:49393275	CENPQ	chr6:49431096-49460820:+	-0.28	-5.66	2.91E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463479	chr6:49393275	MUT	chr6:49398994-49431031:-	0.28	5.53	5.94E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463480	chr6:49400795	CENPQ	chr6:49431096-49460820:+	-0.28	-5.77	1.67E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9463480	chr6:49400795	MUT	chr6:49398994-49431031:-	0.28	5.54	5.63E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs946529	chr1:46485548	CCDC163P	chr1:45960581-45965646:-	-0.34	-6.43	3.9E-10	Body mass index	
BLCA	cis	1	rs947211	chr1:205752665	RAB7L1	chr1:205737115-205744610:-	0.27	3.97	8.64E-5	Parkinson's disease	
BLCA	cis	1	rs9473549	chr6:49380020	CENPQ	chr6:49431096-49460820:+	-0.29	-5.87	9.55E-9	Folate pathway vitamin levels	
BLCA	cis	1	rs9473549	chr6:49380020	MUT	chr6:49398994-49431031:-	0.26	5.03	7.58E-7	Folate pathway vitamin levels	
BLCA	cis	1	rs9473550	chr6:49385182	CENPQ	chr6:49431096-49460820:+	-0.39	-8.5	4.43E-16	Homocysteine levels	
BLCA	cis	1	rs9473552	chr6:49387154	CENPQ	chr6:49431096-49460820:+	-0.28	-5.66	2.91E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473552	chr6:49387154	MUT	chr6:49398994-49431031:-	0.28	5.53	5.94E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473553	chr6:49395977	CENPQ	chr6:49431096-49460820:+	-0.28	-5.69	2.46E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473553	chr6:49395977	MUT	chr6:49398994-49431031:-	0.28	5.5	6.86E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473555	chr6:49409487	CENPQ	chr6:49431096-49460820:+	-0.28	-5.82	1.22E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473555	chr6:49409487	MUT	chr6:49398994-49431031:-	0.27	5.46	8.78E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473560	chr6:49427918	CENPQ	chr6:49431096-49460820:+	-0.28	-5.65	3.17E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473560	chr6:49427918	MUT	chr6:49398994-49431031:-	0.28	5.51	6.48E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473561	chr6:49428755	CENPQ	chr6:49431096-49460820:+	-0.28	-5.65	3.17E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473561	chr6:49428755	MUT	chr6:49398994-49431031:-	0.28	5.51	6.48E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473563	chr6:49453651	CENPQ	chr6:49431096-49460820:+	-0.29	-5.82	1.25E-8	Folate pathway vitamin levels	
BLCA	cis	1	rs9473563	chr6:49453651	MUT	chr6:49398994-49431031:-	0.26	4.96	1.07E-6	Folate pathway vitamin levels	
BLCA	cis	1	rs947583	chr6:136133659	PDE7B	chr6:136172834-136516708:+	0.23	4.1	5.08E-5	Phosphorus levels	
BLCA	cis	1	rs948562	chr11:58347765	CNTF	chr11:58390146-58393203:+	0.3	3.91	0.00011	Lymphoma	
BLCA	cis	1	rs9487605	chr6:111582885	KIAA1919	chr6:111580482-111590259:+	-0.3	-4.58	6.16E-6	Inflammatory skin disease	
BLCA	cis	1	rs9491142	chr6:124693017	NKAIN2	chr6:124125069-125146784:+	0.27	4.71	3.51E-6	Neuroticism	
BLCA	cis	1	rs950169	chr15:84706461	LOC388152	chr15:84867600-84898920:-	-0.26	-4.36	1.64E-5	Schizophrenia	
BLCA	cis	1	rs951366	chr1:205685352	PM20D1	chr1:205797154-205819245:-	-0.21	-4.06	6.05E-5	Menarche (age at onset)	
BLCA	cis	1	rs951366	chr1:205685352	RAB7L1	chr1:205737115-205744610:-	0.31	5.2	3.31E-7	Menarche (age at onset)	
BLCA	cis	1	rs9527	chr10:104623578	C10orf32	chr10:104613967-104624718:+	-0.37	-5.72	2.18E-8	Arsenic metabolism	
BLCA	cis	1	rs9546652	chr13:36773131	SOHLH2	chr13:36742347-36871992:-	0.32	4.49	9.57E-6	Economic and political preferences	
BLCA	cis	1	rs955196	chr6:86729951	SNHG5	chr6:86386726-86388451:-	0.54	9.72	4.06E-20	Response to antipsychotic treatment	
BLCA	cis	1	rs955197	chr6:86729675	SNHG5	chr6:86386726-86388451:-	-0.53	-9.41	4.79E-19	Response to antipsychotic treatment	
BLCA	cis	1	rs955227	chr6:86651032	SNHG5	chr6:86386726-86388451:-	-0.54	-9.62	9.41E-20	Response to antipsychotic treatment	
BLCA	cis	1	rs958283	chr6:151887150	C6orf97	chr6:151815175-151942327:+	0.28	4.16	3.94E-5	Bone mineral density (spine)	
BLCA	cis	1	rs9606830	chr22:31717799	C22orf30	chr22:32072242-32146120:-	0.21	4.02	7.07E-5	Paclitaxel-induced neuropathy	
BLCA	cis	1	rs9606831	chr22:31732512	C22orf30	chr22:32072242-32146120:-	0.21	4	7.63E-5	Paclitaxel-induced neuropathy	
BLCA	cis	1	rs9609254	chr22:31705942	C22orf30	chr22:32072242-32146120:-	0.22	4.06	5.86E-5	Paclitaxel-induced neuropathy	
BLCA	cis	1	rs9610986	chr22:39025277	JOSD1	chr22:39081549-39096459:-	-0.23	-3.86	0.000135	Resting heart rate	
BLCA	cis	1	rs9647603	chr6:86639341	SNHG5	chr6:86386726-86388451:-	-0.55	-10.02	3.91E-21	Response to antipsychotic treatment	
BLCA	cis	1	rs9653557	chr2:73795962	ALMS1P	chr2:73872046-73912692:+	0.34	5.08	5.95E-7	Metabolite levels	
BLCA	cis	1	rs9665468	chr10:75938838	ADK	chr10:75910965-76469059:+	0.3	4.45	1.12E-5	Soluble interleukin-2 receptor subunit alpha	
BLCA	cis	1	rs9665626	chr10:104300638	SFXN2	chr10:104474298-104498946:+	0.46	5.7	2.46E-8	Schizophrenia	
BLCA	cis	1	rs9674872	chr17:79581931	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs968567	chr11:61595564	FADS2	chr11:61583728-61634825:+	0.38	4.41	1.35E-5	Blood metabolite levels;Rheumatoid arthritis;Glycerophospholipid levels	
BLCA	cis	1	rs9689	chr1:25688276	RHD	chr1:25598981-25656935:+	-0.48	-8.41	8.47E-16	Erythrocyte sedimentation rate	
BLCA	cis	1	rs9747349	chr17:79584297	TSPAN10	chr17:79609349-79615778:+	0.49	8.84	3.52E-17	Eye color traits	
BLCA	cis	1	rs9748176	chr17:79584043	TSPAN10	chr17:79609349-79615778:+	0.49	8.8	4.7E-17	Eye color traits	
BLCA	cis	1	rs975459	chr6:151876909	C6orf97	chr6:151815175-151942327:+	0.28	4.07	5.63E-5	Bone mineral density (spine)	
BLCA	cis	1	rs9767077	chr6:150109615	NUP43	chr6:150045453-150067688:-	-0.28	-4.54	7.64E-6	Lung cancer	
BLCA	cis	1	rs9769882	chr7:65642925	CCT6P1	chr7:65216092-65228661:+	-0.35	-4.71	3.52E-6	Diabetic kidney disease	
BLCA	cis	1	rs9783304	chr11:43660255	HSD17B12	chr11:43702143-43878160:+	0.43	7.08	7.06E-12	Forced vital capacity	
BLCA	cis	1	rs9783347	chr11:18384938	GTF2H1	chr11:18343816-18388590:+	0.29	5.55	5.44E-8	Pancreatic cancer	
BLCA	cis	1	rs9809619	chr3:134280948	ANAPC13	chr3:134196547-134204865:-	0.49	7.74	8.99E-14	Height	
BLCA	cis	1	rs9809619	chr3:134280948	CEP63	chr3:134204575-134293852:+	0.23	3.97	8.43E-5	Height	
BLCA	cis	1	rs9810077	chr3:195005422	C3orf21	chr3:194789015-194991895:-	0.31	6.1	2.65E-9	Body mass index	
BLCA	cis	1	rs9812647	chr3:48448914	TREX1	chr3:48501186-48509043:+	0.21	4.16	3.94E-5	Longevity	
BLCA	cis	1	rs9813774	chr3:134227100	ANAPC13	chr3:134196547-134204865:-	0.49	7.99	1.6E-14	Height	
BLCA	cis	1	rs9813774	chr3:134227100	CEP63	chr3:134204575-134293852:+	0.24	4.2	3.36E-5	Height	
BLCA	cis	1	rs9814567	chr3:134218557	ANAPC13	chr3:134196547-134204865:-	-0.49	-7.66	1.5E-13	Height	
BLCA	cis	1	rs9814567	chr3:134218557	CEP63	chr3:134204575-134293852:+	-0.26	-4.4	1.39E-5	Height	
BLCA	cis	1	rs9815354	chr3:41912651	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs9818169	chr3:41860599	ULK4	chr3:41288091-42003660:-	0.63	9.78	2.63E-20	Diastolic blood pressure	
BLCA	cis	1	rs9819532	chr3:134288644	ANAPC13	chr3:134196547-134204865:-	0.49	7.81	5.66E-14	Height	
BLCA	cis	1	rs9819532	chr3:134288644	CEP63	chr3:134204575-134293852:+	0.22	3.83	0.00015	Height	
BLCA	cis	1	rs9820192	chr3:41889281	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs9823254	chr3:41894768	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs9824731	chr3:41889698	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs9825741	chr3:41761828	ULK4	chr3:41288091-42003660:-	-0.62	-9.57	1.36E-19	Diastolic blood pressure	
BLCA	cis	1	rs9826058	chr3:41762062	ULK4	chr3:41288091-42003660:-	0.64	9.9	9.78E-21	Diastolic blood pressure	
BLCA	cis	1	rs9826496	chr3:134224437	ANAPC13	chr3:134196547-134204865:-	0.47	7.38	9.98E-13	Height	
BLCA	cis	1	rs9826496	chr3:134224437	CEP63	chr3:134204575-134293852:+	0.23	3.87	0.000127	Height	
BLCA	cis	1	rs9827987	chr3:134272621	ANAPC13	chr3:134196547-134204865:-	0.5	7.97	1.89E-14	Height	
BLCA	cis	1	rs9827987	chr3:134272621	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.33E-5	Height	
BLCA	cis	1	rs9828398	chr3:41895893	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs9828815	chr3:134265749	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs9828815	chr3:134265749	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs9829092	chr3:134229866	ANAPC13	chr3:134196547-134204865:-	0.51	8.27	2.3E-15	Height	
BLCA	cis	1	rs9829092	chr3:134229866	CEP63	chr3:134204575-134293852:+	0.26	4.64	4.9E-6	Height	
BLCA	cis	1	rs9830064	chr3:41881801	ULK4	chr3:41288091-42003660:-	0.64	9.86	1.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs9830469	chr3:41762535	ULK4	chr3:41288091-42003660:-	0.64	9.9	9.78E-21	Diastolic blood pressure	
BLCA	cis	1	rs9832785	chr3:134213070	ANAPC13	chr3:134196547-134204865:-	0.5	8.02	1.28E-14	Height	
BLCA	cis	1	rs9832785	chr3:134213070	CEP63	chr3:134204575-134293852:+	0.25	4.35	1.77E-5	Height	
BLCA	cis	1	rs9834098	chr3:41833493	ULK4	chr3:41288091-42003660:-	0.63	9.79	2.36E-20	Diastolic blood pressure	
BLCA	cis	1	rs9834755	chr3:134206845	ANAPC13	chr3:134196547-134204865:-	0.5	8.06	9.6E-15	Height	
BLCA	cis	1	rs9834755	chr3:134206845	CEP63	chr3:134204575-134293852:+	0.25	4.39	1.49E-5	Height	
BLCA	cis	1	rs9835204	chr3:134261342	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs9835204	chr3:134261342	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs9836053	chr3:150885877	P2RY12	chr3:151055238-151102544:-	0.26	3.85	0.000138	Heschl's gyrus morphology	
BLCA	cis	1	rs9837038	chr3:156568469	LEKR1	chr3:156544076-156763918:+	-0.24	-4.65	4.62E-6	Multiple sclerosis (severity)	
BLCA	cis	1	rs9838618	chr3:48487353	TREX1	chr3:48501186-48509043:+	-0.2	-4.13	4.45E-5	Longevity	
BLCA	cis	1	rs9838965	chr3:41927938	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs9839399	chr3:41928044	ULK4	chr3:41288091-42003660:-	-0.63	-9.83	1.72E-20	Diastolic blood pressure	
BLCA	cis	1	rs9840037	chr3:41827522	ULK4	chr3:41288091-42003660:-	0.63	9.72	4.22E-20	Diastolic blood pressure	
BLCA	cis	1	rs9840532	chr3:41885697	ULK4	chr3:41288091-42003660:-	0.64	9.83	1.74E-20	Diastolic blood pressure	
BLCA	cis	1	rs9841212	chr3:134191938	ANAPC13	chr3:134196547-134204865:-	0.45	7.15	4.56E-12	Height	
BLCA	cis	1	rs984222	chr1:119503843	WARS2	chr1:119573841-119683295:-	-0.26	-4.06	6.07E-5	Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio	
BLCA	cis	1	rs9842261	chr3:41822708	ULK4	chr3:41288091-42003660:-	-0.54	-7.72	1.02E-13	Diastolic blood pressure	
BLCA	cis	1	rs9842305	chr3:41998412	ULK4	chr3:41288091-42003660:-	-0.63	-9.76	2.93E-20	Diastolic blood pressure	
BLCA	cis	1	rs9846634	chr3:41894049	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs9847006	chr3:41755359	ULK4	chr3:41288091-42003660:-	0.61	9.48	2.76E-19	Diastolic blood pressure	
BLCA	cis	1	rs9847975	chr3:41786904	ULK4	chr3:41288091-42003660:-	0.62	9.23	1.84E-18	Diastolic blood pressure	
BLCA	cis	1	rs9848754	chr3:41753647	ULK4	chr3:41288091-42003660:-	0.67	9.83	1.73E-20	Diastolic blood pressure	
BLCA	cis	1	rs9850015	chr3:134269541	ANAPC13	chr3:134196547-134204865:-	0.5	7.97	1.89E-14	Height	
BLCA	cis	1	rs9850015	chr3:134269541	CEP63	chr3:134204575-134293852:+	0.24	4.09	5.33E-5	Height	
BLCA	cis	1	rs9851441	chr3:134315091	ANAPC13	chr3:134196547-134204865:-	0.47	7.43	7.28E-13	Height	
BLCA	cis	1	rs9852303	chr3:41759525	ULK4	chr3:41288091-42003660:-	0.64	9.9	9.78E-21	Diastolic blood pressure	
BLCA	cis	1	rs9854299	chr3:134206728	ANAPC13	chr3:134196547-134204865:-	0.48	7.68	1.35E-13	Height	
BLCA	cis	1	rs9854299	chr3:134206728	CEP63	chr3:134204575-134293852:+	0.23	4.03	6.79E-5	Height	
BLCA	cis	1	rs9854833	chr3:41775577	ULK4	chr3:41288091-42003660:-	0.64	9.46	3.23E-19	Diastolic blood pressure	
BLCA	cis	1	rs9854838	chr3:41805670	ULK4	chr3:41288091-42003660:-	0.63	9.7	4.95E-20	Diastolic blood pressure	
BLCA	cis	1	rs9855965	chr3:41860508	ULK4	chr3:41288091-42003660:-	0.63	9.78	2.63E-20	Diastolic blood pressure	
BLCA	cis	1	rs9856088	chr3:41860482	ULK4	chr3:41288091-42003660:-	0.63	9.78	2.63E-20	Diastolic blood pressure	
BLCA	cis	1	rs9856633	chr3:42013850	ULK4	chr3:41288091-42003660:-	0.61	9.4	5.26E-19	Diastolic blood pressure	
BLCA	cis	1	rs9856693	chr3:134306913	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs9857175	chr3:41822054	ULK4	chr3:41288091-42003660:-	0.63	9.47	2.92E-19	Diastolic blood pressure	
BLCA	cis	1	rs9858774	chr3:183652736	VWA5B2	chr3:183948317-183960116:+	-0.24	-3.84	0.000141	Anterior chamber depth	
BLCA	cis	1	rs9863786	chr3:134247203	ANAPC13	chr3:134196547-134204865:-	0.49	7.69	1.3E-13	Height	
BLCA	cis	1	rs9863915	chr3:41762002	ULK4	chr3:41288091-42003660:-	0.64	9.9	9.78E-21	Diastolic blood pressure	
BLCA	cis	1	rs9864217	chr3:41762206	ULK4	chr3:41288091-42003660:-	0.66	9.8	2.19E-20	Diastolic blood pressure	
BLCA	cis	1	rs9864346	chr3:134312352	ANAPC13	chr3:134196547-134204865:-	0.48	7.6	2.33E-13	Height	
BLCA	cis	1	rs9864439	chr3:134298671	ANAPC13	chr3:134196547-134204865:-	0.47	7.51	4.32E-13	Height	
BLCA	cis	1	rs9865127	chr3:41807448	ULK4	chr3:41288091-42003660:-	0.63	9.71	4.45E-20	Diastolic blood pressure	
BLCA	cis	1	rs9865780	chr3:41895802	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs9865905	chr3:156649594	LEKR1	chr3:156544076-156763918:+	0.24	4.52	8.11E-6	Multiple sclerosis (severity)	
BLCA	cis	1	rs9866092	chr3:41895967	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs9866759	chr3:41758418	ULK4	chr3:41288091-42003660:-	0.62	9.61	9.94E-20	Diastolic blood pressure	
BLCA	cis	1	rs9867627	chr3:41795841	ULK4	chr3:41288091-42003660:-	-0.6	-9.14	3.72E-18	Diastolic blood pressure	
BLCA	cis	1	rs9869207	chr3:41878661	ULK4	chr3:41288091-42003660:-	0.64	9.91	9.53E-21	Diastolic blood pressure	
BLCA	cis	1	rs9869282	chr3:41756064	ULK4	chr3:41288091-42003660:-	0.61	9.48	2.76E-19	Diastolic blood pressure	
BLCA	cis	1	rs9869440	chr3:41763155	ULK4	chr3:41288091-42003660:-	0.63	9.87	1.26E-20	Diastolic blood pressure	
BLCA	cis	1	rs9869981	chr3:134248801	ANAPC13	chr3:134196547-134204865:-	0.49	7.74	9.0E-14	Height	
BLCA	cis	1	rs9869981	chr3:134248801	CEP63	chr3:134204575-134293852:+	0.23	3.92	0.000106	Height	
BLCA	cis	1	rs9871305	chr3:134213538	ANAPC13	chr3:134196547-134204865:-	0.5	8.09	7.9E-15	Height	
BLCA	cis	1	rs9871305	chr3:134213538	CEP63	chr3:134204575-134293852:+	0.25	4.43	1.21E-5	Height	
BLCA	cis	1	rs9873207	chr3:41884750	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs9874513	chr3:41909508	ULK4	chr3:41288091-42003660:-	0.64	9.5	2.29E-19	Diastolic blood pressure	
BLCA	cis	1	rs9874975	chr3:41764300	ULK4	chr3:41288091-42003660:-	0.63	9.75	3.36E-20	Diastolic blood pressure	
BLCA	cis	1	rs9875083	chr3:41775786	ULK4	chr3:41288091-42003660:-	0.64	9.46	3.23E-19	Diastolic blood pressure	
BLCA	cis	1	rs9875107	chr3:41822313	ULK4	chr3:41288091-42003660:-	0.63	9.67	6.38E-20	Diastolic blood pressure	
BLCA	cis	1	rs9876658	chr3:134179453	ANAPC13	chr3:134196547-134204865:-	-0.39	-6.06	3.31E-9	Height	
BLCA	cis	1	rs9876960	chr3:41985812	ULK4	chr3:41288091-42003660:-	-0.63	-9.71	4.41E-20	Diastolic blood pressure	
BLCA	cis	1	rs9881491	chr3:48487911	TREX1	chr3:48501186-48509043:+	-0.2	-4.07	5.62E-5	Longevity	
BLCA	cis	1	rs9882329	chr3:41767154	ULK4	chr3:41288091-42003660:-	0.63	9.78	2.69E-20	Diastolic blood pressure	
BLCA	cis	1	rs9883753	chr3:134247231	ANAPC13	chr3:134196547-134204865:-	0.47	7.57	2.76E-13	Height	
BLCA	cis	1	rs9883759	chr3:48463618	TREX1	chr3:48501186-48509043:+	-0.19	-3.86	0.000134	Longevity	
BLCA	cis	1	rs9884031	chr3:134256500	ANAPC13	chr3:134196547-134204865:-	0.49	7.7	1.15E-13	Height	
BLCA	cis	1	rs9884031	chr3:134256500	CEP63	chr3:134204575-134293852:+	0.23	3.93	0.000102	Height	
BLCA	cis	1	rs9890205	chr17:28382704	EFCAB5	chr17:28256874-28435469:+	-0.22	-3.85	0.00014	Coffee consumption (cups per day)	
BLCA	cis	1	rs9890886	chr17:28391076	EFCAB5	chr17:28256874-28435469:+	-0.22	-3.85	0.00014	Coffee consumption (cups per day)	
BLCA	cis	1	rs9891871	chr17:28370191	EFCAB5	chr17:28256874-28435469:+	-0.22	-3.85	0.00014	Coffee consumption (cups per day)	
BLCA	cis	1	rs9891968	chr17:64132846	AXIN2	chr17:63524685-63637183:-	0.56	4.92	1.3E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs9892365	chr17:59491384	C17orf82	chr17:59489112-59490641:+	0.19	4.12	4.56E-5	Sitting height ratio	
BLCA	cis	1	rs9894429	chr17:79596811	TSPAN10	chr17:79609349-79615778:+	0.49	8.59	2.28E-16	Eye color traits	
BLCA	cis	1	rs9896062	chr17:28357047	EFCAB5	chr17:28256874-28435469:+	-0.23	-4	7.57E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs9902453	chr17:28349095	EFCAB5	chr17:28256874-28435469:+	-0.23	-4.1	5.11E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs9902706	chr17:64186988	AXIN2	chr17:63524685-63637183:-	0.53	4.5	9.15E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs9903204	chr17:40288062	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs9904677	chr17:56873025	RAD51C	chr17:56769963-56811690:+	0.29	5.15	4.09E-7	Cognitive test performance	
BLCA	cis	1	rs9905385	chr17:59498250	C17orf82	chr17:59489112-59490641:+	0.19	4.16	3.93E-5	Sitting height ratio	
BLCA	cis	1	rs9905408	chr17:64190684	AXIN2	chr17:63524685-63637183:-	0.52	4.4	1.41E-5	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs9905704	chr17:56632543	SKA2	chr17:57187308-57232800:-	0.22	4.02	6.96E-5	Testicular germ cell tumor	
BLCA	cis	1	rs9906340	chr17:28398977	EFCAB5	chr17:28256874-28435469:+	-0.23	-4.32	1.97E-5	Coffee consumption (cups per day)	
BLCA	cis	1	rs9908597	chr17:64134683	AXIN2	chr17:63524685-63637183:-	0.54	4.63	4.91E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs9909	chr11:47799775	C1QTNF4	chr11:47611216-47615961:-	-0.3	-5.65	3.22E-8	Subjective well-being	
BLCA	cis	1	rs9910950	chr17:64131710	AXIN2	chr17:63524685-63637183:-	-0.51	-4.77	2.61E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs9911603	chr17:64131902	AXIN2	chr17:63524685-63637183:-	0.56	4.92	1.3E-6	Presence of antiphospholipid antibodies	
BLCA	cis	1	rs9912088	chr17:40288278	DHX58	chr17:40253422-40264751:-	-0.25	-4.56	6.82E-6	Fibrinogen levels	
BLCA	cis	1	rs9912741	chr17:28359511	EFCAB5	chr17:28256874-28435469:+	-0.22	-3.85	0.00014	Coffee consumption (cups per day)	
BLCA	cis	1	rs9915255	chr17:40284191	DHX58	chr17:40253422-40264751:-	-0.25	-4.65	4.66E-6	Fibrinogen levels	
BLCA	cis	1	rs9926996	chr16:20395908	C16orf88	chr16:19717676-19729492:-	-0.37	-4.01	7.16E-5	Urinary uromodulin levels	
BLCA	cis	1	rs9968172	chr3:134231251	ANAPC13	chr3:134196547-134204865:-	-0.51	-8.22	3.15E-15	Height	
BLCA	cis	1	rs9968172	chr3:134231251	CEP63	chr3:134204575-134293852:+	-0.28	-4.84	1.86E-6	Height	
BLCA	cis	1	rs997872	chr22:25878614	CRYBB2	chr22:25615612-25627836:+	0.93	9.71	4.39E-20	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs997873	chr22:25878282	CRYBB2	chr22:25615612-25627836:+	0.91	9.5	2.28E-19	Bipolar disorder with mood-incongruent psychosis	
BLCA	cis	1	rs9983229	chr21:30137674	N6AMT1	chr21:30244513-30257693:-	0.29	4.75	2.84E-6	Cognitive test performance	
BLCA	cis	1	rs9985356	chr3:134232920	ANAPC13	chr3:134196547-134204865:-	-0.47	-7.68	1.3E-13	Height	
BLCA	cis	1	rs9986596	chr6:28219661	ZNF389	chr6:28129551-28137375:+	-0.33	-4.07	5.63E-5	Depression	
BLCA	cis	1	rs9988866	chr11:18392983	GTF2H1	chr11:18343816-18388590:+	0.3	5.59	4.32E-8	Pancreatic cancer	
BLCA	cis	1	rs9989967	chr3:134238964	ANAPC13	chr3:134196547-134204865:-	0.47	7.49	4.72E-13	Height	
BLCA	cis	1	rs9990351	chr3:134239191	ANAPC13	chr3:134196547-134204865:-	-0.46	-7.23	2.58E-12	Height	
BLCA	cis	1	rs9995007	chr4:76897791	NAAA	chr4:76831809-76862166:-	-0.37	-6.16	1.88E-9	Longevity	
BLCA	trans	1	rs10005460	chr4:12580386	KRTAP13-1	chr21:31768392-31769136:+	0.15	6.43	3.77E-10	Obesity-related traits	
BLCA	trans	1	rs10023638	chr4:12576387	KRTAP13-1	chr21:31768392-31769136:+	0.15	6.21	1.4E-9	Obesity-related traits	
BLCA	trans	1	rs10037055	chr5:176691279	LOC388955	chr2:63849182-63850159:-	-0.54	-11.98	2.71E-28	Migraine without aura	
BLCA	trans	1	rs1003719	chr21:38491095	LZTFL1	chr3:45865446-45957534:-	0.31	6.1	2.54E-9	Eye color traits	
BLCA	trans	1	rs10214634	chr6:26564582	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs10484442	chr6:26555879	ZNF322B	chr9:99957633-99961910:-	0.46	8.01	1.43E-14	Educational attainment	
BLCA	trans	1	rs10514847	chr13:44626749	MED4	chr13:48627462-48669251:-	-0.88	-6.11	2.52E-9	Uric acid levels	
BLCA	trans	1	rs1056667	chr6:26510564	ZNF322B	chr9:99957633-99961910:-	0.45	7.92	2.6E-14	Educational attainment	
BLCA	trans	1	rs1078679	chr6:26568741	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs10794671	chr1:121168242	NBPF14	chr1:148003643-148346791:-	0.29	6.44	3.58E-10	Hip geometry	
BLCA	trans	1	rs10903159	chr1:121181997	NBPF14	chr1:148003643-148346791:-	0.28	6.19	1.51E-9	Hip geometry	
BLCA	trans	1	rs10903161	chr1:121178741	NBPF14	chr1:148003643-148346791:-	0.28	6.23	1.24E-9	Hip geometry	
BLCA	trans	1	rs10946834	chr6:26533664	ZNF322B	chr9:99957633-99961910:-	0.46	8.02	1.27E-14	Educational attainment	
BLCA	trans	1	rs10946835	chr6:26533757	ZNF322B	chr9:99957633-99961910:-	0.46	8.02	1.27E-14	Educational attainment	
BLCA	trans	1	rs11249350	chr1:121178446	NBPF14	chr1:148003643-148346791:-	0.28	6.19	1.51E-9	Hip geometry	
BLCA	trans	1	rs11249351	chr1:121171942	NBPF14	chr1:148003643-148346791:-	0.29	6.4	4.53E-10	Hip geometry	
BLCA	trans	1	rs11756120	chr6:26529808	ZNF322B	chr9:99957633-99961910:-	0.45	7.95	2.07E-14	Educational attainment	
BLCA	trans	1	rs11965538	chr6:28239915	BTN3A2	chr6:26365398-26378546:+	-0.38	-6.06	3.17E-9	Depression	
BLCA	trans	1	rs12069385	chr1:35779988	KRTAP13-1	chr21:31768392-31769136:+	0.2	6.79	4.17E-11	Night sleep phenotypes	
BLCA	trans	1	rs12145080	chr1:121185531	NBPF14	chr1:148003643-148346791:-	-0.28	-6.21	1.36E-9	Hip geometry	
BLCA	trans	1	rs12526680	chr6:26550954	ZNF322B	chr9:99957633-99961910:-	0.48	8.51	3.92E-16	Educational attainment	
BLCA	trans	1	rs12999430	chr2:70306785	C1orf115	chr1:220863628-220872499:+	0.43	6.01	4.28E-9	Obesity-related traits	
BLCA	trans	1	rs1321479	chr6:26501897	ZNF322B	chr9:99957633-99961910:-	-0.46	-7.94	2.2E-14	Educational attainment	
BLCA	trans	1	rs1321480	chr6:26532742	ZNF322B	chr9:99957633-99961910:-	0.45	7.89	3.22E-14	Educational attainment	
BLCA	trans	1	rs1321481	chr6:26538210	ZNF322B	chr9:99957633-99961910:-	0.46	8.01	1.35E-14	Educational attainment	
BLCA	trans	1	rs1419183	chr6:28242794	BTN3A2	chr6:26365398-26378546:+	-0.38	-6.06	3.17E-9	Depression	
BLCA	trans	1	rs1535277	chr6:26567802	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs1591882	chr1:121183313	NBPF14	chr1:148003643-148346791:-	0.28	6.12	2.33E-9	Hip geometry	
BLCA	trans	1	rs17051818	chr5:167492558	KRTAP3-3	chr17:39149682-39150385:-	0.3	6.18	1.63E-9	Uric acid levels	
BLCA	trans	1	rs1764786	chr1:197300496	CSNK1A1	chr5:148872949-148931007:-	-0.29	-6.01	4.28E-9	Lupus nephritis in systemic lupus erythematosus	
BLCA	trans	1	rs1832558	chr1:121177380	NBPF14	chr1:148003643-148346791:-	0.28	6.14	2.01E-9	Hip geometry	
BLCA	trans	1	rs1833196	chr16:52821090	RPL19P12	chr7:102781717-102782850:-	0.39	6.26	1.04E-9	Tetralogy of Fallot	
BLCA	trans	1	rs1856572	chr1:121169579	NBPF14	chr1:148003643-148346791:-	0.29	6.44	3.52E-10	Hip geometry	
BLCA	trans	1	rs1884946	chr6:26545308	ZNF322B	chr9:99957633-99961910:-	0.46	8	1.46E-14	Educational attainment	
BLCA	trans	1	rs1884948	chr6:26567988	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs1884949	chr6:26568067	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs2084385	chr3:196553867	LOC646214	chr15:21932514-21940739:-	-0.67	-7.32	1.5E-12	Total ventricular volume (Alzheimer's disease interaction)	
BLCA	trans	1	rs2084386	chr3:196554020	LOC646214	chr15:21932514-21940739:-	-0.7	-7.13	5.0E-12	Total ventricular volume (Alzheimer's disease interaction)	
BLCA	trans	1	rs2154536	chr21:38492147	LZTFL1	chr3:45865446-45957534:-	0.31	6.13	2.19E-9	Eye color traits	
BLCA	trans	1	rs2185281	chr1:121179991	NBPF14	chr1:148003643-148346791:-	0.28	6.19	1.51E-9	Hip geometry	
BLCA	trans	1	rs2208331	chr6:26507319	ZNF322B	chr9:99957633-99961910:-	0.45	7.92	2.6E-14	Educational attainment	
BLCA	trans	1	rs2224380	chr6:26553943	ZNF322B	chr9:99957633-99961910:-	0.47	8.29	1.88E-15	Educational attainment	
BLCA	trans	1	rs2255070	chr6:26501777	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.21E-15	Educational attainment	
BLCA	trans	1	rs2292239	chr12:56482180	RPS26P11	chrX:71264259-71264809:+	0.39	6.51	2.43E-10	Cognitive function	
BLCA	trans	1	rs2393670	chr6:26535541	ZNF322B	chr9:99957633-99961910:-	0.46	8.01	1.42E-14	Educational attainment	
BLCA	trans	1	rs2835607	chr21:38491973	LZTFL1	chr3:45865446-45957534:-	0.31	6.08	2.86E-9	Eye color traits	
BLCA	trans	1	rs2835608	chr21:38493455	LZTFL1	chr3:45865446-45957534:-	0.31	6.13	2.19E-9	Eye color traits	
BLCA	trans	1	rs28558133	chr6:26531433	ZNF322B	chr9:99957633-99961910:-	0.45	7.95	2.07E-14	Educational attainment	
BLCA	trans	1	rs3736781	chr6:26505362	ZNF322B	chr9:99957633-99961910:-	0.45	7.92	2.6E-14	Educational attainment	
BLCA	trans	1	rs3736782	chr6:26505403	ZNF322B	chr9:99957633-99961910:-	0.45	7.92	2.6E-14	Educational attainment	
BLCA	trans	1	rs41321847	chr3:34927004	RXFP2	chr13:32313679-32377008:+	-0.43	-6.89	2.27E-11	Tonometry	
BLCA	trans	1	rs4272382	chr8:8433488	CHMP7	chr8:23101150-23119512:+	-0.57	-6.02	4.05E-9	Response to cytidine analogues (gemcitabine)	
BLCA	trans	1	rs4272382	chr8:8433488	R3HCC1	chr8:23145612-23153791:+	-0.57	-6.45	3.41E-10	Response to cytidine analogues (gemcitabine)	
BLCA	trans	1	rs4713006	chr6:26519872	ZNF322B	chr9:99957633-99961910:-	0.45	7.91	2.73E-14	Educational attainment	
BLCA	trans	1	rs4713008	chr6:26538268	ZNF322B	chr9:99957633-99961910:-	0.46	8.01	1.35E-14	Educational attainment	
BLCA	trans	1	rs4844607	chr1:121184059	NBPF14	chr1:148003643-148346791:-	-0.29	-6.3	8.24E-10	Hip geometry	
BLCA	trans	1	rs4844616	chr1:121171208	NBPF14	chr1:148003643-148346791:-	0.29	6.43	3.86E-10	Hip geometry	
BLCA	trans	1	rs4871	chr6:26545632	ZNF322B	chr9:99957633-99961910:-	0.46	8.01	1.42E-14	Educational attainment	
BLCA	trans	1	rs4889910	chr17:77839795	RPL13AP3	chr14:56232963-56234434:+	0.37	6.54	2.01E-10	Electroencephalogram traits	
BLCA	trans	1	rs4889910	chr17:77839795	RPS26	chr12:56435686-56438005:+	-0.4	-6.45	3.32E-10	Electroencephalogram traits	
BLCA	trans	1	rs545076	chr12:115119903	LOC100130932	chr19:14599758-14600688:+	0.38	6.5	2.54E-10	Colorectal cancer	
BLCA	trans	1	rs545076	chr12:115119903	RPL19P12	chr7:102781717-102782850:-	0.39	6.55	1.86E-10	Colorectal cancer	
BLCA	trans	1	rs550098	chr1:197297408	CSNK1A1	chr5:148872949-148931007:-	-0.28	-5.95	5.89E-9	Lupus nephritis in systemic lupus erythematosus	
BLCA	trans	1	rs57066147	chr4:12578947	KRTAP13-1	chr21:31768392-31769136:+	0.15	6.43	3.77E-10	Obesity-related traits	
BLCA	trans	1	rs643025	chr1:197298860	CSNK1A1	chr5:148872949-148931007:-	0.28	6.01	4.33E-9	Lupus nephritis in systemic lupus erythematosus	
BLCA	trans	1	rs6456733	chr6:26566804	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs6456734	chr6:26566965	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs6586778	chr8:18706170	KCTD15	chr19:34287751-34306665:+	-0.3	-5.96	5.66E-9	Obesity-related traits	
BLCA	trans	1	rs6801365	chr3:34953109	RXFP2	chr13:32313679-32377008:+	0.35	6.01	4.36E-9	Tonometry	
BLCA	trans	1	rs6842440	chr4:12477324	KRTAP13-1	chr21:31768392-31769136:+	0.14	5.99	4.84E-9	Obesity-related traits	
BLCA	trans	1	rs6886255	chr5:176718361	LOC388955	chr2:63849182-63850159:-	0.55	12.18	4.48E-29	Migraine without aura	
BLCA	trans	1	rs6903973	chr6:26499942	ZNF322B	chr9:99957633-99961910:-	0.46	8.03	1.23E-14	Educational attainment	
BLCA	trans	1	rs6910899	chr6:26524339	ZNF322B	chr9:99957633-99961910:-	0.45	7.96	2.01E-14	Educational attainment	
BLCA	trans	1	rs6922824	chr6:26553815	ZNF322B	chr9:99957633-99961910:-	-0.48	-8.63	1.66E-16	Educational attainment	
BLCA	trans	1	rs6924838	chr6:26571756	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.04E-15	Educational attainment	
BLCA	trans	1	rs6925703	chr6:26521589	ZNF322B	chr9:99957633-99961910:-	0.45	7.96	2.01E-14	Educational attainment	
BLCA	trans	1	rs6925895	chr6:26572165	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.04E-15	Educational attainment	
BLCA	trans	1	rs6926629	chr6:26499903	ZNF322B	chr9:99957633-99961910:-	0.46	8.03	1.23E-14	Educational attainment	
BLCA	trans	1	rs6930120	chr6:26555484	ZNF322B	chr9:99957633-99961910:-	0.47	8.29	1.88E-15	Educational attainment	
BLCA	trans	1	rs6932156	chr6:26571506	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.04E-15	Educational attainment	
BLCA	trans	1	rs6933176	chr6:26540178	ZNF322B	chr9:99957633-99961910:-	0.46	8.01	1.43E-14	Educational attainment	
BLCA	trans	1	rs6940053	chr6:26562122	ZNF322B	chr9:99957633-99961910:-	0.47	8.29	1.87E-15	Educational attainment	
BLCA	trans	1	rs6940188	chr6:26562029	ZNF322B	chr9:99957633-99961910:-	0.47	8.29	1.87E-15	Educational attainment	
BLCA	trans	1	rs7238856	chr18:48746230	SLC45A1	chr1:8384390-8404226:+	-0.6	-6.39	4.95E-10	Immune response to anthrax vaccine	
BLCA	trans	1	rs73061959	chr3:34951800	RXFP2	chr13:32313679-32377008:+	0.34	5.96	5.84E-9	Tonometry	
BLCA	trans	1	rs735765	chr6:28170297	BTN3A2	chr6:26365398-26378546:+	-0.44	-6.38	5.24E-10	Depression	
BLCA	trans	1	rs767471	chr6:26557854	ZNF322B	chr9:99957633-99961910:-	0.47	8.29	1.88E-15	Educational attainment	
BLCA	trans	1	rs9295695	chr6:26528250	ZNF322B	chr9:99957633-99961910:-	-0.45	-7.72	1.01E-13	Educational attainment	
BLCA	trans	1	rs9357010	chr6:26527945	ZNF322B	chr9:99957633-99961910:-	0.44	7.75	8.08E-14	Educational attainment	
BLCA	trans	1	rs9393728	chr6:26509330	ZNF322B	chr9:99957633-99961910:-	0.45	7.92	2.6E-14	Educational attainment	
BLCA	trans	1	rs9393729	chr6:26514166	ZNF322B	chr9:99957633-99961910:-	0.45	7.91	2.73E-14	Educational attainment	
BLCA	trans	1	rs9393731	chr6:26529374	ZNF322B	chr9:99957633-99961910:-	0.45	7.95	2.07E-14	Educational attainment	
BLCA	trans	1	rs9393732	chr6:26530898	ZNF322B	chr9:99957633-99961910:-	0.45	7.95	2.07E-14	Educational attainment	
BLCA	trans	1	rs9461259	chr6:26504835	ZNF322B	chr9:99957633-99961910:-	0.45	7.92	2.6E-14	Educational attainment	
BLCA	trans	1	rs9461271	chr6:26554968	ZNF322B	chr9:99957633-99961910:-	0.47	8.29	1.88E-15	Educational attainment	
BLCA	trans	1	rs9467773	chr6:26498426	ZNF322B	chr9:99957633-99961910:-	0.46	8.03	1.23E-14	Educational attainment	
BLCA	trans	1	rs9467774	chr6:26505036	ZNF322B	chr9:99957633-99961910:-	0.45	7.92	2.6E-14	Educational attainment	
BLCA	trans	1	rs9467778	chr6:26534743	ZNF322B	chr9:99957633-99961910:-	0.46	8.02	1.27E-14	Educational attainment	
BLCA	trans	1	rs9467779	chr6:26536687	ZNF322B	chr9:99957633-99961910:-	-0.46	-8.07	9.0E-15	Educational attainment	
BLCA	trans	1	rs9467782	chr6:26542773	ZNF322B	chr9:99957633-99961910:-	0.46	8.01	1.43E-14	Educational attainment	
BLCA	trans	1	rs9467783	chr6:26542894	ZNF322B	chr9:99957633-99961910:-	0.46	8.02	1.27E-14	Educational attainment	
BLCA	trans	1	rs9467787	chr6:26556769	ZNF322B	chr9:99957633-99961910:-	0.47	8.29	1.88E-15	Educational attainment	
BLCA	trans	1	rs9467791	chr6:26562486	ZNF322B	chr9:99957633-99961910:-	-0.49	-8.48	5.06E-16	Educational attainment	
BLCA	trans	1	rs9467796	chr6:26568411	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs9467797	chr6:26568473	ZNF322B	chr9:99957633-99961910:-	0.46	8.07	9.07E-15	Educational attainment	
BLCA	trans	1	rs9986382	chr6:26550619	ZNF322B	chr9:99957633-99961910:-	0.47	8.27	2.21E-15	Educational attainment	
